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Abstract 
The study’s overall aim was to support the Impact Assessment process of the EC and 
inform this process by generating data and evidence. In doing so, it provides inputs for 
analysing the impact of the current situation (baseline scenario) as well as potential 
future policy options (POs) for EU cooperation on Health Technology Assessment (HTA) 
beyond 2020 and utilises the data and information collected to undertake an Impact 
Assessment of the different cooperation options. The POs for further cooperation at EU 
level were proposed by the European Commission (EC) and combined with potential 
business models by the authors in close cooperation with the EC.  
In order to establish the baseline scenario, a case study comprising a product sample of 
health technologies was analysed, which included 20 Pharmaceuticals, 15 medical 
devices and five ‘other technologies’ (including complex health interventions). The study 
team collected detailed information on the HTA process each technology underwent in 
the MS. Additionally, the costs of performing a HTA were identified for both the technolo-
gy developer and the HTA body. Finally, the case study captured the influence of the 
regulatory framework on technology developers.  
In order to analyse impacts of identified POs on future European cooperation in the field 
of HTA, a survey was performed on the economic and social impacts, complemented by 
focus groups, a number of interviews and findings from a literature review. A multi-
criteria analysis served as an analytical approach for assessing impacts for each stake-
holder group.  Finally, a cost prognosis was performed to estimate potential costs and 
savings for implementing and maintaining the investigated POs and business models. An 
expert panel was involved throughout the study and validated the data obtained. 
Study results provide an overview of current HTA practices and processes in Europe 
including advantages and drawbacks. An analysis of various POs for a future cooperation 
on HTA across Europe is provided. 
 
Étude sur l'analyse d'impact des options politiques pour renforcer la coopération de l'UE sur l’évaluation  
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Résumé 
L'objectif général de l'étude était de soutenir le processus d'évaluation d'impact de la 
Commission Européenne, notamment par l’apport de données et de preuves. Elle fournit 
également des informations pour l’analyse de l'impact de la situation actuelle (scénario 
de base) ainsi que sur les options politiques (OP) potentielles relatives à la coopération 
sur l’évaluation des technologies de santé (ETS) à l’échelle européenne après 2020 et 
met à profit les données et les informations recueillies pour mener une évaluation de 
l’effet des différentes perspectives de coopération. Les OP pour une coopération appro-
fondie au niveau de l'UE ont été proposées par la Commission européenne (CE) et 
combinées à des modèles commerciaux potentiels par les auteurs en étroite coopération 
avec la CE. 
Afin d'établir le scénario de base, une étude de cas comprenant un échantillon de 
produits de technologies de santé a été analysée, comprenant notamment 20 produits 
Pharmaceutiques, 15 dispositifs médicaux et cinq « autres technologies » (notamment 
des interventions sanitaires complexes). L'équipe d'étude a recueilli des informations 
détaillées sur les processus d’ETS auxquels chaque technologie a été soumise dans les 
EM. En outre, les coûts de la réalisation d'une ETS ont été déterminés à la fois pour le 
développeur de technologie ainsi que pour les organismes d’ETS. Enfin, l'étude de cas a 
permis de saisir l'influence des cadres réglementaires sur les développeurs de technolo-
gies. 
Afin d'analyser les impacts des OP identifiées sur la future coopération européenne dans 
le domaine de l'ETS, une enquête a été réalisée sur les effets économiques et sociaux, 
soutenue par des groupes de discussion, plusieurs interviews et des conclusions sur de la 
documentation. Les effets potentiels des options politiques proposées pour les différents 
groupes d'acteurs ont été étudiés à travers une analyse multicritère (AMC). Enfin, un 
pronostic des coûts a été effectué pour estimer les coûts de la participation volontaire ou 
obligatoire à la production conjointe et les économies liées dans la production nationale 
des OP proposées et les coûts liés aux structures organisationnelles spéci-
fiques/mécanismes de mise en œuvre comprenant des outils communs. Un panel 
d'experts a été impliqué tout au long de l'étude et a validé les données obtenues. 
Les résultats de l'étude donnent un aperçu des pratiques et processus actuels d’ETS à 
l’échelle Européenne, comprenant les avantages et les inconvénients. Une analyse des 
différentes OP sur les développements futurs potentiels de la coopération d’ETS en 
Europe est aussi fournie. 
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EFSA European Food Safety Authority 
E.g. Exempli gratia; for example 
EMA  European Medicines Agency  
EPAR  European Public Assessment Report 
EPF  European Patients’ Forum 
ESIP   European Social Insurance Platform 
ESMO  European Society for Medical Oncology 
EU  European Union 
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EUCOPE  European Confederation of Pharmaceutical Entrepreneurs 
Eu-LISA European Agency for the Operational Management of large-scale IT Systems 
in the Area of Freedom, Security and Justice 
EUnetHTA   European network for Health Technology Assessment 
EUPHA  The European Public Health Association 
EURORDIS  European Organisation for Rare Diseases 
FC   Functional Class 
Fimea  Finnish Medicines Agency 
FinOHTA  Finnish Office for Health Technology Assessment 
FR  France 
FTE  Full-Time Equivalent 
G-BA  Gemeinsamer Bundesausschuss (Federal Joint Committee, Germany) 
GMDN   Global Medical Device Nomenclature 
GOEG  Gesundheit Österreich GmbH (Austria) 
GO FP  Gesundheit Österreich Forschungs- und Planungs GmbH  
GSK  GlaxoSmithKline 
HAS  Haute Autorité de Santé (France) 
HCC  Chronic Hepatitis C 
HEN  Health Evidence Network 
HIFU  High-Itensity Focused Ultrasound 
HIQA  Health Information and Quality Authority 
HIV  Human Immunodeficiency Virus 
HPV  Human Papillomavirus 
HR  Human Resources 
HSCT   Haematopoietic Stem-Cell Transplantation 
HTA   Health Technology Assessment 
HTAi  Health Technology Assessment international  
HU  Hungary 
ICER   Incremental Cost-Effectiveness Ratio  
I.e.  Id est (that is to say) 
IE  Ireland 
IFPMA International Federation of Pharmaceutical Manufacturers & Associations  
IMI  Innovative Medicines Initiative 
INAHTA International Network of Agencies for Health Technology Assessment 
INAMI Institut National d'Assurance Maladie Invalidité (Belgium) 
INFARMED National Authority of Medicines and Health Products, I.P. (Portugal) 
IPD Invasive Pneumococcal Disease 
IPF  Idiopathic Pulmonary Fibrosis 
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IQWIG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Germany) 
ISPOR International Society for Pharmacoeconomic and Outcomes Research  
IT  Information Technology 
IT  Italy 
IVF  In-Vitro Fertilisation  
JA  Joint Action 
J & J  Johnson & Johnson 
JRC  Joint Research Center 
KCE   Belgian Health Care Knowledge Centre 
LBI HTA  Ludwig Boltzmann Institute Health Technology Assessment (Austria) 
LSE  London School of Economics 
MA  Market Authorisation 
MAX  Maximum 
MCA  Multi-criteria analysis 
MedTech  Medical Technologies 
MeSH  Medical Subject Heading 
MIN  Minimum 
MS  Member State 
MTA  Multi Technology Assessment 
NAATs   Nucleic Acid Amplification Tests 
NCPE  National Centre for Pharmacoeconomics  
NHS  National Health Service 
NICE  National Institute for Health and Care Excellence (UK) 
NL  Netherlands 
OECD   Organisation for Economic Co-operation and Development 
OGYÉI   National Institute of Pharmacy and Nutrition (Hungary) 
PAP  Papanicolaou Test 
PET  Positron Emission Tomography  
PL  Poland 
PM  Person Month 
PO  Policy Option 
POP  Planned and Ongoing Projects 
PPP Purchasing Power Parity 
QALY   Quality-Adjusted Life Year  
RCT   Randomized Controlled Trial 
REA  (Rapid) Relative Effectiveness Assessment 
RRMS   Relapsing-Remitting Multiple Sclerosis 
RNA  Ribonucleic Acid  
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RWE  Real World Evidence 
SEED Shaping European Early Dialogues for Health Technologies Group 
SH  Social/Health Impacts 
SMC   Scottish Medicines Consortium 
SME  Small and Medium-Sized Enterprises 
SMR   Service Médical Rendu 
SOS   Sinusoidal Obstructive Syndrome  
STA  Single Technology Assessment 
SVJ   Social Value Judgement 
TLV  Dental and Pharmaceutical Benefits Agency 
UK  United Kingdom 
VMT   Vitreomacular Traction 
VOD   Veno-occlusive disease 
WHO   World Health Organization 
ZiN  Zorginstituut Nederland (the Netherlands) 
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Glossary 
Additional evidence generation 
Generation of additional clinical evidence refers to all studies and provision of data in 
addition to clinical studies performed for marketing authorization within the course of an 
HTA process. 
Administrative data 
Administrative data (typically retrospective or real-time, if possible) are collected 
primarily for reimbursement, but contain some clinical diagnosis and procedure use with 
detailed information on charges. Claims databases lend themselves to retrospective 
longitudinal and cross-sectional analyses of clinical and economic outcomes at patient, 
group, or population level. 
Assessment 
Assessment relates to the process of HTA when clinical, economic or other evidence is 
reviewed and described. 
Appraisal 
Appraisal relates to the process following the assessment phase when recommendations 
on the use of health technology are given, it includes value judgement. 
Business models 
The business models presented in this report combine implementation mechanisms with 
output production (e.g. joint REA). The business models presented are illustrative 
scenarios. Other combinations of implementation mechanisms and output productions 
are possible. 
Early Dialogue 
Early Dialogues are undertaken with the aim of helping Pharmaceutical and MedTech 
companies understand the evidence and information needs of the HTA organisations and 
reimbursement bodies in order to improve the quality and adequacy of early evidence 
generation. 
Electronic health records/medical chart reviews 
Electronic health records/medical chart reviews, such as the UK General Practice Re-
search Database, contain more detailed, longitudinal information, including disease-
specific symptoms at the personal level, and should greatly expand the use of this type 
of information. 
Full HTA 
Full HTA not only addresses the medical/therapeutic added value of a new technology 
(assessment of clinical domain), but also covers the assessment of other aspects such as 
cost-effectiveness, budget impact, ethical aspects, legal considerations and impact on 
patients as well as on the health care systems. 
Health survey 
Health surveys are designed to collect descriptions of health status and well-being, 
health-care utilization, treatment patterns, and health-care expenditures from patients, 
providers, or individuals in the general population, which are representative of the target 
population. Health surveys are methodologically rigorous (for example, relying on 
complex sample survey designs). 
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Horizon Scanning 
Horizon Scanning is the systematic identification of health technologies that are new, 
emerging or becoming obsolete and that have the potential to affect health, health 
services and/or society. 
HTA 
The EUnetHTA definition for HTA is: a multidisciplinary process that summarises infor-
mation about the medical, social, economic and ethical issues related to the use of a 
health technology in a systematic, transparent, unbiased, robust manner. 
HTA submission 
HTA submission refers to submitting evidence (study or clinical/economic data and 
studies) to an HTA Body/regulatory body for assessing the value of a health technology. 
HTA processes 
In the context of this study HTA processes relate to all current and future activities in the 
area of HTA including all four types of outputs defined in the Policy Options (Common 
tools, Methodologies and Templates; Early Dialogues; REA, Full HTA).  
Internal audit 
An internal audit is used to assess operational efficiencies and resource management. It 
is often compulsory for public bodies to verify cost records and adherence to acceptable 
cost accounting procedures. 
Joint Assessment 
A joint assessment is structured information for rapid or full/comprehensive HTAs, which 
is the output of joint production where two or more countries and/or organisations 
worked together to prepare shared products or agreed outcomes.  
Multiple technology assessment 
Multiple technology assessment normally covers more than one technology, or one 
technology for more than one indication respectively.  
Non-clinical domains (see EUnetHTA  core model) 
Costs and economic evaluation, ethical analysis, organisational aspects, patients and 
social aspects and legal aspects. 
Practical clinical trials 
Practical or pragmatic clinical trials (also called ‘large simple trials’) involve prospective, 
randomized assignment but are aimed at larger, more diverse real world populations. 
Practical or pragmatic clinical trials have the important strength of randomization, which 
minimizes bias in the estimation of treatment effects. These trials are by design larger 
than conventional randomized controlled trials. For this reason, they are more likely to 
have sufficient power to capture significant differences in key outcomes of interest, such 
as hospitalizations. 
Predictability 
Predictability in the context of this study refers to the harmonization of methodologies, 
processes and evidence requirements in relation to HTA processes.  
Registry data 
Registries are prospective, observational cohort studies of patients who have a particular 
disease and/or are receiving a particular treatment or intervention. They can be used for 
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understanding natural history, assessing or monitoring real world safety and effective-
ness, assessing quality of care and provider performance, and assessing cost-
effectiveness. 
Relative Effectiveness Assessment (REA) 
REA is a specific element of Health Technology Assessment (HTA) that focuses on the 
clinical benefit of the intervention, whereas HTA is broader and can also include other 
aspects, such as ethical, cost, and cost-effectiveness considerations. 
Single technology assessment 
An assessment which covers a single technology for a single indication.  
Supplement to randomised controlled trial 
To provide additional data alongside standard clinically focused randomized controlled 
trials, researchers often gather information on variables such as patient-reported 
outcomes, medical resource use, and costs. Such efforts can add valuable evidence on 
treatment patterns for common events, such as the doses of drugs used to treat rejec-
tion in kidney transplantation. 
Uptake 
Within the context of this study, up-take concerns using or considering the results and 
findings of the HTA cooperation, reaching from jointly developed submission templates to 
full HTA. The subsequent pricing and reimbursement decision remains purely at national 
level.  
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Executive Summary 
Background 
The Member States (MS) and the European Union (EU) have recognised the growing 
importance of Health Technology Assessment (HTA) for decision- and policy-making for 
some time. HTA is considered as valuable tool that can contribute to the sustainability of 
national health systems. Still, the generation of HTA outputs (namely Early Dialogues, 
Relative Effectiveness Assessment (REA) and, finally, Full HTA reports with economic 
evaluation) is quite diverse in the EU partly because HTA systems are fragmented.  
Cooperation on HTA at EU level commenced in 2009 with the establishment of the 
EUnetHTA collaboration. Two Joint Actions (JA) were undertaken, the first 2010-2012 
(EUnetHTA JA 1) and the second 2012-2015 (EUnetHTA JA 2). The third Joint Action 
(EUnetHTA JA 3) started in June 2016 with the general objective to increase the use, 
quality and efficiency of joint HTA work at EU level, to support evidence-based, sustaina-
ble and equitable choices in healthcare. 
In this context, the question of sustainable cooperation beyond 2020 when the current 
EUnetHTA Joint Action expires is addressed in line with the ‘Better Regulation’ agenda of 
the European Commission (EC), aiming at the design and evaluation of EU policies in a 
transparent manner, considering both evidence and stakeholder views. 
The EC has launched an Impact Assessment initiative (1) to identify and assess various 
Policy Options (POs) on how to continue HTA cooperation at EU level beyond 2020.  
Rationale and objective of the study  
The study’s overall aim is to support the Impact Assessment process of the EC and 
inform this process by generating relevant data and evidence. In doing so, it provides 
inputs for analysing the impact of different POs for EU cooperation on HTA beyond 2020 
and utilises the data and information collected to analyse the potential impacts of the 
different POs. Accordingly, the study’s specific objectives are: 
• To collect data, generate evidence and provide in-depth analysis of what would 
happen in the absence of further action at EU level including the associat-
ed impacts (baseline scenario) 
• To collect data, generate evidence and provide analysis of the potential impacts of 
identified POs for cooperation of the EC 
• To collect relevant literature on HTA, with a specific focus on the EU, to understand 
the way HTA is used across EU Member States (MS) 
While HTA provides input that determines pricing and reimbursement decisions in some 
countries, the study focuses on the assessment aspect, as in all POs any subsequent 
appraisal and pricing and reimbursement decision for medical technologies, whether 
medical devices or Pharmaceuticals, remain the competence of each MS.  
A consortium consisting of Gesundheit Österreich Forschungs- und Planungsgesellschaft 
(Austria), The London School of Economics - LSE Health (UK) and SOGETI (Luxembourg), 
undertakes this study.  
                                                                                                                                    
 
(1) https://ec.europa.eu/health/technology_assessment/consultations/cooperation_hta_en  
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Policy Options for Impact Assessment: characteristics and analytical context 
The EC has proposed POs for further cooperation at EU level in the Inception Impact 
Assessment (1), which the authors combined with potential business models.  
The POs are defined along several key characteristics extended beyond the benchmark 
scenario of ‘no further action at EU level’, including (a) HTA outputs to be covered by the 
joint cooperation, (b) the proposed nature of the cooperation, (c) different models of 
governance and (d) funding options for the joint cooperation initiative. 
 
● Joint HTA outputs to be covered by the cooperation include a range as follows: 
• Common tools and procedures such as common submission templates, an IT sys-
tem with planned and ongoing assessments, common methodologies (e.g. EU-
netHTA  Core Model), a joint prioritisation process, and cooperation on data re-
quirements, including Horizon Scanning 
• Early Dialogues 
• Relative Effectiveness Assessments 
• Joint Full Health Technology Assessments 
 
● Proposed nature of the cooperation between MS  
POs differ regarding the nature of cooperation, as reflected by the type of participation 
(voluntary or mandatory) and/or the uptake2 of joint outputs (voluntary or mandatory):  
• Voluntary participation/voluntary uptake (V/V): Cooperation is voluntary and the 
MS can decide if they wish to participate in the production and uptake of the re-
spective outputs.  
• Voluntary participation/mandatory uptake (V/M): The participation in the creation 
of joint work is voluntary, meaning that MS may decide to opt-in3 to the joint co-
operation. However, once a MS has opted in, the uptake of the joint work into the 
national setting is mandatory. 
• Mandatory participation/mandatory uptake (M/M): Both participation in the pro-
duction of outputs and uptake of these into the national setting are mandatory for 
MS. 
 
● Models of governance for joint EU cooperation 
A variety of governance models for EU cooperation were investigated ranging from loose 
project-based cooperation to a permanent secretariat within a new EU agency, as 
follows: 
• Project-based cooperation (PO2)  
• A permanent secretariat hosted by a MS (PO3)  
• A permanent secretariat hosted by the EC (PO4.1)  
• A permanent secretariat hosted by an existing EU agency (PO4.2) 
• A permanent secretariat hosted by a new EU agency (PO5) 
                                                                                                                                    
 
(2)  Up-take concerns using or considering the results and findings of the HTA cooperation, reaching from jointly developed 
submission templates to outcomes in full HTA. The subsequent pricing and reimbursement decision remains purely on 
national level. Also providers / developers need to adhere to this process. 
(3) Opt-in by MS is by output, not by individual products e.g. once a MS has opted in for joint REA, they take part in all joint 
REAs – but not necessarily as an author. 
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
 22 
Across the board, the assumption has been that scientific work and expertise (i.e. the 
developments of joint outputs) would stay with national agencies. For governance models 
comprising a permanent secretariat, dedicated MS Committee(s) were foreseen to ensure 
the quality of joint work and consideration of national agendas. Regardless of the type of 
cooperation, there are common elements to the governance structure, which are defined 
by the joint output. 
 
 Funding options for the joint EU cooperation 
In order to finance the joint cooperation, a combination of several sources is conceivable, 
although this was not explored in any meaningful depth or detail in the study: 
• EU funding, either through a Public Health program or another financial instrument 
• Funding by the MS joining the collaboration 
• Funding through industry fees 
The following table provides an overview for each proposed PO, including the degree of 
covered outputs, the extent to which cooperation is compulsory and the envisaged 
implementation/funding mechanism. 
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Table 1: Overview of Policy Options  
 
Legend. PO: Policy Option; V/V: Voluntary participation/ voluntary uptake; V/M: Voluntary participation/mandatory uptake; M/M: Mandatory participation/mandatory uptake; ED: Early Dialogue; REA: Relative Effectiveness 
Assessment; MS: Member State; HTA: Health Technology Assessment 
                                                                                                                                                                                                              
 
(4) Assuming that 50% of the Member States (MS) participate, a mix of high/low income, large/small MS.  
(5) ED - Early Dialogue: Here mandatory uptake means that the MS cannot repeat an ED that was done at the EU level. Technology providers initiate Early Dialogues. 
(6) Either at time of market or re-assessment. 
(7) A gradual introduction of products during a transitory period that allows to manage the workload while the structures/implementation models are being developed. 
 Baseline Non-legislative Legislative 
 
PO 1 PO 2 PO 3 PO 4 (4) PO 5 
No EU action 
after 2020 
 
Voluntary 
cooperation 
through Public 
Health Programme 
Legislation covering 
common tools and 
Early Dialogues 
 
Legislation covering 
Joint work on REA 
Plus 
common tools and Early Dialogues 
Legislation covering 
Joint work on Full HTA 
(including REA) 
Plus 
common tools and Early 
Dialogues 
4.1 
REA V/M 
4.2 
REA M/M 
O
u
tp
u
ts
 
Common tools, 
including templates, 
methodology 
V/V V/M M/M M/M M/M M/M 
Early Dialogue (5) V/V V/M V/M V/M M/M M/M 
Joint REA (6) V/V V/M V/V V/M M/M M/M 
Joint Full HTA (6) V/V V/V V/V V/V V/V V/M 
Implementation No EU input 
Project based  
cooperation 
EU/MS secretariat Existing EU agency Existing EU agency New EU agency 
Financing None from EU EU+MS EU+MS+fees from industry for Early Dialogues, joint REA and Full HTA 
Scope  
All  Pharmaceuti-
cals , medical and 
other technologies 
Tools: all  Pharma-
ceuticals , medical 
technologies, other 
technologies 
(phasing in), 
ED: industry 
submission 
Tools and ED see PO 3. REA: certain 
categories of  Pharmaceuticals (e.g. 
centrally authorised, high value/budget 
impact, agreement between MS) and 
medical technologies (e.g. high risk, high 
value products) and other technologies 
(agreement and prioritisation between 
MS) – phasing in(7) 
Tools and ED see PO 3, REA 
see PO4. For others: ad hoc 
agreement and prioritisation 
between MS 
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
 24 
Methods 
Overall approach 
In order to establish the baseline scenario, a case study comprising a product sample of 
health technologies was analysed, which included 20 Pharmaceuticals, 15 medical 
devices and five ‘other technologies’ (including complex health interventions). The study 
team collected detailed information on the HTA-process each technology underwent in 
the MS. Additionally, the costs of performing a Health Technology Assessment were 
identified for both the technology developer and the HTA body. Finally, the case study 
captured the influence of the regulatory framework on technology developers.  
In order to analyse the impacts of identified POs for the EC, a survey was performed on 
the economic and social impacts of the identified POs, complemented by focus groups, a 
number of interviews and findings from literature review. The study investigated the 
following impacts, for which one or more indicators were defined: 
The impacts investigated included economic (EC) and social health (SH) criteria: 
EC1 Costs SH1 Employment 
EC2 Administrative burden SH2 Governance, participation and 
good administration 
EC3 Competitiveness of EU health technology sector SH3 Access to social protection and 
health systems 
EC4 Innovation and research SH4 Sustainability of health systems 
EC5 International trade innovation and research SH5 Public health 
EC6 Functioning of the internal market and competition   
EC7 
Consumers and households   
EC8 Macroeconomic environment   
The study also provides a description of the implementation mechanisms (for instance, a 
joint secretariat) and an estimation of the associated costs. 
 
Data collection 
In order to collect a comprehensive data set for analysing the baseline scenario and 
the potential impacts of the EC’s identified POs, a variety of data collection methods 
was utilised (see Figure 1 on the next page).  
Both a systematic literature review and desk research were performed to identify 
relevant literature, which has been used to put in context, verify and complement the 
findings of the case studies and the survey. The aim was to provide an overview of the 
status quo and impact of HTA systems across EU MS. 
An online survey was undertaken targeted at Public Administrations (e.g. HTA bodies), 
the Pharmaceutical and MedTech Industries as well as Patients and Health Professionals, 
which yielded responses predominantly from Public Administrations and Industry.  
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
 25 
The case study, covering 40 health care technologies (20 Pharmaceuticals, 15 medical 
devices(8) and 5 ‘other technologies’) sought to systematically capture and depict the 
elements composing the status quo of HTA across EU MS, by adopting a multi-stage, 
mixed qualitative and quantitative analytical approach.  
Figure 1: Overview about streams of activities 
Additional data collection and validation of findings included:  
• Interviews with industry (Pharmaceutical and medical device) and patient repre-
sentatives; 
• Short surveys/follow-up questions addressed to Public Administrations and Indus-
try aiming to gather more data on costs as well as additional information relevant 
to interpret the results;  
• Use of findings of a further EC study (2) conducted to support the Impact Assess-
ment process; 
• Focus group meetings with stakeholders from Public Administrations and both 
industry sectors (Pharmaceuticals and devices) to discuss the results of the online 
survey and to gather additional insights and feedback on the results; 
• Involvement of an expert group which was set up for the duration of the study; 
and  
• Peer review by leading experts in the field.  
Limitations of the Study  
The study has several limitations, many of which are linked to the assumptions that 
were, and had to be, made (e.g. on the future number of joint HTA outputs or IT costs). 
For some elements (e.g. the current number of ED in Europe) no data was readily 
available or the granularity of available information was very different among EU 
countries and HTA bodies. The cost estimates need to be read with caution, taking into 
account all challenges and limitations, as described in detail in the report. 
                                                                                                                                   
 
(8) In this report the word ‘devices’ is used generically and includes medical devices and associated medical technologies. 
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With regards to the baseline scenario information on the MedTech sector and ‘other 
technologies’ was sometimes scarce compared to Pharmaceuticals, because for the 
MedTech industry HTA is less common than the Pharmaceutical sector.  
Regarding the stakeholder survey, two issues are worth noting: a low response rate from 
patients and health professionals, as they felt more addressed by the public consultation 
that was conducted by the EC in parallel; and the level of detail in the questions because 
the study team had to capture many potential effects of a number of POs as required in 
the EU ‘Better Regulation Guideline’ (3). As a consequence, not all EU MS could be 
covered, but there were respondents from all parts of the EU, including countries with 
well integrated and less well integrated HTA systems.  
Analysis 
Case study – Analysis of baseline scenario 
We compared and analysed the sample of 40 health technologies to identify the key 
elements of value assessment of health technologies across different European coun-
tries. Although the primary aim of the study is to capture assessments, due to the 
heterogeneity of the HTA role across countries, in some cases appraisals were also 
captured. Thus we identified final HTA decisions, the restrictions put in place in order to 
include or suggest the inclusion of a technology in the benefits catalogue of each country 
or setting and how these and the length of the process differed or aligned across 
countries or settings. Indeed, the systematic analysis identified: (a) the presence of an 
assessment and the final recommendation made by HTA bodies, capturing possible 
duplications in assessment; (b) how HTA is currently used in different contexts and what 
clinical and economic evidence is used in conducting the assessments; (c) the timeline of 
performing the assessment across different country or setting; (d) the cost related to the 
HTA process; and (e) perspectives from industry and HTA bodies on methods and 
processes. 
The systematic approach allowed an understanding of the variability in methods and 
processes currently employed by different HTA bodies across the EU and enabled 
the identification of possible duplication of efforts or cases where greater 
consensus would be needed around HTA processes and methods. It also contrib-
uted to identifying areas where consistency and transparency in the criteria used 
for decision-making could be improved. 
The systematic analysis of HTA recommendations across MS and for the 40 technologies 
identified, included the examination and reporting of the following endpoints: (a) 
Presence of HTA assessments across the sample of technologies; (b) inclusion of clinical 
and economic evidence; (c) social value judgments; (d) agreement vs. disagreement 
among HTA bodies in recommendations, through the use of the Kappa score statistic; (e) 
the direction of HTA recommendations; (f) clinical restrictions in HTA recommendations; 
(g) economic restrictions in HTA recommendations; (h) HTA timelines relative to MA; (i) 
baseline HTA costs based on primary data collection (survey) from manufacturers and 
HTA bodies; and (j) industry views on HTA processes. 
Due to the incomplete nature or the low quality of clinical and economic evidence, 
decision makers need to make judgements based on considerable uncertainty about the 
clinical and economic impact of a treatment or accept ICERs that are, strictly speaking, 
above implicit or explicit national willingness to pay (WTP) thresholds. In this context, 
social value judgements (SVJs) aim to interpret key elements related to the impact of 
the treatment on patients and society. As such, SVJ have increasingly been included in 
HTA decisions. They have been identified and coded across all HTA reports, and classified 
into eleven main categories notably: (a) Significant innovation, (b) Life expectancy 
improvements, (c) Small population, (d) Equality issues, (e) Wider societal benefits, (f) 
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Impact on quality of life and daily activities, (g) Impact on the family and carers, (h) 
Unmet need for treatments, (i) Rarity and severity of the disease and, (j) Other consid-
erations, which may be related to the disease or the product in question. 
Cost prognosis 
One task of the project team was to give input to the EU Impact Assessment regarding 
the likely evolution of cost for coordinated HTA in the EU. Cost prognosis includes 
estimates on costs and savings from the implementation of the POs from 2021 onwards, 
as follows:  
• On future joint outputs (common tools; Early Dialogues (ED); Joint REA; and 
Joint Full HTA);  
• On savings that arise from the reduction in related national outputs (diminished 
by the costs of adaptation of joint outputs to national context);  
• On the various proposed implementation mechanisms and governance struc-
tures (project-based cooperation, MS secretariat, EU secretariat located at EC 
level, integration of such a secretariat into an existing EU agency, founding a new 
EU agency). 
Costs of implementation mechanisms include potential one-time investment costs (if 
estimable) and operating costs. Several sources, including published and unpublished 
studies, (validated) data from the study survey and baseline scenario as well as addi-
tional information provided by stakeholders and EC services were the basis of the cost 
prognosis. If cost data and/or information were not available, the team made justified 
assumptions to derive estimates. Considering cost evolution for output and some other 
parameters, sensitivity analyses aimed to investigate related uncertainties. Potential 
funding mechanisms for POs and business models were not part of the prognosis.  
Assumptions on the future number of joint outputs were made for the Pharmaceutical 
and MedTech sectors separately and are outlined in detail in the full report; the same 
applies for the expected opt-in rates of MS for the voluntary POs and the expected 
overlaps between joint and national outputs (indicating potential savings). An imple-
mentation mechanism without EC funding was not considered in this study, 
because intergovernmental cooperation without EU input is strictly the respon-
sibility of the MS. Detailed assumptions regarding the establishment of a permanent 
secretariat were made, addressing the general structure and personnel requirements, 
including the establishment of three MS expert committees responsible for quality 
assurance and consideration of national agendas.  Underlying assumptions were based 
on literature or other sources, if available. 
The main limitations of this approach were as follows: We could not incorporate ED fully 
within the calculations due to a lack of data. Further cost impacts like system change 
costs at country level could not be quantified on an aggregate level and are, therefore, 
depicted in a descriptive way. Current HTA outputs are heterogeneous across Europe and 
data sources for current costs and quantities of outputs at MS level show many gaps and 
uncertainties. At national level, there may be an uptake of joint output (and related 
savings or costs) for other purposes than reimbursement decisions. Finally, it was not 
possible to quantify the long-term overall impact of centrally organised mandatory HTA 
outputs on national HTA systems, e.g. in terms of transparency, standardisation or 
methodological quality. 
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Assessment of Policy Options  
Potential impacts of the proposed POs on the different stakeholder groups were assessed 
by multi-criteria analysis (MCA). These findings were validated by focus groups, 
follow-up discussion and literature. The MCA approach captures multiple criteria, permits 
differentiation between stakeholder groups (i.e. Public Administrations, the Pharmaceuti-
cal Industry, and the MedTech industry) and allows differences or similarities between 
the stakeholder groups to be shown. 
Identification of relevant criteria for assessing economic and social/health impacts took 
place in collaboration with DG SANTE and were based on the impacts stated in the EC’s 
Better Regulation Guideline (3, 4). For each impact one or more indicators were defined, 
such as Research and Innovation in the European market, the fragmentation of HTA 
systems in Europe, the number of health technologies assessed or available, and 
sustainability or resource efficiency in HTA processes in Europe. A consultation with the 
expert group set up for this study was performed in order to validate the relevance of 
the identified impacts and indicators and to identify potential missing impacts/indicators.  
The direction (positive or negative) and the extent (scale from -100 to +100, i.e. 
increase or decrease) for each impact was surveyed and represented an important 
source for analysis and an attempt to quantify estimates. Additional to the effect of the 
respective POs on the impacts, the MCA included an assessment of the importance or 
relevance of the impacts for different stakeholder groups. In order to capture variability 
within stakeholder groups in the analysis of survey results, additional sub-group anal-
yses were performed, e.g. separate analysis for different company sizes and a compari-
son of responses of companies with and without experience in the field of HTA. Different 
data plausibility checks were performed to investigate the reliability and robustness of 
survey data as well as the response behaviour of stakeholder groups.  
Additional information collected through literature, stakeholder focus groups, stakeholder 
interviews and information derived through the analysis of the baseline scenario and the 
cost prognosis supplemented the survey results. Results were depicted separately for 
each stakeholder group. To strengthen the stakeholder group of patients and consumers, 
an additional follow-up targeted further information collection to depict the stakeholder 
groups’ perspective adequately. Follow-up consisted of interviews with consumer and 
patient organisations at EU level.  
The main limitation of this approach was that the different levels of detail in the evidence 
across the different HTA bodies, the number of functional differences across HTA bodies 
in Europe and their different levels of transparency (e.g. not all assessments are in the 
public domain or were shared with the study team) may have affected our analysis.  
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Results 
Analysis of baseline scenario – Case study approach 
The baseline scenario analysed forty technologies (20 Pharmaceutical products, 15 
medical technologies (predominantly devices) and five ‘other technologies’ (e.g. 
HPV vaccination) in detail to capture critical aspects of HTA processes in the MS. The 
main objective was to provide clarity on HTA models, processes and outcomes in the MS 
through comparative analysis of HTA recommendations across the selection made.  
HTA across the sample of technologies: In the Pharmaceutical products sample, 
evidence showed that the same product-indication pair had been assessed at least by 10 
HTA bodies in as many countries. An average across the sample of 13 out of 24 bodies 
assessed the same product-indication pair. This is confirmed by HTA bodies such as HAS 
(France), G-BA (Germany) and AIFA (Italy) due to their topic selection process –
evaluating all new Pharmaceuticals applying for MA (Marketing Authorization) – and the 
high level of agreement among other HTA bodies such as TLV (Sweden) and NICE 
(England) or INFARMED (Portugal).  
Clearly, not all HTA bodies assess all Pharmaceutical products. Some well-developed HTA 
systems assess all new Pharmaceutical products. Others have explicit prioritisation and 
topic selection processes, which (a) results in a proportion of all new product-indication 
pairs being assessed in a given year, (b) results in a very small number of technologies 
being assessed, or (c) only results in simply performing HTA referencing. Additionally, 
the assessment of each product-indication pair carried out is highly influenced by the 
model of HTA (e.g. clinical benefit assessment vs. clinical and cost-effectiveness) and the 
overall approach to HTA prevailing in each country (i.e. arms’ length or integrated 
approach).  
The situation in HTA for medical technologies and ‘Other Technologies’ is less 
developed and established across EU MS. The sample shows that the number of 
HTAs per product-indication pair was lower than in Pharmaceuticals. On average, one 
medical technology or one ‘Other Technology’ was evaluated by six HTA bodies, with at 
least four countries evaluating the same medical technology.  
Inclusion of clinical and economic evidence. In terms of clinical evidence across the 
entire Pharmaceutical sample, all HTA bodies had a clear preference for phase III 
clinical trials, followed by phase II trials and other sources of evidence. The most 
commonly used trial comparators were placebo/current standard of care. Across the 
medical technologies sample, a clear preference is shown for RCT trials (28%) 
followed by observational studies (17%) and safety studies (19%). The most commonly 
used trial comparator was the current standard of care. Finally, in the ‘Other Technolo-
gies’ sample on average 6 clinical studies showed a general preference for literature 
reviews (89%), which include different aspects of public health programmes and not just 
the clinical and cost effectiveness of technologies. 
There is a clear difference in preferences among HTA bodies for the type of evidence 
required for Pharmaceuticals compared to medical technologies and ‘other technologies’. 
This is partly driven by what is feasible in the context of either medical technologies or 
‘other technologies’ and highlighted by the high proportion of retrospective studies and 
safety studies (in the medical devices sample) and literature reviews (in the ‘other 
technologies’ sample).  
In terms of economic assessment, not all countries assessed the clinical and cost 
effectiveness of each study technology, and the criteria for assessment varied considera-
bly. In the Pharmaceuticals sample, eight countries considered an economic evaluation 
in their assessment and, on average, 1.5 economic studies were considered for each 
Pharmaceutical product/indication pair. Findings showed that, in general, a cost-utility 
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analysis was considered across all study Pharmaceuticals (in 85% of cases), followed by 
budget impact analysis (43% of cases). Only in a limited number of cases (6%) was a 
cost-minimization analysis performed. The most commonly used trial comparators were 
a direct comparator (86%). Across studied countries, in 68% of the cases, the 
comparator included was the same across HTA bodies. In the medical technologies 
sample, eight countries considered economic evaluation, with an average number of 2.5 
studies per technology considered. Looking at the type of economic analysis, the trend 
was confirmed with mostly cost-utility studies (67%), followed by cost comparisons 
(21%). In the ‘other technologies’ sample, seven countries considered economic 
evaluation with 73% accounting for cost utility analysis, followed by 45% of a budget 
impact analysis. 
Social value judgments. Social value judgments (SVJs) are increasingly used in 
informing HTA recommendations. Across the selected HTA bodies, only three have 
elicited/revealed their social value judgments in their guidelines: NICE in the context of 
end-of life (EoL) criteria, SMC with the so-called ‘disease modifiers’ and TLV with the 
‘human dignity, needs and solidarity’ principle. Other HTA bodies also account for these 
values, but not in a consistent manner. Considering specific trends across different 
health technologies, the highest number of SVJs was identified in the Pharmaceuticals 
sample (n=304) followed by the medical devices sample (n=67) and the ‘other Technol-
ogies’ sample (n=4). 
Agreement vs. disagreement among HTA bodies in recommendations. In the 
Pharmaceutical sample, the level of agreement in the recommendations across HTA 
bodies varies significantly and is affected by HTA body topic selection processes, leading 
some HTA bodies to not assess all technologies. However, the level of agreement in HTA 
recommendations across HTA bodies that assess all technologies is very high (as 
indicated by the kappa score, k>0.8). This indicates a high level of agreement across 
HTA bodies in recommendations made, i.e. in the same direction of recommendations 
(e.g. accept, accept with criteria, or reject).  
This trend is not confirmed for the medical technologies or the ‘other technologies’ 
samples. The number of assessments of the former is lower and fragmented across the 
sample illustrated by a poor K score (k<0.20). Equally, in the ‘other technologies’ 
sample, the level of agreement is generally poor with 64% of the HTA bodies achieving a 
poor level of agreement (k<0.2) and 36% achieving an agreement between fair 
(0.21<kj<0.4) to very good (0.81<k<1). 
Direction of HTA recommendations. Seventy six percent (76%) of the technologies 
received a positive recommendation with or without restrictions. Breaking down this 
figure: 62% were positive with restrictions whereas the remaining were positive without 
restrictions. Across the sample of Pharmaceuticals and medical technologies this trend 
was confirmed with 81% and 64% respectively receiving a positive recommendation, of 
which 63% and 59% respectively received a positive recommendation with restrictions. 
Across the ‘other technologies’ sample, most recommendations were positive with 
restrictions (66%). 
Clinical restrictions in HTA recommendations. Across the entire sample, the most 
common type of restriction was clinical (56% of all cases). In the Pharmaceutical 
sample, the most common clinical restrictions were related to sub-groups of patients 
(67%) followed by therapeutic pathway restrictions (18%). For Pharmaceuticals and 
medical technologies, common restriction types were specialist prescribing and 
setting restrictions. The first relates to a health technology that can be prescribed only 
by a specialised physician, whereas setting restrictions refer to a condition on the 
location where the treatment can be prescribed or offered. In the medical technolo-
gies sample, the most common clinical restrictions were patient sub-groups 
(67%) followed by therapeutic pathway restrictions (32%). In the ‘other technologies’ 
sample, the most common clinical restrictions were related to a technology-specific 
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feature, i.e. a recommendation made for one technology over another (58%), followed 
by programme design, i.e. a recommendation made regarding various features of the 
programme in order to improve the clinical performance of the entire programme (34%).  
Economic restrictions in HTA recommendations. Economic restrictions were mainly 
present in the Pharmaceuticals sample and based on information that was publicly 
available. Of all economic restrictions, 64% referred to the introduction of a 
risk-sharing or a Managed Entry Agreement in reimbursing the product, and 14% 
requested a further price negotiation. In the medical technologies sample, only five 
economic restrictions were identified with main focus on the use of special price negotia-
tions with the regulatory agency responsible for reimbursement decisions.  
HTA timelines relative to MA. There is often a significant time lag between marketing 
authorisation (MA) and publication of a HTA recommendation. This time lag is not 
uniform and differs by country or HTA body and by type of technology. On average, the 
longest time between MA and HTA recommendation in the Pharmaceutical sample was 
found to be 21.6 months, while the shortest was 9 months. However, it should be 
acknowledged that this difference might be related to factors such as willingness to 
submit a report or delays in HTA submission by the relevant company, the different 
selection criteria in the choice of technologies to assess and the different role of the HTA 
body. In the medical technology sample, looking at the average time lag between the CE 
mark and the submission of an HTA, the timing is much longer, approximately 60 
months, although caution is required due to the scarcity of publicly available data on CE 
mark dates (an indication being the certificates, but these are usually not published). 
Importantly, across HTA bodies, on average the time lag between assessments 
was three years. In the ‘other technologies’ sample and similarly to medical technolo-
gies, there was significant time difference between assessments for the same technology 
across HTA bodies; in the case of colorectal cancer screening, for example, the pro-
gramme was evaluated in 2006 in one jurisdiction and in 2016 again in two other 
jurisdictions. 
Baseline HTA costs based on primary data collection (survey) from manufactur-
ers and HTA bodies. Survey results revealed significant differences between the 
Pharmaceutical and the MedTech industries. For the Pharmaceutical sector, the results 
indicate a high variability in HTA spending (between EUR 73 000 to EUR 1 700 000 per 
HTA submission), and in additional evidence generation (between EUR 50 000 to EUR 20 
000 000). The diversity in the figures reported may reflect the heterogeneity in evidence 
assessment across settings or the different needs for data generation and does not 
provide a definitive picture of average spending across products or manufacturers. 
Although a global value dossier is generated for each product, this is usually the main 
source of input for manufacturer HTA teams and is subject to adaptation based on the 
HTA circumstances prevailing in each setting. HTA submission figures of the MedTech 
industry revealed a range of EUR 1 000 to EUR 3 400 000 while additional evidence 
generation in the context of HTA submission ranged from EUR 17 000 to EUR 12 800 
000. MedTech industry representatives argued that the current number of medical 
device assessments across countries differs considerably. Therefore constructing an 
average based on the above ranges would not be reliable.  
In terms of the composition of the cost components, in both, the Pharmaceutical and 
the MedTech industry, personnel costs (internal and external) were the key expenditure 
drivers. However, focus group discussion showed that another key driver for HTA-related 
costs was (additional) evidence generation. It was mainly in the larger markets that 
companies perform additional evidence generation studies requested by HTA bodies. 
Alternatively, existing knowledge gaps may be covered by post-marketing studies.  
Evidence on Early Dialogue indicates a completely different level of engagement 
between Pharmaceutical and MedTEch industry. The former actively engages in 
early dialogue (69% of responses) with an average cost of EUR 55 750 per case, the 
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latter showing a much lower level of engagement (28% of responses) and a lower level 
of spending (around EUR 21 700) per case. In focus group discussion, MedTech industry 
representatives confirmed that they do not engage routinely in ED for medical devices.  
In terms of the costs reported by HTA bodies, cost differences are highly influenced by 
factors such as the type of HTA process in place, the type of assessment performed and 
the level of integration of HTA bodies with government entities. In general, it appears 
that the cost of performing a Single Technology Assessment (STA) among ‘arms’ length 
bodies’ is higher than among ‘integrated’ structures (the highest reported figure for STA 
was EUR 135 000 for the former vs. EUR 100 000 for the latter), while the maximum 
reported figure for REA was EUR 55 000 for arms’ length bodies and EUR 100 000 for 
integrated structures. However, as the data received in some cases contain missing 
values, these estimates should be interpreted with caution. 
Industry views on HTA processes. Overall, interviews across the Pharmaceutical and 
MedTech industries showed that the different national procedures have different impacts 
on HTA. National methodologies lead to substantial variations in final recommenda-
tions/outcomes showing substantial variation in the way the same product is valued 
across countries. However, it is important to highlight that these differences are also 
influenced by the therapeutic areas of individual products. 
Manufacturers highlighted that the current fragmented HTA system across Europe 
requires companies to cater to a diversified range of demands. Our analysis confirms 
that this might lead to difficulties in submitting reports or multiple re-submissions to the 
same HTA bodies. 
There is consensus across the Pharmaceuticals industry respondents that EU collabora-
tion on HTA may be possible for generating a REA. By contrast, MedTech respondents 
highlighted the heterogeneity and diversity of the medical device/technology market in 
comparison with Pharmaceuticals. MedTech representatives highlighted that HTA 
currently plays a minor role for medical devices and related technologies in most settings 
(due to the extremely fragmented market access of medical devices), and therefore the 
current impact of HTA on their business is low.  
The predictability of the HTA process was agreed to be a key element for investment and 
resource decisions, particularly for smaller companies. It was commonly stated that, the 
harmonization of processes and evidence requirements, would contribute to 
minimize misunderstandings and enhance the level of predictability in the 
system.  
Transparency of evidence requirements, consistency of methods, acceptability of indirect 
comparisons and predictability of outcomes have been highlighted by several companies 
as desirable characteristics. Specifically, interviewees from the Pharmaceutical industry, 
advocated for a better summary and inclusion of information on important issues such as 
indirect comparisons and secondary endpoints and a clear definition of the appropriate 
comparators. By contrast, MedTech interviewees suggested that, while long RCTs may 
be desirable from an evidence standpoint, they may not always be appropriate, feasible 
or sufficient for medical devices and related technologies, advocating for a lighter touch 
approach to HTA in this sector because of its peculiarities, the fact that innovations 
typically come from smaller-sized companies and the innovation cycle is significantly 
shorter compared to Pharmaceuticals. 
Early Dialogue and scientific advice are viewed as extremely useful exercises 
helping to increase transparency from an industry perspective, suggesting that a 
system aligned with what is currently done with EMA would be beneficial and simplify 
development programmes. However, a few respondents stated the importance of not 
introducing a parallel system where countries impose additional requirements. 
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Finally, manufacturers highlighted a number of issues relating to innovation: poor 
predictability, high complexity and high fragmentation constitute barriers to health 
innovation. There is a ‘tension’ between regulators who want to promote accelerated 
access, and reimbursement authorities that are cautious due to evidence uncertainty and 
resource constraints. We understood that harmonisation of evidence require-
ments, if accompanied by MS acceptability, would facilitate investment deci-
sions for technology providers. Additionally, an EU HTA with a solid methodology 
would de-risk the submission process and help eliminate arguments resulting from low-
quality assessments and data misinterpretation. Greater consistency in HTA assessments 
would be very beneficial and could be facilitated by early advice and greater clarity on 
payer expectations. Finally, evidence requirement harmonisation would give the 
EU a stronger influence on clinical trial development. 
Summarising the findings confirmed that there is still heterogeneity in the way health 
technologies are assessed across different countries. However, micro-level analysis 
showed a tendency towards a homogenisation of assessment processes across 
countries. 
Cost prognosis 
The cost prognosis addressed two issues:  
1. The estimate of the costs of voluntary or mandatory joint outputs and related 
savings in national outputs of the proposed POs; and  
2. The costs related to specific organisational structures/implementation 
mechanisms, including common tools. 
An implementation mechanism without EU funding was not considered in this study 
because intergovernmental cooperation without EU input is the sole responsibility of the 
MS. All types of implementation mechanisms include production of HTA outputs by 
different HTA bodies and the support provided to the HTA bodies by the central coordina-
tion unit. The support includes administrative, scientific/technical, legal and IT support, 
which differ in extent for different mechanisms. The main differentiation criteria between 
implementation mechanisms is the establishment of a permanent central coordination 
unit (5 out of 6 mechanisms) compared to the project-based mechanism oriented on 
EUnetHTA structures. 
Besides the central coordination unit, there are three main pillars anticipated for the 
business models: 
• Management Board (defines work programme and consists of MS representatives) 
• HTA output production (contracted to HTA bodies) 
• MS expert committees (comprised of MS experts to review and discuss HTA out-
puts for quality assurance). 
Permanent central coordination units perform project coordination and overall support 
for the respective Work Packages of output production, the Management Board and the 
Committees. The business models combine predictions of joint outputs, organisation-
al/implementation mechanisms, are the basis for further developments and represent 
illustrative scenarios. Other combinations of POs with business models than the ones 
analysed in more detail are possible as well (e.g. a new agency already for PO 4.1). The 
presented combinations are considered the most plausible ones. 
Cost prognosis was based on several sources:  
• Information obtained from the study by Julia Chamova (2) 
• Information provided from EUnetHTA members 
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• Data gathered through the baseline survey 
• An additional follow-up on costs via a short survey distributed by e-mail 
• Focus group input by Public Administrations, the Pharmaceutical Industry and the 
MedTech industry  
• Other sources, e.g. EC Services or Agencies (explicitly stated if applicable) 
Two models were proposed with one distinctive factor: the basic model covers 65 
jointly produced REAs, 40 on Pharmaceuticals and 25 on medical technologies, and the 
advanced model with 115 joint REAS in total, 90 on Pharmaceuticals and 25 on 
medical devices. Assessment of both models included adaptation of implementation 
mechanisms, specifically human resources, according to the anticipated joint output. 
Estimated output production is relevant for the period until structures and processes are 
well-established. After adaptation, i.e. an increase from 65 REAs to 115 REAs (90 on 
Pharmaceuticals, 25 on medical technologies) (9), covering all centrally authorised new 
substances and indications, could be considered. Accordingly, more staff will be needed 
to handle this expanded output production. Therefore, the number of staff would 
increase for POs 4.1, 4.2 and 5 (Table 17 of main study). A sensitivity analysis was 
performed to account for related uncertainties. 
Basic assumptions on the cost elements included a categorization of MS by annual HTA 
output volume or HTA reports mainly produced by HTA bodies or produced by industry 
and reviewed by HTA bodies. Within the majority of countries, HTA bodies produce less 
than 60 HTA reports on Pharmaceuticals and less than 50 HTA reports on medical 
devices. The majority of HTA reports are industry-based and reviewed by HTA bodies.  
Regarding the implementation mechanisms, personnel costs and costs resulting from MS 
expert committees account for the majority of expected costs. Estimates of personnel 
costs were based on EU staff regulations, indexed to MS if applicable, and EC expert 
fees. Overall estimates on implementation mechanisms increase by twofold from PO2 to 
PO5. Moreover, costs for the basic model and the advanced model differ significantly for 
PO4.1, PO4.2 and PO5 due to increased output production. 
Calculations also show that, taking the underlying assumptions into account, especially 
with PO 4.1, 4.2 and 5 – i.e. the more ‘legislative’ and mandatory options – overall 
savings at EU level for MS and the industry sector can be expected, and that 
savings rise with each successive POs. However, several additional factors that cannot 
reliably be quantified, but which may have an impact on overall costs/savings and may 
reverse or diminish some of the results, have to be considered additionally. Examples 
are costs related to implementing the mandatory uptake of joint output within national 
procedures, laws and regulations but on the other hand also potential additional savings 
related to a reduced number of national ED or reduction in additional evidence genera-
tion requested by HTA bodies. 
Concluding, calculations show on the one hand, a significant increase in costs for 
establishing a new framework from PO2 to PO5, but on the other hand a potential 
savings increase from PO2 to PO5. 
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Overall assessment of POs 
We investigated, guided by the Better Regulation Guidelines (5), a number of impacts in 
order to establish a comprehensive picture of how the different POs and business models 
would affect different stakeholder groups.  
The analysis of impacts focused on three main stakeholder groups, i.e. Public Admin-
istration, Pharmaceutical Industry and MedTech Industry, as these provided the 
most input. We also analysed the impact on patient groups and health professionals, 
whenever information was available (10).  
An overview of the results per stakeholder group for each impact category, from 
Economic Criteria (EC) to Social and Health Impacts (SH), are described in detail in 
chapter 7.3 of the study. In sum, the survey results and the focus group discussion 
showed that the perceived effects of the POs as well as the perceptions and expecta-
tions regarding the future cooperation on HTA in Europe differ between the 
stakeholder groups in a number of ways. 
Information collected indicates that Public Administration does not expect any 
major effects with regard to HTA-related processes for PO1 and PO2. But, with 
POs covering a legislative framework (PO3-PO5), positive effects are expected by Public 
Administration, which are amplified with each output that is covered by the legislative 
framework. This is confirmed by our assessment as POs with a legislative framework 
(PO3 to PO5) are more likely to positively influence the sustainability of health 
systems than further non-binding cooperation.  
This increase in positive effects with stronger requirements and central governance 
relates to the expectation that the uptake of joint outputs will increase with each of 
these subsequent POs. Stricter regulation could be a key element for sustainable, 
successful collaboration, since otherwise the impact of the cooperation is 
limited. Moreover, it was expected that the number of evidence-based assess-
ments available for decision-making can be increased with joint outputs because 
potentially more health technologies can be covered due to the fact that single HTA 
bodies might not have the capacity to assess the same numbers per year. Countries 
with less mature HTA processes and countries with a low number of profes-
sionals working in HTA might especially benefit from joint outputs, in particular 
from joint REAs.  
None of the POs is considered to have a substantial effect on the administrative 
burden of Public Administrations across EU MS and no or only little effect on costs 
for HTA-related outputs were indicated in the online survey. This relates to the fact that 
national processes will still remain in some form. However, some HTA bodies voiced the 
expectation that indeed a closer collaboration would reduce their cost. This is confirmed 
by our cost calculations, which indicate potential savings across MS, especially from 
PO4.1 onwards. 
For the Pharmaceutical Industry, results indicate no changes for PO1 and PO2 while 
positive effects of POs including joint work on REA at EU level, namely PO3 and 
PO4, are stated. These POs are estimated to reduce inefficiencies and workload for the 
Pharmaceutical sector, improving the functionality of the internal market. Moreover, an 
increase in predictability of HTA processes and requirements is expected by the Pharma-
ceutical Industry, which was highlighted to be a very important factor for research and 
investment decisions. 
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The Pharmaceutical Industry expects negative effects for PO5, which includes a 
strictly mandatory and binding HTA process also covering Full HTA in Europe. Underlying 
reasons for this were indicated during the interviews as well as in comments to the 
survey and in the focus group with Pharmaceutical company representatives: mandatory 
joint economic evaluations as foreseen in PO 5 are perceived as an unrealistic scenario 
due to country specificities with regard to economic requirements and the fact that 
pricing and reimbursement decisions remain at national level. Instead, joint work on 
REA was repeatedly indicated to have the potential to reduce inefficiencies and 
workload for the Pharmaceutical sector. 
With regard to costs for HTA processes, respondents from the Pharmaceutical sector 
expect no major changes with the exception of PO5, where a substantial cost increase is 
feared. Based on focus group discussions this relates to the fact that possible increases 
and decreases of cost components would level each other out, meaning that costs on MS 
level might decreases while at the same time costs on EU level increases.  
Still, the results of our cost prognosis for 2020+ indicate that actual savings due to a 
reduction in duplicated assessments can be achieved for the Pharmaceutical 
Industry across the EU for all POs. Potential savings are considerably higher in POs that 
comprise both a mandatory production and mandatory uptake of joint REAs (PO4.2 and 
PO5). Options comprising a permanent secretariat and higher joint output lead to 
substantially larger savings as compared to the project-based cooperation (EUR 3.7 
million in PO2 versus more than EUR 60 million in PO4.2). 
For MedTech, our analysis yielded a different picture: MedTech industry represent-
atives indicated a negative effect for all POs except for PO 2. This negative assessment is 
related to the peculiarity of the medical devices market. Whereas Pharmaceutical 
products have a well-established pathway from Marketing Authorization to HTA evalua-
tion and an established HTA process in a large number of EU MS, MedTech companies 
follow heterogeneous rules or processes regarding the evaluation of their products. 
Moreover, the market for medical devices is intrinsically different from that of Pharma-
ceuticals with a higher level of competition from market entry onwards. While HTA has 
been largely developed for Pharmaceuticals, there appears to be a need for adaptation 
and development of established HTA processes for the MedTech sector as well.  
The negative assessment of POs covering a legislative framework links to the 
expectation of MedTech industry that this will function as a driver for an upsurge of HTA 
activities in MS. This point was perceived as a very important element of unpredictable 
change and additional burden for the MedTech industry, as HTA activities have not 
played a major role in the medical technologies’ market access path until now. Related 
uncertainty was seen to subsequently influence the attractiveness of the European 
market and potential delays in first revenues are feared due to the likelihood of longer 
processes. Another key impact is the expected decrease in competitiveness and innova-
tion. According to focus group discussions and the interviews, this is due to the per-
ceived unpredictable change in the market access path of medical technologies, also 
attributed to the two new EU Regulations on medical devices. Potential new administra-
tive barriers, which are typically the most burdensome for the first movers (innovators) 
are thus expected. A further important aspect is the expected increase in costs, driven 
by additional evidence generation. Study findings indicate that this impact seems to be 
overestimated by the MedTech industry. One identified reason for this is that the actual 
level of experience with HTA for the respondents from this sector is considerably lower 
than for the respondents from the Pharmaceutical Industry.  
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Our cost calculations did not confirm the expectation of cost increase for 
MedTech industry. On the contrary, findings indicate that the MedTech industry might 
also benefit from the ‘tighter’ POs under consideration when it comes to costs (aggregat-
ed across Europe). Potential savings are especially noticeable for POs with a legislative 
framework (PO4.1, 4.2 and 5).  
In summary, POs with a legislative framework entail some negative effects for the 
MedTech industry in the sense of additional burden (from their perspective), especially if 
joint REAs are covered. However, for PO3 only a slight negative effect is expected and in 
the long-run, the development of joint common tools and templates could lead to clearer 
HTA requirements, which may subsequently facilitate HTA processes for MedTech 
industry.  
Finally, patient groups call for improved transparency in this field, which is considered to 
strengthen the quality and safety of technology. Strengthening HTA of Medical Technolo-
gies inherits potential positive effects for patients because better evidence for decision-
making is available. Ultimately, therefore, we expect positive effects regarding the safety 
of medical devices. 
The following table gives a concise overview of the potential effects of the POs – 
aggregated across all investigated impacts – for each stakeholder group. Green colours 
indicate positive and red colours negative perceptions based on the judgment of the 
study team, considering all collected evidence and information regarding the different 
stakeholder groups and combining all retrieved information. 
Table 2: Conclusion - Effect of Policy Options 
Stakeholder 
group 
Baseline 
scenario 
(PO1) 
Project-
based co-
operation 
(PO 2) 
MS/EU 
secretariat 
(PO 3) 
Existing EU 
agency 
(PO4.1) 
Existing EU 
agency 
(PO 4.2) 
New EU 
agency 
(PO 5) 
Public Admin-
istration 
      
Pharma       
MedTech       
Overall, the perceived effects of the POs and the perceptions and expectations regarding 
the future cooperation on HTA in Europe differ between the stakeholder groups in a 
number of ways. 
For Public Administration, POs providing a legislative framework for HTA cooperation 
in Europe (PO3 onwards) will potentially have a positive effect, gradually increasing as 
we move along the PO range. The predictability of the HTA system in Europe is expected 
to considerably increase for PO3 and the positive effect is amplified with each of the 
subsequent Policy Options. 
For the Pharmaceutical Industry POs with mandatory uptake of joint REAs will have a 
positive effect, while PO5 is considered as unrealistic by representatives of the industry. 
While this position could be endorsed in general by the study team, our analysis shows 
also cost savings for PO5 in the long run. 
For the MedTech Industry, a voluntary project-based cooperation (PO2) is favoured, 
since this will not entail a legislative framework which is perceived as additional 
burden for the industry with negative effects. This relates to the fact that HTA is 
not as common and related methods are not as developed for the MedTech sector as 
compared to the Pharmaceutical sector.  
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Based on our analysis, a successful and sustainable future HTA system at EU level needs 
to respect the peculiarities of the MedTech industry. One solution might be that the same 
PO and business model(s) shall not apply to both sectors. A starting point for the 
MedTech sector could be the development and mandatory use of common tools 
because further development of methods will help provide a clearer picture of 
requirements related to HTA processes. Moreover, the voluntary conduct of joint 
REA could be envisaged simultaneously, as this could provide significant input for 
decision-making across the EU. This would also contribute to (a) the reduction of a 
divergent evidence base across EU MS for medical technologies and (b) public health and 
patient safety.  
Key findings 
●  Overall, the vast majority of clinical evidence considered by HTA bodies in the case of 
Pharmaceuticals comes from phase III clinical trials and less so from phase II trials. 
The latter are increasingly used in those cases where the production of evidence from 
phase III trials is challenging, or in those circumstances where the likely clinical 
benefit is considered significant and the treatment would merit conditional marketing 
authorisation (CMA). Only a fraction of the clinical evidence is considered related to 
other types of clinical evidence (extension trials or observational studies). It is thus 
reasonable to suggest that there is a fair amount of duplication taking place as 
the evidence considered across settings is by and large the same. 
 There is a clear difference in the preferences of HTA bodies for the type of evidence 
required for Pharmaceuticals compared with medical devices/technologies and ‘other 
technologies’; this is partly driven by what is feasible in the context of either medical 
devices or ‘other technologies’ and is highlighted by the high proportion of retrospec-
tive studies and safety studies (in the medical devices sample) and literature reviews 
(in the ‘other technologies’ sample).  
 In terms of economic evidence, although there are both similarities and differences 
across MS in terms of preferences in approach, modelling or models, one issue worth 
noting was that across MS, and for those MS pursuing economic evaluation, in 68% 
of all cases, the comparator was the same across HTA bodies. 
 From an industry perspective, harmonisation of evidence requirements, if accompa-
nied by MS acceptability, would facilitate easier investment decisions. Additionally, an 
EU HTA with a solid methodology would de-risk the submission process and help 
eliminate arguments resulting from low-quality assessments and data misinterpreta-
tion. Greater consistency in HTA assessments would be beneficial, and could be facili-
tated by early advice and greater clarity on payer expectations. Finally, harmonisation 
of evidence requirements would give the EU a stronger influence on clinical trial de-
velopment. 
 The Pharmaceutical Industry is in favour of options covering mandatory 
uptake of joint REAs. Due to the currently fragmented HTA systems, they will bene-
fit from a reduction in submissions and better predictability across the EU. It might be 
necessary to relocate staff to a central level, but the number of staff is expected to 
remain stable.  
 Both the MedTech and the Pharmaceutical Industry perceive Full HTA at EU 
level as not meaningful, despite cost estimates showing that industry in 
general could benefit from additional savings compared to REA only. That, 
however, very much depends on the nature of topics that are chosen for coverage 
under Full HTA. Experience with Full HTA at EU level so far is limited. The additional 
domains of Full HTA (economic, organizational, legal, ethical and social aspects) tend 
to contain many ‘non-transferable’ issues; to that end, they need to be substantially 
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adapted at national level. These points may explain in part the perceived scepticism 
on the industry side.  
 The MedTech industry sees the most challenges when introducing a legisla-
tive framework for future cooperation in HTA at EU level. Currently, the 
MedTech industry faces lower regulations regarding market access for their products 
due to the significant heterogeneity of products, pointing out the great fragmentation 
within the sector. Two recently established regulations on medical devices at EU level 
aim to better govern the heterogeneous market. Because the MedTech industry has 
little experience with HTA processes, they expect a massive burden on procedures 
and processes and slower market access for their products. 
 Synergies for Public Administration can be expected since potentially more 
assessments will be available for decision-making. One HTA body might not 
have the capacity to conduct all assessments decision-makers would need in their 
country. Additionally, with potential future growth in patient mobility in Europe, as 
addressed by the Cross-Border Healthcare Directive, it can be seen as advisable to 
base decision-making on the same evidence.  
 General success factors identified for sustainable joint cooperation include 
(1) the use of common tools and templates, (2) business models with 
stronger governance structures (3) timely assessment processes (4) cross-
country expertise and inputs and (5) mandatory national uptake of joint 
outputs (11), all of which are inter-related. The latter applies in the Pharmaceuti-
cal sector only. Using common tools and templates facilitates joint work while suffi-
cient institutional capacity and strong governance form the basis to provide timely 
assessment processes. Timely assessment is important to ensure that uptake can 
occur at a time when the results are relevant in national settings. Adequate expert 
input is needed to ensure the quality of assessments performed, thus increasing 
efficiency of process for all stakeholder groups. Finally, mandatory uptake of results is 
important and ensures that the purpose of joint work is met. These factors will be 
relevant for setting up future cooperation on HTA, although the peculiarities of the 
MedTech sector may need to be taken into account and success factors may be more 
relevant for HTA in Pharmaceuticals. 
 Legislative cooperation can create institutional capacity for HTA cooperation 
and expertise can be better streamlined. Our study findings suggest that pro-
cesses can be set up more efficiently when they are coordinated and facilitated by one 
permanent institution, since all relevant information is centralised, expertise can be 
streamlined and overall savings can materialise.  
 Potential savings are considerably higher in POs that comprise both a 
mandatory production and mandatory uptake of joint REAs and Joint HTA 
(PO4.2 and PO5). Options comprising a permanent secretariat or a new Agency, 
which is linked to higher joint output, lead to substantially higher savings in the long 
run as compared to project-based cooperation (in total nearly EUR 4 million across all 
countries in PO2 versus around EUR 70 million with PO4.2 and EUR 77 million with 
PO5). Regarding the results of the cost prognosis, there are uncertainties in data 
collection, as is clearly outlined in the corresponding sectors of our study.  
                                                                                                                                   
 
(11) Up-take concerns using or considering the results and findings of the HTA cooperation, reaching from jointly developed 
submission templates to outcomes in full HTA. The subsequent pricing and reimbursement decision remains purely on 
national level.  
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 Improved sustainability and a mandatory nature to HTA cooperation in 
Europe potentially leads to benefits for patients. An increase in the number of 
health technologies assessed will increase the evidence-base for decision-making 
across the EU, especially in MS where HTA is not well-developed, thus also contrib-
uting to a decrease in cross-country inequalities.  
 From a patient perspective, future EU cooperation in HTA POs with mandatory 
participation and uptake will increase availability of safe and effective Pharma-
ceuticals and medical technologies and ensure standardised monitoring of 
health technologies prior to market access. Transparent and independent HTA 
processes require consideration of all relevant stakeholder perspectives to increase 
efficiency and prevent conflict of interest. Sufficient financial resources are vital to 
establish a respective mechanism. Besides required investments, stakeholders should 
draw their attention to the potential return on investment different mechanisms offer. 
 Previous patient involvement in HTA processes is characterised by good intentions on 
the part of involved stakeholder groups, but successful implementation was limited so 
far by either the extent or the role of involvement. There are clear signals both from 
Public Administration and the Pharmaceutical Industry to improve and standardise 
patient involvement in HTA processes. Stronger governance regarding HTA 
assessment might positively influence patient involvement. Overall, sustaina-
ble and transparent long-term cooperation in the field of HTA offers the potential to 
prevent selective assessment of Pharmaceuticals, reduce availability of health tech-
nologies with little or no added value and improve the accessibility of publicly availa-
ble information. 
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Sommaire 
Contexte 
Les États membres (EM) et l'Union européenne (UE) ont saisi l'importance croissante des 
systèmes d'évaluation des technologies de santé (ETS) dans les processus de prise de 
décision et d'élaboration de politiques depuis quelque temps maintenant. L'ETS est 
unanimement reconnu comme un outil précieux, qui peut contribuer à la durabilité des 
systèmes de santé nationaux. Pourtant, la production de résultats d'ETS (notamment les 
Dialogues préliminaires, Évaluations de l'efficacité relative (EER) et Rapports définitifs sur 
l'ETS avec évaluation économique) reste du moins éparse et diverse en Europe, car les 
systèmes d'ETS sont partiellement fragmentés dans l'Union.  
La coopération sur l'ETS à l'échelle européenne a commencé en 2009, avec la création du 
Réseau européen pour l'évaluation des technologies de la santé (EUnetHTA). Deux 
actions communes (AC) ont été lancées; la première en 2010–2012 (EUnetHTA  JA 1), et 
la seconde en 2012–2015 (EUnetHTA  JA 2). Une troisième action commune (EUnetH-
TA  JA 3) a démarré en juin 2016 avec pour objectif général d'accroître l'utilisation, la 
qualité et l'efficacité des travaux communs sur l'ETS à l'échelle européenne, afin de 
permettre des choix durables, équitables et fondés sur des faits dans les domaines des 
soins et technologies de santé, mais également pour garantir une réutilisation des 
rapports et activités nationales ou régionales relatives à l'ETS.  
Dans ce contexte, nous aborderons la question d'une coopération durable après 2020, 
lorsque l'action commune EUnetHTA actuelle aura pris fin, en accord avec l'agenda 
« Mieux légiférer » de la Commission européenne (CE) visant l'élaboration et l'évaluation 
de politiques européennes de manière transparente, en prenant en compte à la fois les 
faits et le point de vue des acteurs concernés. 
La CE a déployé une initiative d'évaluation d'impact (12) afin d'identifier et de mesurer 
diverses options politiques (OP) concernant la poursuite de la coopération sur l'ETS à 
l'échelle européenne après 2020.  
Motif et objectif de l'étude  
L'objectif général de cette étude est de soutenir les processus d'évaluation d'impact de la 
CE, notamment par l'apport de données et de preuves pertinentes. Elle fournit également 
des informations pour l'analyse de l'impact de différentes OP relatives à la coopération 
sur l'ETS à l'échelle européenne après 2020, et met à profit les données recueillies pour 
mener une évaluation de l'effet des différentes OP. Ainsi, les objectifs spécifiques de 
l’étude sont: 
• Recueillir des données, apporter des preuves et fournir une analyse approfondie 
des événements qui pourraient survenir en l'absence d'action prolongée à l'échelle 
européenne et des conséquences afférentes (scénario de base); 
• Recueillir des données, apporter des preuves et fournir une analyse sur l'impact 
potentiel des OP identifiées pour la coopération avec la CE; 
• Rassembler les documents pertinents sur l'ETS, avec une attention particulière 
pour l'Union européenne, afin de comprendre leur mode de fonctionnement dans 
les EM de l'UE. 
                                                                                                                                    
 
(12) https://ec.europa.eu/health/technology_assessment/consultations/cooperation_hta_en  
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Bien que l'ETS fournisse des informations qui permettent de déterminer les pratiques de 
tarification et de remboursement dans certains pays, l'étude se concentre sur l'évaluation 
de toutes les OP, ainsi que des décisions en matière de tarification et de remboursement 
liées aux technologies médicales, pour déterminer si les dispositifs ou produits Pharma-
ceutiques relèvent de la compétence de chaque État membre.  
Cette étude a été réalisée par un consortium composé de Gesundheit Österreich 
Forschungs- und Planungsgesellschaft (Autriche), de l'université London School of 
Economics - LSE Health (Royaume-Uni) and de SOGETI (Luxembourg). 
Options politiques pour l'évaluation de l'impact: caractéristiques et contexte 
analytique 
La CE a proposé des OP pour la poursuite de la coopération sur l'évaluation de l'impact  à 
l'échelle européenne, que les auteurs ont combinées avec de potentiels modèles de 
gestion.  
Les OP sont définies selon différentes caractéristiques clés allant au-delà du scénario de 
base (« aucune action supplémentaire à l'échelle européenne »), comprenant (a) des 
résultats d'ETS devant être traités par l'action commune, (b) la nature proposée de la 
coopération, (c) différents modèles de gouvernance et (d) plusieurs options de finance-
ment pour l'initiative d'action commune. 
● Les résultats d'ETS devant être traités par l'action commune comprennent les 
éléments suivants: 
• Procédures et outils uniformes tels qu'un modèle de présentation de référence, un 
système informatique avec des évaluations planifiées et en temps réel, des métho-
dologies communes (par exemple, EUnetHTA  Core Model), un processus de défini-
tion des priorités commun et une coopération sur les exigences en matière de 
données, y compris l'exploration de l'horizon. 
• Dialogues préliminaires 
• Évaluations de l'efficacité relative 
• Évaluations communes des technologies de santé  
 
● Nature proposée de la coopération entre les États membres  
Les OP diffèrent selon la nature de la coopération, comme cela se reflète dans le type 
de participation (volontaire ou obligatoire) et/ou d'assimilation des résultats communs 
(volontaire ou obligatoire):  
• Participation volontaire et assimilation volontaire (V/V): La coopération se déroule 
sur une base volontaire, et les EM peuvent décider de participer à la production 
des résultats respectifs, ainsi que de les assimiler, ou pas.  
• Participation volontaire et assimilation obligatoire (V/O): La participation à la créa-
tion de travaux communs est volontaire, aussi les EM peuvent décider de prendre 
part (13) à l'action commune ou non. Cependant, une fois qu'un État membre s'est 
engagé dans une initiative commune, l'assimilation des travaux à l'échelle natio-
nale est obligatoire. 
                                                                                                                                    
 
(13) http://ec.europa.eu/smart-regulation/roadmaps/docs/2016_sante_144_health_technology_assessments_en.pdf 
Étude sur l'analyse d'impact des options politiques pour renforcer la coopération de l'UE sur l’évaluation  
des technologies de santé (ETS) 
 
 
 43 
• Participation obligatoire et assimilation obligatoire (O/O): Les EM ont l'obligation de 
participer à la production de résultats et d'assimiler ces derniers dans le contexte 
national 
● Modèles de gouvernance pour la coopération européenne 
L'étude a examiné une variété de modèles de gouvernance pour la coopération euro-
péenne, allant d'une coopération flexible fondée sur des projets à la création d'un 
secrétariat permanent au sein d'une agence européenne, comme présenté ci-dessous.  
• Coopération sur base de projets (OP 2)  
• Secrétariat permanent hébergé par un État membre (OP 3)  
• Secrétariat permanent hébergé par la CE (OP 4.1)  
• Secrétariat permanent hébergé par une agence européenne existante (OP 4.2) 
• Secrétariat permanent hébergé par une nouvelle agence européenne (OP 5) 
De manière générale, nous avons supposé que les travaux scientifiques et les expertises 
(c.-à-d. les développements de résultats communs) resteraient au sein des agences 
nationales. En ce qui concerne les modèles de gouvernance composés d'un secrétariat 
permanent, la création d'un ou de plusieurs Comités serait nécessaire. Dans tous les 
types de coopération se retrouvent des éléments communs à la structure de gouver-
nance, qui sont définis par les résultats communs. 
 
● Options de financement pour la coopération européenne 
Plusieurs sources de financement de l'action commune sont envisageables, mais n'ont 
pas été étudiées en détail dans l'étude: 
• Financement européen, soit par un programme de santé publique soit par un autre 
instrument financier 
• Financement par les États membres prenant part à la coopération 
• Financement par les taxes imposées aux industries 
Le tableau suivant présente un aperçu de chaque option politique, avec l'étendue de 
résultats couverte, le type de participation à l'action commune et les mécanismes de 
mise en œuvre/financement envisagés.  
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Tableau 3: Aperçu des options politiques 
OP: option politique; V/V: participation volontaire/assimilation volontaire; V/O /: participation volontaire/assimilation obligatoire; O/O: participation obligatoire/assimilation obligatoire; DP: dialogue préliminaire; EER: évalua-
tion de l'efficacité relative; EM: États membres; ETS: évaluation des technologies de santé 
                                                                                                                                                                                                              
 
(14) À supposer que 50% des États membres participent à l'action, un mélange de revenus élevés/faibles et de grands/petits États membres.  
(15) DP: dialogue préliminaire Dans ce cas, l'assimilation obligatoire implique l'impossibilité pour les États membres de répéter un dialogue préliminaire qui s'est déroulé à l'échelle nationale. Les fournisseurs de 
technologie lancent les dialogues préliminaires. 
(16) Soit au moment de la commercialisation soit à la réévaluation 
(17) Une introduction progressive des produits au cours d'une période de transition qui permet de gérer la charge de travail pendant que les structures/les modèles de mise en œuvre sont développés. 
 Scénario de base Non législatif Législatif 
 
OP 1 OP 2 OP 3 OP 414 OP 5 
Aucune action 
européenne après 
2020 
Coopération 
volontaire à 
travers le 
programme de 
santé publique 
Législation visant les 
outils communs et les 
dialogues prélimi-
naires 
Législation visant les travaux communs sur l'EER 
ainsi que les outils communs et les dialogues 
préliminaires 
Législation visant les 
travaux communs sur 
l'ETS (comprenant une 
EER) ainsi que les outils 
communs et les 
dialogues préliminaires 
4.1 
EER V/O 
4.2 
EER O/O 
R
é
su
lt
a
ts
 
Outils communs, y 
compris modèles et 
méthodologie 
V/V V/O O/O O/O O/O O/O 
Dialogue 
 préliminaire(15) 
V/V V/O V/O V/O O/O O/O 
EER commune(16) V/V V/O V/V V/O O/O O/O 
ETS commune 
complète(6) 
V/V V/V V/V V/V V/V V/O 
Mise en œuvre 
Aucune participation 
de l'UE 
Coopération 
fondée sur des 
projets 
Secrétariat UE/EM 
Agence européenne 
existante 
Agence européenne 
existante 
Nouvelle agence 
européenne 
Financement Aucun de l'UE UE + EM UE + EM + taxes sur les industries pour les dialogues préliminaires, l'EER commune et l'ETS complète 
Portée  
Tous les 
médicaments, 
technologies 
médicales et 
autres dispositifs 
Outils: tous les 
médicaments, autres 
technologies 
(introduction 
progressive), DP: 
présentation à 
l'industrie 
Outils et DP, voir OP 3. EER: certaines catégories de 
médicaments (par exemple, médicaments autorisés 
par procédure centralisée, fort impact sur la valeur/le 
budget, accord entre EM), certaines catégories de 
technologies médicales (par exemple, produits à haut 
risque et haute valeur) et d'autres systèmes (accord et 
définition des priorités entre EM) – introduction 
progressive (17) 
Outils et DP, voir OP 3; 
EER, voir OP 4 Pour les 
autres: accord ad hoc et 
définition des priorités 
entre EM 
Étude sur l'analyse d'impact des options politiques pour renforcer la coopération de l'UE sur l’évaluation des technolo-
gies de santé (ETS) 
 
 
 45 
Méthodes 
Approche générale 
Afin d'établir le scénario de base, nous avons mené une étude de cas sur des échantil-
lons de produits de technologie de santé, dont 20 produits Pharmaceutiques, 
15 dispositifs médicaux et 5 « autres technologies » (notamment des interventions 
complexes). L'équipe de l'étude a recueilli des informations détaillées sur les processus 
d'ETS auxquels chaque technologie a été soumise dans les EM. En outre, elle a détermi-
né les coûts de la réalisation d'une ETS pour les deux parties concernées, les dévelop-
peurs de technologies et les organismes d'ETS. Enfin, l'étude a permis de saisir 
l'influence des cadres réglementaires sur les développeurs de technologies.  
Afin d'analyser l'impact des OP de la CE, l'équipe a également réalisé une enquête sur 
les effets économiques et sociaux des OP identifiées, soutenue par des groupes de 
discussion, un certain nombre d’entrevues et des conclusions sur de la documentation. 
L'étude visait les effets suivants, pour lesquels nous avons défini un ou plusieurs 
indicateurs: 
Les effets étudiés comprenaient des critères économiques (CE) et de santé sociale (SS): 
CE1 coûts SS1 emploi 
CE2 charge administrative SS2 gouvernance, participation et bonne 
administration 
CE3 compétitivité du secteur européen des 
technologies de santé 
SS3 accès aux systèmes de protection 
sociale et de santé 
CE4 innovation et recherche SS4 durabilité des systèmes de santé 
CE5 innovation et recherche dans le commerce 
international 
SS5 santé publique 
CE6 fonctionnement du marché interne et de la 
concurrence 
  
CE7 consommateurs et ménages   
CE8 environnement macroéconomique   
L'étude fournit également une description des mécanismes de mise en œuvre (notam-
ment un secrétariat commun) et une estimation des coûts afférents. 
 
Recueil de données 
Afin de rassembler une large base de données pour l'analyse du scénario de base et de 
l'impact potentiel des OP de la CE identifiées, l'équipe a employé différentes méthodes 
de recueil des données, comme le montre l'image 1 sur la page suivante.  
Nous avons réalisé une recherche documentaire systématique afin d'identifier les 
textes pertinents, qui nous ont permis d'établir le contexte, de vérifier et de compléter 
les résultats des études de cas et de l'enquête. Le but était de fournir un aperçu du 
statu quo et de l'impact des systèmes d'ETS dans les EM de l'UE. 
L'équipe a mené une enquête en ligne visant les administrations publiques (comme les 
organismes d'ETS), l'industrie Pharmaceutique et des technologies médicales, ainsi que 
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les patients et les professionnels de santé, ce qui a engendré des réponses principale-
ment des administrations publiques et des industries.  
L'étude de cas, couvrant 40 technologies de santé (20 produits Pharmaceutiques, 
15 dispositifs médicaux et 5 « autres technologies »), a systématiquement tenté de 
saisir et de décrire les éléments composant le statu quo de l'ETS dans les EM de l'UE, en 
adoptant une approche analytique multiniveau qualitative et quantitative.  
Schéma 2: Aperçu des flux d'activité 
Les travaux supplémentaires de recueil de données et de validation des résultats 
comprenaient:  
• des entrevues avec des représentants de l'industrie (produits Pharmaceutiques et 
dispositifs médicaux) et des patients; 
• de courtes enquêtes et questions complémentaires destinées à recueillir davan-
tage de données sur les coûts et d'informations utiles à l'interprétation des résul-
tats;  
• l'utilisation des résultats dans une étude  supplémentaire de la CE2 menée en 
parallèle; 
• des réunions de groupes de discussion rassemblant des acteurs des administra-
tions publiques et des secteurs industriels (Pharmaceutiques et dispositifs médi-
caux) afin de débattre des résultats de l'enquête en ligne et mettre en commun 
les suggestions et commentaires de chacun; 
• l'implication d'un groupe d'experts mis en place pour la durée de l’étude; et  
• un examen par des pairs avec des experts leaders dans le secteur.  
  
Recherches docu-
mentaires systéma-
tiques et approfon-
dies 
Objectif Objectif 
Analyse documentaire 
Étude de cas 
Processus d'enquête Couvrant 
40 technologies de santé 
(produits Pharmaceu-
tiques, dispositifs 
médicaux et autres) 
enquête en ligne (en 
2 parties) et interviews 
 
Fournir un aperçu des 
documents sur l'impact 
et le statu quo des 
systèmes d'ETS 
européens 
Mesurer et définir 
systématiquement les 
éléments composant le 
statu quo des systèmes 
d'ETS dans les États 
membres de l'UE 
 Répertorier les coûts des 
processus actuels d'ETS européens 
 Évaluer les effets des poli-
tiques/modèles commerciaux 
proposés 
 Mesurer l'influence des processus 
d'ETS européens dans l'industrie 
européenne 
 
 
 
Objectif 
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Limites de l'étude  
L'étude s'est vue imposer différentes limites, dont la plupart sont liées aux hypothèses 
qui ont été avancées ou qui devaient l'être (par exemple, sur le futur montant de 
production commune ou coûts informatiques). En outre, aucune donnée sur des élé-
ments simples, tel que le nombre actuel de discussions préliminaires en Europe, n'était 
facilement accessible, ou la granularité des informations disponibles différait significati-
vement d'un État membre et d'un organisme d'ETS à l'autre. L'estimation des coûts doit 
notamment être appréhendée avec précaution, considérant tous les défis et limitations 
décrits en détail dans le rapport. 
Les informations de base sur le secteur des technologies médicales et des autres 
technologies étaient parfois éparses comparé à l'industrie Pharmaceutique, notamment 
en raison du manque d'expérience du secteur technologique avec l'ETS. 
L'enquête sur les acteurs a rencontré deux problèmes notables: un faible niveau de 
réponse de la part des patients et professionnels de santé, car ils se sentaient moins 
affectés par la concertation publique qui se déroulait en parallèle; et le niveau de détail 
des questions, car l'équipe de l'étude devait analyser de nombreux effets potentiels d'un 
certain nombre d'OP, comme le veulent les lignes directrices européennes sur le pro-
gramme « Mieux légiférer »26. Par conséquent, l'étude n'a pas pu couvrir tous les EM de 
l'UE, mais a rassemblé des réponses de toutes les régions d'Europe y compris de pays 
dotés de systèmes d'ETS solidement intégrés comme d'autres avec des systèmes moins 
assimilés. 
Analyse 
Étude de cas: analyse du scénario de base 
Nous avons analysé et comparé un échantillon de 40 technologies de santé pour 
déterminer les éléments clés qui composent les estimations de valeur de ces technolo-
gies dans les différents pays européens. Bien que le but principal de l’étude fût d’obtenir 
des évaluations, étant donné l’hétérogénéité des rôles de l’ETS entre les pays, certaines 
estimations ont également été enregistrées. Nous avons ainsi pu identifier les décisions 
d'ETS définitives, les restrictions mises en place afin d'inclure et de suggérer l'inclusion 
d'un produit spécifique dans le catalogue de bénéfices de chaque pays, et la façon dont 
ces processus, et leur durée, différaient ou s'alignaient dans les différents contextes. 
Ainsi, l'analyse systématique a permis d'identifier: (a) la présence d'évaluation et la 
décision finale rendue par l'organisme d'ETS, en rassemblant les cas de répétition; (b) 
l'utilisation actuelle de l'ETS dans les différents contextes, ainsi que les informations 
cliniques et économiques utilisées au cours de l'évaluation; (c) le délai de mise en œuvre 
des processus dans différents contextes nationaux; (d) les coûts liés aux processus 
d'ETS; et (e) les perspectives de l'industrie et des organismes d'ETS sur les méthodes et 
procédées.  
Cette approche systématique permettrait de comprendre la variabilité des méthodes 
et processus actuellement utilisés par les différents organismes d'ETS en UE, 
ainsi que d'identifier les répétitions possibles des efforts ou situations où un 
consensus plus large pourrait être nécessaire autour des procédures et mé-
thodes d'ETS. Il serait aussi plus aisé de déterminer les domaines où l'uniformité et la 
transparence des critères utilisés pour la prise de décision pourraient être 
améliorées. 
Par l'analyse systématique des recommandations d'ETS dans les différents EM pour les 
40 technologies identifiées et la synthèse des preuves réunies, nous avons identifié un 
certain nombre de paramètres: (a) ETS sur l'échantillon de technologies; (b) soumis-
sions des preuves cliniques et économiques; (c) jugements de valeurs sociales; (d) 
accords/désaccords sur les recommandations entre organismes d'ETS, malgré l'utilisation 
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de statistiques kappa; (e) orientation des recommandations d'ETS; (f) restrictions 
cliniques aux recommandations d'ETS; (g) restrictions économiques aux recommanda-
tions d'ETS; (h) délais d'ETS relatifs à l'autorisation de mise sur le marché; (i) prévision 
de base des coûts d'ETS fondée sur le recueil de données initial (enquête) visant les 
fabricants et les organismes d'ETS; et (j) perspective de l'industrie sur les processus 
d'ETS. 
En raison de la nature incomplète ou de la faible qualité des preuves cliniques et 
économiques, les responsables doivent émettre des jugements fondés sur un faible de 
taux de certitude ou accepter des rapports coûts-efficacité différentiels qui sont au-
dessus du seuil de consentement à payer (SCP) des ménages. Dans ce contexte, les 
jugements de valeurs sociales (JVS) visent à interpréter les éléments clés liés à 
l'impact d'un traitement sur les patients et la société. Ainsi, ces jugements de valeurs 
sont de plus en plus souvent inclus dans les décisions d'ETS. Ces jugements ont été 
identifiés et codifiés dans tous les rapports d'ETS, mais également classés en onze 
catégories principales: (a) innovation significative; (b) augmentation de l'espérance de 
vie; (c) faible population; (d) enjeux relatifs à l'égalité; (e) avantages sociaux plus 
larges; (f) impact sur la qualité de vie et les activités quotidiennes; (g) impact sur les 
familles et la carrière; (h) besoins de traitement non satisfaits; (i) rareté et gravité de la 
maladie; et (j) les autres considérations qui peuvent être liées à la maladie ou le produit 
en question. 
Pronostic des coûts 
L'une des tâches de l'équipe du projet consistait à fournir des informations sur les 
évaluations d'impact européennes concernant l'évolution probable des coûts de coordina-
tion d'ETS en Europe. Ce pronostic comprend une estimation des coûts et économies à 
prévoir dès la mise en œuvre des options politiques pour 2021 et au-delà:  
• sur la prochaine production conjointe (outils communs, dialogues préliminaires 
(DP), EER commune, ETS complète conjointe) 
• sur les économies réalisées à partir de la diminution de la production nationale 
(réduite par les coûts d'adaptation de la production commune au contexte natio-
nal) 
• divers mécanismes de mise en œuvre et structures de gouvernance (coopé-
ration fondée sur des projets, secrétariat EM, secrétariat UE hébergé par la Com-
mission, intégration d'un tel secrétariat dans une agence européenne existante, 
création d'une nouvelle agence européenne).  
Les coûts des mécanismes de mise en œuvre comprennent des frais liés aux potentiels 
investissements ponctuels (si mesurables) et charges opérationnelles. Le pronostic des 
coûts se fonde sur différentes sources, notamment des études publiées ou non, des 
données (vérifiées) issues de l'enquête, le scénario de base, ainsi que des informations 
recueillies auprès des acteurs concernés et des services de la Commission européenne. 
Lorsqu'aucune donnée/information sur les coûts n'était disponible, l'équipe a émis des 
hypothèses justifiées pour obtenir une estimation. Au vu de l'évolution des coûts de 
production et certains autres paramètres, l'équipe a réalisé des analyses de sensibilité 
destinées à étudier les incertitudes liées. Le mécanisme de financement potentiel pour 
les options politiques et les modèles de gestion n'ont pas été pris en compte dans ce 
pronostic.  
Nous avons émis des hypothèses concernant le futur montant de production commune 
pour le secteur Pharmaceutique et des dispositifs médicaux séparément, et ces hypo-
thèses sont décrites en détail dans le rapport complet. Il en va de même pour les 
prévisions de taux d'assimilation volontaire des options politiques par les États membres 
et la corrélation attendue entre la production nationale et conjointe (dénotant des 
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économies potentielles). L'étude n'a pas envisagé de mécanisme de mise en œuvre 
sans financement par la Commission européenne, car la coopération intergou-
vernementale sans apport de l'UE relève strictement de la responsabilité des 
États membres. Plus particulièrement, la création d'un secrétariat permanent com-
prend des hypothèses détaillées sur les exigences en matière de structure et d'effectif, 
notamment pour la création de trois Comités d'experts au sein des États membres. Les 
hypothèses sous-jacentes étaient fondées sur des textes ou d'autres sources, lorsque 
disponibles. 
Principales restrictions: Nous n'avons pas pu incorporer les dialogues préliminaires 
entièrement dans nos calculs en raison d'un manque de données. Les autres impacts sur 
les coûts, tels que les frais de changement de système à l'échelle nationale, n'ont pas pu 
être mesurés à un niveau global, et sont ainsi présentés de manière descriptive. À 
l'heure actuelle, les recherches sur l'ETS sont hétérogènes en Europe, et les sources de 
données pour les coûts et quantités de production actuels à l'échelle nationale montrent 
de grandes lacunes et incertitudes. L'on pourrait assister à une plus grande adhésion à la 
production commune (ainsi qu'aux économies et coûts liés) au niveau national à d'autres 
fins que les décisions de remboursement. En outre, il ne fut pas possible de mesurer 
l'impact global à long terme des résultats d'ETS obligatoire et organisée de manière 
centralisée sur les systèmes d'ETS nationaux, par exemple, en matière de transparence, 
normalisation ou qualité méthodologique. 
Évaluation des options politiques  
Les effets potentiels des options politiques proposées pour les différents groupes 
d'acteurs ont été étudiés à travers une analyse multicritère (AMC). Les résultats ont 
ensuite été vérifiés par des groupes de discussion, des réunions complémentaires et des 
documents. L'approche AMC se concentre sur plusieurs critères, permet une différencia-
tion entre les groupes d'acteurs (c.-à-d. les administrations publiques, l'industrie 
Pharmaceutique et le secteur des technologies médicales) et met en évidence les 
disparités ou similarités entre ces groupes. 
L'identification des critères pertinents pour l'évaluation de l'impact économique et 
social/sur la santé a été réalisée en collaboration avec la DG SANTÉ et s'est fondée sur 
les effets mentionnés dans les lignes directrices de la Commission européenne pour le 
programme « Mieux Légiférer »3, 4. Chaque effet contient un ou plusieurs indicateurs, 
tels que la recherche et l'innovation sur le marché européen, la fragmentation des 
systèmes d'ETS en Europe, le nombre de technologies de santé évaluées ou disponibles, 
ainsi que la durabilité ou l'efficacité d'utilisation des ressources dans les processus d'ETS 
en Europe. De plus, le groupe d'experts a été impliqué dans le processus d'élaboration 
des effets et des indicateurs. L'objectif spécifique de la réalisation d'une consultation 
d'experts concernait la validation de la pertinence des effets et indicateurs identifiés, 
ainsi que le potentiel et l'identification des possibles effets et indicateurs manquants.  
L'orientation (positive ou négative) et la portée (de -100 à +100, diminution ou augmen-
tation) de chaque effet ont fait l'objet d'une enquête, qui a fourni une importante source 
d'analyse et une tentative de quantification des estimations. Outre les effets supplémen-
taires de chaque OP sur les impacts, l'AMC comprend une évaluation de l'importance ou 
la pertinence des impacts pour les différents groupes d'acteurs. Afin de saisir la variabili-
té au sein de chaque groupe d'acteurs dans l'analyse des résultats de l'enquête, des 
études complémentaires sur des sous-groupes ont été réalisées, notamment une analyse 
séparée pour des entreprises de différentes tailles et une comparaison des réponses des 
sociétés avec et sans expérience dans le domaine de l'ETS. Les données ont été sou-
mises à différents contrôles de plausibilité pour évaluer la fiabilité et la solidité des 
données de l'enquête ainsi que le comportement de réponse des groupes d'acteurs.   
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Aux résultats de l'enquête viennent s'ajouter le pronostic des coûts ainsi que des 
informations supplémentaires recueillies à partir de documents, de groups de discussion 
composés d'acteurs concernés, d'entrevues avec les acteurs et de renseignements 
dérivés de l'analyse du scénario de base. Les résultats sont détaillés séparément pour 
chaque groupe d'acteurs. Afin de renforcer le groupe des patients et consommateurs, 
nous avons réuni des informations supplémentaires via des discussions de suivi pour 
décrire les perspectives des groupes de manière adéquate. Ces discussions prenaient la 
forme d'entrevues avec nos organisations de consommateurs et patients au niveau de 
l’UE.  
Les principales restrictions de cette approche ont mis en évidence que les différents 
niveaux de détail dans les informations des organismes d'ETS, le nombre de disparités 
fonctionnelles entre les organismes d'ETS européens et le degré variable de transpa-
rence (par exemple, toutes les évaluations ne relèvent pas du domaine public ou n'ont 
pas été partagées avec l'équipe de l'étude) ont affecté notre analyse. 
Résultats 
Analyse du scénario de base: étude de cas 
Le scénario de base a étudié 40 technologies (20 produits Pharmaceutiques, 
15 dispositifs médicaux (principalement des appareils) et 5 « autres technolo-
gies » (comme la vaccination anti-VPH) pour permettre de comprendre les aspects 
fondamentaux des processus d'ETS dans les EM. L'objectif principal visait à apporter de 
la clarté sur les modèles, processus et résultats d'ETS dans les EM par le biais d'une 
analyse comparative sur les recommandations d'ETS au sein de la sélection effectuée.  
ETS de l'échantillon de technologies. Dans l'échantillon de produits Pharmaceu-
tiques, les résultats ont monté que la même paire produit-indication a été évaluée par au 
moins 10 agences dans plusieurs pays. En moyenne, 13 agences sur les 24 étudiées ont 
évalué la même paire produit-indication. Ce phénomène se confirme dans des orga-
nismes d'ETS tels que HAS (France), G-BA (Allemagne) et AIFA (Italie), en raison de leur 
processus de sélection (évaluant tous les nouveaux produits Pharmaceutiques deman-
dant une autorisation de mise sur le marché) et du degré élevé de consensus entre les 
organismes d'ETS tels que TLV (Suède), NICE (Royaume-Uni) et INFARMED (Portugal).  
Manifestement, les organismes d'ETS n'évaluent pas tous l'ensemble des produits 
Pharmaceutiques. Certains systèmes d'ETS bien développés évaluent tous les nouveaux 
produits Pharmaceutiques. D'autres suivent des processus explicites de définition de 
priorité et de sélection des sujets, ce qui permet uniquement (a) l'évaluation d'une 
proportion de toutes les nouvelles paires produit-indication à une année donnée et (b) 
d'un très faible nombre de technologies, tandis que (c) d'autres se contentent de 
référencement à l'ETS. En outre, l'évaluation de chaque pair produit-indication effectuée 
a été fortement influencée par le modèle d'ETS (par exemple, évaluation des bénéfices 
cliniques c/ efficacité clinique et rentabilité) et l'approche globale d'ETS prévalant dans 
chaque pays (c.-à-d. approche autonome ou intégrée).  
L'ETS est bien moins développé et établie dans les EM de l'UE en ce qui con-
cerne les technologies médicaux et les « autres technologies ». L'échantillon 
montre que le nombre d'ETS réalisées par paire de produit-indication était inférieur que 
dans l’industrie Pharmaceutique. En moyenne, une technologie médicale ou une « autre 
technologie » ont été évalués par 6 agences d’ETS, avec au moins 4 pays étudiant la 
même technologie médical.  
Soumission des preuves cliniques et économiques En termes de preuves cliniques, 
dans l'ensemble d'échantillons de produits Pharmaceutiques, tous les organismes d'ETS 
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montrent une préférence claire pour les essais cliniques de phase III, suivis par les 
essais de phase II et d'autres sources de fondement. Les comparateurs les plus souvent 
utilisés étaient les placébos/traitements standards actuels. Dans l'échantillon de techno-
logies médicales, il apparaît une claire préférence pour les essais contrôlés rando-
misés (28%), suivis par les études rétrospectives (22%) et les études de sécurité. Le 
comparateur le plus souvent utilisé était le traitement standard actuel. Cependant, un 
nombre considérable d'essais envisagés dans cet échantillon n'étaient pas contrôlés. 
Enfin, dans l'échantillon des « autres technologies », une moyenne de 6 études cliniques 
a montré une préférence pour l'analyse documentaire (89%), qui comprend différents 
aspects de programmes de santé publique et non uniquement les avantages cliniques et 
la rentabilité des technologies. 
Une nette différence de préférence apparaît chez les organismes d'ETS dans les types de 
preuves requises pour les produits Pharmaceutiques, comparé aux technologies médi-
cales et aux « autres technologies ». Ce phénomène est en partie lié aux possibilités 
dans le contexte des technologies médicales ou des « autres technologies », et mis en 
avant par la forte proportion d'études rétrospectives et de sécurité (dans l'échantillon 
des dispositifs médicaux), ainsi que d'analyses documentaires (dans l'échantillon des 
« autres technologies »).  
En matière d'évaluation économique, tous les pays n'ont pas analysé les avantages 
cliniques et la rentabilité de chaque étude technologique, et les critères d'évaluation 
variaient considérablement. Dans l'échantillon Pharmaceutique, 8 pays ont envisagé une 
évaluation économique dans leur étude et, en moyenne, 1,5 étude économique fut 
considérée pour chaque paire de produit Pharmaceutique-indication. Les résultats ont 
montré qu'en général, une analyse coût-utilité a été envisagée pour tous les types de 
médicaments à l'étude (dans 85% des cas), suivie par une évaluation de l'impact 
budgétaire (43% de cas). Une analyse de minimisation des coûts n'a été envisagée que 
dans un nombre limité de cas (6%). Les comparateurs les plus souvent utilisés était un 
comparateur direct (86%). Parmi les pays étudiés, dans 68% des cas, le compara-
teur utilisé était identique à celui des organismes d'ETS. Dans l'échantillon des 
technologies médicales, 8 pays ont envisagé une évaluation économique, avec une 
moyenne de 2,5 études par technologie considérée. En ce qui concerne le type d'ana-
lyses économiques, la tendance a confirmé la prépondérance des études coût-utilité 
(67%), suivies par les comparaisons de coûts (21%). Dans l'échantillon des « autres 
technologies », 7 pays ont envisagé une évaluation économique, dont 73% concernaient 
l'analyse coût-utilité et 45%, l'analyse de l'impact budgétaire. 
Jugements de valeurs sociales Les jugements de valeurs sociales (JVS) occupent une 
place croissante dans les informations sur les recommandations d'ETS. Parmi les 
organismes d'ETS sélectionnés, seuls trois ont défini/révélé leurs jugements de valeurs 
sociales dans leurs lignes directrices: NICE, dans le contexte des critères de fin de vie; 
SMC, avec les « modificateurs de maladie »; et TLV, avec le principe: « la dignité 
humaine repose sur la solidarité ». D'autres organismes d'ETS prennent en considération 
des valeurs, mais pas de manière cohérente. Étant donné les tendances spécifiques 
parmi les différentes technologies de santé, le plus grand nombre de JVS fut identifié 
dans l'échantillon Pharmaceutique (n=304), suivi par celui des dispositifs médicaux 
(n=67) et les « autres technologies » (n=4). 
Accords et désaccords dans les recommandations des organismes d'ETS Dans 
l'échantillon Pharmaceutique, le degré de consensus dans les recommandations varie 
significativement entre organismes d'ETS et est lié au fait que tous les organismes 
n'évaluent pas l'ensemble des technologies. Toutefois, les organismes d'ETS qui évaluent 
toutes les technologies enregistrent un très haut degré de consensus (comme le montre 
la note kappa, k>0,8). Ceci démontre un haut degré de consensus entre les organismes 
d'ETS dans leurs recommandations, c.-à-d. une même orientation des recommandations 
dans tous les organismes (par exemple: accepté, accepté avec critères ou rejeté).  
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En revanche, cette tendance ne se confirme pas dans les échantillons des technologies 
médicales et des « autres technologies ». Le nombre d'évaluations est plus faible pour 
les « autres technologies », et l'échantillon est plus fragmenté, comme le montre la 
faible note kappa (k<0.2). Le degré de consensus est généralement faible dans cet 
échantillon, avec 64% des organismes d'ETS enregistrant une mauvaise note kappa 
(k<.02) et 36%, un degré de consensus allant du raisonnable (0.21<ki<0.4) au très 
élevé (0.81<k<1). 
Orientation des recommandations d'ETS Dans l'étude de cas, soixante-six pour-
cent (66%) des technologies ont fait l'objet de recommandations positives, 
avec ou sans restrictions. Si l'on détaille ce chiffre: 62% des recommandations 
étaient positives avec des restrictions et les autres (n=75), positives et sans restrictions. 
Cette tendance se confirme dans les échantillons des médicaments et des technologies 
médicales, avec respectivement 81 et 64% recevant une recommandation positive, et 
respectivement 63% et 59% faisant l'objet d'une recommandation positive sans restric-
tion. Dans l'échantillon des « autres technologies », la plupart des recommandations 
étaient positives et sans restrictions (66%). 
Restrictions cliniques aux recommandations d'ETS Dans l'ensemble des échantil-
lons, la restriction la plus récurrente était d'ordre clinique (56% des cas). Pour 
l’échantillon Pharmaceutique, les restrictions cliniques les plus communes étaient liées 
aux sous-groupes de patients (67%), suivies par les restrictions concernant le parcours 
thérapeutique (18%). Les produits Pharmaceutiques et les technologies médicales 
sont le plus souvent concernés par des restrictions prescrites et liées aux 
professionnels spécialistes et au contexte. La première restriction se rapporte aux 
technologies de santé qui peuvent uniquement être prescrites par un médecin spécia-
liste, et la seconde, au contexte de l'endroit où le traitement peut être prescrit ou 
prodigué. Dans l'échantillon des technologies médicales, les restrictions cliniques 
les plus communes étaient liées aux sous-groupes de patients (67%), suivies 
par les restrictions concernant le parcours thérapeutique (32%). Dans l'échantillon des 
« autres technologies », les restrictions les plus courantes concernaient les caractéris-
tiques spécifiques des technologies (58%), c.-à-d. les recommandations émises pour une 
technologie comparée à une autre, suivies par la conception du programme (34%), c.-à-
d. les recommandations liées aux différentes caractéristiques d'un programme afin 
d'améliorer les performances cliniques du programme entier.  
Restrictions économiques aux recommandations d'ETS Les restrictions écono-
miques concernaient principalement l'échantillon des produits Pharmaceutiques et sont 
fondées sur les informations accessibles au public. 64% des restrictions écono-
miques concernaient l'introduction d'un accord de partage des risques ou 
d'accords de participation gérée au remboursement des produits, et 14% exi-
geaient une négociation de prix complémentaire. Nous avons identifié seulement 
5 restrictions économiques dans l'échantillon des technologies médicales, avec une 
attention particulière sur l'utilisation de négociations de prix spéciales avec l'agence de 
réglementation compétente pour les décisions de remboursement.  
Délais d'ETS relatifs à l'autorisation de mise sur le marché L'on constate souvent 
un délai significatif entre l'obtention d'une autorisation de mise sur le marché (AMM) et 
la publication de recommandations d'ETS. Ce délai n'est pas uniforme et varie selon le 
pays ou l'organisme d'ETS et le type de technologies. En moyenne, le délai le plus long 
entre les AMM et les recommandations de l’ETS en ce qui concerne l’échantillon Pharma-
ceutique a été enregistré à 21,6 mois, et le plus court, à 9 mois. Cependant, il convient 
de reconnaître que cette différence pourrait être liée à des facteurs tels que la volonté de 
soumettre un rapport ou des retards dans la soumission de l'ETS par l’entreprise 
concernée, les différents critères de sélection dans le choix des technologies à évaluer et 
le rôle différent de l’organisme d’ETS. Dans l'échantillon des technologies médicales, le 
délai moyen entre le marquage CE et la réalisation d'une ETS est bien plus important, 
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environ 60 mois, bien qu'il faille traiter ce chiffre avec précaution en raison de la rareté 
des données accessibles au public sur les dates de marquage CE (une indication faisant 
office de certificat, mais n'étant généralement pas publiée). Notamment, nous avons 
identifié, parmi les organismes d'ETS, un délai moyen entre évaluations de trois 
ans. Dans l'échantillon des « autres technologies » comme dans celui des technologies 
médicales, l'on remarque un délai significatif entre plusieurs évaluations d'une même 
technologie parmi les organismes d'ETS. Dans l'exemple du dépistage du cancer colorec-
tal, le programme a été évalué en 2006 dans une juridiction, puis à nouveau en 2016 
dans deux autres juridictions. 
Estimation de base des coûts d'ETS fondée sur le recueil de données initial 
(enquête) visant les fabricants et les organismes d'ETS Les résultats de l'enquête 
ont révélé d'importantes différences entre l'industrie Pharmaceutique et le secteur des 
technologies médicales. Dans le secteur Pharmaceutique, les résultats indiquent une 
forte variabilité dans les dépenses d'ETS (entre 73 000 euro et 1 700 000 euro par 
soumission d'ETS) et dans la production de preuves supplémentaires (entre 50 000 euro 
et 20 000 000 euro). La diversité des chiffres mentionnés pourrait refléter hétérogénéité 
des évaluations de résultats entre les différents contextes ou besoins de production de 
données, et ne permet pas de dresser le tableau définitif des dépenses moyennes parmi 
les produits ou fabricants. Bien qu'un rapport de valeur global ait été élaboré pour 
chaque produit, ce dernier est souvent la principale source d'information pour les 
équipes d'ETS des fabricants, et il est sujet à adaptation selon les conditions d'ETS 
prévalentes dans chaque contexte. Dans l'industrie des technologies médicales, les 
chiffres de soumissions d'ETS révèlent une fourchette de 1 000 euro à 3 400 000 euro, 
et la production de preuves supplémentaires, 17 000 euro à 12 800 000 euro. Les 
représentants du secteur des technologies médicales ont avancé que le nombre actuel 
d'évaluations de dispositifs médicaux variait considérablement selon les pays. Ainsi, il ne 
serait pas raisonnable de définir une moyenne fondée sur les fourchettes présentées ci-
dessus.  
En ce qui concerne la composition des éléments de coûts, dans le secteur Pharma-
ceutique comme dans celui des technologies médicales, les coûts d'effectifs (internes et 
externes) sont les principales composantes qui motivent les dépenses. Cependant, les 
groupes de discussion ont permis de mettre en lumière un autre facteur clé de coûts liés 
à l'ETS: la production de preuves (supplémentaires). Ce sont principalement les plus 
importants marchés qui voient le plus d'entreprises réaliser des études de production de 
preuves supplémentaires exigées par des organismes d'ETS. En outre, les lacunes de 
connaissances actuelles pourraient être comblées par des études post-commercialisation.  
Les preuves issues du dialogue préliminaire suggèrent un niveau d'implication 
complètement différent entre l'industrie Pharmaceutique et celle des technolo-
gies médicales. Le secteur des technologies médicales s'est activement impliqué dans 
le dialogue préliminaire (69% des réponses), avec un coût moyen de 55 750 euro par 
dossier, tandis que celui des produits Pharmaceutiques a fait preuve d'un engagement et 
de dépenses plus faibles (28% des réponses et environ 21 700 euro) par dossier. Au 
cours des groupes de discussion, les représentants de l'industrie des technologies 
médicales ont reconnu ne pas s'impliquer régulièrement dans le dialogue préliminaire 
concernant les dispositifs médicaux.  
En ce qui concerne les coûts notifiés par les organismes d'ETS, les différences de 
dépenses sont fortement influencées par des facteurs tels que le type de processus 
d'ETS en place, le genre d'évaluation réalisée et le degré d'intégration des organismes 
d'ETS dans les agences gouvernementales. De manière générale, il semble que les coûts 
de réalisation d'une évaluation de technologie unique (ETU) soient supérieurs parmi les 
organismes autonomes que chez les structures intégrées (les frais d'ETU les plus élevés 
rapportés étaient de 135 000 euro pour les agences autonomes et de 100 000 euro pour 
celles intégrées). En ce qui concerne l'évaluation d'efficacité relative (EER), les maxi-
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mums rapportés étaient de 55 000 euro pour les premiers types d'organismes, et de 
100 000 euro pour les derniers. Toutefois, puisque les données recueillies comportaient, 
dans certains cas, des valeurs manquantes, ces estimations devraient être interprétées 
avec précaution. 
Perspective de l'industrie sur les processus d'ETS De manière générale, les 
entrevues réalisées dans l'industrie Pharmaceutique et celle des dispositifs médicaux ont 
démontré que les diverses procédures nationales avaient un impact différent sur 
l'évaluation des technologies de santé. Les méthodologies nationales entraînent d'impor-
tantes variations dans les recommandations/résultats, indiquant une différence significa-
tive sur la manière dont un même produit est perçu dans plusieurs pays. Cependant, il 
est important de souligner que ces différences sont également influencées par les 
domaines thérapeutiques de chaque produit. 
Les fabricants ont mis en avant le fait que la fragmentation des systèmes actuels d'ETS 
en Europe imposait aux entreprises de répondre à un éventail diversifié de demandes. 
Notre analyse confirme que ce phénomène pourrait entraîner des difficultés dans la 
soumission ou la resoumission de rapports aux mêmes organismes d'ETS. 
Il existe un consensus entre les représentants de l'industrie Pharmaceutique interrogés, 
selon lequel une collaboration à l'échelle européenne sur l'ETS serait possible pour 
réaliser des EER. En revanche, les représentants des technologies médicales ont mis en 
avant l'hétérogénéité et la diversité du marché des technologies/dispositifs médicaux, 
comparé à l'industrie Pharmaceutique. Ces derniers ont également insisté sur le faible 
rôle actuel de l'ETS sur les dispositifs médicaux et les technologies connexes dans la 
plupart des contextes, en raison de l'accès extrêmement fragmenté à ce marché. Ainsi, 
l'impact actuel de l'ETS sur leur activité est très bas.  
La prévisibilité des processus d'ETS est apparue comme un élément clé dans les déci-
sions d'investissement et d'utilisation des ressources, notamment pour les petites 
entreprises. Tout le monde s'est accordé sur la nécessité d'harmonisation des proces-
sus et exigences en matière de preuves pour garantir une large compréhension 
et améliorer le niveau de prévisibilité dans le système.  
Plusieurs entreprises ont mis en avant la transparence des exigences en matière de 
preuves, l'uniformité des méthodes, la recevabilité des comparaisons indirectes et la 
prévisibilité des résultats parmi les caractéristiques désirables. Notamment, les repré-
sentants de l'industrie Pharmaceutique interrogés ont recommandé une meilleure 
synthèse et inclusion des informations sur des sujets importants tels que les comparai-
sons indirectes et les évaluations secondaires, ainsi qu'une définition claire des compara-
teurs appropriés. En revanche, les représentants du secteur des dispositifs médicaux ont 
suggéré que, bien que les essais contrôlés randomisés à long terme soient désirables du 
point de vue des preuves, ils peuvent ne pas toujours être appropriés, réalisables ou 
suffisants dans le domaine des dispositifs médicaux et les technologies connexes. Ces 
derniers recommandent une approche plus modérée de l'ETS dans le secteur, en raison 
de ses spécificités et du fait que les innovations sont généralement issues des petites 
entreprises, avec un cycle d'innovation plus court comparé à l'industrie Pharmaceutique. 
Les dialogues préliminaires et les avis scientifiques sont considérés comme des 
tâches très utiles à l'amélioration de la transparence, de la perspective de l'indus-
trie, suggérant qu'un système aligné sur les pratiques actuelles de l'Agence européenne 
des médicaments (EMA) serait bénéfique et simplifierait les programmes de développe-
ment. Cependant, peu de représentants interrogés ont mentionné l'importance de la 
non-introduction d'un système parallèle dans les pays imposant des exigences supplé-
mentaires. 
Enfin, les fabricants ont mis en avant un certain nombre de problèmes liés à l'innova-
tion: la faible prévisibilité, la haute complexité et la forte fragmentation constituent des 
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barrières à l'innovation dans le domaine de la santé. Il existe une certaine « tension » 
entre les organes de réglementation qui souhaitent promouvoir un accès accéléré et les 
autorités de remboursement qui restent prudentes à cause de l'incertitude des preuves. 
Nous avons compris que l'harmonisation des exigences en matière de preuves, 
si elle est accompagnée d'une acceptation par les EM, faciliterait les décisions 
d'investissement des fournisseurs de technologies. En outre, un système d'ETS 
européen comprenant une solide méthodologie réduirait le risque dans les processus de 
soumission et aiderait à éliminer les débats liés à la faible qualité des évaluations et des 
interprétations de données. Une plus grande uniformité des évaluations d'ETS serait 
véritablement bénéfique, et pourrait être facilitée par un recueil d'avis préliminaire ainsi 
qu'une plus grande transparence sur les attentes des payeurs. Enfin, l'harmonisation 
des exigences en matière de preuves offrirait une influence plus importante à 
l'UE sur le développement d'essais cliniques. 
La synthèse des résultats a confirmé l'hétérogénéité des évaluations de technologies de 
santé selon les différents pays. Pourtant, une analyse de niveau micro a démontré une 
tendance à l'homogénéisation des processus d'évaluation dans les EM. 
Pronostic des coûts 
Le pronostic des coûts s'est intéressé à deux sujets:  
1. l'estimation des coûts de la participation volontaire ou obligatoire à la production 
conjointe et les économies liées dans la production nationale des OP 
proposées.  
2. Les coûts liés aux structures organisationnelles spécifiques/mécanismes de mise 
en œuvre comprenant des outils communs.  
L'étude n'a pas envisagé de mécanisme de mise en œuvre sans financement par l'UE, 
car la coopération intergouvernementale sans apport de l'UE relève de l'unique respon-
sabilité des EM. Tous les types de mécanismes de mise en œuvre comprennent la 
production de résultats d'ETS par différents organismes d'ETS et une unité de coordina-
tion centrale pour soutenir les organismes d'ETS. Ce soutien serait d'ordre administratif, 
scientifique/technique, juridique et informatique, dans une étendue différente selon le 
mécanisme. Le principal critère de différenciation des mécanismes de mise en œuvre 
repose sur l'établissement d'une unité centrale de coordination permanente 
(5 mécanismes sur 6), comparé au mécanisme sur base de projets orienté sur les 
structures du réseau EUnetHTA.  
Outre l'unité de coordination centrale, trois autres piliers principaux sont prévus pour les 
modèles de gestion: 
• Conseil d'administration (composé de représentants des EM et qui définit le pro-
gramme de travail) 
• Production de résultats d'ETS (contractée auprès des organismes d'ETS) 
• Comités des EM (composés de spécialistes qui analyseront et débattront des ré-
sultats d'ETS) 
L'unité de coordination centrale permanente assurerait la coordination des projets et 
apporterait un soutien global aux modules de travail respectifs, au conseil d'administra-
tion et aux comités.  
Représentant des scénarios illustratifs, les modèles de gestion allient des prévisions de 
résultats conjoints et de mécanismes organisationnels/de mise en œuvre, et jette les 
fondements pour les futurs développements. D'autres combinaisons OP et de modèles de 
gestion que celles analysées plus en détail sont également possibles (par exemple, la 
création d'une nouvelle agence pour l'OP 4.1). Les combinaisons présentées sont 
Étude sur l'analyse d'impact des options politiques pour renforcer la coopération de l'UE sur l’évaluation des technolo-
gies de santé (ETS) 
 
 
 56 
considérées comme les plus plausibles. Le pronostic des coûts se fonde sur plusieurs 
sources:  
• Les informations issues de l'étude de J. Chamova(2);  
• Les informations fournies par les membres du réseau EUnetHTA; 
• Les données recueillies dans l'enquête de base; 
• Un débat complémentaire sur les coûts par l’intermédiaire d’un questionnaire 
envoyé par e-mail;  
• Les informations issues des groupes de discussions composés de représentants 
d'administrations publiques, de l'industrie Pharmaceutique et du secteur des 
technologies médicales; et, 
• D'autres sources, par exemple, services de la Commission ou d'agences euro-
péennes (explicitement mentionnées le cas échéant). 
Deux modèles furent proposés, avec un seul élément distinctif: le modèle de base, qui 
couvre 65 EER réalisées conjointement, 40 sur des médicaments et 25 sur des technolo-
gies médicales; et le modèle avancé, avec 115 EER conjointes au total, 90 sur des 
médicaments et 25 sur des dispositifs médicaux. L'évaluation des deux modèles compre-
nait l'adaptation des mécanismes de mise en œuvre, notamment des ressources 
humaines, selon les résultats conjoints anticipés. 
La production commune estimée se montre pertinente pour les périodes, jusqu'à ce que 
les structures et processus soient bien installés. À l'issue de l'adaptation, c.-à-d. l'aug-
mentation de 65 EER à 115 EER (90(18) sur des médicaments et 25 sur des technologies 
médicales), il était envisageable de couvrir toutes les nouvelles substances et indications 
autorisées par procédure centralisée. Ainsi, plus d'effectif sera nécessaire pour assurer 
cette croissance de production de résultats. Le nombre d'effectifs nécessaire augmente-
rait donc pour les OP 4.1, 4.2 et 5 (tableau 17 l'étude principale). Une analyse de 
sensibilité a été réalisée pour représenter les incertitudes liées. 
Les hypothèses de base concernant les éléments de coûts comprenaient une classifica-
tion des EM selon le volume de leurs résultats annuels d'ETS ou de rapports d'ETS émis 
principalement par les organismes d'ETS, ou par l'industrie et revus par les organismes. 
Dans la plupart des États, les organismes d'ETS produisent moins de 60 rapports d'ETS 
sur les produits Pharmaceutiques et moins de 50 sur les dispositifs médicaux. La 
majorité des rapports d'ETS sont issus de l'industrie et revus par des organismes d'ETS.  
En ce qui concerne les mécanismes de mise en œuvre, ce sont les coûts d'effectifs et les 
coûts liés aux comités d'experts des EM qui représentent la majorité des dépenses 
attendues. Les estimations des coûts d'effectifs sont fondées sur les réglementations 
européennes en matière de personnel, indexés sur les EM le cas échéant, et sur les frais 
d'experts de la Commission. Les estimations globales sur les mécanismes de mise en 
œuvre de l'OP 5 sont deux fois supérieures à l'OP 2. En outre, les coûts du modèle de 
base et du modèle avancé diffèrent significativement de l'OP 4.1 à l'OP 4.2 et l'OP 5 en 
raison de l'augmentation de la production commune. 
Les chiffres montrent également que, notamment pour les OP 4.1, 4.2 et 5 – c.-à-d. 
les options à l'aspect plus « législatif » et obligatoire – les EM et l'industrie peuvent 
s'attendre à réaliser des économies à l'échelle européenne, si l'on prend en 
compte les hypothèses sous-jacentes, et que ces économies augmenteront avec les OP 
ultérieures. Toutefois, plusieurs autres facteurs, qui ne peuvent être mesurés avec 
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fiabilité, mais pourraient influencer les coûts/économies généraux, et ainsi inverser ou 
diminuer certains résultats, doivent également être considérés. Par exemple, les coûts 
liés à la mise en œuvre d'une assimilation obligatoire des résultats au sein des procé-
dures, législations et réglementations nationales, ainsi que les potentielles économies 
supplémentaires dégagées grâce à la réduction du nombre de dialogues préliminaires à 
l'échelle nationale ou du montant de production de preuves supplémentaires exigé par 
les organismes d'ETS. 
En conclusion, les chiffres montrent d'un côté une augmentation significative des coûts 
d'établissement d'un nouveau cadre de l'OP 2 à l'OP 5, et de l'autre un potentiel accrois-
sement d'économies de l'OP 2 à l'OP 5. 
Évaluation globale des options politiques 
Nous avons étudié, à la lumière des lignes directrices « Mieux légiférer » (5), un certain 
nombre d'effets afin d'établir un aperçu complet de l'impact qu'auraient les différentes 
OP et modèles de gestion proposés sur les divers groupes d'acteurs.  
L'analyse de l'impact s'est concentrée sur trois principaux groupes d'acteurs: l'adminis-
tration publique, l'industrie Pharmaceutique et le secteur des technologies 
médicales, car ce sont ces groupes qui ont fourni le plus d'informations. Les auteurs ont 
également analysé l'impact sur les groupes des patients et professionnels de santé, 
lorsque des informations étaient disponibles19.  
Un aperçu des résultats par groupe d'acteurs pour chaque catégorie d'impact (des 
critères économiques (EC) aux effets sociaux et sur la santé (SS) est présenté en détail 
dans le chapitre 7.3 de l'étude. En résumé, les résultats de l'enquête et du groupe de 
discussion ont montré que les effets perçus des OP ainsi que les perceptions et 
attentes en ce qui concerne la future coopération européenne sur l'ETS diffè-
rent selon le groupe d'acteurs dans plusieurs aspects. 
Les informations rassemblées indiquent que l'administration publique ne s'attend à 
aucun impact significatif en ce qui concerne les processus liés à l'ETS pour les 
OP 1 et 2. Cependant, avec les OP comprenant un cadre législatif (OP 3–OP 5), l'admi-
nistration publique perçoit des effets positifs, qui sont amplifiés par chaque résultat 
couvert par le cadre. Ce phénomène se confirme dans notre évaluation, étant donné que 
les OP comprenant un cadre législatif (OP 3 à OP 5) sont plus susceptibles 
d'avoir une influence positive sur la durabilité des systèmes de santé que la 
poursuite d'une coopération non contraignante.  
Cette augmentation d'effets positifs avec des exigences plus strictes et un système de 
gouvernance centralisé se rapporte à l'hypothèse d'une augmentation de l'assimilation 
des résultats conjoints avec chacune des OP suivantes. Des réglementations plus 
strictes pourraient former un élément clé pour une collaboration durable et 
fructueuse, car sans elles, l'impact sur la coopération resterait limité. En outre, 
nous avons estimé que le nombre d'évaluations fondées sur des preuves dispo-
nibles pour les prises de décision pouvait être augmenté avec les résultats 
conjoints, puisque davantage de technologies pourraient être couvertes en raison du fait 
d'un unique organisme d'ETS pourrait ne pas disposer des capacités nécessaires pour 
analyser le même nombre d'évaluations chaque année.  Les pays dotés de processus 
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sources et/ou de manière indirecte. 
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d'ETS moins matures pourraient particulièrement profiter de la production 
commune, notamment grâce aux ETS conjointes.  
Aucune OP n'est jugée avoir un impact significatif sur la charge administrative 
ou les administrations publiques sur les EM de l’UE, et aucun sinon peu d'effets sur 
les coûts de résultats liés à l'ETS n'ont été indiqués dans l'enquête en ligne. Ce phéno-
mène est inhérent au fait que les processus nationaux devraient perdurer d'une quel-
conque façon. Toutefois, certains organismes d'ETS s'attendent à une collaboration plus 
étroite qui réduirait leurs coûts. Cette hypothèse se confirme dans nos calculs de coûts, 
qui indiquent de potentielles économies parmi les EM, notamment pour l'OP 4.1 et les 
suivantes. 
Dans l'industrie Pharmaceutique, les preuves n'indiquent aucun changement entre 
l'OP 1 et l'OP 2, tandis qu'elles suggèrent des effets positifs des OP comprenant 
des travaux d'ETS conjoints au niveau de l’UE, les OP 3 et 4. Ces OP devraient 
permettre de diminuer les facteurs d'inefficacité, d'améliorer le fonctionnement du 
marché intérieur et d'augmenter la charge de travail du secteur Pharmaceutique. Nous 
attendons également un accroissement de la prévisibilité dans le secteur Pharmaceu-
tique, un facteur également considéré très important dans les entrevues avec les 
représentants de l'industrie et dans les réponses apportées à l'enquête, puisqu'elle 
facilite également l'innovation à travers des décisions d'investissement facilitées. 
L'industrie Pharmaceutique prévoit des effets négatifs dans l'OP 5, qui comprend des 
processus d'ETS strictement obligatoires et contraignants, couvrant également une ETS 
complète en Europe. Les raisons sous-jacentes de ce phénomène ont été identifiées au 
cours des entrevues, dans les réponses à l'enquête et lors des groupes de discussion 
réalisés avec les représentants des entreprises Pharmaceutiques: les évaluations 
économiques conjointes obligatoires, telles qu'établies dans l'OP 5, sont considérées 
comme un scénario irréaliste en raison des spécificités de chaque pays en ce qui 
concerne les exigences économiques, mais également à cause de la stagnation des 
décisions de tarification et de remboursement à l'échelle nationale. Il est apparu à 
plusieurs reprises que les travaux d'ETS communs, notamment, ont le potentiel 
de réduire les facteurs d'inefficacité et la charge de travail du secteur Pharma-
ceutique. 
En ce qui concerne les coûts liés aux processus d'ETS, les représentants de l'industrie 
Pharmaceutique interrogés n'envisagent aucun changement important, à l'exception de 
l'OP 5, qui fait peser un risque d'augmentation significative des dépenses. Cette hypo-
thèse est liée au fait que les augmentations et diminutions potentielles des facteurs de 
coûts s'annuleraient mutuellement, selon les débats réalisés en groupes de discussion.  
Néanmoins, les résultats de notre pronostic des coûts pour 2021 et au-delà montrent les 
économies réelles que l'industrie Pharmaceutique pourrait réaliser dans toute 
l'UE grâce à la réduction des duplications d'évaluations, et ce pour toutes les OP. Les 
économies potentielles augmentent considérablement dans les OP qui comprennent une 
production et une assimilation obligatoires des ETS conjointes (OP 4.2 et OP 5). Les 
options qui prévoient un secrétariat permanent et une production conjointe plus élevée 
entraîneraient des économiques largement plus importantes, en comparaison avec une 
coopération fondée sur des projets (3,7 millions d'euros dans l'OP 2 contre plus de 
60 millions d'euros dans l'OP 4.2). 
Pour le secteur des technologies médicales, notre analyse dresse un tableau 
différent: Les représentants de l’industrie des technologies médicales ont indiqués un 
effet négatif pour toutes les OP, à l'exception de l'OP 2. Cette évaluation négative est 
liée à la particularité du marché des dispositifs médicaux. Alors que les produits Pharma-
ceutiques peuvent profiter d'un parcours bien établi, de l'autorisation de mise sur le 
marché jusqu'à l'évaluation ETS, ainsi que de processus d'ETS matures dans un grand 
nombre d’EM de l’UE, les technologies médicales et les « autres technologies » doivent 
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suivre des règles et processus d'évaluation hétérogènes de leurs produits. En outre, le 
marché des dispositifs médicaux est intrinsèquement différent de celui des produits 
Pharmaceutiques, qui connaît un niveau élevé de concurrence dès l'entrée sur le marché. 
Bien que l'ETS soit largement développée dans l'industrie Pharmaceutique, elle semble 
souffrir d'un besoin d'adaptation et de développement de processus matures dans le 
secteur des dispositifs médicaux.  
L'évaluation négative des OP dotées d'un cadre législatif est liée au fait que, selon 
l'industrie, ces options devraient entraîner une recrudescence des activités d'ETS dans 
les EM. Ce phénomène a été perçu comme un élément décisif de changements imprévi-
sibles et de charge supplémentaire pour l'industrie des technologies médicales, étant 
donné que les travaux d'ETS ne jouent pas un rôle important dans le parcours d'accès au 
marché à l'heure actuelle. L'industrie voit cette incertitude comme un élément qui 
influencera ultérieurement l'attrait du marché européen et redoute des délais dans les 
premiers revenus en raison des processus potentiellement plus longs. Un autre élément 
clé repose sur la diminution attendue de la compétitivité et de l'innovation. Selon les 
groupes de discussion et les entrevues, cet élément est lié au changement imprévisible 
perçu dans le parcours d'accès au marché des technologies médicales, qui serait 
attribuable aux deux nouvelles réglementations européennes sur les dispositifs médi-
caux132. L'industrie prévoit ainsi la possibilité de nouvelles barrières administratives, qui 
constituent généralement la charge la plus lourde pour les précurseurs (ou innovateurs). 
Un aspect tout aussi important est l'augmentation attendue des coûts, entraînée par la 
production de preuves supplémentaires. Selon les résultats de l'étude, cet impact semble 
être surestimé par l'industrie des technologies médicales; l'une des raisons identifiées 
étant que le niveau actuel d'expérience en ETS des représentants des technologies 
médicales interrogés est largement inférieur à ceux du secteur des produits Pharmaceu-
tiques. En outre, l'analyse de base montre une tendance à l'alignement des procédures 
et comparateurs utilisés. 
Par ailleurs, nos calculs de coûts n'ont pas confirmé l'hypothèse d'une augmenta-
tion des dépenses dans l'industrie des technologies médicales. Au contraire, les 
résultats suggèrent que ce secteur pourrait également tirer profit des OP plus 
« strictes » proposées en ce qui concerne les coûts (agrégés entre les EM). Des écono-
mies potentielles notables sont à prévoir dans les OP dotées d'un cadre législatif (OP 4.1, 
4.2 et 5).  
En résumé, les OP dotées d'un cadre législatif impliquent certains effets négatifs pour 
l'industrie des technologies médicales sous la forme d'une charge supplémentaire (selon 
leur perspective), notamment lorsque des ETS conjointes sont concernées. Cependant, 
pour les OP 3, seul un léger impact négatif est à prévoir, et sur le long terme, le 
développement d'outils et de modèles communs permettra l'établissement d'exigences 
d'ETS plus claires qui, in fine, faciliteront également les processus d'ETS dans l'industrie 
des technologies médicales. Les groupes de patients ont également manifesté leur 
besoin d'une meilleure transparence dans ce secteur, qu'ils perçoivent comme un moyen 
de renforcer la qualité et la sécurité des technologies. 
Le renforcement des processus d'ETS pour les technologies médicales entraînerait de 
potentiels effets positifs sur les patients, grâce aux meilleures preuves à disposition pour 
les prises de décision. Nous prévoyons donc, in fine, des effets positifs sur la sécurité des 
dispositifs médicaux. 
Le tableau suivant présente un bref aperçu de l'impact potentiel des OP, agrégé entre 
tous les effets étudiés, pour chaque groupe d'acteurs. Le vert indique une perception 
positive et le rouge, une négative, selon les jugements de l'équipe de l'étude, qui a pris 
en compte toutes les preuves et informations réunies sur les différents groupes d'acteurs 
et compilé tous ces renseignements. 
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Tableau 4: Conclusion: effets des options politiques 
Groupe 
d'acteurs 
Scénario 
de base 
(OP 1) 
Coopération 
fondée sur 
des projets 
(OP 2) 
Secrétariat 
hébergé 
par EM/UE 
(OP 3) 
Agence 
européenne 
existante 
(OP 4.1) 
Agence 
européenne 
existante 
(OP 4.2) 
Nouvelle 
agence 
européenne 
(OP 5) 
Administration 
publique 
      
Pharma       
MedTech       
De manière générale, les effets perçus des OP ainsi que les perceptions et attentes en ce 
qui concerne la future coopération européenne sur l'ETS diffèrent selon le groupe 
d'acteurs dans plusieurs aspects. 
Les OP dotées d'un cadre législatif pour la coopération européenne sur l'ETS (OP 3 et 
suivantes) peuvent avoir des effets positifs sur l'administration publique. La prévisibi-
lité des systèmes d'ETS en Europe devrait augmenter considérablement pour l'OP 3, et 
les effets positifs sont amplifiés avec chaque option ultérieure. 
Les OP comprenant une assimilation obligatoire des résultats d'ETS conjointes auront un 
effet positif sur l'industrie Pharmaceutique, l'OP 5 étant considérée comme la moins 
plausible par les représentants du secteur. Cette position pourrait être approuvée par 
l’équipe d’étude dans l’attente que nos analyses indiquent également des économies à 
long terme pour l’OP 5. 
Une coopération volontaire fondée sur des projets (OP 2) serait favorable au secteur des 
technologies médicales, puisqu'elle ne comprendrait aucun cadre législatif, qui est 
perçu comme une charge supplémentaire pour l’industrie aux effets négatifs. Ce 
phénomène est lié au fait que l'ETS n'est pas encore très répandue dans le secteur, et 
les méthodes liées ne sont pas suffisamment matures dans l'industrie des dispositifs 
médicaux, en comparaison avec celui des produits Pharmaceutiques.  
Selon notre analyse, il est nécessaire de prendre en considération les particularités de 
l'industrie des technologies médicales afin de développer un système d'ETS durable et 
efficace. Une solution consisterait à appliquer différentes OP et modèles de gestion aux 
deux secteurs. Dans le secteur des technologies médicales, un bon point de départ serait 
la création et l'utilisation obligatoire d'outils communs, alors que le développe-
ment de méthodes supplémentaires aiderait à dresser un tableau clair des 
exigences liées aux processus d'ETS. Par ailleurs, la réalisation volontaire d'EER 
conjointes pourrait être envisagée en parallèle, puis qu'elles fourniraient d'importantes 
informations, utiles aux prises de décision dans toute l’UE. Ces études contribueraient 
également à (a) réduire la base de preuves divergentes dans tous les EM de l’UE pour les 
technologies médicales, mais également à (b) renforcer la santé publique et la sécurité 
des patients.   
Principaux résultats 
 De manière générale, la vaste majorité des preuves cliniques étudiées par les 
organismes d'ETS concernent principalement les produits Pharmaceutiques soumis à 
un essai clinique de phase III, et dans une moindre mesure ceux soumis à un essai de 
phase II. Ces derniers connaissent une utilisation croissante dans les cas où la pro-
duction de preuves issues d'essais de phase III est compliquée, où lorsque le bénéfice 
clinique est jugé important et que le traitement nécessiterait une autorisation de mise 
sur le marché conditionnelle (AMMC). Seule une portion des preuves cliniques ont été 
examinées en relation avec d'autres types de preuves cliniques (essais prolongés ou 
études par observation). Il est donc raisonnable d'avancer l'existence d'un certain 
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montant de duplications à l'heure actuelle étant donné que la preuve consi-
dérée dans tous les paramètres est en général la même. 
 L'on constate une différence claire de préférences parmi les organismes d'ETS envers 
le type de preuves exigées pour les produits Pharmaceutiques, en comparaison avec 
les technologies médicales et les « autres technologies ». Ce phénomène est en partie 
lié aux possibilités dans le contexte des dispositifs médicaux ou des « autres techno-
logies », et mis en avant par la forte proportion d'études rétrospectives et de sécurité 
(dans l'échantillon des dispositifs médicaux), ainsi que d'analyses documentaires 
(dans l'échantillon des « autres technologies »).  
 En ce qui concerne les preuves économiques, bien que des similarités et disparités se 
retrouvent parmi les différents EM en matière de préférence d'approche, de gestion ou 
de mise en œuvre, il est important de noter que, parmi les pays étudiés et pour ceux 
qui réalisent des évaluations économiques, le comparateur était identique dans 
68% des organismes d'ETS. 
 L'harmonisation des exigences en matière de preuves, si elle est accompagnée d'une 
acceptation par les EM, faciliterait les décisions d'investissement. En outre, un sys-
tème d'ETS européen comprenant une solide méthodologie réduirait le risque dans les 
processus de soumission et aiderait à éliminer les débats liés à la faible qualité des 
évaluations et des interprétations de données. Une plus grande uniformité des évalua-
tions d'ETS serait véritablement bénéfique, et pourrait être facilitée par un recueil 
d'avis préliminaire ainsi qu'une plus grande transparence sur les attentes des 
payeurs. Enfin, l'harmonisation des exigences en matière de preuves offrirait une 
influence plus importante à l'UE sur le développement d'essais cliniques. 
 L'industrie Pharmaceutique se montre favorable aux options comprenant une 
assimilation obligatoire des résultats d'ETS conjointes. En raison du système 
d'ETS actuellement fragmenté, le secteur profitera d'une réduction des soumissions et 
d'une meilleure prévisibilité dans toute l’UE. Il pourrait être nécessaire de relocaliser 
les effectifs vers une structure centralisée, mais leur nombre devrait rester stable.  
 L'industrie des technologies médicales comme celle des produits Pharmaceu-
tiques ne saisissent pas importance d'une ETS complète à l'échelle euro-
péenne, bien que notre estimation des coûts indique que le secteur profite-
rait d'économies supplémentaires, en comparaison avec l'EER seule. Cepen-
dant, cela dépend fortement de la nature des sujets sélectionnés pour une ETS com-
plète. L'expérience en ETS complète dans toute l’UE est encore limitée à l'heure ac-
tuelle. Les domaines complémentaires de l'ETS complète (économique, organisation-
nel, juridique, étique et social) comprennent souvent de nombreux sujets « non trans-
férables », et doivent donc être substantiellement adaptés à l'échelle nationale. Ces 
éléments pourraient en partie expliquer les scepticismes de l'industrie.  
 Le secteur des technologies médicales envisage plus de défis lorsque la 
future coopération sur l'ETS à l'échelle européenne comprend un cadre légi-
slatif. À l'heure actuelle, l'industrie des dispositifs médicaux se heurte à un nombre 
inférieur de réglementations concernant l'accès au marché des produits, en raison de 
l’hétérogénéité significative des produits et de la fragmentation du secteur. Deux 
réglementations européennes récentes sur les dispositifs médicaux visent à améliorer 
la gestion de ce marché hétérogène. Étant donné que le secteur des dispositifs médi-
caux ne profite que d'une expérience limitée avec les processus d'ETS, elle prévoit 
une importante charge sur les procédures et processus, ainsi qu'un accès au marché 
ralenti. 
 L'on peut prévoir différentes synergies dans l'administration publique, 
puisque davantage d'évaluations seront potentiellement disponibles (si la 
coopération est fructueuse) pour les prises de décision. Un seul organisme 
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d'ETS pourrait ne pas disposer des capacités nécessaires pour réaliser toutes les 
évaluations dont les dirigeants auraient besoin à l'échelle nationale. En outre, avec la 
croissance attendue de la mobilité des patients en Europe à l'avenir, comme prévu par 
la directive sur les soins transfrontaliers, des prises de décisions plus harmonieuses et 
fondées sur les mêmes preuves seraient souhaitables.  
 Les facteurs de réussite généraux identifiés pour la poursuite d'une coopéra-
tion durable comprennent: (1) l'utilisation d'outils et de modèles communs, 
(2) des modèles de gestion avec une structure de gouvernance renforcée, 
(3) des processus d'évaluation opportuns, (4) une expertise et des informa-
tions transfrontalières, et (5) l'assimilation obligatoire des résultats à 
l'échelle nationale(11) (ce dernier point uniquement dans le secteur Pharmaceu-
tique), qui sont liés: L'utilisation d'outils et modèles communs facilite la réalisation de 
travaux conjoints avec la capacité institutionnelle suffisante, tandis qu'une solide 
gouvernance est fondamentale pour assurer des processus d'évaluation opportuns. La 
réalisation des évaluations en temps opportun est cruciale pour garantir une assimila-
tion au moment ou les résultats sont pertinents pour le contexte national. Des avis 
d'experts adéquats sont nécessaires pour assurer la qualité des évaluations réalisées, 
ce qui augmentera l'efficacité des processus pour tous les groupes d'acteurs. Enfin, 
l'assimilation obligatoire des résultats est pertinente pour garantir le succès des ob-
jectifs des travaux conjoints. Ces facteurs se montreront pertinents pour la mise en 
place de la future coopération sur l'ETS, bien qu'il faille prendre en considération les 
spécificités du secteur des technologies médicales, et le fait que les facteurs de succès 
pourraient être mieux adaptés à l'industrie Pharmaceutique. 
 Une collaboration législative pourrait notamment créer la capacité institu-
tionnelle nécessaire pour cette coopération, et les expertises pourraient être 
rassemblées. Par ailleurs, les résultats de notre étude montrent que les processus 
peuvent être mis en place de manière plus efficace lorsqu'ils sont coordonnés et facili-
tés par une institution permanente, puisque toutes les informations pertinentes sont 
centralisées, dégageant ainsi des économies globales.  
 Les économies potentielles augmentent considérablement dans les OP qui 
comprennent une production et une assimilation obligatoires des EER et ETS 
conjointes (OP 4.2 et OP 5). Les options qui prévoient un secrétariat permanent ou 
une nouvelle agence, impliquant une production conjointe plus élevée, entraîneraient 
des économiques largement plus importantes sur le long terme, en comparaison avec 
une coopération fondée sur des projets (environ 4 millions d’euros pour tous les pays 
dans l’OP 2, 70 millions dans l’OP 4.2 et 77 millions dans l’OP 5). En ce qui concerne 
les résultats du pronostic des coûts, il convient de noter certaines incertitudes dans le 
recueil de données, qui sont clairement indiquées dans les secteurs correspondants de 
notre étude.  
 Une durabilité accrue et une nature obligatoire renforcée de la coopération 
sur l'ETS en Europe pourraient entraîner des bénéfices pour les patients: une 
augmentation du nombre de technologies évaluées accroîtrait la base de preuves pour 
les prises de décision dans toute l’UE, notamment dans les EM ou l'ETS n'est pas 
encore bien développée, contribuant ainsi à une diminution des inégalités transfronta-
lières.  
 De la perspective des patients, la future coopération européenne sur l'ETS, avec 
des OP comprenant une participation et une assimilation obligatoires, augmenterait 
la disponibilité de médicaments et de technologies médicales sûrs et effi-
caces, et garantirait un contrôle normalisé des technologies de santé avant la 
mise sur le marché. Des processus d'ETS transparents et autonomes exigent la 
prise en considération de la perspective de tous les acteurs concernés afin d'améliorer 
l'efficacité et de prévenir les conflits d'intérêts. Des ressources financières suffisantes 
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sont indispensables pour établir les mécanismes respectifs. Outre les investissements 
requis, les acteurs devraient porter leur attention sur le potentiel retour sur investis-
sement des différents mécanismes.   
 La participation antérieure des patients aux processus d'ETS est caractérisée par de 
bonnes intentions de la part des groupes d'acteurs impliqués, mais les applications 
fructueuses sont encore limitées, soit par l'étendue ou l'objectif de la participation. 
L'administration publique et l'industrie Pharmaceutique émettent des signaux clairs 
indiquant un besoin d'amélioration et d'uniformisation de l'implication des 
patients dans les processus d'ETS. De manière générale, une coopération à long 
terme transparente dans le domaine de l'ETS offre le potentiel de prévenir les évalua-
tions sélectives des médicaments, de réduire la disponibilité des technologies de santé 
avec peu ou pas de valeur et d'augmenter la disponibilité d'informations accessibles 
au public. 
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1 Introduction  
The European Commission (EC) is exploring options for a new and sustainable mecha-
nism for Health Technology Assessment (HTA) in Europe after 2020.  
As part of that pursuit, the Directorate General for Health and Food Safety (DG SANTE) 
of the EC launched a new initiative, which addresses the question of whether and how to 
continue HTA cooperation at EU level beyond 2020, when the current EUnetHTA  Joint 
Action 3 (JA3) ends.  
The initiative commenced in summer 2016 with an Impact Assessment process (1) to 
support the initiative on strengthening the EU cooperation on Health Technology Assess-
ment. This was resulting in the launch of a Public consultation (6) by EC between 21 
October 2016 and 13 January 2017 (20). The consultation showed that 87% of respond-
ing citizens and stakeholders supported an EU cooperation beyond 2020 (6). 
In the context of this process, the EC commissioned the consortium of Sogeti, the 
Austrian Public Health Institute, Gesundheit Österreich Forschungs und Planungsgesell-
schaft GmbH (GÖ FP) and the London School of Economics and Political Science (LSE 
Health) to conduct an impact analysis of Policy Options (POs) for strengthened EU 
cooperation on HTA to support the preparation of the Impact Assessment and the 
formulation of the EC initiative with data and evidence.  
The so-called ‘baseline scenario’, which takes into account both national and EU policies 
and practices currently in place, and reflects possible developments until 2020 is the 
defined starting point of the study.  
This final report is the deliverable for Specific Contract N° CHAFEA/2016/Health/16 under 
Framework Contract N° CHAFEA/2013/Health/01 for Health reports (Lot 1) for the ‘Study 
on impact analysis of POs for strengthened EU cooperation on HTA’. 
In parallel, the EC commissioned two further studies to support the Impact Assessment 
process, notably (1) a mapping of HTA national organisations, programmes and process-
es in the EU and Norway, undertaken by Julia Chamova (2) and a mapping of HTA 
methodologies in the EU, undertaken by Finn Børlum Kristensen (7). This report cross-
references these two studies.  
 
                                                                                                                                   
 
(20)  http://ec.europa.eu/health/technology_assessment/consultations/cooperation_hta_en.htm 
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2 Background and context 
This study aims to provide input to the above mentioned Impact Assessment process and 
analyses the likely impact of the identified Policy Options for strengthened EU coopera-
tion on HTA.  
The specific objectives of the study are to: 
• Gather data and generate evidence on and provide an in-depth analysis of the 
baseline scenario including its impacts on different stakeholders; 
• Collect data and generate evidence on and provide an in-depth analysis of the 
potential impacts of identified options for future HTA collaboration and 
• Collect relevant literature on HTA, focusing on the European context. 
There are several definitions of HTA, but within the Europe Union, HTA is defined as ‘a 
multidisciplinary process that summarises information about the medical, social, econom-
ic and ethical issues related to the use of a health technology in a systematic, transpar-
ent, unbiased, robust manner´.  
The aim of the study is to inform the formulation of safe, effective, health policies that 
are patient focused and seek to achieve best value (8). In doing so there are several 
steps and in the context of this study, it is important to highlight the difference between 
Assessment and Appraisal.  ‘Assessment’ is defined as the collection and synthesis of 
evidence focusing on the traceability/replicability of results, whereas ‘Appraisal’ is the act 
of contextualizing evidence and formulating recommendations, i.e. defining impact and 
applicability (8, 9). 
The study focuses on the ‘Assessment’ aspect, and stresses that any subsequent pricing 
and reimbursement decision for medical technologies, devices or Pharmaceuticals 
remains purely at national level, as stated in the Inception Impact Assessment in relation 
to the initiative on strengthening of EU HTA cooperation. 
Over the past few decades, the diffusion of HTA has increased and its application has 
become more common across health systems in Europe. By now, public HTA bodies have 
been established in most Member States (MS) of the European Union (EU) and the 
European Economic Area (EEA), providing evidence-based information for both decision- 
and policy-making (10). 
Organisations conducting HTAs have become institutionalized elements of the respective 
health system in which they operate thereby providing information on the (clinical and 
cost-) effectiveness of health care interventions but also on promising technologies, 
which could lead to innovation in health care delivery (11). This process does not have 
the same speed in all MS, resulting in some countries having more advanced HTA 
systems while others are still in the initial phase of establishing HTA systems (12). 
At EU level, the value of HTA and the fact that joint work could facilitate the implementa-
tion of HTA processes and reduce redundancies regarding the assessment of technologies 
has been recognized. Already in the 1980, the Health Services Research Committee of 
the EC began to assign contracts for economic appraisals and mechanisms for the 
regulation of expensive health technologies in different countries. Between 1993 and 
2002, three projects were funded by the EC to support collaboration on HTA between MS 
(13). Subsequently, project reports were provided in the course of a political process on 
cross-border health care and the need for a sustainable European network for HTA was 
identified (14). In 2004, the EC and Council of Minsters requested the establishment of a 
sustainable European network on HTA. This was initiated in 2005 when a group of 35 
organisations started the EUnetHTA project, which explored possibilities and key chal-
lenges for an enhanced transnational collaboration for the following years and thus 
examined the HTA-process regarding its political links (14, 15). 
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In 2009, the EUnetHTA collaboration was founded and two Joint Actions were undertaken 
between both 2010 and 2012 (EUnetHTA Joint Action 1) and 2012 and 2015 (EUnetHTA 
Joint Action 2). During the Joint Actions, the joint work conducted was organised in 
several work streams, focusing mainly on the development of common methodologies 
and the creation of common IT Tools. Moreover, one purpose of the Joint Action was to 
reduce duplication of work between national agencies (16, 17).  
The third Joint Action (EUnetHTA JA3) started in June 2016, includes 81 partners and will 
run for 48 months. The general objective is to increase the use, quality and efficiency of 
joint HTA work at EU level to support evidence-based, sustainable and equitable choices 
in healthcare and health technologies and to ensure re-use in regional and national HTA 
reports and activities, in order notably to avoid duplication of assessments. Another 
overarching objective is to develop a general strategy, principles and a proposal for a 
scientific and technical mechanism of permanent sustainable European Collaboration on 
HTA in the light of the Directive 2011/24/EU on the application of patients’ rights in 
cross-border healthcare (CBHC) (18). 
Key outputs created by the two previous Joint Actions are (1) the HTA Core Model, which 
provides a methodological framework for shared production and sharing of HTA infor-
mation to enable the conduct of high quality HTA evidence in a structured format; (2) 
guidelines for rapid relative effectiveness assessment (REA), which address issues on the 
endpoints used for REA in Pharmaceuticals, the choice of the most appropriate compara-
tor(s) as well as direct and indirect comparison(s); and (3) guidelines addressing the 
level of evidence such as internal validity. 
A tool established during the Joint Actions is the ‘Planned and Ongoing Projects’ (POP) 
Database, which aims to facilitate the collaboration among European HTA bodies and to 
reduce the duplication of work by providing an overview of ongoing or recently published 
projects of participants. Within the first two Joint Actions, members of EUnetHTA 
undertook a total of 20 joint assessments of Pharmaceuticals and medical technologies 
including REA and Full HTAs (19). 
Additionally, the Health Technology Assessment Network was established based on 
Directive 2011/24/EU on patients' rights in cross-border healthcare (18), stipulating the 
support of cooperation between national authorities or designated national bodies 
responsible for HTA by the European Union (16). It is a voluntary network, which 
supports the cooperation between national authorities on HTA and focuses on strategic 
aspects of the European cooperation on HTA. All MS participate in this network (16), 
which set up a strategy for EU Cooperation on HTA that will be implemented by JA3 (20). 
While there have been several positive developments in HTA at EU level, there are 
several shortcomings in the current state of the art. Until now, the inclusion of joint work 
in HTA processes at national level has remained limited (also leading to the production of 
a reflection paper addressing the re-use of joint work in a national setting, which was 
published by the HTA network, aiming to provide concrete recommendations to increase 
the uptake of joint work) (21).  
One reason for this could be that participation in EUnetHTA and the uptake of joint work 
within the MS is strictly voluntary. There are some variations regarding the procedural 
frameworks and administrative capacities between MS because their HTA Bodies are 
embedded in different institutional settings. As HTA procedures differ between EU MS, 
diverging data requirements for the industry and outcomes for the same products across 
countries exist.  
Furthermore, HTA cooperation at EU level is currently funded solely through the Joint 
Actions and does not constitute a long-term funding and cooperation instrument. As a 
result, there is still a considerable duplication of work in assessing health technologies 
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within EU MS, and the fragmented landscape regarding HTA-procedures and methodolo-
gies complicates the situation for patients, payers and suppliers of technology(22).  
At the same time, no sustainable business model for implementation after the completion 
of the third Joint Action in 2020 has been developed so far. According to EU Financial 
Regulations, recurring activities cannot be funded. Therefore, other financial options need 
to be identified. In this context, the question of sustainable cooperation beyond 2020 is 
addressed in line with the ‘Better Regulation’ agenda of the EC, aiming at the design and 
evaluation of EU policies in a transparent manner considering both evidence and stake-
holder views (3, 4).  
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3 Study overview 
In line with the Request for Specific Services, the overall aim of the study is to support 
the Impact Assessment process of the EC with data and evidence and, in so doing, 
provide key inputs for analysing the impact of different Policy Options for EU cooperation 
on HTA beyond 2020. Possible Policy Options for cooperation on HTA at EU level have 
been identified within the Inception Impact Assessment published by the EC. These are 
further developed by the EC in the course of the study, validated by experts and com-
plemented by Business models/implementation mechanisms.  
 
The aims of the study in particular are to: 
• Collect data and generate evidence and provide an in-depth analysis of what 
would happen in the absence of further action at EU level, including its 
impacts (baseline scenario); 
• Collect data and generate evidence and provide analysis on the potential impacts 
of identified Policy Options for cooperation of the EC; and 
• Collect relevant literature on HTA, with a specific focus on the European Union. 
 
The study comprises several activities, including: 
• A systematic literature review as well as a desk research of HTA and its use in 
EU MS; 
• A detailed case study covering 40 health technologies; 
• A data collection process (survey complemented by focus groups) for both 
Public Administration and industry costs and impacts of the identified Policy Op-
tions; 
• Interviews with industry representatives; and 
• An analysis of these impacts by Policy Option for different stakeholder groups. 
 An overview of these activities is provided in Table 5.  3.1.1
For establishing the baseline scenario, a case study comprising a product sample of 
health technologies has been analysed, which includes 20 Pharmaceuticals, 15 medical 
devices and five other technologies (including complex health interventions). Detailed 
information on the HTA-process each health technology underwent across EU MS was 
collected in the course of the case study. Additionally, the costs of performing an HTA 
were identified for both the technology developer and the HTA body. Finally, the case 
study captured the influence of the regulatory framework on technology developers. The 
findings from the case study were complemented with focus groups (5.3.4), interviews 
(7.1.13) and the literature review (5.1).  
To assess the impacts of the Policy Options on the stakeholders the study team surveyed 
a number of economic and social health criteria (5.3.1) via an online survey, comple-
mented by focus groups, and findings from the literature review. 
The study also provided a description of the implementation mechanisms and business 
models (i.e. secretariat) and a calculation of the costs (see 7.2). 
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Table 5: Overview of activities within the study 
 
Baseline scenario 
Impacts of identified Policy 
Options of the EC 
Implementation mechanisms 
Key  
questions 
How do the current systems of 
HTA in Europe affect the key 
stakeholders (HTA bodies, 
industry, patients, etc.)? 
How would the proposed options 
affect the key stakeholders (HTA 
bodies, industry, patients, etc.)? 
Complemented by the description 
of the implementation mecha-
nisms (i.e. secretariat) 
How would the proposed 
cooperation be coordinated?  
Key  
indicators  
Indicators on the HTA processes 
and outcomes, costs for industry 
and HTA bodies, influence of the 
regulatory framework on 
technology developers 
Economic impacts (e.g. cost and 
administrative burden or impacts 
on the innovation), social impacts 
(e.g. access to and sustainability of 
health systems) 
Organisational and financial 
aspects of the implementation 
mechanism 
Data 
sources  
40 case studies 
Survey and focus group (cost part)  
Interviews 
Literature 
Survey and focus group (cost + 
impacts part)  
Own calculations for cost prognosis 
Interviews 
Literature 
Survey and focus group (cost part)  
Information from EUnetHTA  JA / 
other EU institutions 
Literature 
3.2 Involvement of experts 
 Expert group 3.2.1
An expert group was set up to validate assumptions made during the course of the study 
and to create a comprehensive overview regarding the definition of the baseline scenario, 
the Policy Options and the corresponding business models/implementation mechanisms. 
This section provides an overview about the members of the expert group and their 
contribution, and describes the different steps of expert involvement within this study. 
Based on the proposed list of experts included in the offer and further discussions 
between EC/CHAFEA, GÖ FP and LSE, a list of experts was defined. For this, specific 
attention was given to a well-balanced geographical mix. Furthermore, the study team 
aimed to incorporate different views on the outlook for EU cooperation on HTA. There-
fore, both EUnetHTA members and experts from the scientific community in Health Policy 
and Health Economics with experience in HTA were selected for the expert group. 
In early October 2016, 13 experts were contacted by E-Mail, highlighting the main 
objectives of the study, their envisaged role and the importance of the project. A letter of 
endorsement by EC/CHAFEA was shared with the experts as well. Twelve of the contact-
ed experts accepted the invitation and were subsequently asked to sign a confidentiality 
agreement developed by CHAFEA, which was done by all experts. An overview of the 
members of the expert group is depicted in Table 6.   
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Table 6: Overview of the expert group 
 
Name Position Country 
1 Jacek Walczak Vice President Laser Analytica PL 
2 Wim Goettsch Executive Board Chair EUnetHTA  JA, Zorginstitut Nederland NL 
3 Zoltán Vokó 
Prof. MSc MD PhD Head of Department 
Eötvös Loránd University, Budapest. 
HU 
4 Expert 
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen 
(IQWiG), Germany 
DE 
5 Mairin Ryan 
Director of HTA, Health Information and Quality Authority (HIQA), 
Ireland 
IE 
6 Marina Cerbo 
Director of Innovation Research and Development, Agenas – The 
National Agency for Regional Health Services; Italy 
IT 
7 Nick Crabb 
Programme Director, Scientific Affairs; National Institute for Health 
and Clinical Excellence 
UK 
8 Rosa Giuliani ESMO (European Society for Medical Oncology) EU 
9 
Francois Meyer/ 
Chantal Bélorgey 
HAS FR 
10 Karen Facey 
Past Chair HTAi Interest Sub-Group for Patient/Citizen involvement 
in HTA  
UK 
11 Reinhard Busse 
Professor and Department Head for Health Care Management at 
Technische Universität Berlin 
DE 
12 Claudia Wild 
Director of Ludwig Boltzmann Institute for Health Technology 
Assessment 
AT 
The involvement of experts took place in two steps. Firstly, a written expert consultation 
was initiated to receive feedback on the quality, feasibility and relevance of the POs on 
HTA cooperation. For this, a comprehensive document (see Annex 1) was set up, 
including information on the baseline scenario and the POs. Moreover, a list of impacts 
and indicators was presented for feedback to ensure that all relevant impacts and 
indicators for all stakeholder groups were covered within the study. The document for the 
expert consultation was sent by email on 17 November 2016 to all participating experts 
who were invited to comment on the issues raised. Of the 12 experts, eight responded, 
three experts did not respond and one expert chose not to respond because the expert 
perceived the approach of providing written feedback as inappropriate. Feedback and 
provided input was used for further discussions regarding the final version of the POs and 
the indicators to use for the assessment of the POs.  
Secondly, experts were invited to a face-to-face meeting in Brussels on 14 March 2017. 
There, we discussed the preliminary findings of the study and received input on these. 
Representatives of the consortium, EC Services including CHAFEA and DG SANTE, and 
two additional guests, Julia Chamova and Raf Mertens, also participated in the meeting 
(see Table 6). The recommendations of the expert group both for analysis and for 
additional data collection processes to address potential limitations of the survey were 
taken into account. One major follow-up to the expert group meeting was the organisa-
tion of the focus groups (see Chapter 5.3.4) to discuss and validate the results of the 
survey and case studies. 
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 Peer-review process 3.2.2
The study was scrutinised by scientific peer reviewers who were initially selected in 
cooperation with DG SANTE officers. They gave comments on the draft final study after 
DG SANTE’s initial feedback. A personal meeting was foreseen but was not considered 
necessary at the end of the undertaking. The peer review time was two weeks.  
Peer reviewers were: 
• Senior Expert Valérie Paris, OECD 
• Prof. Dr. Irina Cleemput, Belgian Health Care Knowledge Center (KCE) 
• Prof. Dr. Jaime Espin, Andalusian Public Health School (EASP) 
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4 Policy Options  
The EC has proposed core options for further cooperation at EU level in the Inception 
Impact assessment (1) and the Public Consultation, whose results were published in May 
2017 (6). 
The contractor has combined these core Policy Options with different potential business 
models. These were discussed, refined and further developed in close collaboration with 
EC/CHAFEA in the course of the study. To capture all the key points for the impact 
assessment, the expert group was consulted to provide feedback on and ensure the 
feasibility of the Policy Options/business models (see description of the expert consulta-
tion in 3.2.1). 
After inclusion of expert feedback, a final version of the POs, including a baseline 
scenario combined with different business models, was defined. It served as the basis for 
the online survey on impacts (for details on the online survey see section 5.3.1) 
Within this section, the key characteristics of these final POs are summarized and a short 
description for each of the options is given. 
4.1 Status quo 
The baseline Scenario is linked to the status quo of European HTA cooperation in 2016, 
taking possible developments until 2020 (end of EUnetHTA Joint Action 3) into account. 
This status quo is characterized by: 
• A heterogeneous situation regarding the relevance of HTA in national decision-
making processes. 
• Strictly voluntary cooperation between the EC and the EU MS through (1) Joint 
Actions (Scientific and technical- developing methodologies and tool and perform-
ing joint assessments) and (2) the HTA Network (providing strategic guidance). 
• No guarantee that any joint output is taken up in national HTA activities. 
 
Planned Work until 2020 – expected outcomes 
The general objective of the EUnetHTA  Joint Action 3 (2016 – 2020) is to support 
voluntary cooperation at the scientific and technical levels between Health Technology 
Assessment bodies to validate the model for joint work to be continued after EU funding 
under the Health Programme. The cooperation between national and regional HTA Bodies 
is to meet the provisions set out by Article 15 of Directive 2011/24/EU on patient’s rights 
in cross-border healthcare (18)  and to create synergy with the strategic HTA Network 
set up under this Directive. 
Joint Action 3 is aiming to establish an inventory of available methodological documents 
and tools, consequently identifying gaps and adjusting or maintaining existing guidelines 
and tools. Moreover, all tools should be integrated in an Online Handbook for HTA-
Doers, Early Dialogue communication should be provided, and a tool for post-launch 
evidence generation as well as a prioritisation process for the topics of Joint 
Assessments should be developed.  
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In EUnetHTA JA 3, there was a higher amount of joint production work than in the last 
Joint Actions; namely 51 Joint Assessments (21) – 33 on Pharmaceuticals and 18 on 
other technologies – and 29 so called ‘Collaborative Assessments’ (22) – four on 
Pharmaceuticals and 25 on other technologies – are planned.  
Until 2020, the Joint Action is financed by the 3rd Health Programme and MS’ contribu-
tions in kind. A new Joint Action is not foreseen, as it is a mechanism that should pilot 
new cooperation mechanisms, but not fund them over the long term. Therefore, it is 
anticipated that after expiration, and without further EU action, MS would depend solely 
on their national/regional HTA procedures and budgets. Although MS will be free to 
cooperate regarding HTA, on what scale joint work might continue is not certain. 
4.2 Key characteristics of Policy Options 
The different Policy Options for cooperation on HTA after 2020 are defined along 
several key characteristics, focusing on HTA output, participation and uptake from MS' 
perspectives, organisational aspects, funding aspects and timelines. These are explained 
in the following: 
 The scope of the cooperation is defined by several outputs (23) created by a joint 1.
collaboration, comprising of: 
• Common tools and procedures, including common submission templates, an IT 
system with planned and ongoing assessments, common methodologies (e.g. EU-
netHTA  Core Model), a joint prioritization process, and cooperation on data re-
quirements, including Horizon Scanning; 
• Performing joint Early Dialogues; 
• Performing joint Relative Effectiveness Assessments (REA can take place at time of 
market launch, or later – reassessment); 
• Performing joint Full Health Technology Assessments (Full HTA can take place at 
time of market launch, or later – reassessment); and 
  The engagement in participation and uptake (24) of jointly produced outputs can be 2.
either voluntary or mandatory:  
• Voluntary participation/Voluntary uptake (V/V): MS can decide if they wish to 
participate in the production of outputs and take up the respective output; cooper-
ation is entirely voluntary.  
• Voluntary participation/Mandatory uptake (V/M): The participation in the creation 
of joint work is voluntary, meaning that MS can decide to opt in (25) to the joint 
                                                                                                                                   
 
(21)  A Joint Assessment is defined as a prioritized topic, submission-based (using the submission templates as were developed 
in EUnetHTA  JA2), an authoring team of two to three agencies and at least five dedicated reviewers, English as working-
language, use of HTA Core Model and Guidelines, EUnetHTA  procedures on stakeholder involvement (scoping meeting with 
manufacturer etc.), internal and external quality assurance. A Joint Assessment can be a REA or a Full HTA.  
(22) A collaborative assessment is defined by a lower level of centralized work organization, but equal criteria in quality 
assurance: the collaborative assessments shall include at least three to five partners, however in justified cases, two 
partners would be acceptable. Such constitutes a less centralised topic selection/priority selection process. English as 
working language, use of HTA Core Model and Guidelines, not necessarily submission based, internal QA by review by at 
least two other EUnetHTA  partners (support by WP 4) and QA by external peer review, stakeholder involvement at one 
point in time (further criteria to be agreed upon). 
(23) The scope of the activities may differ between Pharmaceuticals, medical devices and other technologies. 
(24) Uptake concerns using or considering the results and findings of the HTA cooperation, reaching from jointly developed 
submission templates to outcomes in full HTA. The subsequent pricing and reimbursement decision would remain purely at 
the national level. Providers/developers also need to adhere to this process. 
(25)  Opting in by MS is by output, not by individual products. E.g. once a MS has opted in for joint REA, they take part in all 
joint REAs – but not necessarily as an author.  
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cooperation. However, once a MS has opted in, the uptake of the joint work into 
the national setting is mandatory.  
• Mandatory participation/Mandatory uptake (M/M): Both participation in the produc-
tion of outputs and the uptake of these into the national setting are mandatory. 
For each of the POs, different combinations of voluntary or mandatory participation 
and uptake per Output are possible. 
  For organizing the creation of these joint HTA outputs, a number of different organi-3.
sational mechanisms are conceivable: 
• Project-based cooperation – The secretariat is set up by the MS that participate 
(similar to EUnetHTA). 
• EU/MS secretariat – A permanent Secretariat is established.  
• Existing EU agency – A permanent Secretariat is integrated in an already existing 
EU agency. This Secretariat will coordinate the work of national experts in HTA 
bodies in carrying out assessments. There is no further specification on which EU 
agency might be considered. 
• New EU agency – A permanent Secretariat is integrated in a NEW EU agency. This 
Secretariat will coordinate the work of national experts in HTA bodies in carrying 
out the assessments.  
  For financing the joint cooperation several funding mechanisms are conceivable: 4.
• EU funding, either through a Public Health program or another financial instrument 
• Funding by MS joining the collaboration; and 
• Funding through industry fees 
 Timelines for implementation of the proposed POs after 2020 range from immediately, 5.
without delay, for option 1 (i.e. 2021) to transitional periods for implementing options 
4 or 5 in a new legal framework. 
Table 7 provides an overview of each Policy Option and the envisaged implementation/ 
funding mechanism. A short summary for each Policy Option can be found afterwards. 
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Table 7: Overview of Policy Options 
Legend. PO: Policy Option; V/V: Voluntary participation/ voluntary uptake; V/M: Voluntary participation/mandatory uptake; M/M: Mandatory participation/mandatory uptake; ED: Early Dialogue; REA: Relative Effectiveness 
Assessment; MS: Member State; HTA: Health Technology Assessment
                                                                                                                                                                                                        
 
(26) Assuming that 50% of the Member States (MS) participate, a mix of high/low income, large/small MS.  
(27) ED - Early Dialogue: Here mandatory uptake means that the MS cannot repeat an ED that was done at EU level. Technology providers initiate Early Dialogues. 
(28) Either at time of market or re-assessment. 
(29) A gradual introduction of products during a transitory period that allows to manage the workload while the structures/implementation models are being developed. 
 Baseline Non-legislative Legislative 
 
PO 1 PO 2 PO 3 PO 4 (26) PO 5 
No EU action 
after 2020 
 
Voluntary 
cooperation 
through Public 
Health Pro-
gramme 
Legislation 
covering 
common tools and 
Early Dialogues 
 
Legislation covering 
Joint work on REA 
Plus 
common tools and Early Dialogues 
Legislation covering 
Joint work on Full HTA 
(including REA) 
Plus 
common tools and Early 
Dialogues 
4.1 
REA V/M 
4.2 
REA M/M 
O
u
tp
u
ts
 
Common tools, 
including templates, 
methodology 
V/V V/M M/M M/M M/M M/M 
Early Dialogue (27) V/V V/M V/M V/M M/M M/M 
Joint REA (28) V/V V/M V/V V/M M/M M/M 
Joint Full HTA (6) V/V V/V V/V V/V V/V V/M 
Implementation No EU input 
Project based  
cooperation 
EU/MS secretariat Existing EU agency Existing EU agency New EU agency 
Financing None from EU EU+MS EU+MS+fees from industry for Early Dialogues, joint REA and Full HTA 
Scope  
All  Pharmaceuti-
cals , medical and 
other technologies 
Tools: all  
Pharmaceuticals , 
medical technolo-
gies, other 
technologies 
(phasing in), ED: 
industry submission 
Tools and ED see PO 3. REA: certain 
categories of  Pharmaceuticals (e.g. 
centrally authorised, high value/budget 
impact, agreement between MS) and 
medical technologies (e.g. high risk, 
high value products) and other 
technologies (agreement and prioritisa-
tion between MS) – phasing in29 
Tools and ED see PO 3, REA 
see PO4. For others: ad hoc 
agreement and prioritisation 
between MS 
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4.3 Short descriptions of Policy Options 
 
Policy Option 1. Baseline scenario - No EU action after 2020: 
The ‘no policy change’ baseline scenario supposes that the current EUnetHTA, Joint 
Action 3, ends in 2020 and it is the last Joint Action on this topic, i.e. EU funding stops. 
Without EU funding specifically devoted to it and/or a regulatory framework to support it, 
the European cooperation will be limited to the high-level policy-strategic discussions 
within the HTA Network of MS. According to the available budget, EC internal priority 
setting and the outcome of yearly negotiations between MS and the relevant EU Institu-
tions, the EU may support ad hoc scientific research projects, for instance through the 
H2020 programme. MS are free to cooperate on joint output (e.g. common tools, 
templates, Early Dialogues, REA or Full HTA) on a voluntary basis, relying on national 
resources (human and financial), which are expected to remain sporadic. 
 
Policy Option 2. Voluntary cooperation supported by the Public Health Pro-
gramme: 
This option foresees a voluntary cooperation model, partially supported by EU funding 
but without any regulatory framework.  
The potential joint outputs produced through the voluntary cooperation could cover the 
whole spectrum; it could cover common (IT) tools, templates, methodologies; Early 
Dialogue; joint REA and Full HTA. To address one of the shortcomings of the current 
cooperation model, in particular the low uptake of joint outputs, a contractual obligation 
could be included in any possible future project to make EU funding subject to the 
uptake. Further analysis in this possibility has indicated that, while theoretically possible 
(provided that the negotiating parties would agree) there is no effective possibility for 
the EC to enforce these contractual obligations.  
As the cooperation is fully voluntary, the scope of the products subject to the coopera-
tion would not be limited. 
This option would be project-based cooperation model. The costs would be co-funded by 
the EU and MS. Similarly to policy option 1, also for policy option 2, the source and the 
amount of funding is dependent on the negotiations of the Multiannual Financial Frame-
work (within the EC and the other relevant EU Institutions) and subject to renewal in 
every budgeting period.  
 
Policy Option 3. Legislation covering common tools and Early Dialogues: 
Policy options 3, 4, and 5 foresee the introduction of a legal framework for HTA coopera-
tion 
In Option 3, the legal framework would cover common (IT) tools, templates, methodolo-
gies; Horizon Scanning and Early Dialogue. The participation and uptake for common 
(IT) tools, templates, and methodologies is mandatory. For Early Dialogues, MS can 
choose to participate. However, uptake is mandatory, meaning that the MS cannot 
repeat an ED that was done at EU level. Outside of the legal framework, MS are free to 
cooperate on further outputs, i.e. on REA or Full HTA on a voluntary-voluntary basis. 
The product scope would vary by output. The common (IT) tools, templates and meth-
odologies would be applicable to all technologies on which national or regional HTA is 
conducted. Early Dialogues would be initiated by the industry and could cover any 
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Pharmaceutical, medical or other technology. Since the cooperation for joint REA and Full 
HTA is fully voluntary, so there would be a need to establish a contractual framework – 
just like under option 2 – or to work on a regional basis. 
Coordination on mandatory outputs would be organised by a secretariat run by the EC. 
The costs of the cooperation are funded by the EU, the MS and by other sources (e.g. 
company fees for Early Dialogues). 
 
Policy Option 4.1. Opt-in for joint REA plus option 3: 
Option 4 extends option 3 by including the joint REA in the legal framework in addition to 
the common (IT) tools, templates, methodologies; and Early Dialogue. The participation 
and uptake of the common (IT) tools, templates, methodologies and Early Dialogues is 
the same as in Option 3. Opt-in is foreseen in legislation for participating in the produc-
tion of joint REA and mandatory uptake by those who opted in. Outside of the legal 
framework, MS are free to cooperate on Full HTA on a voluntary-voluntary basis. 
The product scope would vary by output. For joint products covered under Option 3, the 
scope remains the same. For joint REA, a defined set of Pharmaceutical, medical and 
other technologies would be included. It would comprise Pharmaceuticals undergoing 
central marketing authorisation as well as Pharmaceuticals prioritised by an MS due to 
their importance considering products of: 
• high value 
• high budget impact 
• responding to unmet medical needs or with significant public health impact 
For joint REA on medical and other technologies, MS would be invited to consider the 
following technologies: 
• innovative and with potentials to transform the organisation of care (‘transforma-
tive technologies’) 
• responsive to unmet or significant medical needs 
• uncertainty regarding clinical effect 
• high impact on health and social care budgets 
• class III implantable devices and class IIb active devices as well as Class D In 
Vitro Diagnostic (IVD) devices (30) 
• where the HTA study is foreseen to have impact, in particular on decision-making 
(pricing/reimbursement) and treatment guidelines 
• Where requests were received from interested stakeholders (e.g. hospitals) 
 
As cooperation for Full HTA is fully voluntary, the scope of the products is not defined. 
The coordination would be organised in an existing EU agency. The costs of the coopera-
tion are funded by the EU, the MS and by other sources (e.g. company fees for ED and 
joint REA).  
 
Policy Option 4.2. Mandatory Joint REA plus option 3: 
Policy option 4.2 is essentially the same as option 4.1 with one important exception: For 
joint REA, both participation and uptake are mandatory.  
                                                                                                                                   
 
(30) These also have the potential to exploit potential synergies with the future scrutiny mechanism of the revised medical 
device and IVD regulations. 
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Policy Option 5: Option 4.2 and Opt-in for Full HTA: 
Option 5 is the most ambitious option, extending option 4.2 by including joint Full HTA in 
the legal framework in addition to the common (IT) tools, templates, methodologies, 
Early Dialogue and joint REA. The participation in and uptake of the joint outputs 
covered in option 3 and 4 remains the same. Opt-in is foreseen in legislation for partici-
pating in the production of joint Full HTA and mandatory uptake by those who opted in.  
For outputs covered under options 3 and 4, the scope remains the same. Full HTA would 
be undertaken on all technologies where a joint REA is undertaken.  
The coordination would be organised in a new EU agency. The costs of the cooperation 
are funded by EU, MS and other sources (e.g. company fees for Early Dialogues, joint 
REA and Full HTA). 
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5 Data Collection 
In order to collect a comprehensive data set, various methods of data collection were 
performed. The overall data collection process consisted of three parts:  
• A literature review comprised of a systematic literature research and a thorough 
desk research (see part 5.1) 
• A case study including 40 technologies of Pharmaceuticals, medical devices and 
other technologies (see part 5.2) 
• A survey process (see part 5.3) which comprised two parts, an online survey and 
interviews performed with health technology manufacturers. The online survey 
contained two separate questionnaires, one addressed to companies and associa-
tions and one addressed to MS, HTA bodies, patient organizations and health care 
providers (see part 5.3.1) 
Figure 3: Overview about streams of activities  
 
5.1 Literature review  
The aim of the literature review was to collect the most relevant and recent literature on 
HTA to provide an additional evidence base for the impact assessment. Thereby, the 
focus was set to literature regarding EU cooperation on HTA as well as national HTA 
systems in European countries. Both a systematic literature search in a set of databases 
as well as a comprehensive desk research were performed for retrieving the relevant 
literature. The methodology and the results are discussed briefly in what follows. 
For the systematic literature review, the following databases were used: Medline, 
Embase Cochrane Databases (Cochrane Central Register of Controlled Trials, Cochrane 
Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane 
Methodology Register, Health Technology Assessment, NHS Economic Evaluation 
Database), CINAHL, ECONLIT and Scopus. 
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For performing the literature search, a search strategy comprising the following search 
terms was set up (simplified presentation, full search strategy can be in Annex 2): 
 
 
 
 
AND 
 
 
 
 
 
Differences between the databases (for example, regarding different mesh terms) were 
considered when setting up the search strategy for each database. Search terms were 
searched for in titles and abstracts in English. Free-text truncation – e.g. truncation like 
comparison*, etc. And subject headings (e.g. Medical Subject headings (MeSH) – were 
used when appropriate. The identified references were collected in an Endnote® file and 
duplicates were removed. Afterwards, the publications were selected in two consecutive 
steps, following pre-defined inclusion and exclusion criteria. In general, studies were 
considered relevant if they were issued in the period between 2012 and 2016, written in 
English, French or German and published by regulators, HTA bodies and industry or 
stakeholder organisations.  
Authors considered a study relevant, if the following criteria (inclusion criteria I1 – I5) 
were met: 
Inclusion criteria 
I1 Publication describes a national HTA system in a European country with regard to its 
structure, developments, reforms or methods applied. 
I2 Publication is comparing or reviewing two or more EU HTA systems regarding methodolog-
ical issues (e.g. clinical aspects, economic aspects), outcomes or structural components of the 
HTA system. 
I3 Publication describes EU cooperation/bilateral cooperation in the field of HTA (e.g. REA, 
Early Dialogue) regarding joint assessment or joint procurement.  
I4 Publication describes cooperation in the field of HTA (e.g. REA, Early Dialogue) in non-EU 
countries regarding joint assessment or joint procurement, but can be relevant to the European 
context. 
I5 Publication is a document from stakeholder groups (e.g. Industry/patients) addressing HTA 
regarding current European cooperation or methodological issues. 
A study was excluded, if the following criteria (exclusion criteria E1 – E6) were met: 
Exclusion criteria 
E1 HTA as a concept/political instrument is not the primary investigated subject of the publication.  
E2 Study was published in a language other than English, French or German or before 2012.  
E3 No clear description of the context/no abstract available.  
E4 Description of non-European HTA system with no connecting factor to the topic of this study. 
E5 Publication is addressing a specific technology in one country (no country comparison). 
E6 Publication is a conference abstract, interview or comment. 
(Technology Assessment, Biomedical OR Health Technology Assessment OR Europe-
an public assessment study OR relative effective assessment OR outcome assess-
ment OR process assessment clinical assessment OR joint assessment OR evidence-
based medicine)  
 
 
(Decision-making, Organizational/ OR Health Policy/ OR International Cooperation/ 
OR international comparison OR international cooperation OR health policy OR 
European cooperation OR European collaboration) 
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The de-duplicated systematic literature search within the mentioned databases yielded 
993 results in total. Of these, 96 publications were included after the second 
selection.  
The relevant literature has been used in the subsequent sections to put in context, verify 
and complement the findings of the case studies and the survey.  
To identify relevant grey literature, a thorough desk research was performed to 
complement the systematic literature search. This search included Google Scholar 
(searching for terms such as ‘HTA’, ‘cooperation’ and ‘EU’) and the websites of national 
HTA institutes as well as international organizations, EU projects and networks within the 
HTA sector: 
• European Union (EC particularly of DG SANTE, DG ENTR, DG, COMP, DG Research 
and Horizon 2020 and FP7, European Parliament, Council of the EU, CHAFEA pro-
ject database, Joint research centre JRC) 
• AdHopHTA 
• INTEGRATE HTA  
• MedtechHTA 
• Advance HTA  
• European Medicines Agency (EMA) 
• European Network for Health Technology Assessment (EUnetHTA ) 
• Central and Eastern European Society of Technology Assessment in Health Care 
(CEESTAHC) 
• Organisation for Economic Co-operation and Development (OECD) 
• World Health Organization (WHO) 
• Health Evidence Network (HEN) 
• Health Technology Assessment international (HTAi) 
• International Network of Agencies for Health Technology Assessment (INAHTA) 
• The European Public Health Association (EUPHA) 
• Innovative Medicines Initiative (IMI) 
• International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 
• National HTA Institutes  
• International Journal of Technology Assessment in Health Care 
• Google Scholar 
• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)  
• European Federation of Pharmaceutical Industries and Associations (EFPIA) 
• MedTech Europe 
The websites of these institutions/organisations were searched for publications on the 
issue of HTA systems and EU/international HTA cooperation. This included grey literature 
such as HTA reports, annual reports of HTA bodies, presentations and posters. Relevant 
publications were provided in an Excel file. Inclusion and exclusion criteria for the 
systematic literature review were used as an orientation for applicability of publications.  
The identified literature was read, relevant information was extracted and clustering has 
been used in the subsequent sections to put in context, verify and complement the 
findings of the case studies and the online survey.  
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5.2 Case study – data collection on 40 technologies 
In this section, we outline the data collection process for the forty case study technolo-
gy-indication pairs, which followed a process comprising four tasks:  
1. The identification of a sample of suitable case studies of technology-indication 
pairs;  
2. Primary analysis of secondary data through desk research of the identified case 
studies;  
3. Primary data collection through the administration of an EU-wide survey of medi-
cal technology manufacturers and HTA bodies; and  
4. Primary data collection through semi-structured interviews of medical technology 
executives.  
The information retrieved was compiled into the table of indicators and follows the 
structure outlined below:  
• Indicators in Annex 12 were filled by the desk research (publicly available data 
from official documents); 
• Table in Annex 13 refers to the costs of performing HTA. The costs were collected 
through the survey delivered by GO-FP;  
• Table in Annex 14 includes ten concrete examples on how HTA practices shaped 
industry behaviour, informed by stakeholder interviews. 
Details on the process to acquire the information required and build the evidence base 
are provided in the sections that follow. 
 Sample selection for case studies 5.2.1
In order to understand the variability in methods and processes currently employed by 
different HTA bodies and the influence that different methods and processes have had on 
final HTA outcomes, we selected 40 technologies for in-depth analysis. The unit of 
measurement and analysis was the technology-indication pair, bearing in mind that the 
same technology could be indicated for different diagnoses. Data collection commenced 
in October 2016 and was completed in February 2017.  
The sample was selected based on the following criteria:  
• Technologies should have been marketed by at least 10 EU MS for the indication 
under consideration;  
• Technologies would need to have been assessed between January 2012-August 
2016 for the selected indication in order to include the most recent technology as-
sessments, but, for data availability reasons, this was subsequently revised to the 
period from January 2006-August 2016;  
• At least 5 HTA bodies across the EU should have assessed the technology; and  
• The assessment information and relevant reports for each technology-indication 
pair should be publicly available and preference was given to technologies with a 
higher number of publicly available HTA reports; the minimum requirement for 
this purpose was 5 HTA agency reports for the same technology-indication pair in 
order to ensure a degree of comparability across HTA processes and outcomes.  
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
 83 
For the selection of the sample of the health technologies, a four-step process was 
adopted outlined as below.  
Figure 4: Selection process 
 
First, forty one HTA bodies across all EU MS were identified and recorded. In some 
countries (Austria, Germany, Italy, Spain and UK), more than one HTA body was 
included in order to showcase the key role played by regional HTA bodies in those 
countries. At EU level, EUnetHTA was also included in order to account for joint assess-
ments conducted by more than one country together. Luxembourg and Greece do not 
have an explicit central Health Technology Assessment process, therefore they were 
excluded from the final sample. In 2011, Denmark discontinued the conduct of HTA at 
central level, thus it was not considered for this task. Overall, most HTA bodies have an 
advisory function and their actual roles and manpower are quite heterogonous. 
Having identified the HTA bodies, we recorded some of their key operational attributes 
and the methodological approaches and processes they employ. In doing so, we were 
able to comment on: (i) their operational model (for example, if they operate at national 
or regional level or if their role is regulatory or advisory); (ii) the inclusion of examples 
of different HTA approaches (for example, if they conduct only REAs or Full HTAs); (iii) 
the presence of an established agency; and, (iv) the availability of publicly available 
information on assessments performed. For each HTA agency, its contribution to the final 
pricing/reimbursement decision and the level at which it operates, were captured. 
Table 6 (Annex 5) showcases (i) the competent HTA bodies by country, (ii) whether the 
scope of their recommendation is national or regional, (iii) the type of technologies 
assessed/appraised by the HTA body, iv) the role of HTA and whether it is regulatory or 
advisory to the final pricing/ reimbursement decision and v) whether HTA recommenda-
tions are publicly available. 
Second, websites of the selected HTA bodies were queried in order to identify relevant 
data and HTA reports and to ascertain the feasibility of data availability across technolo-
gies and countries. Data were collected from publicly available reports only, which were 
posted online on the websites of the selected HTA bodies. The review commenced with 
the inclusion of all HTAs conducted between 1 January 2006 and 31 August 2016. 
Country-specific extraction tables were created in Excel, into which the data was 
inserted. The data was subsequently compared, aiming to identify common health 
technologies appraised across HTA bodies. 
Third, a database was created with all common HTA technology-indication pairs, ranking 
them from those with the highest level of publicly available information and by the 
extent to which they fulfilled the predefined four main criteria outlined in the first step. 
After ranking the technologies by data availability, the sample of technologies was 
selected based on the inclusion criteria outlined in Table 8 regarding sample representa-
tiveness. For a technology to be selected for in-depth study, it would need to fulfil at 
least one of the inclusion criteria. Additionally, the number of combinations of different 
inclusion criteria outlined in Table 8 (e.g. product from a medium-sized company and 
Early Dialogue, or product from a large company and Early Dialogue) was factored into 
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the final selection of technology-indication pairs. When a technology was indicated for 
more than one indication, the indication with the highest number of available data and 
most recently marketed was selected. 
The term medical device31 covers a vast range of technologies surrounded by regulatory 
complexities, which needed to be reflected in the sample. In a first step, the categories 
given by the Global Medical Device Nomenclature (GMDN) were considered for selection 
to ensure a broad scope of different medical devices; the sample adopted the classifica-
tion outlined by the EC in Directive 93/42/EEC Annex IX as well as the definition for 
active implantable medical devices and in vitro diagnostics according to Directive 
90/385/EEC and Directive 98/79/EC, respectively. Overall, the medical device sample 
would include at least one device from each category in order to maximize its represent-
ativeness. 
Table 8: Inclusion criteria 
Type of technology  Criteria 
All technologies  
 Products from different sized companies (e.g. large, medium and SME as 
well as products from different therapeutic areas)  
 Mix of procedures –e.g. Early Dialogue (yes or no), EUnetHTA  or national 
 Different budget impacts will be included 
Pharmaceuticals 
1. Product, which underwent central marketing authorization 
2. Product, which underwent national marketing authorization 
3. Product treating major and chronic disease (MCD)  
4. Product treating orphan diseases 
5. Product treating a paediatric population 
Medical devices 
A. Active implantable devices 
B. Anaesthetic and respiratory devices 
C. Dental devices 
D. Electro mechanical medical devices 
E. Hospital hardware 
F. In vitro diagnostic devices 
G. Non-active implantable devices 
H. Ophthalmic and optical devices 
I. Reusable devices 
J. Single-use devices 
K. Assistive products for persons with disability 
L. Diagnostic and therapeutic radiation devices 
M. Complementary therapy devices 
N.    Biologically-derived devices 
O. Healthcare facility products and adaptations 
P. Laboratory equipment 
Q. Medical software 
Taking into consideration that HTAs are performed on health technologies other than 
Pharmaceuticals and medical devices, in order to account for recent advances in health 
technologies other than Pharmaceuticals and medical devices, the sample included five 
health technologies that were neither Pharmaceuticals nor medical devices. In defining 
these, we searched for HTAs across screening programmes, vaccination campaigns, 
evaluation of surgical and non-surgical interventional procedures, stem cell therapies, 
innovative cancer vaccines, gene therapies and other forms of personalized medicines 
and screening programmes. The identified technologies were classed as ‘Other Technolo-
gies’ and included screening programmes and vaccines.  
                                                                                                                                   
 
(31) In this report the word ‘devices’ is used generically and includes medical devices and associated medical technologies. 
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 Desk research and primary analysis of secondary data 5.2.2
The indicators (see Annex 12) were researched in the available HTA reports along with 
any other relevant information about the HTA process a selected technology has 
undergone. The relevant websites of HTA bodies and National Regulatory Agencies and 
Health Agencies (e.g. AIFA in Italy or the ‘Base de Donnees Publiques des Medicaments’ 
in France) were also screened to capture any information missing from the actual 
reports. Finally, some indicators were adjusted for the study technologies to reflect 
important regulatory or other endpoints that would be different across technologies. For 
instance, in the indicators for medical devices, the CE mark was recorded instead of 
marketing authorisation (MA) date; and indicators, such as the cost of the programme or 
the target group of the programme, were added for the ‘Other Technologies’ sample. 
All the data were compiled in an excel spreadsheet to create an interface between 
qualitative and quantitative data. The information included in the excel captured the 
molecule name, the branded Pharmaceutical name, the HTA recommendation issued in 
each study country and a number of coded parameters, which were identified by 
reviewing the evidence considered by HTA bodies. When a product underwent more than 
one assessment, this was recorded and data were retrieved from the latest assessement 
published. After finalizing the collection of the qualitative data, the database was cleaned 
and, subsequently, variables were coded and categorized in order to obtain quantitative 
data.  
Following consultation with the experts group, a number of HTA bodies were contacted 
to validate the collected information or obtain additional data. IQWIG, HAS and ZiN were 
contacted in order to validate the extracted data. Validation was mainly focused on the 
categorisation of the outcome decision (and whether a technology would be: ‘Listed’, 
‘Listed with Restrictions’ or ‘Rejected’). Data was again cross-checked following the 
submission of the interim study in order to minimize the likelihood of any errors of 
interpretation.  
Each indicator was coded with one or more codes. The coded information was used to 
undertake qualitative analysis in order to understand processes in different settings, and 
for quantitative descriptive analysis, in order to understand trends across countries. This 
approach enabled the transfer of the qualitative value of the criteria identified to a 
quantitative system and to weigh their relevance both on specific countries and on the 
entire sample.  
Overall, the qualitative and quantitative data complemented each other, allowing 
identification of duplication of effort and measurement of the extent of differences across 
case studies. This part of the analysis and the indicators that inform it is partly based on 
a published methodological framework, analysing the quality of evidence, its interpreta-
tion and the factors beyond costs and effects that help shape or inform decisions (23, 
24).  
Coding was conducted systematically and homogeneously across all technology-
indication pairs, such that they were also comparable across countries. The different 
phases of the decision-making process were coded with a specific set of ‘code/name’. 
This was done in order to classify the evidence within which a number of criteria that had 
some influence over the decision-making process were identified. In so doing, we 
ensured that these phases were comparable across the study countries. The different 
stages identified comprised the following: 
●  First, the final decision/HTA recommendations were captured. Final HTA decisions 
were divided into three groups: (a) to ‘List’ the technology as requested in the HTA 
submission for the relevant indication (e.g. positive coverage recommendation), (b) 
to ‘Restrict’ the technology to a subgroup of the indication population or recommend 
use under certain conditions only (e.g. restricted coverage recommendation), and (c) 
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to ‘Reject’ the technology (e.g. negative coverage recommendation) for the indication 
applied for. In the case of a ‘restricted’ outcome, the restrictions listed for the use of 
the technology were also captured. 
●  This classification was applied to all the countries except Germany (IQWIG and G-BA) 
and France (HAS), where the decisions comprise an assessment of the extent of 
clinical benefit. In these two countries, recommendations are established according 
to the drug’s medical benefit, with two scales in both. In France, the medical service 
rendered (SMR) comprises four levels and determines the extent of reimbursement, 
whereas the improvement in therapeutic benefit (ASMR), comprises 5 levels and 
informs price-setting. Free pricing, subject to a ceiling based on a European average, 
applies for ASMR I-III ratings under the condition that the price is similar to other 
European countries and treatment with ASMR IV-V ratings must price their 
Pharmaceutical product close to the price of the treatment alternatives, or at a 
discount. In Germany, the added benefit classification comprises six levels and has 
implications for pricing (Levels 1-4: price negotiation, Levels 5-6: inclusion in 
reference baskets and subjecting the product to reference pricing), whereas the level 
of proof, composed by three categories, gives a value to the clinical effects. 
●  Second, the clinical (number and type of trials, final reasons supporting the clinical 
benefit claims) and economic (type of cost-effectiveness analysis, comparator used 
and final reasons supporting the cost-effectiveness) evidence produced by the 
manufacturer or by the HTA body was recorded. This analysis would allow the 
identification of overlaps in the evidence considered across the agencies and whether 
assessments are correlated with the same or different preferences towards evidence 
(e.g. requirements for indirect comparisons) or other elements. 
●  Third, elicited and non-elicited value judgments and stakeholder input influencing the 
decision were also included. Key variables among them were the severity of disease, 
economic and emotional burden on patients and carers, innovation of the treatment 
and other diseases and therapeutic characteristics relevant in the final decision. This 
should provide an understanding of the extent to which ethical considerations and a 
broader societal perspective would exert an influence on the final HTA 
recommendation and how they are accounted for across countries. 
 Data availability for case studies 5.2.3
Overall, we identified 41 HTA bodies in 25 European countries (see Annexes 16, 17 and 
18). In some countries (Austria, Bulgaria, Germany, Italy, Spain and UK) more than one 
HTA agency were included in order to showcase the key role played by regional HTA 
bodies in those countries. In the UK, NICE and SMC were selected, whereas in Italy, 
UVEF was selected as an example of a regional HTA body, while at national level, AIFA, 
the Italian Medicines Agency, was the default selection, since it plays a pivotal role in the 
pricing and reimbursement process. At European level, EUnetHTA was also considered in 
order to account for the joint assessment conducted by more than one country together. 
Luxembourg, Greece and Denmark were excluded from the sample for the reasons 
explained in section 5.2.1. We found that 11 countries (Bulgaria, Croatia, Cyprus, Czech 
Republic, Hungary, Ireland, Latvia, Lithuania, Malta, Slovakia, Slovenia) do not make 
their HTA reports publicly available, while Ireland only publishes a short summary of its 
HTA reports for a given technology-indication pair. The relevant HTA bodies in these 
eleven countries were contacted in order to obtain the HTA reports on the selected 
technologies. We received responses from Croatia (AZZ) and Ireland (NCPE) only. Even 
though Croatia shared all the requested reports, Ireland (NCPE) advised that due to 
confidentiality between the NCPE, the final decision-maker and the applicant (i.e. the 
company in question), the information of the Full HTA study would remain confidential 
and could not be shared with third parties. Therefore, data collection from Ireland was 
retrieved only in terms of the short summary documents that were available online. After 
consultation with the experts group, we further included in our sample of the HTA 
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bodies two new national agencies, Hauptverband from Austria and INAMI from Belgium, 
and contacted to obtain data, which is not publicly available and is needed for our data 
collection. Finally, OGYEI in Hungary were contacted again to obtain information on 
the HTA evaluations they perform. Overall, 34 agencies were included in the analysis. 
HTA reports that were available in the language of their country of origin were translated 
into English for the purpose of our analysis. When reports were not publicly available, 
the EC, together with LSE, requested these from the relevant HTA countries via direct 
email contact. 
Due to lack of available evidence (HTA reports), the sample had to be modified in two 
cases: ‘HPV testing’ in the Medical Devices sample and ‘cryotherapy’ in the ‘Other 
Technologies’ sample. In the case of HPV testing, the replacement was made because 
the specific test was often included in the evaluation of cervical cancer screening 
programmes and not evaluated as a medical technology per se and also already cap-
tured in the ‘Other Technologies’ sample. This device was substituted with ‘gene expres-
sion profiling and expanded immunohistochemistry tests’ with the same risk class of HPV 
testing and appraised by five HTA bodies. In the case of cryotherapy, the reports found 
in the initial screening were out of scope or fell in other categories (not ‘Other Technolo-
gies’) leading to a lack of data. This technology was replaced by ‘seasonal influenza 
vaccination’. Finally, a few other adjustments were made to increase the accuracy of the 
sample and the assessing bodies; for instance, in the ‘Other technologies sample’, 
AOTMiT was excluded because HTA is performed at regional level and not at national 
level – more than one report being published across regions to evaluate a programme, 
resulting usually in different recommendations. 
The final sample of 40 technologies is displayed in tables. The sample of the 20 Pharma-
ceutical technologies and their indications is shown on Table 22, while the sample of 
medical devices is presented on Table 23. Table 24 shows the sample of ‘Other technol-
ogies’.  
  Cost data extraction methods  5.2.4
In order to capture cost-related data, LSE designed a section of the survey delivered by 
GOEG (see also 5.3.1). Questions endeavoured to capture the cost of performing HTA in 
different European countries. The cost section was tailor-made for HTA bodies and 
manufacturers, respectively, and aimed to obtain information on the different cost 
burdens by geography and by technology. The cost section was divided into four main 
sub-sections. The first sub-section addressed the general cost of performing HTA (HTA 
bodies) or submitting an application (manufacturers). The second sub-section aimed to 
capture the human resource costs of performing HTA. The third sub-section was de-
signed to capture stakeholder costs and the implementation and dissemination costs of 
HTA bodies, while the fourth sub-section aimed to capture the costs of evidence genera-
tion and reassessment for manufacturers. This approach was adopted due to the lack of 
publicly available data on costs and the ‘sensibility’ for the industry regarding some data 
collected.  
It is important to highlight that to capture the real magnitude of the costs related to 
HTA, this set of indicators was considered at the HTA agency and industry levels and not 
at the technology level. This was designed to capture the costs of performing HTA in 
different European countries, besides costs considered in regulatory settings.  
Along with these, some costing data from Chamova 2017 (2) were used to validate and 
complete any missing information on HTA-related costs. Specifically, overall costs 
captured by this study were included and compared with the overall cost information 
obtained by our survey. 
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 Interview methods  5.2.5
In order to supplement results obtained by the desk research and to better capture how 
HTA processes in different European countries influence the decisions and the business 
strategy of Pharmaceutical and medical technology manufacturers, a number of inter-
views across different Pharmaceutical and medical device companies were conducted. 
For this task, a semi-structured interview guide was developed and used at each 
interview. The interview guide was structured in six main sections (see Figure 5 below), 
to capture different elements that might affect the market entry, and decision-making or 
data-generation processes of manufacturers (see Annex 15). For instance, the HTA 
country setting and practice (e.g. the possibility of appeal or resubmission), the delays 
related to the HTA submission (e.g. stop of the clock), the possibility of being engaged in 
an Early Dialogue or rapid assessment and any other relevant comments or examples of 
how the HTA process may have had an influence on the manufacturer decisions and 
market strategy, were discussed in the interviews. Manufacturers were also queried on 
their experience with EUnetHTA and their thoughts on the various Policy Options put 
forward by the EC. 
Figure 5: Discussion topics of the interviews 
 
In selecting manufacturers to conduct these interviews, due consideration was given to 
the case study sample size; we ensured that the majority of interviewee companies had 
at least one product in our case study sample. Both interviewees from Pharmaceutical 
and MedTech companies were included in the interviews, while consideration was also 
given to the size of companies (in terms of turnover) and the implications that this might 
have on their ability to perform and complete/submit HTAs across settings as required. 
As a result, we were able to include both large and smaller Pharmaceutical and MedTech 
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companies. In addition to the above, the study team received requests from other 
manufacturers and trade associations that did not have a case study product in our list 
of case studies and we were therefore in a position to enlarge our interview sample.  
Interviews took place between mid-January and mid-March 2017. A total of 15 manufac-
turer-specific interviews were conducted either face-to-face or by telephone. In a 
number of cases, multiple interviews were conducted with individual manufacturers in 
order to capture different perspectives and ensure the widest possible coverage of 
topics. Participants were assured that all comments and insights provided would remain 
anonymous. When permission was granted, interviews were recorded to facilitate the 
subsequent analysis. If the participant did not provide permission to record, detailed 
notes of the responses were taken.  
The interviews were conducted seeking opinion on six areas: (1) Experience with 
EUnetHTA; (2) Impact of national procedures on manufacturers; (3) Usefulness of Early 
Dialogue and rapid assessment; (4) Additional evidence generation and resubmission 
processes; (5) Impact on innovation and predictability; and (6) Thoughts on EC planned 
POs. Each interview response was screened for relevant insights in any of the six 
categories. After extracting relevant information from all interviews, common insights 
and feedback was aggregated across companies for Pharmaceuticals and for medical 
devices according to each thematic area. Four types of results are presented for each 
thematic area: Problem/Solutions, Positive Feedback, Negative Feedback, and Additional 
Insights. The results of interviews with Pharmaceutical manufacturers, including associa-
tions, are presented in 7.1.13.2. The results of interviews with MedTech Industry, 
including associations, are presented in 7.1.13.3. 
5.3 Survey process – data collection on indicators for costs and 
investment and impacts of POs 
 Online survey 5.3.1
An online survey was performed with the aim to collect data on: 
• Costs of HTA processes, e.g. Horizon Scanning, Early Dialogues, Relative Effec-
tiveness Assessments or conduct of full Health Technology Assessments, provided 
by the respective stakeholders and 
• Effects that different types of Policy Options might have on various indicators.  
To keep the burden on the target group – especially in the light of other surveys 
including the public consultation conducted simultaneously – as low as possible, the 
project team decided together with EC/CHAFEA to have one survey covering both 
aspects. There were two questionnaires, adapted for Industry and Public Administration 
(other organisations). 
The development and conduct of the online survey was set up in three phases and 
subdivided into several tasks (see Figure 6).  
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Figure 6: Overview of online survey process for industry and Public Administration 
questionnaires 
 
 
Phase 1 ‘Design & Verification’ started with identifying and specifying the required 
data from industry and Public Administration. 
The heterogeneity of authorities and stakeholders addressed and their expected different 
perspectives led to the decision to set up two different questionnaires, one for industry 
stakeholders and one for Public Administration, which both followed the same format 
(see below). 
Both questionnaires (see Annex 3 and 4) consisted of four parts:  
● Part 1 included general questions on the respective organization 
● Part 2 included questions related to the costs of HTA processes 
● Part 3 provided an overview of the different POs available to continue cooperation on 
HTA at EU level beyond 2020 
● Part 4 aimed to assess the respondents’, i.e. organizations’, perspective to estimate 
a potential impact on the respective indicators 
The questions in Part 1 and Part 2 differed between the two questionnaires and were 
adapted to the respective stakeholder group (industry vs. Public Administration) taking 
the divergent characteristics of the HTA sector and cost components for each stakeholder 
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into account. Part 3 and Part 4 were identical to ensure comparability of different 
stakeholders’ perspectives. 
To capture cost-related data, LSE designed Part 2 of the survey and questions endeav-
oured to capture the cost of performing HTA in different European countries (for more 
details see 5.2.4). 
The questions regarding the impacts of the different Policy Options (Part 4) were 
developed by GÖ FP and guided by the requirements provided within the EC’s Better 
Regulation Guidelines (4, 5) which state several key impacts to consider. Table 9 depicts 
the included economic and social/health impacts. Details on the specific indicator for 
each impact can be found in the questionnaires (see Annex 3 and 4). 
Table 9: Overview on key impacts in the survey (each impact parameter was 
represented by one or more indicators) 
Economic impacts (EC) Social/health impacts (SH) 
Costs Employment (labour market) 
Administrative burden 
Governance, participation and good admin-
istration 
Competitiveness of EU health technology 
sector 
Access to social protection and health systems 
Innovation and research Sustainability of health systems 
International Trade Public health  
Functioning of the internal market and 
competition 
 
Consumers and households  
Macroeconomic environment  
After drafting the questionnaires for industry and Public Administration, two online 
questionnaires were established using the online survey tool ‘Questback’®.  
As a next step, the questionnaires underwent a piloting process. Different members of 
the consortium and other colleagues not involved in the study tested the feasibility of the 
questionnaires. Moreover, industry stakeholders from both, the Pharmaceutical and 
MedTech, sectors piloted the industry questionnaire, whereas the Public Administration 
questionnaire was piloted by a representative of an HTA institute. The piloting parties 
submitted their feedback to the questionnaires which was subsequently incorporated. In 
general, the feedback was positive although the questionnaires were considered quite 
complex. Given the short time frame, no alternative procedure was available. The layout 
of the questionnaires was adapted at some parts to enhance consistency. 
Phase 2, ‘Implementation’ started with launching the survey in mid-December 2016. 
To fully capture the costs of HTA processes and the impacts of the different Policy 
Options, the survey was distributed to a variety of stakeholder groups. These included 
MS authorities (government, HTA bodies, pricing and reimbursement bodies), industry 
(e.g. Pharma, medical technologies and other technologies), patient groups, healthcare 
providers (doctors, hospitals) and payers (health insurers, public health schemes). 
For distributing the online questionnaire, a top-down process was used, addressing 
organizations at EU level and asking for their support to distribute the survey to the 
respective organizations or national responsible authorities. This approach was chosen to 
maximize the number of possible respondents. Contacts with industry associations at EU 
level and EUnetHTA Joint Action (JA) members were established prior to the survey 
launch to inform them about the upcoming survey. Moreover, a short informational 
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document (a ‘two-pager’) was sent prior to the survey launch, customised per stake-
holder group. 
Table 10 depicts the stakeholder groups and organisations the survey was distributed to, 
channelled through DG SANTE. For approaching these organisations, DG SANTE sent an 
email invitation including a short description of the survey, stating the objective and aim 
of the study, a link to the online questionnaire, short information on the structural issues 
of the survey tool (e.g. the possibility to go back and forward in the questionnaire) and 
the survey deadline of 22 January 2017. Moreover, the invitation email contained two 
attachments, an outline of the questionnaire and a short overview of the study. 
Table 10: Overview of approached stakeholder groups 
Stakeholder group Organisation to which invitation for 
survey was sent for further distribution 
Specific stakeholder group 
Industry 
 
 
 
 
EFPIA Pharmaceutical sector -> distributed question-
naire to Pharmaceutical companies throughout 
Europe 
EUCOPE 
Medicines for Europe 
Medtech Medical technologies sector -> distributed 
questionnaire to MedTech companies throughout 
Europe 
COCIR 
 EuropaBio Biotech sector-> distributed questionnaire to 
biotech companies throughout Europe 
Public Administration Ministry of Health/Health Attachés  -> all MS 
 
HTA Network 
HTA bodies -> all MS 
ESIP Payers 
AIM  
EUnetHTA  distributed by EUnetHTA  to all members 
EURORDIS Patients 
EPF 
EU Patient 
HCD Economics Academic /Consultancy Sector 
 University of Chester 
Simultaneous to the survey launch, survey support by GÖ FP commenced. The survey 
team provided support by email and by telephone to answer questions regarding 
technical issues as well as questions regarding the content of the online questionnaire. 
This service was used by several industry and Public Administration and several issues 
were raised – for example, regarding the framework, methodology and design of the 
questionnaire. In specific cases, telephone conferences with respective stakeholders 
were organized and answers were provided by the survey team of the consortium and 
representatives of DG SANTE.  
Due to requests by both industry and Public Administration respondents, an extension of 
the period was granted and the survey was finally closed on 16 February 2017. Before-
hand, two reminders were sent via E-Mail. 
After closing the survey, the ‘Verification & Validation’ phase started with a final 
review of survey responses. Throughout the duration of the survey, responses were 
checked for completeness and early follow-up was performed to maximize the number of 
responses. All respondents who did not complete the whole questionnaire were ad-
dressed by e-mail (if available) and asked to complete all parts. Moreover, persons that 
provided their e-mail but no further input were addressed. 
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The follow-up showed that some survey participants announced to disregard their 
previous response and that a new response would be submitted in the near future. Other 
survey participants asked if it was possible to receive the answers already indicated in 
order to continue. Several respondents from the Pharmaceutical and medical technolo-
gies industry and Public Administrations invested time to send comprehensive feedbacks 
by email and explain their organizations’ perspective on the study and the survey. 
After completing the follow-up, the data set was cleaned to retrieve a final data set for 
analysis. The adjustment of the data set included following tasks: 
• Deletion of responses if explicitly demanded by survey participants  
• Deletion of incomplete responses by participants who provided complete respons-
es at a later time (considering responses received through the follow-up) 
• Merging of incomplete responses with continued response at a later time 
After obtaining the final dataset as described in part 5.3 and a first analysis of its 
features, several adaptions regarding the categorisation of stakeholder groups were 
made in order to facilitate further analysis. 
Regarding the data of Public Administrations and other organisations, survey respond-
ents were initially given eight options for indicating the type of organization. For correct 
analysis, the authors checked the responses for consistency within the respondents. 
Moreover, the responses were cross-checked with the self-categorisation given at the 
Open Public Consultation run by DG SANTE and the mapping study of HTA national 
organisations, programmes and processes done by Julia Chamova, which feed into the 
Impact Assessment process. Finally, four categories representing the survey participants 
were established, namely 1) Public Administration, 2) Academia, 3) Payers and 4) 
Patient Organization. 
When answering to the online survey, industry stakeholders had the possibility to 
indicate to belong to the Pharmaceutical sector, the MedTech sector or to be operating in 
both sectors. Moreover, they could indicate the category ‘other’ and then specify. Since 
the group of companies that stated to be operating in both sectors or to belong to the 
category ‘other’ was quite low, these companies were categorised in line with their main 
business branch (32). As a result of the categorisation, a total of 13 companies were 
assigned to the medical technologies sector and 2 companies to the Pharmaceutical 
Industry. Company representatives were notified by email about the categorisation and 
asked for their consent.  
                                                                                                                                   
 
(32) Companies were informed about this re-categorisation and did not object. 
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 Responses to the online survey 5.3.2
An overview about respondents to the online survey is summarized in Figure 7, including 
all respondents who:  
• Provided solely information on the costs for HTA processes (Part 2 of the online 
survey), 
• Provided solely information on the impacts of the different Policy Options (Part 3 
and 4 of the online survey), or 
• Provided information on both parts.  
Therefore, the number of respondents differs between the datasets used for the assess-
ment of impacts and cost of business options. 
Altogether, 120 MedTech industry stakeholders, 20 Pharmaceutical Industry 
stakeholders and 37 stakeholders representing Public Administration and other 
organisations (177 in total) participated in the online survey by responding to at least 
one of the parts (as stated in Figure 7). 
Figure 7: Number of survey responses by stakeholder group (total n=177) 
 
Source: GÖ FP / LSE survey 2017  
Looking at the type of perspective of survey participants, 86% of the 37 respondents of 
Public Administrations and other organizations responded from an organisational 
perspective, while 14% responded from a personal perspective.  
With respect to industry stakeholders, 87% of 120 survey participants from the MedTech 
industry indicated responses from an organisational perspective and 13% from a 
personal perspective. With regard to the Pharmaceutical Industry, 80% of 20 survey 
participants responded from an organizational perspective and 20% from a personal 
perspective (see Figure 8). In the analysis of responses, no distinction was made 
between individual and organisational responses. 
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Figure 8: Perspective of responses by stakeholder group 
 
Source: GÖ FP / LSE survey 2017  
Despite the extensive follow-up on incomplete responses by the authors, some respond-
ents only indicated answers for certain parts of the survey. Either respondents, irrespec-
tive of the stakeholder group, indicated information on costs, on the impacts, or both. 
Some respondents provided reasons for this selective answering behaviour. For example, 
some stakeholders were not allowed to study costs (although they would have been 
treated as confidential) and other stakeholders reported that they were not in the 
position to have an opinion on the questions raised when assessing economic and 
social/health impacts. 
Relating to the Pharmaceutical Industry, out of 20 respondents, four completed the 
questions on costs, eight on the impacts and eight responded to both parts. 
Regarding Public Administrations and other organizations, from the total of 37, 
six respondents answered in each case to the part on costs/impacts only, whereas 
25 provided information on both parts.  
In conclusion, the industry respondents were less likely to respond to the cost part than 
the Public Administrations (which is likely to be due to the confidential nature of industry 
costs, which is not an issue for many publicly funded organisations). Figure 9 provides 
an overview of how many respondents stated information on the respective parts of the 
questionnaires, separated for the medical technologies industry, the Pharmaceutical 
Industry and Public Administration and other organisations’ respondents. Out of 120 
respondents of the MedTech Industry, 24 respondents reported information on 
costs only, 44 on impacts only and 52 reported information on both the costs 
and the impacts.  
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Figure 9: Number of responses by level of information per part per stakeholder group 
 
Source: GÖ FP / LSE survey 2017  
Focusing on industry stakeholders, different industry sectors and types of organisations 
were approached. First, a distinction of companies between Pharmaceutical, medical 
technologies and other technologies was made in order to assess potentially differential 
perspectives. Secondly, industry stakeholders were asked to indicate the type of 
organisation, i.e. whether they represent a manufacturer or a trade association. With 
these two pieces of information gathered through the online survey, respondents were 
further categorized, aiming to display the split of respondents by Manufacturers for each 
product scope and Trade Associations for each product group (33). 
Figure 10 shows the distribution of respondents according to these groups. In total, 107 
of the respondents stated to be manufacturers and 33 trade associations. Out of the 107 
manufacturers, 92 operate in the medical technologies sector and 15 in the Pharmaceu-
tical sector. With respect to trade associations, 28 represented the medical technologies 
industry and five the Pharmaceutical Industry. 
                                                                                                                                   
 
(33) In total, eight respondents stated they were from another sector, but were grouped to the Medical Device sector based on 
their indicated field of work. 
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Figure 10: Number of responses by type of organization and industry sector 
 
Source: GÖ FP / LSE survey 2017  
While the number of respondents from the Pharmaceutical sector is considerably lower 
than that of the respondents from the MedTech sector (20 vs 120), looking at the 
respondents, it can be concluded that the major players of the sectors are well repre-
sented in the survey as 11 of the 20 biggest Pharmaceutical companies responded. Table 
11 and Table 12 provide an overview about the contribution of the Pharmaceutical 
Industry to the survey and/or the case study and display the degree of contribution by 
the world’s 20 biggest Pharmaceutical companies (highlighted in green) (34).  
                                                                                                                                   
 
(34) According to www.statista.com, 2015. 
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Table 11: Overview of participation in survey by Pharmaceutical companies 
Company / Trade Association 
National/  
International 
Answered part of questionnaire 
on: 
Costs Impacts 
AbbVie International Yes No 
Biogen International GmbH International Yes Yes 
Boehringer Ingelheim  International Yes No 
Celgene International Yes Yes 
Da Volterra International Yes No 
Eli Lilly & Co International Yes Yes 
Esteve International No Yes 
F. Hoffmann-La Roche AG, Pharma Division International Yes Yes 
Janssen: Pharmaceutical Companies of Johnson 
& Johnson 
International No Yes 
Medac GmbH International Yes No 
Merck  International Yes Yes 
Novartis Pharmaceuticals International Yes Yes 
Novo Nordisk  International Yes Yes 
Pfizer International Yes Yes 
Teva Pharmaceuticals  International No Yes 
Trade Associations 
 
Part not asked 
to trade 
association 
 
Dutch Association Innovative Medicines National - Yes 
EFPIA International - Yes 
Irish Pharmaceutical Healthcare Association National - Yes 
Legemiddelindustrien (LMI) National - Yes 
Pharmig National - Yes 
Green indicates members of the TOP-20 Pharmaceutical companies by sales in 2015 (www.statista.com) 
As presented in Table 11, the majority of big Pharmaceutical companies partici-
pated in the survey, the case study or both. Four of the major Pharmaceutical 
companies, Sanofi, Allergan, Amgen and Shire, did not participate in any part of the data 
collection and did not express their interest in participating.  
Referring to Table 12, nine of the major Pharmaceutical companies were covered 
by the case study. Moreover, additional companies expressed their interest in an 
interview in the framework of the case study. For details, please see part 7.1. 
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Table 12: Case study participants of Pharmaceutical Industry  
Company National/ European/ International 
Astellas Pharma Europe B.V. European 
AstraZeneca AB International 
Bayer Pharma AG International 
Boehringer Ingelheim International GmbH International 
Bristol-Myers Squibb International 
Celgene Europe Limited European 
Eli Lilly Nederland B.V. European 
Gentium S.r.l. International 
Genzyme Therapeutics Ltd International 
Gilead Sciences International Ltd International 
Janssen-Cilag International N.V. International 
Novartis Europharm Ltd European 
Otsuka Pharmaceutical Europe Ltd European 
PTC Therapeutics International Limited International 
ThromboGenics NV International 
Vertex Pharmaceuticals (Europe) Ltd European 
Green indicates members of the TOP-20 Pharmaceutical companies by sales in 2015 (www.statista.com) 
The following table shows the top 10 MedTech companies and their participation in the 
survey. With six out of the 10 biggest MedTech companies, more than half of these were 
represented in the survey, some of them with multiple replies from different countries. 
Since MedTech companies often fall into the category of small- or medium-sized compa-
nies, the representation of large companies can be seen as sufficient. 
Table 13: Overview of participation in survey by top 10 MedTech companies35 
Company / Trade Association 
National/  
International 
Answered part of 
questionnaire on: 
Costs Impacts 
1 Medtronic International Yes yes 
2 Johnson & Johnson (medical device 
segment) 
International Yes yes 
3 Philips Healthcare (Royal Philips Electronics) International No yes 
4 GE Healthcare(General Electric) International No Yes 
5 Fresenius (medical care segment) International Yes Yes 
6 Siemens Healthineers (Siemens) International No No 
7 Cardinal Health (medical segment) International No No 
8 Becton, Dickinson (medical segment) International Yes Yes 
9 Baxter (medical products segment) International Yes Yes 
10 Stryker International Yes Yes 
Green indicates members of the TOP-10 MedTech companies by sales in 2015 (www.statista.com) 
Looking at the participation of SME (small- or medium-sized) Pharmaceutical and 
medical technologies manufacturers (see Figure 11), 33% of 15 Pharmaceutical 
companies were small- or medium-sized and 67% large companies. Regarding 
the medical technologies industry, 46% of 92 companies were small- or medi-
um-sized, whereas 54% were large companies. 
                                                                                                                                   
 
(35) Medical Design & Outsourcing annual 2016. 
 
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
 100 
Figure 11: Responses by company size for Pharmaceutical and MedTech manufacturer 
 
 Source: GÖ FP / LSE survey 2017  
With respect to Public Administrations and other organizations, Figure 12 illustrates the 
level of participation across the addressed countries. 
Respective organizations of countries marked in green were approached and participated 
in the survey, while countries marked in orange were approached but did not respond to 
the survey. We received responses from 19 different countries, meaning that 62% 
of all addressed countries submitted at least one response. 
Overall, a good geographic distribution is visible, covering both large and small 
countries as well as different types of HTA systems. 
When comparing the participating institutions of Public Administration with the taxonomy 
of HTA systems described in section 6.1, each type of HTA system is represented by 
at least one body. 
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Figure 12: Participation of Public Administrations and other organizations 
 
 
The highest number of survey responses for Public Administration was obtained by 
Spain, followed by Italy, which might be due to the high number of regional HTA 
bodies in these countries. 
When it comes to arm’s-length bodies, two responding countries are clustered to this 
HTA system with advisory role, three responding countries to a regulatory role and eight 
responding countries are clustered to an HTA system with an arm’s lengths body with 
coordinating role. 
HTA systems with an incorporated or integrated HTA function are represented with one 
country that has an independent HTA function within an insurance body and five 
countries that have an incorporated or integrated HTA function, thereby using HTA to 
determine pricing or coverage decisions. 
Two of the responses were given by European Associations, namely the European 
Society of Cardiology and the European Patients' Forum. The participation rate by patient 
groups was low, but one explained, for instance, that they focussed on replying to the 
Public Consultation that was ongoing in parallel instead. Moreover, the first part of the 
questionnaire (cost of HTA processes) was not relevant for such organisations. 
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Figure 13: Number of responses by type of organization for Public Administration and 
other stakeholders 
Source: GÖ FP / LSE survey 2017  
Similar to the distinction by organizational type and sector for industry stakeholders, 
stakeholders of Public Administration and other organizations had to indicate the type of 
organization as well.  
32 representatives of Public Administrations participated, two responses were 
received from academia, two from payer organizations and one representative 
of a patient organization responded to the online survey (see Figure 13). 
Due to the low number of responses from academia, patients and payers, it was decided 
that these responses are treated individually and in the overall analysis will focus on the 
administrations (HTA bodies).  
 Limitations and challenges 5.3.3
Despite all efforts regarding a sound methodical approach the contractors and the 
EC/CHAFEA project, officers were faced with several challenges during the project. The 
contractors took a number of measures to mitigate risks as much as possible (see 5.4), 
but some of the challenges arising were caused by the overall context of the study.  
Examples are several parallel activities and ongoing surveys (36) that caused a high 
burden of work to some members of the target group and made huge efforts necessary 
to obtain a significant number of responses and input.  
Even with all efforts to communicate the objectives, tasks and expected deliverables of 
the study (including a number of additional meetings and personal talks with both 
members of industry and Public Administration), some participants have found the online 
survey very complex and difficult to respond to.  
                                                                                                                                   
 
(36)  Several other researchers conducted studies in the field of HTA in 2016 that also included surveys for data collection and 
involved similar stakeholders. Secondly, the public consultation issued by the EC shortly before this survey resulted in 
respondents mixing up these two separate undertakings that served two different purposed (evidence generation vs. 
collection of opinions). 
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This is illustrated by the following issues raised by respondents and within the expert 
group meeting:  
• The survey on impacts captured expectations and opinions of stakeholders, rather 
than facts about the future and should be interpreted as such. However, due to 
the nature of impacts investigated it was not possible to gather ‘hard facts’ for 
some of the indicators, especially because effects between indicators are interwo-
ven 
• Regarding the planned methodology, some respondents called for sensitivity anal-
ysis (which was performed and planned from the beginning) and questioned the 
accuracy of the metering scheme from -100 to +100 in Part 4 of the question-
naire. It was pointed out that the results show general trends, but should not 
drive quantitative conclusions. 
• Respondents claimed to be overwhelmed with the complexity of the questionnaire, 
citing complex Policy Options and the large number of indicators (note: indicators 
are based on the EU ‘Better Regulations Guideline’ (5) which requires the assess-
ment of a number of impacts). 
• At the same time, it was stated that the options described mainly the legislative 
framework, but not how the system would function (e.g. whether the new system 
would work centralized and efficiently or whether it would become an ineffective 
bureaucracy, or how it would affect the quality of the reports). 
• The non-applicability of the survey to some stakeholders was addressed, e.g. 
small- and medium-sized MedTech companies who do not perform HTAs.  
• It was questioned whether separate questionnaires for Pharmaceuticals, medical 
technologies or other technologies should be given. 
• Technical issues were raised, e.g. on the required format of response or accessing 
the online questionnaire. 
Another major challenge was that, at the time of the survey’s development, the planned 
Policy Options were not fixed and were thus slightly modified in collaboration between EC 
Services and the contractors. Furthermore, a number of respondents claimed that they 
would have rather commented on the different business models separately and not in 
combination with one of the Policy Options. This led to different interpretations by the 
respondents and a need for cautious interpretation of results by the project team. 
However, evaluating both Policy Options and Business models in one step was necessary 
to minimize complexity and was in line with the assignment.  
Finally, we want to point out that the topic is of high (political) relevance to industry, 
MS, EC services and other stakeholders such as patients with very differing ideas and 
perceptions of the role of HTA in national systems and Europe. Despite all efforts in 
communication it is clear that some of the positions cannot be converged easily. This 
explains some of the concerns expressed.  
 Focus groups 5.3.4
As a follow-up to the online survey focus group meetings were set up with stakeholders 
from Public Administration and industry to discuss the results of the online survey and to 
gather additional insights and feedback to the findings. 
Three meetings were set up in Brussels: one for Public Administration, one for the 
Pharmaceutical Industry and one for the medical technologies industry. 
All survey respondents from the Pharmaceutical Industry and all survey respondents 
from the Medical technologies industry, which also answered to the follow-up question 
on HTA experience, were invited by email. For the focus group meeting with Public 
Administration, one meeting of the EUnetHTA Executive board was utilized and results 
were discussed with these experts.  
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
 104 
In all three focus group meetings results for the following impact topics were discussed:  
• Costs 
• Administrative burden  
• Innovation and Research 
• Public Health  
• Sustainability of health systems 
A similar structure was followed for each meeting. First, the study team presented each 
impact, showing only the results of the respective stakeholder group within a power 
point presentation. After each presented impact, experts were asked for open feedback 
first. Afterwards, specific questions were asked by the study team in case of specific 
issues that needed clarification. 
Minutes were taken compiling the discussed items and conclusions drawn within the 
discussions. These were shared with the members of the focus groups afterwards and 
are included in Annex 6, 7 and 8.  
Overall, the findings of the study were confirmed by the focus groups with some specific 
remarks. The details are included in the relevant sections of the description of impacts.  
 Limitations 5.3.5
A number of limitations arise from the methodological approach outlined in the previous 
sections.  
First, the research analyses HTA recommendations rather than final coverage decisions. 
If the HTA body has an advisory role, the final decision-maker may or may not adopt the 
recommendation in the final coverage decision. In practice however, evidence suggests 
that HTA recommendations are translated into final decisions and are implemented. 
A second limitation is the different level of detail in the evidence across the different HTA 
bodies. For example, TLV often do a public-only short summary of the decision, leaving 
out a significant amount of detail. The publicly available HTA reports, which have been 
analysed in this study, may not contain all the information and discussions that were 
associated with the final decision. However, the main reasons for the final recommenda-
tions were clearly identified in all the reports. As a result, and despite different levels of 
detail being provided, the evidence base compiled offers a good overview of the different 
decision-making processes. 
A third limitation is the assumption around transparency in the decision-making process-
es from HTA bodies, as the study focuses mainly on secondary evidence and the publicly 
available HTA report(s) and information provided to justify the decision. Information 
about the context within which the decision was taken may not have been captured. 
Fourth, there are a number of limitations relating to the data collection process specific 
to HTA processes. Several gaps were identified in compiling the indicator table; these 
were mainly around two areas: first, the timeline for HTA and final decision and second, 
delays incurred during the HTA process, e.g. ‘stop of the clock’ situations. On a number 
of occasions, the date of the dossier submission to the HTA body and the date of pricing 
and reimbursement decision were not publicly available or were not possible to retrieve 
from HTA body websites. Additionally, it was not possible to capture information on the 
delays faced by the companies in the submission of HTAs, such as the number and the 
length of ‘stop-the-clock’ situations. In an attempt to capture some of this information, 
tailor-made questions were added to the survey as well as the interviews. However, 
these questions aim to capture these data from the technology developer and HTA body 
points of view, rather than at the technology-indication level. 
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Fifth, there were a number of functional differences across HTA bodies and different 
levels of transparency, which exerted an influence on the analysis. For example, HTA 
agency roles are not homogeneous. HTA processes also differ across countries and this 
may give rise to the problem of comparability across HTA appraisals. For example, in 
countries with a well-established HTA system (e.g. France, Sweden, UK and Germany), it 
was possible to clearly draw common points between HTA appraisals, whereas the same 
common points were not present in countries where HTA processes are supplementary to 
national reimbursement decisions (e.g. Austria) or were integrated into a broader model 
of reimbursement, where HTA is one of the criteria (e.g. Italy). This difference in 
competences and processes is also reflected in the different level of detail across the 
different HTA bodies. For example, TLV often compiles a public-only short summary of 
the decision, leaving out a significant amount of detail. The publicly available HTA 
reports, which have been analysed in this study, may not contain all the information and 
discussions that were associated with the final decision. Different levels of transparency 
in the decision-making processes of the HTA bodies may help explain gaps in the data. 
Indeed, some HTA bodies do not publicly share their timeline in assessing a medical 
technology; finally, some information is kept confidential following requests from the 
technology developer. Despite the above, the main reasons for the final recommenda-
tions were identified in all case study reports. We can, therefore, conclude that despite 
different levels of detail being provided, the results offer a good standard of the key 
elements the led to and/or influenced the decisions at HTA level. 
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5.4 Further actions undertaken for data collection 
Several actions were undertaken in the course of the study to maximize the amount and 
the reliability of data, facts and figures gathered by different data collection processes.  
With regard to the case study, several requests to HTA bodies across Europe were 
made in the course of the study, asking for HTA assessments that were not publicly 
accessible. This aimed at maximising the number of HTA assessment per technology-
indication pair. 
Several members of HTA bodies remarked that questions regarding the current costs of 
HTA processes (Section 2 in the online survey) were too detailed for them to respond 
to, since only data on a more aggregated level could be provided. Therefore, an addi-
tional questionnaire was set up to survey the different cost components of performing 
HTA on a more aggregated level. This questionnaire was sent to EUnetHTA members, 
aiming to increase the available amount of data for assessing the baseline costs of this 
stakeholder group (see Annex 23). In total, eight responses were received to this follow-
up questionnaire in addition to the responses received in the survey. 
In order to increase the soundness of survey responses, follow-up questions were 
launched for companies of the MedTech industry in order to allow for more in-depth 
analysis. Respondents to the online survey received three follow-up questions with the 
intention to assess their level of experience with HTA processes. They were asked if their 
company: 
• Was involved in an Early Dialogue process with at least one product in the EU/EEA 
• Had an HTA submission for at least one product in an EU/EEA country 
• Why Policy Option 3 was rated to be significantly more expensive than Policy 
Option 2, asking for a brief explanation 
24 company representatives responded to this follow-up. Five companies were involved 
in an Early Dialogue and a HTA submission with at least one product in the EU/EEA 
region, eight survey participants indicated being neither involved in an Early Dialogue 
nor in a HTA submission with at least one product in the EU/EEA region, and 11 compa-
nies stated that they were not involved in an Early Dialogue but had at least one product 
subject to HTA in the EU/EEA region.  
Follow-up questions to focus group meetings (5.3.4) were addressed to industry 
representatives of both industry sectors.  
For Pharmaceutical companies, this included the following questions: ‘Can you give us 
further information on additional data that is requested by HTA bodies in the context of a 
REA/Full HTA process? In particular an estimate how often it is required; typically by 
which MS; through which way was this collected; and any further information on the 
costs’.  
MedTech companies were approached with the questions: ‘How do you define transform-
ative medical technologies? Could you please give examples for these? Do you have an 
estimation about their number per year?’ 
Due to the low response rate of stakeholders in patient organisations, an additional 
follow-up was started to collect further information. The follow-up included interviews 
with three representatives of patient organisations, consumer organisations and public 
health cooperatives at EU level. 
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6 Analytical approach 
6.1 Baseline scenario 
The aim of the case studies is to systematically capture and depict the elements compos-
ing the status quo of HTA across EU MS. In order to capture the baseline scenario of HTA 
bodies in the Europe Union, a multistage mixed qualitative-quantitative analytical 
approach was adopted. The different stages are shown in Figure 14 and comprise a 
sampling phase, a desk research and analysis of secondary data stage, a round of 
interviews and a final quantitative and qualitative analysis of the data retrieved. 
Figure 14: Analytical approach baseline scenario 
 
This approach was adopted in order to understand the variability in methods and 
processes currently employed by different HTA bodies across the EU and to capture 
duplication of efforts in HTA by combining quantitative and qualitative elements.  
For the sampling phase, a systematic review of HTA reports was conducted. This aimed 
to maximise the information from the sample as well as fulfil all selection criteria. 
Additionally, it enabled the selection of an objective sample, representing – as much as 
possible – the heterogeneity of HTA processes and eliminating the need for data valida-
tion by the respective agencies. The HTA body perspective, rather than the industry 
perspective, was considered in our selection. 
The next phase in the HTA data collection and analysis was based on a standardised 
analytical framework developed and applied to compare and evaluate HTA evidence 
using a mixed methods approach (51, 52). 
This framework was adapted to fulfil the scope of this study. It enables the translation of 
qualitative information into quantitative data by coding a set of variables contained in 
HTA reports. Breaking down the HTA decision processes into three key stages, the 
framework enables an in-depth understanding and systematic comparison of HTA 
evidence across countries, including criteria accounted for within, e.g. clinical trials, cost-
effectiveness model and beyond, e.g. stakeholder influence or social value judgements, 
standard methods of HTA. The criteria selected to perform the analysis matched the key 
components required by the indicators identified comprising: (1) the clinical and eco-
nomic evidence; (2) the timeline of the process; (3) the inclusion of external considera-
tions and stakeholder opinion; and (4) the final decision/recommendation. 
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The first component enabled an understanding of the type and the quantity of evidence 
considered across countries, while the second dealt with the timeline of the process from 
Marketing Authorization (MA) to HTA decision/recommendation. The third component 
analysed the value judgments made throughout the assessment process and stakeholder 
input considered by HTA bodies, while the final component provided information on the 
final recommendation and different effects on market access (economic and clinical 
limitations). 
In order to capture the level of agreement by different HTA bodies across Europe, 
Cohen’s Kappa scores were calculated across the sample, providing a measure of the 
degree to which two or more bodies concur in the type of assessment of the studied 
technologies and the final decision (25). By examining the inter-rate reliability coefficient 
calculated using the Kappa statistic, it was possible to assess the level of agreement 
across different HTA bodies. Independently of the Kappa score, the proportion of 
agreement between some agencies were also calculated within each of the Kappa’s 
categories separately in order to overcome the ‘Kappa paradox’ (26).This paradox 
causes the Kappa statistic to be estimated in a distorted manner, especially when the 
sample of assessed technology-indication pairs is different across countries and assumes 
values that often lead to underestimation of the actual concordance present in the data. 
In order to overcome this, a sample of technology-indication pairs was selected that is 
common across the highest number of agencies to showcase the level of agree-
ment/concordance and disagreement. 
The interpretation of Kappa values is performed based on the following guidelines: 
K<0.2 = poor agreement; 0.21<K ≤ 0.4 = Fair agreement; 0.41<K ≤ 0.60 = Moderate 
agreement; 0.61<K ≤ 0.80 = Good agreement; K> 0.80 = Very good agreement (Table 
14). 
Table 14: Kappa score agreements level  
Poor agreement <0.20 
Fair agreement 0.21-0.4 
Moderate agreement 0.41-0.6 
Good agreement 0.61-0.8 
Very good agreement 0.8-1 
In the final data analysis and in order to capture the heterogeneity and the different role 
of HTA bodies across Europe, a published taxonomy of HTA body categories was em-
ployed in order to filter results. Analysis has been conducted for the entire sample as 
well as for the subcategories depicted in the taxonomy. 
Currently, the role and the function of HTA bodies can vary based on their scope within 
the healthcare system. The taxonomy differentiates the HTA bodies based on their level 
of integration within governmental bodies and the functions they perform (27). The two 
broader categories comprise ‘HTA bodies at Arm’s length’ and ‘HTA function which 
is integrated’; the former are independent bodies and autonomous from governmental 
agencies, while in the latter the HTA function is integrated within a governmental body. 
Each HTA body is further characterised according to its function as an Advisory, Coordi-
nation or Regulatory entity. An advisory body (e.g. NICE in England and HAS in France) 
provides recommendations to governmental bodies on coverage decisions to be imple-
mented at national or regional level, whereas a regulatory body is directly accounta-
ble/responsible for the final pricing and reimbursement decision (e.g. AIFA, TLV). Lastly, 
coordination bodies mainly collect, produce and disseminate assessments research 
results. 
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This taxonomy was used in order to draw a clear line distinction between assessment 
and appraisals, distinction made in a regulatory and organizational context, leading to 
different system implications. ‘Assessment’ is defined as the collection and synthesis of 
evidence focusing on the traceability/replicability of results. It triggers HTA and usually 
provides information to providers in supporting investments coverage decisions on 
Health technologies. ‘Appraisal’ is the act of contextualizing evidence and formulating 
coverage recommendations and resource implications, i.e. defining impact and applica-
bility (8, 9). Negative or positive recommendation contained in an assessment does not 
necessarily imply a final negative or positive coverage decision. 
Embedding the multi-stage methodology in the taxonomy serves two purposes: first, to 
contribute to the understanding of the key factors considered in the HTA decision-making 
process, allowing the identification of possible duplication of assessment across EU MS 
and second, to capture the heterogeneity of the current HTA baseline scenario in a 
systematic way. 
6.2 Policy Options and business models 
 Multi-criteria analysis 6.2.1
In order to carefully assess the different impacts of the proposed Policy Options on the 
various stakeholder groups, a multi-criteria analysis (MCA) was adopted. 
The aim of an MCA is to support the analysis of multi-criteria environments (in the case 
of this study multiple impacts) and also to facilitate decision-making processes. In this 
study the MCA was preliminary used for compiling and analysing the stakeholder survey 
results (see section 7.3) as well as additional information gathered through various 
measures. MCA is considered suitable particularly for questions, which:  
• Need to consider multiple impacts 
• Need to visualise different points of view (need for cross-examination in terms of 
different stakeholders) 
• Do not necessarily require or allow for a monetary evaluation of decision outcomes 
• Have to be tackled with a strong participatory component (stakeholder involve-
ment) (28) 
Nearly all these criteria are fully met by the questions this study addresses, some of 
them will be further described in the following steps (based on a categorisation in the 
publication ‘Multi-criteria Analysis: a Manual’) (29), which were incorporated and 
performed embedding the results gathered through the stakeholder survey (see section 
5.3.1). 
 Establishment of the decision context 6.2.1.1
The first step of an MCA addresses the establishment of the decision context, meaning 
the aims of the analysis should be clearly identified and that all structures surrounding 
this should be examined. This includes the identification of relevant stakeholder groups.  
Based on that, key players for HTA cooperation in Europe in the future were identified 
and clustered for the survey and subsequent analysis in three main stakeholder groups: 
• Public Administrations 
• The Pharmaceutical Industry  
• The MedTech Industry 
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For other stakeholders that were initially addressed in the survey, such as patient 
organizations or academia, survey results could finally not be taken into account due to 
a very low response rate leading to risk for distortion in the analysis results. Whenever 
there are effects identified on patients or health professionals, these are pointed out in 
the relevant sections in 7.3. Within the three main stakeholder groups, further distinc-
tions were made possible through the design of the online survey by asking about, for 
example, experience in HTA production or the size of the company. 
Sub-group analyses were performed throughout the study including: 
• Subgroups based on company size: SMEs and large companies for both industry 
sectors (Pharmaceutical and MedTech Industry) were grouped and compared to 
each other. 
• Separate analysis was done for MedTech Industry, comparing companies with 
declared HTA experience to companies without HTA experience. 
• Separate analysis for MedTech Industry comparing those who actually stated costs 
for HTA activities with those who did not. 
 Identification of the options under consideration 6.2.1.2
The survey questionnaire, on which the MCA was based, aimed at examining the 
identified Policy Options (POs) compared to the status quo. POs were proposed by DG 
SANTE in the inception impact assessment and were further developed throughout the 
course of the study in close collaboration with DG SANTE and with the involvement of 
the expert group. 
 
The POs compared in the MCA were (see chapter 3.2 for details): 
• Policy Option 1: Baseline scenario - No EU action after 2020 
• Policy Option 2: Voluntary cooperation supported by the Public Health Programme 
• Policy Option 3: Legislation covering Common Tools and Early Dialogues 
• Policy Option 4.1: Opt-in for Joint REA plus option 3 
• Policy Option 4.2: Mandatory Joint REA plus option 3 
• Policy Option 5: Option 4.2 and Opt-in for Full HTA 
 Identification of criteria that reflect the value associated with the 6.2.1.3
consequences of each option 
An important step of the MCA process relates to the definition of the specific criteria 
which are utilized for assessing the effects of the different options. 
For developing these criteria, the list of impacts that have to be considered was defined 
by the EC’s Better Regulation Guidelines (5) which served as a starting point. After 
reviewing these potential impacts some were disregarded straight away due the fact that 
no connection between the European cooperation on HTA process and the impact 
existed, which is the case for example for environmental impacts. This was done based 
on the experience of the study team and in close collaboration with the project team 
from DG SANTE. 
After the relevant impact areas were defined, indicators were developed for each of the 
impacts (ranging from 2-8 indicators per impact) in order to ensure a detailed assess-
ment and to capture all relevant aspects for each impact area. In order to ensure that all 
relevant impacts and indicators for all stakeholder groups were covered, these were 
presented to an expert group in the course of a structured questionnaire process (see 
5.3 for details), which fed back on the scope and the content. Experts were asked to:  
• Rate the indicator with regard to its relevance for assessing the POs’ impacts  
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• Comment on the indicator  
• Add sources of information or references to literature, if known  
• Add relevant but missing indicators  
 
Final impacts for the stakeholder survey, clustered by economic criteria (EC) and social 
health (SH) impacts were therefore carefully selected and included the following 
impacts: 
 Economic impacts (EC): 
EC1 Costs 
EC2 Administrative burden 
EC3 Competitiveness of EU health technology sector 
EC4 Innovation and research  
EC5 International Trade 
EC6 Functioning of the internal market and competition 
EC7 Consumers and households 
EC8 Macroeconomic environment 
 Social/health impacts (SH) 
SH1 Employment (labour market) 
SH2 Governance, participation and good administration 
SH3 Access to social protection and health systems 
SH4 Sustainability of health systems 
SH5 Public health  
 
The aim of the online survey with regard to usability for the multi-criteria analysis was to 
gather an estimate of the relative importance of impacts per stakeholder group 
and an understanding of the direction (positive or negative) of influence of the 
different impacts. 
Regarding the relative importance of impact, it should be noted that MCA sometimes is 
further developed into MCDA (multi-criteria decision analysis), which is a recognized 
method for decision support in policy assessment and allows for systematic comparison 
and also ranking and weighing of different options across several criteria. Therefore, 
initially the stakeholder survey contained a part on the assignment of weights for each 
impact. Stakeholders were asked to assign weights for each of the impacts to reflect 
their relative importance to the Policy Option.  
Initially it was planned to combine this information with the answers gathered by impact 
and Policy Option to obtain the most preferred Policy Option per stakeholder group 
including the relevance of impacts. Yet, this step has not been performed due to the low 
number of respondents providing both information, as this would have led to uncertainty 
of results and was considered misleading regarding the presentation and interpretation 
of results by the experts, the study team and the EC.  
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Regarding the direction of influence of the different impacts, because the results from 
the stakeholder survey had to feed into the multi-criteria analysis, questions were 
designed respectively in a quantitative way, leaving room for the stakeholders to add 
further comments on each response. Respondents were asked to assess each policy 
option according to their economic and social impacts. Thereby, they were indicating for 
each impact whether the respective indicators may decrease (-) or increase (+) for each 
policy option on a range from -100 to +100. This procedure allowed for the assessment 
of each Policy Option in a comparable manner. The decision to use this multi-criterial 
approach therefore was also based on the fact that a broad range of impacts needed to 
be addressed and a majority of the considered impacts could not be expressed in 
monetary terms (see criteria in 6.2.1.1). 
 Description of the expected performance of each option against the 6.2.1.4
criteria and examination of the results 
Results of the multi-criteria analysis are presented per impact type and per stakeholder 
group. For each impact type, relevant indicators as well as an aggregated value is 
presented. For some aggregated values, single indicators had to be inverted to assure 
for a correct interpretation of data. This was because for some indicators an increase 
(meaning a value between 0 and +100) is positive (e.g. increase in innovation), while for 
some indicators an increase is considered negative (e.g. increase in costs).  
To increase the validity and reliability of the results of the MCA derived from the online 
survey with different groups of stakeholders, all results were interpreted and supported 
by further information, such as literature or feedback gathered through interviews with 
Pharmaceutical and MedTech industry as well as focus groups. For a thorough descrip-
tion and explanation of these results, see chapter 7.2. 
For creating an overview table on impacts the quantitative survey results (mean values) 
were translated into the following categories: 
Table 15: Allocation of quantitative results to effect categories:  
Ranges of mean value 
per impact 
Attributed effect category Abbreviation 
100 71 Strong positive effect  + + + 
71 43 Moderate positive effect + + 
43 14 Slight positive effect + 
14 -14 
neutral (+ or – representing the direction of 
the answers, as indication even if the expected 
effect is low ) 
0 
-14 -43 slight negative effect - 
-43 -71 Moderate negative effect - - 
-71 -100 Strong negative effect - - - 
The categorization was subsequently adjusted into a positive or negative direction in 
case more information was available for the specific impact, which amplified or alleviated 
the survey responses. For this, a two-step process was applied. In the first step, 
members of the study team did this adjustment separately after reviewing the available 
information per impact. In the second step, estimates were compared, discussed and 
finalised after agreement. 
 Data plausibility check 6.2.1.5
Several data plausibility checks were performed. These are explained and their results 
are described in section 7.3.7. 
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 Cost prognosis 6.2.2
The cost prognosis consisted of: 
 The estimation of voluntary or mandatory joint outputs and related savings in 1.
national outputs of the proposed POs. 
 Specific implementation mechanisms including common tools 2.
 Output production included four outputs:  
• Common tools (including templates and methodology)  
• Early Dialogue (ED)  
• Joint REA  
• Joint Full HTA (as displayed in Table 7 in section 4.2) 
Each Policy Option outlined a specific set of voluntary and/or mandatory output produc-
tion and was matched with an envisaged implementation mechanism. 
The proposed implementation mechanisms were:  
• Project-based cooperation 
• An MS secretariat 
• An EU secretariat located at EC level  
• The integration of such a Secretariat into an existing EU agency 
• Creation of a new EU agency 
An implementation mechanism without EU funding was not considered in this study since 
intergovernmental cooperation without EU input is strictly the responsibility of the MS.  
The business models presented are the basis for further developments and repre-
sent illustrative scenarios. Outputs and implementation mechanisms were assessed 
separately to allow for adaptations and the possibility to develop additional POs at a later 
stage without the need for additional assessment. 
Cost prognosis of HTA outputs was based on several sources: Information obtained 
by Chamova 2017 (2) and provided from EUnetHTA  members; data gathered through 
the survey conducted for this study plus additional follow-up on costs; focus group input 
by Public Administrations, the Pharmaceutical Industry and MedTech Industry which 
were used for validating and improving comprehension of the survey data; and expert 
validation throughout the whole study process. Additional sources used for the prognosis 
are quoted directly, if applicable. Information obtained through the baseline scenario 
(section 7.1.12) was included, if applicable. Many assumptions had to be made where 
data/information were not available. They are outlined in subsections 6.2.2.1 to 6.2.2.5. 
A sensitivity analysis was performed to account for related uncertainties.  
Costs will be estimated for the Year 2020 onwards, i.e. plus the implementation period. 
Costs will be premeditated as total costs per year. All costs are expressed in 2016 Euro. 
 Assumptions on cost elements for the output related prognosis 6.2.2.1
One task of the project team was to give input to the EU Impact Assessment regarding 
the likely evolution of cost for coordinated HTA in Europe. The overall cost impacts 
regarding the production of outputs for each stakeholder group (MS, EU and industry) 
were calculated by the number of expected additional products per Policy Option 
(including national adaptation) minus the expected reduction in output volumes (e.g. 
fewer national full reports, fewer manufacturer submission reports at national level). For 
this, a number of assumptions had to be made regarding e.g., the overall scope of 
technologies per option or the level of voluntary uptake:  
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●  HTA processes may inform (national) reimbursement decisions as well as evidence 
generation for a new technology. They also give input to national policy strategies / 
general issues on health care provision, the creation of quality standards, guidelines 
etc. Assumption: (Future) EUnetHTA outputs (REA, Full HTA) will focus on providing 
information for national reimbursement (or other policy) decisions after-market 
launch or e.g. change of indication.  
●  Current HTA systems are heterogeneous across Europe, ranging from systems where 
HTA processes explicitly (including legal provisions) inform reimbursement decisions 
(including legal provisions) to systems with HTA processes not directly informing 
reimbursement decisions and (few) systems without an established HTA process. 
Therefore, the expected consequences of the five POs at national level will vary 
between countries – with regard to regulative changes as well as potential cost 
savings. It can be argued that countries doing many HTA-reports per year will be 
able to gain more savings by replacing national activity through joint activity than 
countries doing only a few reports each year (leaving aside, of course, other impacts 
such as enhanced transparency). The amount of national savings thereby is related 
to the number of joint outputs and the overlap between joint and (current) national 
output. Assumption: For the sake of calculation of estimated costs, the MS were 
grouped according to the ‘annual HTA output volume’ as follows: 
• Group 1: MS with a high number of reimbursement-related HTA outputs per year 
(above an assumed cut-off-value of 60 reports per year for Pharma and 50 reports 
per year for MedTech) 
• Group 2: MS with a rather low number of reimbursement related HTA reports per 
year (below an assumed cut-off-value of 60 reports per year for Pharma and 50 
reports per year for MedTech) 
• Group 3: MS with no or purely ‘informative’ HTA systems (and low number of HTA 
reports per year) 
         Each category was further grouped by:  
• Countries/systems(37) where (reimbursement-related) reports are mainly pro-
duced by HTA bodies (with no or some evidence/data submission provided by in-
dustry) 
• Countries/systems (38) where (reimbursement-related) reports are mainly pro-
duced by industries and reviewed by HTA bodies (or reimbursement authority) 
Whereas it was also recognised that countries may, e.g. have systems follow different 
Types across sectors (such as following Type A for Pharmaceuticals and Type B for 
MedTech), sometimes, this might also be mixed within the product sectors, e.g. one of 
the HTA bodies undertakes HTA and analysis and produces HTA reports mainly on their 
own, while another country would mainly review industry submissions. 
The study team categorised the countries based on data and information derived from 
Chamova 2017 (2), which included 29 countries. The consistency check of the obtained 
results contained a match with information of EUnetHTA JA3 WP7, as far as it was 
available to date. Figure 15 shows the percentage of countries within each of the groups.  
Figure 15: Percentage of 29 countries within three groups according to annual HTA 
output volume 
                                                                                                                                   
 
(37) Some countries have two systems (HTA-body-based = A. as well as industry-based = B.) within one branch (MedTech or 
Pharma). 
(38) See above. 
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Group 1: 60 or more reports per year for Pharma and 50 or more reports per year for MedTech  
Group 2: less than 60 reports per year for Pharma and 50 reports per year for MedTech 
Group 3: Countries with no study production or purely ‘informative’ HTA system) 
Source: Authors, based on Chamova 2017 
Figure 16 depicts the percentage of countries with HTA body-based reports and that of 
countries with industry-based reports. Figures do not add to 100% as, even within the 
same sector (Pharmaceuticals or MedTech), some countries have a system that can be 
attributed to two groups (as described above). 
Figure 16: Percentage of 29 countries with HTA body-based reports vs. countries with 
industry-based reports 
Source: Authors, based on Chamova 2017 
 
Countries with mandatory uptake of REA or Full HTA have to implement changes within 
their existing systems, e.g. with regard to regulations for national reimbursement 
submissions, either changing existing regulations and/or setting new ones. 
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 Assumptions:  
● Pharmaceuticals: Requirements for manufacturer submissions for reimbursement at 
national level (at least within the outpatient sector) will be harmonised to a certain 
degree, e.g. with regards to fully using the joint assessments and adding some 
national aspects, such as cost effectiveness analysis. Otherwise, there is no reduction 
in the duplication of reimbursement submissions for industry. 
● Medical technologies (MedTech): If evidence from the manufacturer is required by 
national HTA or reimbursement bodies for interventions connected to medical 
technologies, the requirements for manufacturer submissions will be harmonised to a 
certain degree as described above. 
 Assumptions on the predicted joint output per Policy Option 6.2.2.2
Table 16 depicts the expected likely number of joint outputs, the proportion of countries 
that are expected to opt in and the underlying sources of assumptions, if available, for 
assessments on Pharmaceutical products. For options with voluntary participation and 
mandatory uptake, a proportion of countries that ‘opt in’ (section 4.2) was defined. 
According to the definition of POs for this study (section 4.3), countries that opt in for 
REAs and HTAs are obliged to consider ALL joint assessments within their national 
decision-making process. Countries that opt in for Early Dialogues must not repeat Early 
Dialogues at national level (at least if completely transferable). Countries who participate 
in one or more joint Early Dialogue are required to opt in. 
Table 17 displays assumptions on the expected amount of joint output, the proportion of 
countries who are expected to opt in and underlying sources for assumptions, if availa-
ble, for assessments on medical devices. For options with voluntary participation and 
mandatory uptake, a proportion of countries who ‘opt in’ (see also section 4.2) must be 
defined. Countries with opt in for REAs and HTAs are obliged to consider ALL joint 
assessments within their national decision-making. 
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Table 16: Cost prognosis assumptions for the Pharmaceutical sector 
 Pharma 2020+ 
Number of 
joint output 
per year 
Source (if available)  
Proportion of 
countries 
opting in 
(***) 
Source (if available)  
Early Dialogue (*) 
PO2, 
V/M 
8-10 
Planned amount for Pharma based on EUnetHTA JA3 
2019-2020 (Grant Agreement p. 178 resp. ‘65 / 220’) 
resp. SEED (currently 11 reports, thereof eight on 
Pharmaceuticals) 
Min. 30% 
Proportion based on current SEED 
consortium (14 institutions out of 10 
countries did SEED-reports, thereof nine 
have been involved in Pharmaceutical 
reports) 
PO3, 
V/M 
30 
As above, but higher because of more incentives for 
industry for initiating EDs 
Min. 30% 
Proportion based on current SEED 
consortium, see above 
PO 
4.1, 
V/M 
30 
As above, but higher because of more incentives for 
industry for initiating EDs 
Min. 30% 
Proportion based on current SEED 
consortium, see above 
PO 
4.2, 
M/M 
30 
As above, but higher because of more incentives for 
industry for initiating EDs 
100% Defined by Policy Option 
PO5, 
M/M 
30 
As above, but higher because of more incentives for 
industry for initiating EDs 
100% Defined by Policy Option 
REA 
PO2, 
V/M 
10 EUnetHTA  JA 3 forecast for Joint HTAs + 20% 17% 
Assumption based on EUnetHTA JA 2 
experience: Institutions of five countries 
have been the (main) authors of a 
Pharmaceutical REA (39). Five countries 
had uptakes ‘used in direct decision-
making’ (40) (on four Pharmaceutical 
reports).  
PO3, 
V/V 
0 
As there is no central funding no joint output is assumed. However there may be intergovernmental activities and 
related uptake. 
PO 
4.1, 
V/M 
40 
Includes all centrally authorized new active substances, 
estimates based on EMA annual study 
17% see above 
PO 
4.2, 
M/M 
40 
Includes all centrally authorized new active substances, 
estimates based on EMA annual study 
100% Defined by Policy Option 
PO5, 
M/M 
40 
Includes all centrally authorized new active substances, 
estimates based on EMA annual study 
100% Defined by Policy Option 
Full HTA 
PO2, 
V/V 
0 
Assumption based on the low current output of Full HTA 
and on prevailing methodological uncertainties in 
EUnetHTA  Joint Actions as to what should be included 
within a European economic analysis (ECO domain) (**) 
NR  
PO3, 
V/V 
0 See above NR  
PO 
4.1, 
V/V 
0 See above NR  
PO 
4.2, 
V/V 
0 See above NR  
PO5, 
V/M 
7 
Based on the ratio 1:6 for ‘core HTA’ versus REA in 
EUnetHTA JA2 
17% 
Assumption based on the number of 
countries with authoring institutions of 
core HTA of Pharmaceuticals in EUnetHTA  
JA2 
SEED = Shaping European Early Dialogues for health technologies Group (http://www.earlydialogues.eu/has/?page_id=10), NR=Not relevant 
*) These assumptions have not been incorporated within final calculations as it was not possible to include Early Dialogues in a detailed cost 
prognosis due to a lack of data on the current costs and quantities of Early Dialogues (see 0). 
**) Moreover, it needs to be considered that especially economic analysis mainly plays a role for the reimbursement decision, which however will 
remain at national level.***) As there are no sources or straightforward reasoning to assume differing rates between groups of countries (see 
6.2.2.1), the same opt-in rate is applied to all countries. 
 
                                                                                                                                   
 
(39)   http://www.EUnetHTA .eu/joint-assessments 
(40)  http://www.EUnetHTA .eu/national-uptake  
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Table 17: Cost prognosis assumptions for the MedTech sector 
 MedTech 2020+ 
Number of 
joint output 
per year 
Source (if available)  
Proportion of 
countries 
opting in 
(***) 
Source (if available)  
Early Dialogue (*) 
PO2, 
V/M 
3-5 
Planned amount for MedTech based on EUnetHTA  JA3 
2019-2020 (Grant Agreement p. 178 resp. ‘65 / 220’) 
resp. SEED (currently 11 reports, thereof 3 on medical 
devices) 
Min. 30% 
Proportion based on current SEED 
consortium (14 institutions out of 10 
countries did SEED-reports, thereof nine 
have been involved in MedTech reports) 
PO3, 
V/M 
10 
As above, but higher because of more incentives for 
industry for initiating EDs 
Min. 30% 
Proportion based on current SEED 
consortium, see above 
PO 
4.1, 
V/M 
10 
As above, but higher because of more incentives for 
industry for initiating EDs 
Min. 30% 
Proportion based on current SEED 
consortium, see above 
PO 
4.2, 
M/M 
10 
As above, but higher because of more incentives for 
industry for initiating EDs 
100% Defined by Policy Option 
PO5, 
M/M 
10 
As above, but higher because of more incentives for 
industry for initiating EDs 
100% Defined by Policy Option 
REA 
PO2, 
V/M 
5 EUnetHTA  JA 3 forecast for Joint HTAs + 20% 21% 
Assumption based on EUnetHTA JA2 
experience: Institutions of six countries 
have been (main) authors of a MedTech 
REA (41). Five countries had uptakes ‘used 
in direct decision-making’ (42) (on six 
MedTech reports). 
PO3, 
V/V 
0 
As there is no central funding no joint output is assumed. However there may be intergovernmental activities and 
related uptake. 
PO 
4.1, 
V/M 
25 Assumption based on information provided by DG SANTE 21% see above 
PO 
4.2, 
M/M 
25 Assumption based on information provided by DG SANTE 100% Policy Option 
PO5, 
M/M 
25 Assumption based on information provided by DG SANTE 100% Policy Option 
Full HTA 
PO2, 
V/V 
0 
Assumption based on the low current output of Full HTA 
and on prevailing methodological uncertainties in 
EUnetHTA  Joint Actions as to what should be included 
within a European economic analysis (ECO domain) (*) 
NR  
PO3, 
V/V 
0 See above NR  
PO 
4.1, 
V/V 
0 See above NR  
PO 
4.2, 
V/V 
0 See above NR  
PO5, 
V/M 
4 
Based on the ratio 1:6 for ‘core HTA’ versus REA in 
EUnetHTA  JA2 
21% 
Assumption based on the number of 
countries with authoring institutions of 
core HTA of MedTech in EUnetHTA  JA2 
SEED = Shaping European Early Dialogues for health technologies Group (http://www.earlydialogues.eu/has/?page_id=10), NR=Not relevant 
*) These assumptions have not been incorporated within final calculations as it was not possible to include Early Dialogues in a detailed cost 
prognosis due to a lack of data on the current costs and quantities of Early Dialogues (see 0). 
**) Moreover, it needs to be considered that especially economic analysis mainly plays a role for the reimbursement decision which however will 
remain on the national level. 
***) As there are no sources or straightforward reasoning to assume differing rates between groups of countries (see 6.2.2.1), the same opt in rate 
is applied to all countries. 
 
                                                                                                                                   
 
(41)   http://www.EUnetHTA .eu/joint-assessments 
(42)  http://www.EUnetHTA .eu/national-uptake  
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 Assumptions on the reduction of national output per Policy Option 6.2.2.3
With the production of (voluntary or mandatory) joint outputs, a decrease in outputs 
at national level can be expected, leading to potential savings. These savings depend 
on the overlap between joint and national output. That is, not all of joint output may be 
relevant at national level. Countries that opt in have to consider all relevant joint output 
within national decision-making.  
Countries without ‘opt in’ may still use parts of relevant joint outputs in national deci-
sion-making. In this part, assumptions on the amount of reduction of national outputs 
per Policy Option are presented. These parameters have been set separately for the 
three groups as defined in 6.2.2.2. Table 18 depicts assumptions made for Pharmaceuti-
cal products and Table 19 for medical technologies. 
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Table 18: Assumptions on national output reduction in the Pharmaceutical sector 
 Pharma 
 
Group 1 (60 or more 
reports per year) 
Source (if available)  
Group 2 (less than 
60 reports per year) 
Source (if available)  
Group 3 (no or purely 
‘informative’ HTA 
system) 
Source if available or 
Assumption 
Early Dialogue 
Not enough data are available at national level to make realistic assumptions on the amount of national output reduction. However, it is fair to assume that higher savings could be realised in the case of mandatory options (PO 4.2 and 5). We 
assume that industry has incentives to initiate joint EDs on those products for which they currently need to conduct a number of national EDs. Just under half of the countries conducts (if only irregularly) EDs at status quo, in probably 4-5 main 
markets (Chamova 2017). Therefore, it can be assumed that with option 4.2 and 5 one joint ED replaces at least 4-5 national EDs (given that joint ED will be completely transferable to local settings). 
REA 
PO2, V/M 
with opt in 
100% of joint output 
replaces national 
output 
Assumption: in countries with national outputs 
exceeding 60 reports per year all 10 joint REAs will be 
relevant and therefore can replace national output. 
25% of national 
output is replaced  
Assumption: on average only 25% of the 10 joint REAs 
are assumed to be relevant for countries' decisions that 
have less than 60 reports per year.  
0% 
Assumption because of 
zero to low current 
output 
PO2, V/M 
without opt in 
1 national output per 
year is replaced by 
joint output 
Assumption: Even those countries that did not opt in will 
(be able to) take up one joint REA on a voluntary basis. 
0%  
Assumption: in countries with less than 60 reports per 
year and who did not opt in there won’t be an uptake out 
of the 10 joint REAs for direct decision-making 
0% 
Assumption because of 
zero to low current 
output 
PO3 NR because non joint output is assumed, see Table 16 
PO 4.1, V/M 
with opt in 
100% of joint output 
replaces national 
output 
Assumption: in countries with national outputs 
exceeding 60 reports per year all 40 joint REAs will be 
relevant and therefore can replace national output. 
50% of national 
output is replaced  
Assumption: on average 50% of joint output is assumed 
to be relevant for country' decisions (see also assumption 
for group 1). 
0% 
Assumption because of 
zero to low current 
output 
PO 4.1, V/M 
without opt in 
50% of joint output 
replaces national 
output 
Assumption: Even those countries that did not opt in will 
(be able to) take up one half of assessments on a 
voluntary basis.  
25% of national 
output is replaced  
Assumption: on average 25% of joint output is assumed 
to be relevant and attractive for country' decisions.  
0% 
Assumption because of 
zero to low current 
output 
PO 4.2, M/M 100% of joint output 
replaces national 
output 
Assumption: in countries with national outputs 
exceeding 60 reports per year all 40 joint REAs will be 
relevant and therefore can replace national output. 
50% of national 
output is replaced  
Assumption: on average 50% of joint output is assumed 
to be relevant for countries' decisions (see also assumption 
for group 1). 
0% 
Assumption because of 
zero to low current 
output 
PO5, M/M 
Full HTA 
PO2, V/V NR because no joint output is assumed, see Table 16 
PO3, V/V NR because no joint output is assumed, see Table 16 
PO 4.1, V/V NR because no joint output is assumed, see Table 16 
PO 4.2, V/V NR because no joint output is assumed, see Table 16 
PO5, V/M 
with opt in 
50% of joint output 
replaces national 
output 
Assumption - based on Chamova 2017 (2) (roughly half 
of the MS do – if only rarely – a Full HTA study at 
national level) 
25% of joint output 
replaces national 
output 
Assumption by the authors (to be tested in sensitivity 
analysis) 
0% 
Assumption because of 
zero to low current 
output 
PO5, V/M 
without opt in 
20% of joint output 
replaces national 
output 
Assumption by the authors (to be tested in sensitivity 
analysis) 
20% of joint output 
replaces national 
output 
Assumption by the authors (to be tested in sensitivity 
analysis) 
0% 
Assumption because of 
zero to low current 
output 
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Table 19: Assumptions on national output reduction in the MedTech sector 
 MedTech 
 
Group 1 (60 or 
more reports per 
year) 
Source (if available)  
Group 2 (less 
than 60 reports 
per year) 
Source (if available)  
Group 3 (no or 
purely ‘informative’ 
HTA system) 
Source if available 
or Assumption 
Early Dialogue 
Not enough data are available at national level to make realistic assumptions on the amount of national output reduction. However, it is fair to assume that higher savings could be realised in case of mandatory options (PO 4.2 and 5). Industry has strong 
incentives to initiate joint EDs on those products for which they currently need to conduct a high number of national EDs. The potential will, however, be lower than for Pharmaceutical products since company size varies to a higher degree with a larger 
amount of only locally operating companies and with generally less activity related to EDs (see section 7.1.12.3). Moreover, not every joint ED will be completely transferable to local settings (SEED study, p. 26). 
REA 
PO2, V/M 
with op in 50% of joint 
output replaces 
national output 
Assumption: in countries with national outputs exceeding 50 reports per year one half of all 25 joint 
REAs will be relevant and therefore can replace national output. This is based on the large 
heterogeneity of medical devices as well as on the perceived heterogeneity of the product scope of 
MS HTA systems for medical devices (Chamova 2017) (2) as well as on the larger amount of only 
locally operating companies.  
10% of 
national output 
is replaced  
Assumption: on average 50% of joint 
output is assumed to be relevant for 
countries' decisions (see also assumption 
for group 1). 
0% 
Assumption because 
of none to low 
current output 
PO2, V/M 
without op 
in 
1 national output 
per year is 
replaced by joint 
output 
Assumption: Even those countries that did not opt in will (be able to) take up one joint REA on a 
voluntary basis. 
0%  
Assumption: in countries with <60 
reports per year and who did not opt in 
there won’t be an uptake out of the 10 
joint REAs for direct decision-making 
0% 
Assumption because 
of zero to low current 
output 
PO3 NR because non joint output is assumed, see Table 16 
PO 4.1, 
V/M with 
op in 
50% of joint 
output replaces 
national output 
Assumption: in countries with national outputs exceeding 50 reports per year, one half of all 25 
joint REAs will be relevant and therefore can replace national output. This is based on the large 
heterogeneity of medical devices as well as on the perceived heterogeneity of the product scope of 
MS HTA systems for medical devices (Chamova 2017) (2) as well as on the larger amount of only 
locally operating companies. 
50% of 
national output 
is replaced  
Assumption: on average 50% of joint 
output is assumed to be relevant for 
countries' decisions (see also assumption 
for group 1). 
0% 
Assumption because 
of zero to low current 
output 
PO 4.1, 
V/M 
without op 
in 
25% of joint 
output replaces 
national output 
Assumption: Even those countries that did not opt in will (be able to) take up one half of 
assessments on a voluntary basis.  
25% of 
national output 
is replaced  
Assumption: on average 25% of joint 
output is assumed to be relevant and 
attractive for countries' decisions.  
0% 
Assumption because 
of zero to low current 
output 
PO 4.2, 
M/M 50% of joint 
output replaces 
national output 
Assumption that in countries with national outputs exceeding 50 reports per year one half of all 25 
joint REAs will be relevant and therefore can replace national output. This is based on the large 
heterogeneity of medical devices as well as on the perceived heterogeneity of the product scope of 
MS HTA systems for medical devices (Chamova 20172) as well as on the larger amount of only 
locally operating companies. 
50% of 
national output 
is replaced  
Assumption: on average 50% of joint 
output is assumed to be relevant for 
countries' decisions (see also assumption 
for group 1). 
0% 
Assumption because 
of zero to low current 
output 
PO5, M/M 
Full HTA 
PO2, V/V NR because no joint output is assumed, see Table 16 
PO3, V/V NR because no joint output is assumed, see Table 16 
PO 4.1, 
V/V 
NR because no joint output is assumed, see Table 16 
PO 4.2, 
V/V 
NR because no joint output is assumed, see Table 16 
PO5, V/M 
with opt in 
50% of joint 
output replaces 
national output 
Assumption - based on Chamova 2017 (2) (roughly half of the MS do - if only rarely - a Full HTA) 
25% of joint 
output replaces 
national output 
Assumption by the authors (to be tested 
in sensitivity analysis) 
0% 
Assumption because 
of zero to low current 
output 
PO5, V/M 
without opt 
in 
10% of joint 
output replaces 
national output 
Assumption by the authors (to be tested in sensitivity analysis) 
10% of joint 
output replaces 
national output 
Assumption by the authors (to be tested 
in sensitivity analysis) 
0% 
Assumption because 
of zero to low current 
output 
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 Assumptions on cost elements for the implementation mechanisms 6.2.2.4
For assessing the costs of the implementation mechanism under consideration several 
assumptions with regard to the specific cost elements are necessary. The assessment of 
implementation mechanisms included potential one-time investment costs and operating 
costs. Expertise of former and current JA leaders of EUnetHTA , EUnetHTA  JA budget 
calculations, a study on analysing the structure of EU agencies (30), the EU staff 
regulations (31) and former impact assessments for the establishment of EU agencies, 
namely eu-LISA (European Agency for the Operational Management of large-scale IT 
Systems in the Area of Freedom, Security and Justice), EFSA (European Food Safety 
Authority) and EASA (European Aviation Safety Agency), formed the basis for the 
respective calculations and underlying assumptions.  
For each of the implementation mechanisms it is planned that output production is fully 
coordinated comprising the following outputs (see Table 1 for details): 
• Common tools, including templates, methodologies 
• Early Dialogue 
• joint REA 
• joint Full HTA 
Calculations for implementation mechanisms are based on the assumption of an annual 
output production of the respective policy option (see 6.2.2.1 for details).  
Personnel costs for implementation mechanisms of a project-based cooperation or an MS 
secretariat as well as different price levels of MS were accounted for by indexing the 
calculations based on the EU salary scheme to national price levels.  
 Assumptions on Governance structure 6.2.2.5
Presented information on the potential Governance structures was developed in close 
collaboration with EC. The governance structure of future EU cooperation in the field of 
HTA includes 5 different business models (43): 
• Project-based cooperation (PO2)  
• A permanent secretariat hosted by a MS (PO 3)  
• A permanent secretariat hosted by the EC (PO 4.1)  
• A permanent secretariat hosted by an existing EU agency (PO 4.2) 
• A permanent secretariat hosted by a new EU agency (PO 5) 
The main difference in the organisational structure between the five models can be 
observed between the project-based cooperation (PO2) on the one hand and the 
establishment of a permanent secretariat (PO 3-5) on the other hand. Regardless of the 
type of cooperation, there are common elements to the governance structure, which are 
defined by the joint outputs. For every calculation, the number of potential outputs was 
linked to the assumptions for the POs and business models. 
 
                                                                                                                                   
 
(43) Other combinations of policy options with business models are possible as well (e.g. a new agency already for PO 4.1) but 
the presented variants are considered as the most plausible ones, with experts and DG SANTE. 
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Project-based cooperation 
In MS-driven, project-based cooperation, (PO 2), one HTA agency is responsible for the 
overall coordination. The work is conducted in Work Packages (similar to EUnetHTA JAs) 
by different HTA bodies for the duration of the project. 
The management board is responsible for overall governance and consists of repre-
sentatives from participating MS, which should meet quarterly to discuss topic prioritisa-
tion, progress with outputs, and any other relevant issue to provide guidance on and 
steer the cooperation. 
Support functions, e.g. administrative support for coordination meetings, scientific 
support to perform basic consistency checks on joint outputs, IT support and communi-
cation functions will be provided by the central coordination secretariat of the respective 
HTA agency; and production of the outputs will be managed by the individual work 
packages. The following figure depicts an illustrative presentation of the governance 
structure of PO 2, project-based cooperation. 
Figure 17: Potential governance structure PO2 
 
 
In addition to the anticipated governance structure, it should be noted that project-
based cooperation is implemented for a limited period of time. Hence, project-based 
cooperation requires specific processes (before and after) and has associated costs that 
may not provide optimal conditions for long-term sustainability and efficiency. 
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Permanent secretariat 
The overall structure of permanent cooperation (PO 3-5) is depicted in Figure 18: 
Figure 18: Potential governance structure permanent secretariat 
The management board is responsible for overall governance and consists of repre-
sentatives from participating MS, which should meet quarterly to discuss topic prioritisa-
tion, progress with outputs and any other relevant issue to provide guidance and steer 
the cooperation. 
The permanent secretariat provides central support, including administrative, 
scientific/technical and IT support. The secretariat may be hosted by the EC, a MS or 
located in an existing or new EU agency. 
 
The tasks of this permanent secretariat would include: 
Administrative support 
• Organisation of meetings, travel arrangements and other administrative issues 
relevant to the overall coordination and to the operation of the Management Board 
and Expert committees; 
• Finance, especially important with regards to handling reimbursement of national 
experts and any industry fees, and legal aspects (e.g., on taxing); 
• Communication (including studying and documentation); and 
• Providing support to Management Board.  
  
MS Management Board 
Permanent secretariat  
(MS/EC DG SANTE/EU Agency)  
Administrative support (e.g. meetings, planning, finances ) 
 Scientific/technical support (e.g. scientific secretariat for MS Expert Committees, 
quality management, liaison, implementation )    
 IT support (e.g. submission system, databases, intranet) 
MS EXPERT COMMITTEES 
MS Committee for Early 
Dialogues > Joint EU ED 
(PO4) MS Committee for 
REA > Joint EU REA 
(PO5) MS Committee for 
full HTA > Joint Full HTA  
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Scientific/technical support (scientific secretariat to output-producing HTA bodies and MS 
expert Committees) 
• Support the production of output (Standard Operating procedures for identifying 
and organising the work of experts from national authorities in MS Expert Commit-
tees; provide scientific/technical support to authors and co-authors of the joint 
outputs); 
• Quality management (both from a scientific and editorial perspective); 
• Liaison with stakeholders (patients, industry, health professionals, academia, 
payers etc.); and 
• Provide support for national implementation (e.g. training). 
IT support, particularly for the intranet, communication tools, POP-Database (44) and 
support to MS regarding these matters; and 
Legal support on contract law, development of templates and legal advice on contractual 
agreements. 
Production of the different joint outputs is contracted to HTA bodies and outputs pro-
duced are reviewed by the members of respective committees. The basic workflow for 
this process is shown in Figure 19.  
Figure 19: Organisational workflows for permanent secretariat 
 
 
As displayed in Figure 19, output production and review of outputs are two separate 
processes. Output is going to be produced by one author and one co-author of a national 
HTA body. Experts from participating MS, who are part of the MS expert committee, will 
review outputs to ensure the quality of the outputs and consideration of national 
agendas. Author and co-author will be present for meetings but exempted from commit-
tee responsibilities if they are members of the committee. Both experts from HTA bodies 
and MS committees receive reimbursement of their expenses per diem for their work. 
Initially, three committees on Early Dialogues, REAs and Full HTAs (depending on the 
respective policy option) would be established. Additional ad hoc or permanent commit-
                                                                                                                                   
 
(44) The EUnetHTA Planned and Ongoing Projects (POP) database allows HTA agencies to share information with each other on 
planned, ongoing or recently published projects conducted at the individual agency. 
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tees or working groups on other tasks, e.g. development of methodologies, might be 
established. 
The structure of the committees would be as follows: 
 
 Committee for Early Dialogues: 
The committee includes 18 members from MS with extensive experience in HTA, 
5 members from countries with less-extensive experience in HTA (on a rotational 
basis) and 3 external experts from various fields, e.g. health professionals, pa-
tient representatives, etc.). Meetings will take place four times per annum. 
 Committee for REAs: 
The committee consists of 29 representatives of EU 28 and Norway (including one 
MS Chair) and four co-opted members to provide additional scientific advice. The 
committee meets eight times per annum to discuss and review outputs.  
 Committee for full HTAs: 
The committee consists of 29 representatives of EU 28 and Norway (including one 
MS Chair) and four co-opted members to provide additional scientific advice. The 
committee meets four times per annum to discuss and review outputs.  
Reflecting on the structure of committees, quorums and voting procedures need to be 
determined in a transparent matter (by developing Rules of Procedure). Members will be 
required to declare potential conflicts of interest. 
Online voting and e-meetings with a suitable tool might be an option to reduce the 
workload and time needed for travelling, thus also reducing costs.  
Presented governance structures require similar tasks (see Table 20). Nonetheless, 
support functions can be more readily centralised in a permanent cooperation model as 
compared to project-based cooperation. This is expected to increase the efficiency of 
processes and ensure greater consistency in outcomes. It would also enable national 
agencies and their experts to keep a primary focus on the scientific work and not on the 
administrative and coordination functions, which supports production of high quality joint 
outputs (e.g. organisation of meetings, interaction with experts from other countries 
and/or stakeholders etc.).  
When estimating the resource needs of the permanent cooperation models (MS secretar-
iat for PO3; EU secretariat hosted by the EC based for PO4.1; Existing EU agency for 
PO4.2; and a new EU agency for PO5), similar structures were identified. In other words, 
the cooperation model is determined by the outputs and the tasks necessary for deliver-
ing these outputs. The hosting institution (i.e. a MS Agency, the EC, an existing or new 
EU Agency) will have an impact on the calculations (45) as coordination and support 
effort increases, depending on the scope of outputs, but no major impact on the func-
tions to be performed is expected as there are specific requirements related to high-cost 
investment.  
The different legal and formal requirements for integrating the cooperation model, 
including a central Secretariat and its governing bodies, into an existing national or EU 
agency or founding a new EU agency, are subject to national or EU decision-making 
processes and therefore are not within the scope of this study.  
Besides the overall governance structure, staff compositions for implementation mecha-
nisms for each policy option (PO 2 to PO 5) were identified according to envisaged tasks.  
                                                                                                                                   
 
(45) The different price levels of Member States were accounted for by indexing the calculations based on the EU salary scheme 
to national price levels. 
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Table 20 shows the estimated staff composition for the respective scope of joint 
output production (see Table 20 &  
Table 21 for specifications) taking the expected participation of MS into account. The 
scope of the implementation mechanisms was set as follows (rounded figures in Full 
Time Equivalents (FTE)): 
Table 20: Characteristics and staff needed of potential implementation mechanisms for 
65 joint REA 
Implementation 
Mechanism 
Characteristics 
Project-based 
cooperation 
 Central cooperation management (Leading partner) 
 Human resources (total 12 + 3 (IT) FTE): 
o Lead manager (1 FTE) 
o Lead scientific officer (1 FTE) 
o Project manager (3 FTE) 
o Financial officer (1 FTE) 
o Communication/IT officer (1 FTE) 
o Project management assistant (3 FTE) 
o Administrative assistant (1-2 FTE) 
 Decentralised output management included in output production calculation for Work 
Packages 
 MS expert committee 
 Time horizon: 5 years 
 Tasks: Support functions 
 Maintenance of IT tools, methodology and templates (3 FTE) 
Permanent 
Secretariat (PO3) 
 Central coordination management 
 Human resources: (total 14 FTE)  
 Head (1 FTE) 
 Administrative support (total 4 FTE) 
o Head of administration (1 FTE)  
o Project Manager (1 FTE) 
o Administrative staff (2 FTE) 
 Scientific/technical support (total 6 FTE) 
o Head (1 FTE)  
o Scientific officers (2 FTE) 
o Methodology, guidelines, templates (2) 
o Administrative staff (1 FTE) 
 IT (total 3 FTE) 
o Internal support l (1 FTE) 
o Maintenance of tools and databases (2 FTE) 
 Output production contracted to HTA bodies  
 MS expert committee on ED 
 Time horizon: Permanent  
 Tasks: Central support (including administrative, scientific/technical, IT support, legal 
support), maintenance of tools, methodology and templates  
Permanent 
secretariat (PO4.1) 
 Central coordination management 
 Human resources: (total 31 FTE)  
 Head (1 FTE) 
 Administrative support (total 11 FTE) 
o Head of administration (1 FTE)  
o Project Manager (4 FTE) 
o Administrative (6 FTE) 
 Scientific/technical support (total 15 FTE) 
o Head (1 FTE)  
o Scientific officers (7,5 FTE) 
o Methodology, guidelines, templates (2,5 FTE) 
o Administrative (4 FTE) 
 IT support (total 4 FTE) 
o Internal support (1,5 FTE) 
o Maintenance of tools and databases (2,5 FTE) 
 Output production contracted to HTA bodies  
 MS expert committee on ED and REA 
 Time horizon: Permanent 
 Tasks: Central support (including administrative, scientific/technical, IT support, legal 
support), maintenance of tools, methodology and templates  
Permanent 
Secretariat (PO4.2) 
 Central coordination management 
 Human resources: (total 34,5 FTE)  
 Head (1 FTE) 
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 Administrative support (total 11 FTE) 
o Head of administration (1 FTE)  
o Project Manager (4 FTE) 
o Administrative (6 FTE) 
 Scientific/technical support (total 18,5 FTE) 
o Head (1 FTE)  
o Scientific officers (9,5 FTE) 
o Methodology, guidelines, templates (2,5 FTE) 
o Administrative (5,5 FTE) 
 IT support internal (4 FTE) 
o Internal support (1,5 FTE) 
o Maintenance of tools and databases (2,5 FTE) 
 Output production contracted to HTA bodies  
 MS expert committee on ED and REA 
 Time horizon: Permanent 
 Tasks: Central support (including administrative, scientific/technical, IT support, legal 
support) ), maintenance of tools, methodology and templates 
New EU agency 
(PO5) 
 Human resources: (total 45,5 FTE)  
 Head (1 FTE) 
 Administrative support (total 16 FTE) 
o Head of administration (1 FTE)  
o Project Manager (6 FTE) 
o Administrative (9 FTE) 
 Scientific/technical support (total 23,5 FTE) 
o Head (1 FTE)  
o Scientific officers (11 FTE) 
o Methodology, guidelines, templates (3 FTE) 
o Administrative (8,5 FTE) 
 IT (total 6 FTE) 
o Internal support (2 FTE 
o Maintenance of tools and databases (3 FTE) 
 Output production contracted to HTA bodies 
 MS expert committee on ED, REA and Full HTA 
 Time horizon: Permanent 
 Central support (including administrative, scientific/technical, IT support, legal sup-
port), maintenance of tools, methodology and templates 
 
As depicted in the table, the staff composition of PO 3 is low due to the low number of 
expected outputs. According to the assumptions made in 6.2.2.2, output production is 
limited to 40 Early Dialogues p.a.  
Relating to the staff composition of PO 4.1 and PO 4.2, differences in staff resources 
result from the V/M or M/M participation rate of MS for the Policy Options (for assump-
tions see 6.2.2.2). 
Estimates on staff resources included output of 40 Early Dialogues and/or 65 REAs (40 
on Pharmaceuticals, 25 on medical technologies) and/or 11 Full HTAs (7 on Pharmaceu-
ticals, 4 on medical technologies) depending on the respective policy option. Cost 
estimates on maintenance of tools, methodologies and templates was separately 
assessed to correspond with the description of Policy Options displayed in Table 7, but 
will be integrated in the coordination unit for all options with a permanent secretariat. 
For potential development of tools, methodologies and templates, final cost estimates 
include a lump sum (Table 56). 
Prognosed output production is relevant for the period until structures and processes are 
well-established. After that adaption to EMA processes, i.e. an increase from 65 REAs to 
115 REAs (38 on Pharmaceuticals, 25 on medical technologies), covering all centrally 
authorized new substances and indications is recommended. Accordingly, staff composi-
tion would increase for POs 4.1, 4.2 and 5 due to expanded output production (Table 
21). 
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Table 21: Characteristics and staff needed of potential implementation mechanisms for 
115 joint REA   
Implementation 
Mechanism 
Characteristics 
Permanent 
secretariat (PO4.1)  
 Central coordination management 
 Human resources: (total 38 FTE)  
 Head (1 FTE) 
 Administrative support (total 11 FTE) 
o Head of administration (1 FTE)  
o Project Manager (4 FTE) 
o Administrative (6 FTE) 
 Scientific/technical support (total 22 FTE) 
o Head (1 FTE)  
o Scientific officers (12,5 FTE) 
o Methodology, guidelines, templates (2,5 FTE) 
o Administrative (6 FTE) 
 IT support (total 4 FTE) 
o Internal support (1,5 FTE) 
o Maintenance of tools and databases (2,5 FTE) 
 Output production contracted to HTA bodies  
 MS expert committee on ED and REA 
 Time horizon: Permanent 
 Central support (including administrative, scientific/technical, IT support, legal sup-
port), maintenance of tools, methodology and templates 
Permanent 
Secretariat (PO4.2) 
 Central coordination management 
 Human resources: (total 44 FTE)  
 Head (1 FTE) 
 Administrative support (total 11 FTE) 
o Head of administration (1 FTE)  
o Project Manager (4 FTE) 
o Administrative (6 FTE) 
 Scientific/technical support (total 28 FTE) 
o Head (1 FTE)  
o Scientific officers (16FTE) 
o Methodology, guidelines, templates (2,5 FTE) 
o Administrative (8,5 FTE) 
 IT support (total 4 FTE) 
o Internal support (1,5 FTE) 
o Maintenance of tools and databases (2,5 FTE) 
 Output production contracted to HTA bodies  
 MS expert committee on ED and REA 
 Time horizon: Permanent 
 Central support (including administrative, scientific/technical, IT support, legal sup-
port), maintenance of tools, methodology and templates 
New EU agency 
(PO5) 
 Human resources: (total 54,5 FTE)  
 Head (1 FTE) 
 Administrative support (total 16 FTE) 
o Head of administration (1 FTE)  
o Project Manager (6 FTE) 
o Administrative (9 FTE) 
 Scientific/technical support (total 32,5 FTE) 
o Head (1 FTE)  
o Scientific officers (17,5 FTE) 
o Methodology, guidelines, templates (3 FTE) 
o Administrative (11 FTE) 
 IT support (total 5 FTE) 
o Internal support (2 FTE) 
o Maintenance of tools and databases (3 FTE) 
 Output production contracted to HTA bodies  
 MS expert committee on ED, REA and Full HTA 
 Time horizon: Permanent 
 Central support (including administrative, scientific/technical, IT support, legal sup-
port), maintenance of tools, methodology and templates 
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 Limitations 6.2.2.6
Current HTA outputs are heterogeneous across Europe regarding methods, included 
domains, timelines and available resources. HTA reports may also differ in scope, e.g. 
single technology (STA) vs. multi technology assessment (MTA), initial assessment vs. 
reassessment, and therefore costs for a REA or a Full HTA may vary considerably. 
Although a broad range is assumed for the base case costs of REAs and Full HTAs and 
their estimation is done separately for HTA bodies, the Pharmaceutical and the MedTech-
industry (submission reports) this has to be interpreted with caution. 
Data sources for current costs and quantities of outputs at MS level have gaps and 
uncertainties (main sources: data derived from online survey plus additional follow-up, 
discussions with experts, stakeholders and DG SANTE, Chamova 2017 (2), cross-
checked with other sources where possible, and judged by authors’ own experience). In 
some cases, exact figures on the current amount of national output are not available, 
but known to be higher than zero. Overall annual numbers and thus annual savings 
within the Policy Options at MS level may therefore be underestimated to some degree. 
Early Dialogues are included in the prognosis of expected production costs, but due to a 
lack of data on the current national costs and quantities, the related expected savings in 
‘production costs’ at national level cannot be calculated. Moreover, it may be assumed 
that ED leads to a reduction in additional evidence generation requested by HTA bodies. 
This could not be integrated for the same reason (Moreover, nearly none of the survey 
respondents reported a reduction in HTA costs due to Early Dialogues, see also Table 36 
and Table 37). 
Regarding changes in HTA-expenses at national level, it is neglected that there may be 
an uptake of Joint Output (and related savings or costs) for other purposes than reim-
bursement decisions. Also, the long term overall impact of centrally organised mandato-
ry HTA outputs on national HTA systems e.g. in terms of transparency, standardisation 
or methodological quality cannot be quantified.  
Expenses associated with the adaptation of national regulations for mandatory uptake of 
REA/HTA cannot be quantified either, but have to be taken into account (see also 
6.2.2.1). 
All assumptions and calculations for the output-related cost prognosis are mainly based 
on data from 29 countries (that are included in Chamova 2017) (2), EMA reports and 
EUnetHTA   findings and were at least partly discussed with experts and DG SANTE. 
An adjustment of national costs/prices for purchasing power parity (PPP) was planned. 
But with rather low response rates and many inherent uncertainties, this would add a 
misleading semblance of precision. Additionally, estimates of costs per REA, HTA etc. are 
based mainly on survey responses from all over Europe – so it may be assumed that 
differing PPPs are roughly already in the ranges.  
The Business Models combine output production and implementation mechanisms 
according to the Policy Options displayed in Table 7, Policy Option 1 is linked to the 
implementation mechanism without EU input. According to the assumption made in the 
analytical approach, projects without EU input are strictly the MS’ responsibility. Hence, 
a business model for Policy Option 1 and an implementation mechanism without EU input 
is not covered within this study. 
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7 Results 
7.1 Case study – baseline scenario  
The aim of this case study is to systematically capture and depict the elements compos-
ing the status quo of HTA processes across the EU MS.  
We compared and analysed a sample of 40 health technologies to identify the elements 
composing the value assessments of health technologies across difference European 
countries. This objective would be achieved identifying the final HTA recommendations 
and/or the recommended restrictions in order to include or suggest the inclusion in the 
benefits catalogue of each country of a specific product and how these and the length of 
the process differed or aligned across settings. Indeed, the systematic analysis identi-
fied:  
• The presence of assessment and the final decision taken by HTA bodies, capturing 
the possible duplications;  
• How HTA is currently used in different contexts and, if so, what clinical and eco-
nomic evidence were used in conducting the assessments;  
• The timeline in performing the process across different country setting; and  
• The costs related to the HTA process. 
This allowed an understanding of the variability in methods and processes currently 
employed by different HTA bodies across the EU and enable the identification of possible 
duplication of efforts or cases where greater consensus is needed around HTA processes 
and methods. It also contributed to identifying areas where greater consistency and 
transparency in the criteria used for decision-making can be improved.  
Given the length of this report and the peculiarities arising from specific subsections of 
the results, the discussion section is structured along the presentation of the results.  
 Description of the sample 7.1.1
Initially, 2 576 HTA reports for Pharmaceutical products, 423 HTA reports for medical 
devices(46) and 94 HTA reports for “Other Technologies” were identified, all together 
amount-ing to 3,093 reports. Applying the search criteria, 111 common Pharmaceutical-
indication pairs, 20 common medical device-indication pairs and ten common “Other 
Technologies” indication pairs were identified across at least five EU MS, from which we 
selected the purposive sample based on to the process outlined in 5.2.1. 
Across different categories of health technologies the case study sample included: 
• 20 Pharmaceutical-indication pairs (Table 22 and in more detail in Annex 9) 
• 15 medical device-indication pairs (Table 23 and in more detail in Annex 10) 
• Five other Technology-indications pairs (Table 24 and in more detail in Annex 11) 
Looking at the main features of the sample, three Pharmaceutical products were 
marketed by an SME, whereas all remaining products were marketed by large Pharma-
ceutical companies. Three out of 20 Pharmaceutical products were existing molecules 
considered for a new indication, whereas 17 were considered for the first time by EMA. 
                                                                                                                                   
 
(46) The word ‘devices’ is used generically and includes medical devices and associated medical technologies. 
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As shown in the following tables, a wide range of disease areas were included, compris-
ing three orphan drugs, four Pharmaceuticals treating chronic diseases and four technol-
ogies indicated for a paediatric population. The sample includes molecules approved by 
EMA from 2011 until 2015 (Table 22). 
Table 22: Pharmaceutical – indication pair sample 
GENERIC NAME BRANDED NAME  INDICATION 
Abiraterone Zytiga® Treatment of metastatic castration-resistant 
prostate cancer in adult men whose disease has 
progressed on or after a docetaxel- based 
chemotherapy regimen. 
Aclidinium Bromidum Eklira Genuair® Maintenance bronchodilator treatment for 
relieving symptoms in adults with illness chronic 
obstructive pulmonary disease (COPD). 
Alemtuzumab Lemtrada®  For adult patients with relapsing-remitting 
multiple sclerosis (RRMS) with active disease 
defined by clinical or imaging features. 
Apremilast  Otezla® Treating moderate to severe plaque psoriasis 
Ataluren  Translarna® Translarna is indicated for the treatment of 
Duchenne muscular dystrophy resulting from a 
nonsense mutation in the dystrophin gene, in 
ambulatory patients aged 5 years and older 
Canagliflozin Invokana® Treatment of Diabetes Mellitus Type 2 
Dapagliflozin  Forxiga® Forxiga is indicated in adult diabetes type II 
patients aged 18 years and over, for the 
improvement of glycemic control in the form of 
monotherapy if diet and exercise do not ensure 
proper control of blood glucose levels in patients 
for whom metformin use is not appropriate 
because of intolerance.  
Defibrotide Defitelio® Defitelio is indicated for the treatment of severe 
hepatic veno-occlusive disease (VOD) also known 
as sinusoidal obstructive syndrome (SOS) in 
haematopoietic stem-cell transplantation (HSCT) 
therapy.  
Ivacaftor Kalydeco® Treatment of cystic fibrosis in patients age 6 
years and older who have a G551D mutation in 
the CFTR gene. 
Mirabegron Betmiga® Treatment of symptoms of overactive bladder 
Nivolumab  Opdivo® Treatment of advanced (unresectable or 
metastatic) melanoma 
Nintedanib Ofev® Treatment of Idiopathic Pulmonary Fibrosis (IPF). 
Ocriplasmin Jetrea® Treatment of vitreomacular traction (VMT). 
Ofatumumab Arzerra® In combination with chlorambucil or benda-
mustine for the treatment of chronic lymphocytic 
leukemia (CLL) in patients for this disease not 
previously treated and which are not eligible for a 
treatment based on fludarabine 
Omalizumab Xolair® Treatment of adults, adolescents and children 
(Aged 6 to <12 years) with asthma 
Pasireotide Signifor® Treatment of adult patients with Cushing’s 
Disease for whom surgery is not an option or for 
whom surgery has failed 
Ramucirumab Cyramza® Treatment of advanced gastric cancer or gastro–
oesophageal junction adenocarcinoma previously 
treated with chemotherapy 
Rilpivirine Edurant® In combination with other antiretroviral medicinal 
products for the treatment of human immunodefi-
ciency virus type 1 (HIV-1) infection in 
antiretroviral treatment-naive adult patients with 
a viral load ≤ 100,000 HIV-1 RNA copies/ml. 
Riociguat Adempas® Treatment of adult patients with WHO Functional 
Class (FC) II to III with inoperable CTEPH, 
persistent or recurrent CTEPH after surgical 
treatment, to improve exercise capacity  
Sofosbuvir Sovaldi® In combination with other Pharmaceuticals, for 
the treatment of Chronic hepatitis C (HCC) in 
adults 
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In the case of medical devices, different brands were included across different countries, 
reflecting the heterogeneity of the European market and of medical devices. In total, 15 
branded medical devices were included and five types of medical devices for which the 
brand was not specified. As shown on Table 23, these covered a wide range of disease 
areas. In order to have a representative sample of different type of technologies, we 
included ten invasive medical devices, four non-invasive devices and one in-vitro 
technology.  
Table 23: Medical device-indication pair sample and disease areas included 
Medical device type Disease area 
Endovascular stents Cardiovascular disease  
Home haemodialysis device Kidney diseases 
Transcatheter implantable devices Cardiovascular disease  
Balloon Eustachian Tuboplasty  Diseases of the ear  
Oscillometric blood pressure monitor Cardiovascular disease  
High intensity focused ultrasound (HIFU) Prostate cancer  
Gene expression profiling diagnostics Oncology  
Positron emission tomography (PET)  Oncology  
Cochlear implants Deafness 
Left ventricular assist devices Cardiovascular disease  
LASER KTP Prostate cancer  
Self-monitoring coagulometers Diabetes 
Nucleic acid amplification tests (NAATs) Infectious diseases 
Duodenal-jejunal bypass sleeve  Obesity 
Vitro fertilisation (IVF)  Fertility 
 
This heterogeneity is further enhanced in the ‘Other Technologies’ sub-sample, where 
the evaluations might include different products/tests/technologies under an evaluation 
due to differences in public health programmes across countries and the availability of 
the respective technologies. Some of the reports in this sub-sample offer a comparison 
between technologies in the context of a screening program or vaccination rather than 
an evaluation of the whole program per se.  
As shown on Table 24, three vaccination programmes and two cancer screening pro-
grammes were included. It is important to highlight that the ‘Other Technologies’ sample 
includes different products/tests/technologies under evaluation due to differences in 
public health programmes across countries and the availability of the technology 
included in the program.  
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Table 24: Other technology – indication pair sample and disease areas included 
Intervention name Description Disease area 
HPV Vaccination 
Role of vaccination against human papillomavirus in 
reducing the risk of cervical cancer. 
Oncology 
Colorectal cancer screening 
Screening programme aiming to identify people who 
appear healthy but may be at increased risk of a 
colorectal cancer. 
Oncology 
Pneumococcal vaccination  
Vaccination programme to prevent pneumococcal 
disease (IPD) 
Streptococcus pneumonia 
Rotavirus vaccination  
Rotavirus vaccination is programme to protect against 
rotavirus infections. Usually part of the childhood 
vaccination programme for babies aged 8 weeks and 
16 weeks. 
Acute gastroenteritis 
Cervical cancer 
Screening programme 
Gynaecological cancer screening programme with the 
use of a smear (PAP) test 
Oncology 
 Assessments conducted across the sample 7.1.2
Based on the selection of the 40 technologies, we retrieved a total of 321 reports and 
performed an in-depth analysis on those based on the methodology discussed in section 
6.1. As shown by Table 25, Table 26 and Table 27, 229 reports were retrieved for the 20 
Pharmaceutical sample, 46 for the 15 Medical Device sample and 31 across the ‘Other 
Technologies’ sample.  
The evidence showed that in the Pharmaceutical sample, the same Pharmaceutical-
indication pair has been evaluated at least by 10 agencies with an average across the 
sample of 13.5 agencies evaluating the same Pharmaceutical-indication pair out of 19 
HTA bodies considered. 
By contrast, the current situation in HTA for medical devices and ‘Other Technologies’ is 
less developed and established in comparison to the Pharmaceuticals. Indeed, in the 
medical devices and other technologies samples, the number of HTA evaluations was 
lower. On average, one device or one ‘Other Technology’ was evaluated by six agencies 
with at least four countries evaluating the same medical device.  
These trends are related to the peculiarity of the Medical devices market. Whereas 
Pharmaceutical products have a well-established pathway from Marketing Authorization 
to HTA evaluation and an established HTA process in a large number of European 
countries, medical devices and other technologies follow heterogeneous rules or pro-
cesses regarding their evaluation. This is also reflected in the sample selected. Indeed, 
Pharmaceuticals were selected only if they had undergone an evaluation for the exact 
same indication across settings. In the medical device sample, there would be the same 
type (but with a different branded name or/and a different manufacturer). Additionally, 
medical devices should have undergone an evaluation for the same disease area and not 
the exact same indication. This is because the market for medical devices is intrinsically 
different from that of Pharmaceuticals, with a higher level of competition from market 
entry onwards. While HTA has been largely developed for Pharmaceuticals, there 
appears to be a need for adaptation to and development of established HTA processes 
for the medical devices sector as well (32).  
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Table 25: Pharmaceutical products assessment across settings 
Pharmaceuticals 
Included 
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Abiraterone     X X     X X X X X X X X X X      13 
Aclidinium Bromidium X    X X X    X X   X X X X X X    X  12 
Alemtuzumab     X X X    X X  X X X X X X X   X   12 
Apremilast     X X X   X X X  X X X X X X X  X X   10 
Ataluren     X X X X   X X  X X X X X X X X  X   10 
Canagliflozin     X X X    X X   X X X X X    X   14 
Dapagliflozin     X X X    X X X  X X X X X X      13 
Defibrotide X    X X X X X  X X X X X X X  X X  X X   8 
Ivacaftor X    X X X    X X   X X X X X X  X X   11 
Mirabegron     X X X    X X X  X X X X X X  X X X  10 
Nivolumab     X X X    X   X X X X X X X X  X   12 
Nintedanib     X X X    X X   X X X X X X   X   13 
Ocriplasmin     X X X    X X X X X X X X X X  X    11 
Ofatumumab     X X   X X X X   X X X X X X  X    12 
Omalizumab     X X X  X  X X X X X X X X X X X     10 
Pasireotide X    X X X X   X X X X X X X X X X X  X   8 
Ramucirumab     X X X    X   X X X X X X    X   14 
Rilpivirine X    X X X    X X X X X X X X X X  X    10 
Riociguat X    X X X    X X   X X X X X X   X   12 
Sofosbuvir      X X     X  X X X X X X X      15 
TOTAL ASSESSED 14 20 20 20 1 0 2 17 17 18 1 2 12 8 0 0 0 1 0 2 16 13 8 18 20  
Note: Ticks indicate that the technology has been assessed, while crosses indicate that the technology has not been assessed. Countries with no HTA reports publically available have been excluded from this table (e.g. Hungary, 
Bulgaria, Cyprus, Slovenia, Latvia, etc.) Countries with no HTA reports publically available have been excluded from this table (e.g. Hungary, Bulgaria, Cyprus, Slovenia, Latvia, etc.) ; It may be the case that we have included 
national regulatory bodies to capture also agencies that perform HTA on the side of theire regulatory role. 
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute Autorité de Santé; GÖG: Gesundheit Österreich GmbH; 
LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care Knowledge Centre; NCPHA: The National Center of Public Health and Analyses; MoH: Ministry of Health; AZZ: Agencija za 
kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi; FIMEA: Finnish Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; NCPE: National 
Centre for Pharmacoeconomics; HIQA: Health Information and Quality Authority AIFA: Agenzia Italiana del Farmaco UVEF: Unità di valutazione dell'efficacia del farmaco; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; 
ZVA: Zalu valsts agentura; VASPVT: Valstybinė akreditavimo sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny Technologii Medycznych i Taryfikacji; Infarmed: Instituto Nacional da 
Farmácia e do Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información de Medicamentos; AquAS: Agència de Qualitat i Avaluació Sanitàries de 
Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology Assessment; AETSA: Andalusian Agency for Health Technology Assessment; SECS: Servicio de Evaluacion del Servicio Canario de salud. 
(*KCE does not have a mandate for Pharmaceuticals but it performed an economic evaluation of the Hepatitis C treatments comprising also Sofusbuvir (**) For AIFA the reports were not publicly available but the decision was 
published in Gazzetta Ufficiale (***) The two German bodies IQWIG and G-BA work in the same HTA process; if an assessment is done twice it does not constitute a duplication. Source: The Authors. 
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
                                                                                                       136 
    
Table 26: Medical device assessment across settings 
Medical Devices 
Included 
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Endovascular stents  X X  X  X X X  X X X X X X X X  X  X X X 6 
Home haemodialysis 
device 
 X X    X X X X X X X  X X X X X X X X X X 5 
Transcatheter 
implantable devices 
X  X  X X X X X X X X X X  X X  X   X X X 6 
Balloon Eustachian 
Tuboplasty 
 X X X X  X X X  X X X X X X X X X  X X X X 4 
Oscillometric blood 
pressure monitor 
 X X  X   X X X X X X X X X X X X X X X X X 4 
High intensity focused 
ultrasound (HIFU) 
 X X    X  X X X X X X X X   X X  X X X 8 
Self-monitoring 
coagulometers 
  X    X X X X X X X X X  X X  X X X X X 7 
Positron emission 
tomography (PET) 
X X X X   X  X X  X  X  X X X X X X X X X 6 
Cochlear implants  X X   X  X X X  X  X X X  X X X  X X X 8 
Left ventricular assist 
devices 
 X X    X X X X X X X X X  X X X X  X X X 6 
LASER KTP  X X   X X  X X  X X  X X X  X X  X X X 8 
Gene expression 
profiling diagnostics 
 X  X  X X  X X  X X X X X X X  X  X X X 7 
Nucleic acid 
amplification tests 
(NAATs) 
 X X   X X X X X X X X X X X X X X X X X X X 3 
Duodenal-jejunal 
bypass sleeve 
 X X   X X X X  X X X  X X X X X   X X X 7 
In-vitro fertilisation 
(IVF)  
X X X  X X   X X X X X X X  X X X X  X X X 5 
TOTAL ASSESSED 12 2 1 12 11 8 3 5 0 3 4 0 2 3 2 3 2 3 3 3 9 0 0 0  
Note: Ticks indicate that the technology has been assessed, while crosses indicate that the technology has not been assessed. Some HTA bodies (e.g. HAS and KCE) have published more than one report for type of medical 
devices. In this table however, the reports of these HTA bodies are counted as one. Countries with no HTA reports publically available have been excluded from this table (e.g. Hungary, Bulgaria, Cyprus, Slovenia, Latvia, etc.) It 
may be the case that we have included national regulatory bodies to capture also agencies that perform HTA on the side of theire regulatory role. 
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute Autorité de Santé; GÖG: Gesundheit Österreich GmbH; 
LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care Knowledge Centre; NCPHA: The National Center of Public Health and Analyses; MoH: Ministry of Health; AZZ: Agencija za 
kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi; FIMEA: Finnish Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; OGYEI: Országos 
Gyógyszerészeti és Élelmezés-egészségügyi Intézet; NCPE: National Centre for Pharmacoeconomics; HIQA: Health Information and Quality Authority AIFA: Agenzia Italiana del Farmaco UVEF: Unità di valutazione dell'efficacia del 
farmaco; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; ZVA: Zalu valsts agentura; VASPVT: Valstybinė akreditavimo sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny 
Technologii Medycznych i Taryfikacji; Infarmed: Instituto Nacional da Farmácia e do Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información de 
Medicamentos; AquAS: Agència de Qualitat i Avaluació Sanitàries de Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology Assessment; AETSA: Andalusian Agency for Health Technology 
Assessment; SECS: Servicio de Evaluacion del Servicio Canario de salud. (*) The two German bodies IQWIG and G-BA work in the same HTA process; if an assessment is done twice it does not constitute a duplication. Source: 
The Authors. 
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Table 27: Other technology assessment availability 
Other Technologies 
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HPV Vaccination X X    X X X X X X  X X X X X  X X X  X  X X X  8 
Colorectal Cancer Screening X X    X X   X*  X X X X X X  X X X 
X
*X 
  X X X 10 
Pneumococcal Vaccination X X  X  X X X X X X X* X  X X X  X X X X 
X
*X 
X X X X X 4 
Rotavirus Vaccination X X  X  X X X X X X  X X X X X X X X X X X X X X X X 3 
Cervical cancer screening X X X   X X  X X X X*   X X X X X X X  X X X X X X 6 
TOTAL ASSESSED 0 0 4 3 4 0 0 2 1 0 1 2 1 2 0 0 0 3 0 0 0 3 0 2 1 0 0 1  
Note: Ticks indicate that the technology has been assessed, while crosses indicate that the technology has not been assessed. Countries with no HTA reports publically available have been excluded from this table (e.g. Hungary, 
Bulgaria, Cyprus, Slovenia, Latvia, etc.) It may be the case that we have included national regulatory bodies to capture also agencies that perform HTA on the side of theire regulatory role. 
Legend: NICE: National Institute for Health and Clinical Excellence (NICE); SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits Board; HAS: Haute Autorité de Santé; GÖG: Gesundheit Österreich GmbH; 
LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; KCE: Belgian Health Care Knowledge Centre; NCPHA: The National Center of Public Health and Analyses; MoH: Ministry of Health; AZZ: Agencija za 
kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi; FIMEA: Finnish Medicines Agency KELA: Kansaneläkelaitos; IQWIG: Institute for Quality and Efficiency in Healthcare; G-BA: Gemeinsame Bundesausschuss; OGYEI: Országos 
Gyógyszerészeti és Élelmezés-egészségügyi Intézet; NCPE: National Centre for Pharmacoeconomics; HIQA: Health Information and Quality Authority AIFA: Agenzia Italiana del Farmaco UVEF: Unità di valutazione dell'efficacia del 
farmaco; AGENAS: Agenzia Nazionale per i servizi sanitari regionali; ZVA: Zalu valsts agentura; VASPVT: Valstybinė akreditavimo sveikatos priežiūros veiklai tarnyba; ZiN: Zorginstituut Nederland AOTMiT: Agencja Oceny 
Technologii Medycznych i Taryfikacji; Infarmed: Instituto Nacional da Farmácia e do Medicamento; NAMMD: National Agency for Medicines and Medical Devices; CADIME: Centro Andaluz de Documentación e Información de 
Medicamentos; AquAS: Agència de Qualitat i Avaluació Sanitàries de Catalunya; ISCII: Instituto de Salud Carlos III OSTEBA: Basque Office for Health Technology Assessment; AETSA: Andalusian Agency for Health Technology 
Assessment; SECS: Servicio de Evaluacion del Servicio Canario de salud. (*) shows available reports before 2006-thus, not included in the analysis. (**) Different bodies are performing/requesting the assessment. (National 
Cancer Registry Ireland Health Information and Quality Authority, National Immunisation Advisory Committee) (***) In Poland, HTA assessments are also performed at county level. However, we considered only the national 
programmes (*) The two German bodies IQWIG and G-BA work in the same HTA process; if an assessment is done twice it does not constitute a duplication. Source: The Authors. 
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On the number of assessments conducted by country, the Kappa score was calculated 
(Annexes 16, 17 and 18) to show the level of agreement in the number of product 
assessments performed.  
The comparison of the presence of assessment across countries reflected in the Kappa 
score show a better level of agreement in assessing health technologies in the Pharma-
ceutical sample than in the medical devices and ‘Other Technologies’ samples. It is 
important to acknowledge that looking at the level of agreement across countries when 
assessing a Pharmaceutical product and across all Pharmaceutical products, Annex 16 
shows that the majority of Kappa scores indicate poor levels of agreement, but the 
results may be skewed due to the Kappa paradox. Indeed, as discussed earlier, the 
Kappa statistic is sensitive to the distribution of the marginal totals and can lead to an 
over- or underestimation of agreements levels.  
To interpret the actual level of agreement, it is necessary to take into account the 
different topic selection criteria used by different HTA bodies when deciding what 
technology should be assessed. In other words, the common sample assessed across 
countries can be very small, because not all countries assess all technologies and the 
priority setting mechanisms for HTA vary across settings. For instance, SMC (Scotland) 
and HAS (France) assess all new Pharmaceuticals approved by EMA and marketed in the 
country; the same holds for bodies such as AIFA (Italy) and G-BA (Germany) and IQWIG 
(Germany). Other bodies are far more selective on which technologies they select assess 
and the criteria with which they select technologies for assessment.  
For example, NICE (UK) and ZiN (The Netherlands) have a list of criteria on selecting the 
technologies that will undergo the review process. Such criteria may be the burden of 
disease, resource impact, clinical and policy importance, potential factors affecting the 
timelines for the guidance to be produced and likelihood of guidance having an impact on 
public health and quality of life. Finally, it is important to acknowledge that KCE (Bel-
gium) does not have the mandate of assessing Pharmaceutical products and, therefore, 
just one product was identified, affecting the reliability of the Kappa score results.  
This has led to results across the agencies assessing all the new products on the market 
and indeed would seem to indicate that this agreement is very poor. However, if we 
examine the percentage of agreements across bodies that routinely assess all technolo-
gies that are submitted to them (Table 28) a high level of agreement is obtained.  
Table 28: Proportion of agreement of the recommendation of HTA reports 
Proportion of agreement  HAS G-BA SMC IQWIG AIFA 
HAS  0.9 1 0.85 1 
G-BA 0.9  0.9 0.8889 0.9 
SMC 1 0.9  0.85 1 
IQWIG 0.85 0.8889 0.85  0.85 
AIFA 1 0.9 1 0.85  
Therefore, if we take into account the results across those bodies, having at least a score 
of 0.21, results show a mainly fair level of agreement, with 45% of the agencies 
reaching a Kappa score between 0.21 and 1.  
The trend is not confirmed in the medical devices sample, where the number of assess-
ment is lower and fragmented across the sample. This is shown mostly by a poor Kappa 
score (K<0.20) in the assessment of medical devices across agencies (70% of the cases 
studied). 
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Looking at the other technologies sample, the level of agreement is generally poor with 
64% of the HTA bodies achieving a poor level of agreement (K<0.2) and 36% achieving 
an agreement between fair (0.21<K<0.4) to very good (0.81<K<1). 
 Concluding remarks on assessments conducted across technologies 7.1.3
The analysis from the preceding section suggests that, across the range of Pharmaceuti-
cal products considered, there is a fair level of agreement across HTA bodies, also taking 
into account the type of HTA body and the level of HTA development in the study 
countries.  
Different indicators confirm this broad level of agreement across HTA bodies. First, the 
average number of HTA reports assessed across the sample is high (13.5 out of 20 
products). Second, the Kappa score calculated and adjusted for proportions of agree-
ment on the availability of HTA reports shows that countries with established HTA bodies 
tend to assess the same number of Pharmaceutical products and the same drug-
indication pairs.  
This is confirmed specifically when considering regulatory HTA bodies such as HAS 
(France), G-BA (Germany) and AIFA (Italy) due to their topic selection process (evaluat-
ing all new Pharmaceuticals submitting an application for marketing in their respective 
countries) as well as high level of agreement among other HTA bodies, such as TLV 
(Sweden) and NICE (England) or INFARMED (Portugal). 
Considering the landscape of medical technology, this clearly differs from Pharmaceutical 
products. The level of agreement in the availability of HTAs showed by the kappa score 
is mainly poor. Among others, this is testament to the fragmentation of the MedTech 
sector and the variability with which HTA bodies select medical technology targets for 
assessment. 
Finally, the ‘Other Technologies’ sample shows a low level of agreement across countries 
as well. This may be related to the low number of agencies actively engaging in HTA for 
this category of technology (n=14), the lack of publicly available HTA reports, the 
country priorities relating to public health interventions, including, for example, differ-
ences in vaccination programs due to different interventions considered, or the different 
policies employed in implementing preventive programs. As a result, it is difficult to draw 
conclusions from this part of the sample. 
 HTA recommendations  7.1.4
A categorisation was applied initially to all countries in an attempt to allow preliminary 
comparisons. Final HTA outcomes (assessment) were divided into three categories: (a) 
Positive recommendation, (b) Mildly positive recommendation and (c) Negative recom-
mendation. These categories were linked to different types of recommendation and to 
the commonly accepted categorisation of the outcome (appraisal and pricing and 
reimbursement decision) between: a) to list the drug as requested in the HTA submis-
sion (e.g. positive coverage recommendation), (b) to restrict the drug to a subgroup of 
the population or under certain conditions (e.g. restricted coverage recommendation), 
and (c) to reject the drug (e.g. negative coverage recommendation). 
In the case of ‘Other Technologies’, we are considering the outcome as restricted/mildly 
positive when policy recommendations had been made and there is a need of further 
clinical studies/evidence or clearer decision-making processes. 
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Table 29: Preliminary categorisation of recommendation 
Colour Assessment recommendation Category 
  Rejected Negative 
  Listed with Criteria Mildly positive (restricted) 
  Listed Positive 
ND No decision 
N/A Not applicable 
Following expert advice, the categorisation of outcomes presented captures and clusters 
different categories of decisions as well in order to capture the heterogeneity of the 
current situation. For instance, in Germany the HTA bodies do not reject any Pharmaceu-
ticals but give an assessment of the extent of clinical benefit.  
Across the entire sample, 66% (n=242) of the technologies were positively assessed 
with or without restrictions. Breaking down this figure, and excluding IQWIG and HAS, 
where the benefit is ranked instead of producing a yes/no decision, across the positive 
recommendations, 62% (n=123) were acceptances with restrictions whereas the 
remaining 35% (n=75) were fully accepted (no restrictions).  
Across the sample of Pharmaceuticals and medical devices this trend was confirmed 
with 81% and 64% respectively receiving a positive recommendation, of which 63% and 
59% respectively received a restricted recommendation. Across the ‘Other Technology’ 
sample, most of the recommendations were restricted (66%). 
Due to the limited availability of reports in the medical devices and other technologies 
samples, the Kappa score for these technologies was not possible to estimate. This is 
because of the Kappa paradox. 
Contrary, in the Pharmaceutical sample where no availability issues were faced, a 
sample of Pharmaceuticals was selected to test the Kappa score of the HTA outcomes. 
This is presented in Table 30. 
Looking at the level of agreement calculated with Kappa score, the results show that 
69% showed a ‘poor’ agreement in final decisions, 24% a ‘fair’ agreement and 7% a 
‘moderate’ agreement; this highlighted the heterogeneity across HTA bodies in assessing 
the HTA evidence. 
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Table 30: Kappa score - Consistency of HTA recommendation across of Pharmaceutical products sample 
Kappa 
scores 
UK-
NICE 
UK-
SMC 
Ireland-
NCPE 
France
-HAS 
Swe-
den- 
TLV 
Germany-
IQWIG 
Germa-
ny-G-BA 
Spain-
AEMPS 
Spain-
AQuAs 
Nether-
lands-ZIN 
Romania-
NAMMD 
Portugal- 
Infarmed 
Poland-
AOTMiT 
UK-NICE   0.22 0.31 0.00 0.07 0.00 0.00 N/A 0.00 0.58 0.25 0.00 0.03 
UK-SMC 0.22   0.15 0.00 0.14 0.00 0.00 0.33 0.22 0.18 0.32 0.15 0.00 
Ireland-
NCPE 
0.31 0.15   0.00 0.00 0.00 0.00 0.14 0.31 0.45 0.05 0.50 0.00 
France-HAS 0.00 0.00 0.00   0.00 0.00 0.00 0.00 0.24 0.00 0.00 0.00   
Sweden- 
TLV 
0.07 0.14 0.00 0.00   0.00 0.00 0.29 0.07 0.24 0.07   0.22 
Germany-
IQWIG 
0.00 0.00 0.00 0.00 0.00   0.00 0.23 0.33 0.00 0.00 0.00 0.07 
Germany-
G-BA 
0.00 0.00 0.00 0.00 0.00 0.00   0.00 0.22 0.38 0.00 0.00 0.05 
Spain-
AEMPS 
N/A 0.33 0.14 0.00 0.29 0.23 0.00   N/A 0.04 0.22 0.50 1.00 
Spain-
AQuAs 
0.00 0.22 0.31 0.24 0.07 0.33 0.22 N/A   0.13 0.25 0.41 0.28 
Nether-
lands-ZIN 
0.58 0.18 0.45 0.00 0.24 0.00 0.38 0.04 0.13   0.37 0.11 0.05 
Romania-
NAMMD 
0.25 0.32 0.05 0.00 0.07 0.00 0.00 0.22 0.25 0.37   0.17 0.17 
Portugal- 
Infarmed 
0.00 0.15 0.50 0.00   0.00 0.00 0.50 0.41 0.11 0.17   0.08 
Poland-
AOTMiT 
0,02
67 
0.00 0.00   0.22 0.07 0.05 1.00 0.28 0.05 0.17 0.08   
Note: The table includes values where there is a common sample of products across agencies. Based on this, a number of agencies have been excluded, notably Croatia (AZZ), Finland (Fimea), Austria (LBI), EUnetHTA , Italy 
(UVEF), and Belgium (KCE).   N/A: this quantity cannot be calculated." This occurs only when data entries in the above table include a substantial proportion of zero.. 
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Again, the results should be considered carefully because in the cases of HAS, IQWIG 
and G-BA, their classification algorithms were mainly binary due to the type of HTA they 
perform, which skews the results towards Kappa 0. The results across these agencies 
would seem to indicate that this agreement is really very poor. However, if we look at 
the percentage of agreements in HTA outcomes in comparison with these agencies 
(Table 31), a high level of agreement, especially between IQWIG, G-BA and HAS, can be 
shown. The reason for the discrepancy between the unadjusted level of agreement and 
Kappa is affected by prevalence of the finding under consideration and, for very low 
values of Kappa, may not necessarily reflect low rates of overall agreement. 
Table 31: Proportion of agreement on outcomes 
Proportions of agreement HAS G-BA SMC IQWIG 
HAS  0.8824 0.6111 0.8824 
G-BA 0.8824  0.5882 1 
SMC 0.6111 0.5882  0.5455 
IQWIG 0.85 1 0.5455  
The calculation of the Kappa score was not possible for medical device outcomes due to 
their heterogeneity, showing agreement to always be below 0. 
Looking at the Kappa score for the outcomes in the ‘other technologies’ sample, agree-
ment in decision outcomes between HTA bodies was not significant, suffering from 
limitations due to the small sample. However, as is shown in Annex 19, 22 out of 26 
decisions were to restrict the health intervention, clearly showing agreement in decisions 
across countries. 
 Clinical and economic restrictions 7.1.5
A number of clinical and economic restrictions were identified in the HTA reports of the 
study sample. These have a different level of impact on the actual situation, based on 
the role and the function of the HTA bodies. Following expert opinion in capturing the 
different restrictions, we clustered these based on their respective influence on the 
regulatory setting, particularly in what concerns reimbursement decisions (see Annex 
20). For instance, in the case of HAS we classify the level of reimbursement of Pharma-
ceuticals (0%, 35%, 65%) as ‘economic restrictions’ while in England (NICE) and 
Scotland (SMC), economic restrictions were identified if managed entry agreements 
(patient access schemes) were present. Only direct arrangements related to HTA reports 
were captured in order to shed light on the differences at HTA level, not regulatory.  
All restrictions have been identified and coded across all reports, and classified into two 
main categories: clinical restriction, related to the clinical benefit/ratio of the treatment 
and economic restriction, related to the cost-effectiveness and budget impact of the 
health technology. 
 
Clinical restrictions 
Across the entire sample, the most common type of restriction was clinical, imposed in 
56% (n=69) of all cases. For the Pharmaceuticals sample, results show that the most 
common clinical restrictions are to subgroups of patients (67%) followed by therapeutic 
pathways (18%) (Figure 15). As shown in Figure 20 and  
Figure 21, this trend is confirmed at HTA agency level, where Pharmaceuticals are 
commonly restricted to a specific subgroup. 
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A common clinical restriction across all types of technologies was recommending the 
health technology only for certain subgroups. A subgroup restriction refers to a re-
striction of the indication to a specific subgroup of patients in a disease stage, whereas a 
therapeutic pathway restriction is related to a specific pre-treatment requirement or a 
specific treatment to use in combination with the evaluated technology.  
For Pharmaceuticals and medical devices, common restriction types were specialist and 
setting restrictions. The first one is related to a health technology that can be prescribed 
only by a specialized physician (e.g. only by a neurologist), whereas setting restrictions 
refer to a condition on the location where the treatment can be prescribed (e.g. only in 
hospital settings). 
For Pharmaceuticals, pathway and renewal restrictions were also identified as restrictions 
relating to a specific therapeutic pathway to be followed by patient and physician in 
using the product in question or, conditional renewal upon receiving new clinical data or 
reassessment.  
In the medical device sample the most common clinical restrictions were subgroups 
(67%) followed by the therapeutic pathway (32%). Specifically, the last set of re-
strictions referred to the use of the given technology only as an alternative or after the 
failure of other treatments. 
In the ‘Other Technologies’ sample, the type of restrictions differed significantly from 
Pharmaceuticals and medical devices. Technology-specific is a recommendation made for 
one technology (vaccine or screening) over another, whereas programme design is a 
recommendation made regarding various features of the programme in order to improve 
the clinical performance of the entire programme. In this sample, the most common 
clinical restriction was related to a technology specific-feature (58%) followed by 
programme design (34%) (Figure 22). 
 
Economic restrictions 
For Pharmaceuticals and medical devices, the economic restrictions were categorized 
between the suggestion of price negotiation and/or the presence of a risk-sharing 
agreement (e.g. PAS in UK).  
For ‘Other Technologies’, three main types of economic restrictions were captured: (1) 
subgroup economic restrictions, referring to the case when a programme is recommend-
ed for specific patient groups or a programme is not recommended for specific patient 
group, considering their cost-effectiveness; (2) technology-specific restrictions, when a 
recommendation is made for one technology (vaccine or screening) over another 
considering their cost-effectiveness; and (3) programme design restrictions, when 
recommendations are being made regarding various features of the programme in order 
to improve the clinical performance and the cost-effectiveness of the whole programme.  
Economic restrictions were mainly present in the Pharmaceuticals sample, with the 64% 
referring to the introduction of a risk-sharing agreement (RSA) in reimbursing the 
product and 14% requesting further price negotiation.  
In the medical devices sample, only five economic restrictions were identified with a 
main focus on the use of special price negotiations with the regulatory agency responsi-
ble for reimbursement decisions. 
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Figure 20: Clinical restrictions - Pharmaceuticals sample (n=89) 
 
 
 
Figure 21: Clinical restrictions by Agency - Pharmaceuticals sample (n=89) 
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Figure 22: Clinical restrictions – ‘Other Technologies’ sample (n=41) 
 
 Concluding remarks on HTA recommendations 7.1.6
With regards to HTA recommendations across countries, our results suggest 
that agreement in recommendation outcomes between HTA bodies remains poor, despite 
a general trend favouring ‘List with restrictions´ recommendations. This result is 
particularly prevalent in the Medical devices sample, where substantial inter-country 
variability in HTA recommendations is observed across countries.  
When studying the final outcome of HTA processes, it is important to consider the 
differences between assessment, defined as the analytical process of gathering and 
summarizing information about a health technology, and appraisal, which refers to the 
process of making a decision about whether or not a health technology should be 
covered, taking into account assessment information but also a number of other factors 
and dimensions of value. Nevertheless, a clear distinction between assessment and 
appraisal is not present in all countries. In some cases, decision-making is closely 
integrated with the HTA process. Consequently, the outcomes captured have a different 
effect on the health system of each country and cannot be weighted equally.  
 HTA timelines relative to Marketing Authorisation (MA) 7.1.7
As shown by Figure 23, on average, the longest time in evaluating a Pharmaceutical was 
taken by INFARMED and AOTMiT (648 and 647 days, respectively) after Marketing 
Authorization (MA). The results for FINHOHTA, KCE and LBI should be considered 
carefully due to the small sample size (FINHOHTA n=2; KCE=1, LBI=1). 
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Figure 23: Lag time between MA and publication date by Agency in days 
 
In the medical technology sample, looking at the average lag time between the CE 
marking date and the submission of an HTA, the timing is much longer, around 60 
months. However, the data should again be interpreted with caution, due to the scarcity 
of publicly available data on CE mark dates. Across HTA bodies, on average the time lag 
between evaluations was 3 years, the longest time lag being for duodenal sleeves 
assessed by EUnetHTA in 2013 and by KCE in 2006.  
When analysing ‘Other Technologies’, it is important to acknowledge the time lag 
between evaluations of similar programmes across different countries. Figure 24 shows 
the publication dates of the HTA reports of the selected ‘Other Technologies’ across the 
respective HTA bodies. For instance, KCE (Belgium) evaluated colorectal cancer screen-
ing in 2006, whereas FIMEA (Finland) and G-BA (Germany) evaluated the programme in 
2016. 
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Figure 24: Report publication dates (‘Other Technologies’ sample) 
 
 Clinical evidence  7.1.8
Across the Pharmaceutical sample, on average four clinical studies were considered per 
HTA assessment; a total of 536 trials or studies were considered. Figure 25 shows that, 
across the entire Pharmaceutical sample, all HTA bodies had a preference towards phase 
III clinical trials, followed by phase II trials and other sources of evidence. Specifically, 
phase III RCTs accounted for the majority of the evidence submitted (62% n=334), 
followed by phase II trials (10% n=51), indirect comparisons (6% n=52), with the 
remaining 30% being a range of other types of evidence such as HTA reports (n=26) 
extensions (n=13) and observational studies (n=11). 
Focusing on the proportion of type of trials by HTA bodies,  
Figure 26 clearly shows that Phase III trials are preferred across the sample, with the 
exception of Romania and Croatia (AZZ), where the assessment is mainly based on HTA 
reports produced by other countries (HTA referencing).  
Considering the comparator presented, the most commonly used trial comparators were 
placebo. On average, 61% of 338 primary trials included a placebo or did not include any 
comparator and the remaining 39% included a direct comparator. No comparator was 
considered when the trials include a comparison of different doses of the study drug.  
Across the medical devices sample, Figure 27 shows a clear preference for RCT trials 
(28%) followed by observational studies (17%) and safety studies (19%). On average, 
the HTA considered four clinical studies per medical technology.  
Considering the comparator presented, the most commonly used trial comparators were 
the current standard of care. However, the larger number of trials considered were 
uncontrolled therefore, they did not have a comparator. 
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Across the ‘Other Technology’ sample, on average six clinical studies were presented 
with a general preference for literature reviews (89%). This might be related to the 
general scope of these types of HTA evolutions, which are looking at all the different 
aspects of public health programmes and not solely to the clinical and cost-effectiveness 
of the technologies under evaluation.  
Figure 25: Type of clinical evidence considered across the Pharmaceutical sample 
 
 
Figure 26: Percentage of clinical trials considered by agency- Pharmaceutical sample 
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Figure 27: Type of clinical evidence Medical devices sample 
 
 Economic model  7.1.9
Not all countries assessed the clinical and cost-effectiveness of each study technology 
and the criteria in assessing them can vary considerably from country to country. 
In the Pharmaceuticals sample, eight countries considered an economic evaluation in 
their assessment and, on average, 1.5 economic studies were considered for each 
Pharmaceutical product. Our findings show that, in general, a cost-utility analysis has 
been considered across all study drugs (in 85% of cases), followed by budget impact 
analysis (43% of cases). Only in a limited number of cases (6%), was a cost-
minimization analysis adopted.  
Considering the comparator presented, the most commonly used comparators were a 
direct comparator (86%). Across the countries studied and in 68% of the cases, 
the comparator included was the same across HTA bodies. 
In the medical devices sample, eight countries considered economic evaluation with an 
average number of studies considered by agencies to be slightly higher, reaching 2.5 
studies per technology. Looking at the type of economic evaluation, the trend was 
confirmed with mostly cost-utility studies (67%), followed by cost comparisons (21%).  
In the ‘Other Technologies’ sample, seven countries considered an economic evaluation 
with 73% of the evaluations taking into account at least a cost utility analysis, followed 
by 45% of evaluations also taking into account a budget impact analysis. 
 Social value judgements  7.1.10
Due to the incomplete nature or the low quality of clinical and economic evidence, when 
evaluating health technologies, decision-makers are having to make judgements that 
may influence the decision process in dealing with uncertainty or accepting ICERs that 
are, strictly speaking, higher than national willingness to pay (WTP) thresholds. These 
judgments are commonly called ‘social value judgements’ (SVJs) and aim to interpret 
key elements related to the impact of the treatment on patients and society. As such, 
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SVJ have increasingly been included in HTA recommendations. For instance, NICE in 
England recognizes that special circumstances, such as disease severity, end-of-life 
situations, stakeholder interests and degree of innovation, are taken into consideration 
in addition to the cost per QALY (Quality-adjusted life year). 
The aim of identifying these SVJ was to define whether they are captured, partly 
captured, or not captured by HTA bodies and their potential influence on the assess-
ment. SVJs have been identified and coded across all appraisal reports, and classified 
into eleven main categories notably: (1) Significant innovation, (2) Life expectancy, (3) 
Small population, (4) Equality issues, (5) Wider societal benefit, (6) Impact on quality of 
life and daily activities, (7) Impact on the family and the carers, (8) Unmet need for 
treatments, (9) Rarity and/or (10) severity of the disease and (11) Other considerations, 
which may be related to the disease or the product in question.  
Considering specific trends across different health technologies, the highest number of 
SVJs was identified in the Pharmaceuticals sample (n=304) followed by the medical 
devices sample (n=67). By contrast, in the ‘Other Technology’ sample, only four SVJs 
were considered.  
Across the selected HTA bodies, only three HTA bodies have elicited/revealed their social 
value judgments in their guidelines: NICE in the context of end-of life (EoL) criteria, SMC 
with the so-called ‘disease modifiers’ and TLV with the ‘human dignity, needs and 
solidarity’ principle. However, the other HTA bodies take into account these values 
(albeit not in a consistent manner).  
In the Pharmaceutical sample, the most common SVJ raised by all the agencies were 
about the improvement of quality of life for the patients and the carers (27% N=83) and 
the unmet need in specific disease areas and the treatment innovation (11% N=29). 
Eighty-two percent of SVJs identified provide considerations that favour the treatment. 
Interestingly, across the positive impacts on the quality of life, the administration and 
provision of the treatment is one of the most considered factors. This is probably 
connected to the important benefit gained by a Pharmaceutical product if it is adminis-
tered orally, offering the possibility to take it home, and the positive effect that this 
could have on the organization of the health services and the public expense of health 
systems.  
In the medical devices sample, only 67 SVJs were identified, mainly focused around a 
wider societal benefit arising from the introduction of the new technology in the health 
system (35%; n=23) and the severity of the disease (23%; n=15). 
 Concluding remarks on the evidence presented  7.1.11
An over-arching conclusion of this section is that, considering the evidence included in 
the different HTA reports, there appears to be a trend across HTA bodies studied for the 
same type of clinical and economic evidence. This may suggest a growing trend towards 
the homogenization of clinical and economic evaluation, at least in what concerns the 
primary evidence base that feeds into such evaluations.  
In the case of Pharmaceuticals and in terms of the primary trial types considered by HTA 
bodies, a clear preference was shown for phase III clinical trials. This is hardly surpris-
ing, given this is considered to be the most robust type of evidence. The only exceptions 
were Croatia and Romania, which pursue a type of HTA referencing in the case of 
Pharmaceutical evaluations. AZZ in Croatia performs a literature review to collect the 
HTA decisions at the international level, whereas Romania consults the HTA decisions of 
European countries by employing a score-card system. The results show also that all the 
agencies prefer the inclusion of cost-utility analyses to evaluate the cost-effectiveness of 
new interventions.  
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In the case of medical technology, there are clear differences in comparison to Pharma-
ceutical products. The fragmentation of the sector is highlighted again in the evidence 
considered by HTA bodies. Despite a preference for RCTs, the clinical evidence consid-
ered varied significantly across the sample. This also raises questions regarding 
the preference for RCTs as the main evidence of HTA in the context of medical technolo-
gies. This might be related to absence of RCT data and the need of multiple sources of 
weaker evidence to proof the clinical effectiveness therefore raising also questions 
regarding the central role of RTCs in the evaluation of medical devices as the main 
evidence of HTA assessment. Primary data collection (interviews) and the literature 
suggest that, while long RCTs may be desirable from an evidence standpoint, they may 
not always be appropriate or feasible for medical technologies (33).  
This is also confirmed also by the results from the SJVs, showing high variation across 
countries, showcasing how the quality of reports varies largely. Some important ele-
ments for patients, such as social value judgements, may not necessarily be considered 
on a routine basis.  
Finally, the ‘Other Technologies’ sample shows a moderate level of agreement across 
countries and the use of a common methodology for retrieving and considering clinical 
and economic evidence. 
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  Baseline costs 7.1.12
Thirty-three HTA bodies and 89 manufacturers provided responses to the cost part of the 
survey. All results were compiled in an excel spreadsheet and added to the relevant 
indicators. In order to standardize costs, we used historical national currency exchange 
rates to adjust to Euros. In the survey, four institutions classified themselves as HTA 
bodies, however they fell outside the scope of our research and therefore were excluded. 
Combining the results of the study by Julia Chamova with our results, we obtained data 
from 54 HTA bodies. However, the information was fragmented and incomplete. In order 
to overcome this limitation, HTA bodies were contacted again to obtain more specific 
information. Eight HTA bodies responded, giving a range of detailed costs information.  
Of the 89 companies that responded to the survey, 76 were medical devices and 13 were 
Pharmaceutical companies.  
The quality of the information received from the industry (both Pharmaceutical compa-
nies and medical devices companies) varies significantly. Although there is detailed 
information on staff numbers, there is partially complete information on permanent staff 
and consultant costs and almost no information on Full HTA and Early Dialogue unit 
costs.  
In order to enhance the quantity of cost data further, contacts both with the industry 
and the HTA bodies were established. As detailed in the mitigating factors overviews, 
eight HTA bodies responded to a short request for further of information in order to fill 
some gaps in the cost data. The results were also presented in three different focus 
groups in order to test their reliability. 
 Baseline costs - HTA Bodies 7.1.12.1
In order to capture the different levels of spending of HTA bodies and according to their 
respective role (arm’s length vs. integrated and advisory vs. regulatory vs. coordina-
tion), costs were categorized based on a taxonomy of HTA body types. Table 32 reports 
the average total annual number of REA, Single HTA and Multiple HTA by type of HTA 
body. Single HTA is a full HTA performed for a single indication for a single technology 
whereas Multiple HTA is an assessment which normally covers more than one technolo-
gy, or one technology for more than one indication. 
Table 32: Average number of total assessments - HTA bodies 
Summary 
for HTA 
bodies 
Arm's Length 
Body – Advisory 
Arm's Length 
Body - 
Coordination 
Arm's Length 
Body - 
Regulatory 
HTA Function 
Integrated - 
Advisory 
HTA Function 
Integrated - 
Regulatory 
HTA                  
Uncategorized 
Countries 
UK, Sweden, 
Hungary, Portugal, 
Ireland 
Estonia, 
Belgium, Spain, 
Sweden 
Sweden, Ireland, 
Finland, 
Slovenia 
Belgium, Austria, 
Slovakia, Croatia, 
Estonia, 
Netherlands 
Italy, Bulgaria, 
Slovenia, Latvia, 
Luxembourg, 
Hungary, Slovakia, 
Spain, Croatia, 
Malta,  
Lithuania 
Austria, Latvia, 
Italy, Hungary, 
Cyprus, Czech 
Republic, 
Denmark, Estonia 
Total Annual 
Number REA 
105 29 N/A N/A 7 149 
Total Annual 
Number 
Single HTA 
201 23 59 193 69 108 
Total Annual 
Number 
Multiple HTA 
4 11 2 5 4 26 
The same categorisation based on a taxonomy of type of HTA bodies could not be done 
for the costs because the sample was too small. Indeed, due to the small sample size in 
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each category of HTA body reporting values, a broader categorisation based only on their 
integration within the governmental entities was applied. 
Table 33: Categorisation of HTA bodies by integration into national governments* 
CATEGORY Number of 
agencies 
per 
category 
Number of 
Agencies 
that 
perform 
REA  
Number of 
Agencies 
with cost 
data on 
REA 
Number of 
Agencies 
reporting 
costs on 
STA 
REA costs 
(RANGES -
MIN) 
REA costs 
(RANGES-
MAX) 
STA costs 
(RANGES -
MIN) 
STA costs 
(RANGES-
MAX) 
Arms’ Length Body 22 13 8 12 €4 000 €55 000 €4 000 €135 000 
HTA Function 
Integrated 
23 14 4 5 €6 820 € 100 000 €16 000 €100 000 
Other 5 5 3 4 €40 000 €40 000 €13 241 €80 000 
STA: Single Technology Assessment (Full HTA); REA: Rapid Effectiveness Assessment * Average costs per output 
 
Another classification was based on whether the HTA body is performing REA or not, and 
clustering by REA and STA spending, which is shown in  
Table 34 and  
Table 35.The different classifications were adopted in order to capture both the possible 
influence on the costs of the type of body as well as the size of the body and how this 
can influence the number of agencies actively performing REA or STA.  
 
Table 34: Categorisation of HTA bodies by REA activities and spending* 
CATEGORY 
Number of 
agencies per 
category 
performing 
REA 
Number of 
Agencies that 
report cost on 
STA in the 
same category 
REA costs 
(RANGES -
MIN) 
REA costs 
(RANGES-MAX) 
STA costs 
(RANGES -
MIN) 
STA costs 
(RANGES-MAX) 
Agencies with REA 
costs < EUR 20,000.00 
6 5 €4 000 €20 000 €4 000 €51 000 
Agencies with REA 
costs between 
20,000.00  
<REA costs < EUR 
40,000.00 
6 5 €22 580.65 €40 000 €45 000 €125 000 
Agencies with REA 
costs>EUR 40,000.00 
3 2 €55 000 €100 000 €60 000 €70 000 
STA: Single Technology Assessment (Full HTA); REA: Rapid Effectiveness Assessment * Avarage costs per output 
 
Table 35: Categorisation of HTA bodies by STA activities and spending* 
CATEGORY 
Number of 
agencies 
performing 
STA 
Number of 
Agencies that 
report cost on 
REA in the 
same category 
REA 
(RANGES-MIN) 
REA 
(RANGES-MAX) 
STA 
(RANGES-MIN) 
STA 
(RANGES-MAX) 
Agencies with 
20,000.00 > STA costs  
4 2 €4 000 €20 000 €4 000 €16 000 
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Agencies with STA 
costs between 
20,000.00 <STA costs 
< 40,000.00 
4 2 €6 820 €20 000 €20 461 €35 000 
Agencies with STA 
costs>40,000.00 
13 8 €20 000 €55 000 €45 000 €35 000 
STA: Single Technology Assessment (Full HTA); REA: Rapid Effectiveness Assessment * Average costs per output 
Out of the 52 HTA bodies considered, 32 are actively performing REA and 50 
perform REA and economic assessment. We received information on costs from 40 
HTA bodies, from which four reported on cost data on REA and economic 
assessment, 21 on cost for Single HTA and 15 reported on cost data on REA.  
 Baseline costs – Pharmaceutical Industry  7.1.12.2
For the baseline costs, 13 Pharmaceutical companies responded to the survey, providing 
data on costs in performing HTA. Descriptive results are shown in Table 36. 
Table 36: Descriptive baseline costs - Pharmaceutical industry * 
Summary for Pharmaceuticals Companies 
(**) 
Value 
% of Companies Engaging in Early Dialogue 70% of companies (9/13) 
Average ED costs (Fees + Admin + Other) & HR 
resources (***) 
EUR 55 750.00; and 0.7 FTE 
ED Cost Reduction for general HTA activities No reported cost reduction 
Average PM working for general HTA submission 
activities 
11 PM/HTA 
Range of Cost per general HTA submission 
  EUR 73 000 - EUR 1 700 000 (****)  
(Average EUR 695 500)  
% of companies reporting costs of additional 
clinical evidence generation 
85% of companies 
Range of Cost of additional clinical evidence 
generation per HTA submission 
EUR 50,000 - EUR 20,000,000 depending 
on the type of evidence required  
Notes: (*) All data refers to companies surveyed and therefore are not country specific. (**) Costs are not weighted due to the small sample size. 
(***) HR resources costs vary considerably due to different salary standards across Europe. (****) Ranges were rounded up for confidentiality 
reasons. (*****) Across the companies surveyed; ED: Early Dialogue PM: person per month. When averages are being calculated they are done so 
across all countries in which a company operates. If a company submits HTA in 10 countries, then the base will be 10. If they only report 
consultancy costs in 7 of 10 countries, the base remains 10, and the 3 countries in which they did not report fees are given a value of 0. 
Looking at the descriptive results in Table 36, Pharmaceutical companies (70%) are 
actively engaging in Early Dialogues (ED) at an average cost of EUR 55 750. The cost 
related to ED includes ED fees, ED admin costs, and ED other costs and the human 
resource cost is reported as a Full Time Equivalent (FTE). In the survey, companies 
provided person per month (PM) per HTA figures in each country they operate and the 
value in Figure 28 represents the average across all countries in which a company 
operates. It is important to highlight that both the range and number of countries per 
company is highly variable. For all companies, it is assumed that this only includes 
country-level PM, and not global PM. This result may need to be interpreted with caution 
since only four companies reported information relevant to the sum of cost data, and 
only seven provided FTE data. Due to the low and variable number of companies and 
given the above assumptions, the averages provided here are unlikely to be representa-
tive of the spending across the Pharmaceutical Industry. However, the figures were 
considered reliable during a focus group with Pharmaceutical company representatives. 
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The number of staff employed on HTA varies significantly, depending on whether the 
country has an established HTA submission process or not. 
Investigating the main drivers of the costs for Early Dialogue, it is clear that broad costs 
for Early Dialogue are related to submission fees. However, this can vary significantly by 
country setting due to the different regulations. 
Figure 28: Drivers of costs in Early Dialogue- Pharmaceutical industry 
 
Fees depend on the country of submission. For some companies, the ‘other costs’ exceed ‘fees costs’ due to country setting. Company name were 
blinded for confidentiality 
Looking at the figures relating to an HTA submission reported in Table 36, the cost 
ranged from EUR 73 000 to EUR 1 700 000. This value represents a sum of average 
costs per HTA submission per company. Companies reported staff costs, consultant 
costs, in-house model costs, external model costs, and other costs. These were provided 
by country of company operation. For staff costs, consultant costs, in-house costs, 
external model costs and other costs, an average was taken across all countries for each 
company. These average values were subsequently aggregated to arrive at the average 
cost estimate per HTA submission per company.  
Investigating the main cost drivers of HTA submission, it appears that staff costs 
(internal and external) are the lead driver of expenditure (Figure 29). 
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Figure 29: Drivers of costs in general HTA activities - Pharmaceutical industry 
 
Two main limitations were identified regarding the data submitted by companies. First, in 
some cases it is unclear whether this value is in fact ‘zero’, or if a company simply did 
not report a value. This represents a limitation to the average cost data. However, it was 
deemed that keeping a consistent base for the average was necessary in order to avoid 
over-representation of the extent and impact of consulting costs and other costs, which 
do not necessarily occur in every setting.  
A second limitation relates to how a summary of the HTA cost information should be 
presented. A sum of the various costs reported was chosen for simplicity, and this 
assumes that a sum of permanent staff costs, consultant costs, in house model, external 
model, and other costs is accurate for the average cost of a single submission.  
Regarding average costs of additional evidence generation per HTA submission, within 
the survey data, companies were asked to provide average costs for health surveys, 
supplements to RCTs, practical clinical trials, registry data, electronic health records, 
administrative data, and other. The range of generating new evidence is very wide (from 
EUR 50 000 to EUR 20 000 000), and one company responding to the survey justified 
this high variability with a significant variation in the frequency of generating new 
evidence by country and by therapeutic area. Some of the additional evidence genera-
tion cannot be applied to single HTA submissions, but rather has implications for multiple 
countries and/or multiple submissions. For the purposes of this survey, we have as-
sumed costs to be for individual HTAs. Eventually, averages cannot be interpreted as 
holding across disease or therapeutic areas, as there may be significant differences in 
evidence requirements according to therapeutic area.  
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Figure 30: Drivers of costs in further evidence generation - Pharmaceutical industry 
 
Looking at the main costs afforded by generating new evidence, the highest expenditure 
is related to the generation of new randomized controlled trials (RCTs), followed by 
registry data. However, it is important to highlight that some of the additional evidence 
generation may not be applied to single HTA submissions, but rather has implications for 
multiple countries/multiple submissions. 
 Baseline costs – MedTech Industry 7.1.12.3
76 companies responded to the survey by providing information on the cost of perform-
ing HTA. However, costs reported by the same company but coming from affiliates 
operating in different countries were aggregated in order to have a consistent sample, 
leading to the identification of 46 MedTech companies. 
Table 37: Descriptive costs baseline scenario- MedTech Industry * 
Summary for MedTech & Diagnostic Companies Value 
% of Companies Engaging in Early Dialogue 28% of companies (13/46) 
Average ED costs (Fees + Admin + Other) & HR 
resources (**)  
EUR 21 687.50; and 0.7 FTE 
ED Cost Reduction for General HTA activities 
6% of companies (1/13). No value 
given 
Average PM working on General HTA submission 
activities 
3 PM/HTA 
Range of cost per HTA submission 
EUR 1 000 – EUR 3 400 000  
(Average EUR 410 358) 
% of companies reporting costs of additional clinical 
evidence generation (*****) 
37% of companies (17/46) 
Range of cost of additional clinical evidence genera-
tion per HTA submission 
EUR 17 000 - EUR 12 800 000 (***) 
depending on the type of evidence 
required 
Notes: (*) All data refers to companies surveyed and therefore are not country specific (**) Costs are not weighted due to the small sample size 
(***) HR resources costs vary considerably due to different salary standards across Europe (****) Ranges were rounded up for confidentiality 
reasons (*****) Across the companies surveyed; ED: Early Dialogue PM: person per month. When averages are being calculated they are done so 
across all countries in which a company operates. If for instance a company submits HTA in 10 countries, then the base will be 10. If they only 
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report consultancy costs in 7 of 10 countries, the base remains 10, and the 3 countries in which they did not report consultancy fees are given a 
value of 0. 
Looking at the Early Dialogue results in Table 37, results show that only 28% of compa-
nies engage in Early Dialogue. The average cost of ED is EUR 21 687.5, including fees, 
admin costs, and other ED costs, with less than one person per month dedicated to it.  
Considering the cost related to general HTA activities, the cost varies considerably, 
ranging from EUR 1 000 to EUR 3 400 000. As for the Pharmaceutical Industry, these 
values represent a sum of average costs per HTA submission per company comprising 
staff costs, consultant costs, in-house model cost, external model costs, and other costs 
through the survey. These were provided per country based upon the location a compa-
ny operates. For each of staff costs, consultant costs, in-house costs, external model 
costs, and other costs, an average was taken across all countries for each company. 
These average values were then added to provide an average cost per HTA submission 
for each company.  
Having investigated the distribution of the costs in performing HTA activities, our results 
show that the greatest proportion of costs relate to staff costs (permanent staff and 
consultants). Only in one case is the main cost driver classed as ‘other costs’. However, 
the company in question did not specify the underlying reasons for this classification. 
Figure 31: General HTA activities cost distribution (n=23 out of 46) )* – MedTech 
Industry 
 
*Companies did not answer to all the questions of the survey, leading to a smaller sample size.  
The value for average costs of additional evidence generation per HTA submission 
comprise average costs for health surveys, supplements to RCTs, practical clinical trials, 
registry data, electronic health records, administrative data, and other. 
Similarly to Pharmaceutical Industry data, results show that there is a high variability in 
the cost of generating further evidence, with costs ranging from EUR 17 000 to 
EUR 12 800 000. 
This high variability is confirmed by individual answers across medical device companies, 
which provide extremely large ranges (e.g. EUR 200 000 - EUR 3 000 000). As is the 
case for the Pharmaceutical sector, it is important to highlight that costs related to 
additional evidence generation vary significantly across type of evidence and country. 
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However, there are no data on the frequency with which these additional types of clinical 
evidence are generated.  
This trend is confirmed by investigating the distribution of costs in further evidence 
generation, showing that there is no clear trend across MedTech companies. (Figure 32). 
Figure 32: Distribution of cost of further evidence generation (n=17 out of 46)* – 
MedTech Industry 
 
*Companies did not answer to all the questions of the survey, leading to a smaller sample size. 
 Concluding remarks on baseline costs 7.1.12.4
Data on the costs associated with the submission of HTA dossiers to HTA bodies, the 
conduct of HTAs or additional evidence generation have been obtained through the 
survey in order to capture different stakeholder perspectives (Pharmaceutical companies, 
medical device companies and HTA bodies). Industry focus group discussion confirmed 
the plausibility of these results. 
First, the results of the survey show significant differences between the Pharmaceutical 
and the MedTech industries.  
Second, for the Pharmaceutical sector, the survey results indicate a high variability in 
HTA spending (between EUR 73 000 and EUR 1 700 000 per HTA submission), and in 
additional evidence generation (between EUR 50 000 and EUR 20 000 000). The 
diversity in the figures reported may reflect the heterogeneity in evidence assessment 
across settings or the different needs for data generation and does not provide a clear 
picture of average spending across products or manufacturers. Furthermore, although a 
global value dossier is generated for each product, this is usually the main source of 
input for manufacturer HTA teams and is subject to adaptation based on the HTA 
circumstances prevailing in different countries.  
Third, with regards to the MedTech industry, HTA submission figures revealed a range of 
EUR 1 000 – EUR 3 400 000, while additional evidence generation in the context of HTA 
submission had a range of EUR 17 000 - EUR 12 800 000. MedTech industry representa-
tives argued that the current number of medical device assessments across countries 
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
                                                                                                       160 
    
differs considerably, therefore constructing an average based on the above ranges would 
not be reliable.  
Fourth, in terms of the identified cost evidence, it appears that in both the Pharmaceuti-
cal and the MedTech industry staff costs (internal and external) are the lead expenditure 
driver. However, focus group discussion showed that a key driver for HTA-related costs 
is (additional) evidence generation. It is mainly in the largest markets that companies 
perform additional evidence generation studies requested by HTA bodies. Alternatively, 
existing knowledge gaps may be often covered by post-marketing studies. The focus of 
additional evidence generation studies is predominantly in larger markets and requests 
for additional evidence generation by smaller countries can be disregarded due to the 
latter’s market size. 
Fifth, the Early Dialogue results indicate a completely different level of engagement 
between the Pharmaceutical and MedTech industries. The former actively engages in 
Early Dialogue (69% of responses) with an average cost of EUR 55 750 per case, the 
latter shows a low level of engagement (28% of responses) and a lower level of spend-
ing (EUR 21 687.50) per case. In focus group discussion, MedTech industry representa-
tives confirmed that they do not engage routinely in Early Dialogue for medical devices.  
Sixth, considering the cost evidence responses of HTA bodies, the differences in costs 
are highly influenced by factors such as the type of HTA process in place in different 
settings, the type of assessment performed and the level of integration of HTA bodies 
with government entities. In general, it appears that the cost of performing STA among 
‘arm’s length bodies’ is higher than among ‘integrated’ structures (the highest reported 
figure for STA was EUR 135 000 for arm’s length bodies vs. EUR 100 000 for integrated 
structures), while the maximum reported figure for REA was EUR 55 000 for arm’s 
length bodies and EUR 100 000 for integrated structures. However, as the data received 
in some cases had missing values, these estimates should be interpreted with caution. 
 Interview results 7.1.13
 List of participants 7.1.13.1
The table below presents the manufacturers who participated in the interviews and the 
types of industry they represented. Eight Pharmaceutical companies and five medical 
devices companies participated in semi-structured interviews. Additionally, one Pharma-
ceutical Industry association and one medical device industry association were ques-
tioned during this process. 
Table 38: List of Industry Interviews Performed 
 
Pharmaceuticals 
companies 
Medical devices      
companies 
Companies ranked in the top 10th  by sales* 
5 3 
Companies ranked between top 11th  and 20th  by 
sales* 2 1 
Companies ranked after the top 20th  by sales* 1 1 
Trade association 
1 1 
*For Pharmaceuticals: Pharmaceutical Executive. n.d. Top 50 global Pharmaceutical companies by prescription sales and R&D spending in 2016 (in 
billion U.S. dollars). Statista. Available from https://www.statista.com; For medical devices: Medical Design & Outsourcing annual 2016. Available 
from http://www.medicaldesignandoutsourcing.com 
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 Pharmaceutical company results 7.1.13.2
Experience with EUnetHTA  
Out of nine Pharmaceutical companies/associations interviewed, only four had directly 
participated in an EUnetHTA pilot. An additional four companies elected not to partici-
pate, either because they were not approached or because the pilots were seen as too 
resource-intensive. Comments from companies that did not participate directly were still 
taken into account. The IFPMA did not participate or comment on the EUnetHTA process. 
Insights were captured in terms of problems with EUnetHTA, potential solutions for 
future pilots, and additional feedback on EUnetHTA. The number of companies highlight-
ing a problem, solution or additional insight is provided in brackets. 
Table 39: Pharmaceutical company experience with EUnetHTA  
Problems Solutions Additional feedback 
Uptake of the EUnetHTA reports by 
MS was poor, and as a result the 
pilot became an additional barrier 
to work around. (n=5) 
EUnetHTA appears to have been 
largely an academic exercise 
thusfar, and it is unclear that the 
amount of rigor necessary was 
taken to have an impact at 
national, regional, or local level. 
(n=4) 
The EUnetHTA design was too top-
level, resource-intensive for 
companies, and appeared arbitrary 
with some of the targets set. The 
expectations of EUnetHTA for 
evidence generation were not 
always realistic. (n=3) 
EUnetHTA assessments did not 
occur in a timeline that could help 
inform decision-making. (n=3) 
There wasn't always a consistent 
quality in the reviewer, particularly 
when the review took place in 
countries that were less sophisti-
cated with HTA. This led to 
resistance from larger countries in 
accepting the assessments. (n=2) 
Use/uptake of the reports should be 
mandatory by MS. (n=5) 
More work and consultation with 
local HTA is required in order to 
increase acceptability at MS level. 
Reports must be consistent and 
there must be predictability in how 
the evidence is looked and 
assessed. (n=4) 
Increased collaboration and 
discussion with industry would result 
in improved collaboration and a 
better design. (n=3) 
Assessments should take place in 
parallel with regulatory approval in 
order to provide speed of access 
and efficiency benefits. (n=3) 
There is a need for capacity building 
in some settings to ensure a 
consistently high standard of quality 
for all reports. (n=2) 
EUnetHTA has a good methodolo-
gy. It's not perfect, but overall it is 
good, open and extensive source of 
information. Establishing best 
practices has been one of the 
benefits of this scheme. (n=2) 
EUnetHTA missed an opportunity 
by not adding value from what is 
currently provided in the EMA EPA 
report. (n=1) 
 
Impact of National Procedures on Pharmaceutical Manufacturers 
Insights were captured in terms of problems associated with national procedures, 
potential solutions through EU collaboration or other means, and additional feedback on 
the impact of national procedures. The number of companies highlighting a problem, 
solution or additional insight is provided in brackets. All nine companies provided insights 
to varying extents. 
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Table 40: Impact of national procedures on Pharmaceutical manufacturers 
Problems Solutions Additional feedback 
HTA systems that are fragmented 
and complex are undesirable and 
present challenges in submissions 
(e.g. NICE, Nordics). (n=4) 
Frequentist HTA systems (e.g. 
IQWiG) tend to be narrow in 
scope in terms of the evidence 
they consider. This creates 
barriers to patient access. (n=4)
  
There are substantial differences 
in the way in which countries deal 
with uncertainty, surrogate 
endpoints, and indirect compari-
sons. Evidence requirements vary 
across settings. This creates 
substantial costs for evidence 
development. (n=4) 
There are substantial costs 
associated with HTA submissions. 
Germany in particular has very 
stringent requirements and a 
resulting high cost. (n=4) 
Pharmacoeconomic based HTA 
systems tend to undervalue 
orphan products where health 
gains tend to be far in the future. 
(n=1) 
Companies prefer that clinical 
evaluation and pricing negotiations 
are separate processes (E.g. Italy, 
Spain, France & Germany). (n=4) 
An EU HTA system should be open 
and expansive in terms of the 
information sources they consider 
(E.g. NICE). (n=4) 
Harmonization of evidence 
requirements could alleviate some 
of this burden, but will require 
compromise at MS level. (n=4) 
An EU-wide assessment, if 
accepted at MS level would help to 
reduce some of the costs and 
resources associated with HTA 
submissions. (n=4) 
Orphan drugs require special 
consideration or alternative 
pathways. (n=1) 
NICE is a very complex system. 
They tend to focus too much on 
long-term uncertainty of a 
product, which makes little sense 
given the effective life cycle of 
products. (n=4) 
Many assessments, particularly for 
orphan products, often fail to 
include sufficient input from 
medical experts. (n=1)  
There are differences in the way 
countries value diseases. 
Countries often use their 
methodologies to justify their 
policies. (n=1) 
There are substantial differences in 
quality of assessment across 
countries. Smaller countries, 
particularly in Central and Eastern 
Europe tend to have greater 
issues, particularly when system 
reforms and political reforms 
interrupt the HTA process. (n=1) 
Timelines for assessment and 
access vary substantially across 
countries. Delays and lack of 
speed is a huge opportunity cost 
for industry and for patients. 
(n=1) 
Companies would prefer to 
present an argument on the value 
of a product across all patients, 
and let physicians decide rather 
than have HTA bodies restrict 
access to patient groups. (n=1) 
 
Pharmaceutical manufacturers’ experiences with Early Dialogue and rapid 
assessment 
Seven out of nine Pharmaceutical companies/associations had participated directly in 
early scientific advice or Early Dialogue. One company had not participated in an Early 
Dialogue process. The IFPMA did not comment on Early Dialogue. Insights were captured 
in terms of problems associated with Early Dialogue and rapid assessment, potential 
solutions through EU collaboration or other means, and additional feedback on Early 
Dialogue/rapid assessment. The number of companies highlighting a problem, solution or 
additional insight is provided in brackets. 
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Table 41: Pharmaceutical manufacturers’ experiences with Early Dialogue and rapid 
assessment 
Problems Solutions Additional feedback 
Scientific advice differs widely 
across agencies for a particular 
product. This presents challenges 
for development programmes. 
(n=3) 
Early Dialogue is less useful in 
settings that are too formulaic and 
fail to offer opportunity for 
discussion (e.g. Germany). (n=2) 
  
 
 
A joint scientific advice, or 
consensus on evidence require-
ments would simplify development 
programmes. (n=3) 
Early Dialogue should be a 
cooperative and iterative process 
with opportunities for discussion. 
(n=2) 
In general, Early Dialogue and early 
scientific advice is a very useful 
process. It improves transparency 
on evidence requirements. It helps 
to build a relationship and lowers 
the risk associated with a product. 
It can help answer important 
questions relating to clinical 
development and can help 
companies avoid common 
problems with submissions. (n=7) 
Rapid assessments are unlikely to 
speed up market access considera-
bly. The biggest delay in access is 
during pricing negotiations and 
interpretation of the assessments. 
(n=2) 
Early Dialogue is an excellent tool in 
small companies. Internally it helps 
in negotiations on investment 
decisions on clinical development. 
(n=1) 
NICE in particular has a good 
system for Early Dialogue. It was 
very helpful in shaping clinical trial 
development. (n=2) 
Not all countries have the capacity 
and expertise to have conversa-
tions the company would like to 
have. Language is frequently an 
issue. Outputs can be highly 
variable. (n=1) 
Joint scientific advice platforms, 
where companies can receive 
regulatory and HTA advice at the 
same time, are very useful. (n=3) 
 
Experience with evidence generation, resubmissions, and real world evidence 
Insights were captured on current problems and potential problems through collabora-
tion, potential solutions, and on additional feedback on evidence generation, resubmis-
sion and RWE (real world evidence). Only eight out of nine companies provided insights 
on evidence generation, resubmission and RWE. The number of companies highlighting a 
problem, solution or additional insight is provided in brackets. 
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Table 42: Pharmaceutical manufacturers’ experience with evidence generation, 
resubmissions, and real world evidence 
Problems Solutions Additional feedback 
Divergent philosophies regarding 
the acceptability of different types 
of evidence across countries 
represent a substantial barrier to 
harmonization. Countries differ in 
the way they deal with compara-
tors, indirect comparisons, 
crossover data, meta-analyses, 
and RWE. (n=7) 
Defining the appropriate 
comparator is a significant 
challenge for an EU HTA. There 
are a number of differences across 
countries in terms of standards of 
care. The current pace of science 
also means that the appropriate 
comparator can change frequent-
ly. (n=8) 
Given the heterogeneity of 
treatment and speed of science, 
we cannot always have perfect 
RCTs. In some cases, RCTs are 
unethical. (n=3) 
There are conflicting signals from 
regulators and HTA authorities on 
evidence generation. Regulators 
are promoting accelerated 
approval and patient access, while 
HTA bodies are delaying access 
due to uncertainty in the evidence. 
(n=3) 
Additional evidence generation 
may not be a commercially viable 
option for a company, particularly 
in settings where the outcome of 
resubmission is uncertain and 
where the price following 
resubmission is unlikely to rise. As 
a result, companies may elect to 
pull their product from the market. 
(n=2) 
Compromises will be needed 
regarding evidence requirement 
and appropriate standards of care 
before any EU collaboration can be 
reached. (n=7) 
An EU HTA would likely need to 
wrap its hands around a large 
number of comparators to 
accommodate differences in 
standards of care across Europe. 
(n=8) 
There needs to be some recognition 
and acceptance of when it is 
appropriate for single-arm trials 
and indirect comparisons. (n=3) 
More harmonization is needed 
between regulators and HTA 
authorities. An EU collaboration on 
HTA, if accepted at MS level, could 
help to bridge the gap in evidence 
requirements. (n=3) 
Countries should be open to 
changes in price following 
resubmission or additional evidence 
generation, both upwards and 
downwards. More predictability in 
the result of resubmission would 
facilitate greater additional evidence 
generation. Harmonization would 
lower costs of evidence generation. 
(n=2) 
There are several benefits to RWE. 
This includes facilitating conditional 
reimbursement, collection of 
additional safety data through 
registries, and the answering of 
additional questions about the 
product. (n=5) 
Conditional reimbursements 
requiring resubmission are 
associated with high workloads. 
Beyond costs of evidence 
generation, there submission 
workload is substantial. E.g. The 
submission for the new Cancer 
Drugs Fund was extensive, and 
must be repeated every 18 
months. (n=2) 
The importance of RWE varies by 
disease area. RWE plays less of a 
role in diseases with long-term 
endpoints such as cystic fibrosis. It 
is more relevant in areas such as 
oncology. (n=2). 
There would be significant benefits 
to both industry and patients from 
methodological expansiveness in 
evidence types considered. 
Specifically, greater alignment on 
methodology surrounding 
crossovers would be useful in 
oncology. (n=1) 
There are incentive issues with 
sharing RWE. Access to data and 
data privacy are barriers to 
increasing use of RWE. (n=1) 
 
Impact of HTA on innovation and predictability for Pharmaceutical manufactur-
ers 
Insights were captured in terms of problems with predictability and innovation, potential 
solutions through EU collaboration or other means, and additional feedback on innova-
tion and predictability. Only eight out of nine Pharmaceutical companies provided 
feedback on innovation and predictability. The number of companies highlighting a 
problem, solution or additional insight is provided in brackets. 
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Table 43: Impact of HTA on innovation and predictability for Pharmaceutical 
manufacturers 
Problems Solutions Additional feedback 
Poor predictability, high complexi-
ty, poor transparency, and high 
fragmentation are barriers to 
health innovation and investments 
in development programmes. 
(n=6) 
There are tensions between 
regulators that promote 
accelerated access and reim-
bursement authorities that delay 
access owing to uncertainty of 
data. (n=4) 
Harmonizing HTA evidence 
requirements may result in 
convergence to the strictest 
requirements. This would create 
barriers to entry and discourage 
innovation/investment. (n=1) 
HTA systems tend to incentivize 
me-too products or 2nd, 3rd, 4th 
entrants, rather than the 
innovator. The first-mover tends 
to pave the road, and subsequent 
entrants have an easier time. 
(n=1) 
HTA systems based on cost-
effectiveness (e.g. NICE) can 
punish innovation if the current 
comparator is a generic product. 
Demonstrating cost-effectiveness 
is very challenging, in settings 
where there has not been a new 
innovation in a long time. (n=1) 
Harmonization of evidence 
requirements, if accompanied by 
MS acceptability, would facilitate 
easier investment decisions. (n=6) 
There should be greater consisten-
cy between regulators and 
reimbursement authorities on 
evidence requirements and the 
acceptability of indirect compari-
sons or single arm studies. (n=4) 
Harmonization must be informed 
by good and rational thinking. 
Some compromise is required in 
terms of evidence requirements. 
(n=1) 
Additional incentives are needed to 
sustain innovation. (n=1) 
Additional incentives are needed for 
truly innovative/transformative 
products. (n=1) 
An EU HTA with a solid methodol-
ogy would de-risk the submission 
process and help to eliminate 
arguments resulting from low 
quality assessments and 
misinterpretation of data. Greater 
consistency in HTA assessments 
would be very beneficial. (n=3) 
Innovation can be driven by early 
advice and greater clarity on 
payer expectations. This can help 
establish European priorities for 
innovation. (n=1) 
Clinical trial programmes are 
largely dominated by the FDA, 
due to the fragmented evidence 
requirements within Europe. 
Harmonization of evidence 
requirements would give the EU 
stronger influence on clinical trial 
development. (n=1) 
There is unlikely to be significant 
risk of a negative EU REA report if 
these products have made it 
through regulatory approval. 
Products with surrogate endpoints 
might be the exception. Other 
products would have already been 
removed from development prior 
to regulatory approval. (n=1) 
 
Pharmaceutical manufacturers’ thoughts on EC Policy Options 
Insights were captured in terms of problems in collaboration, potential solutions, and 
additional feedback on the process of collaboration and on the impact of collaboration. 
The number of companies highlighting a problem, solution or additional insight is 
provided in brackets.  
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
                                                                                                       166 
    
Table 44: Pharmaceutical manufacturers’ thoughts on EC Policy Options 
Problems Solutions Additional feedback 
Economic value and Socioeco-
nomic impact of products vary 
substantially across settings. 
(n=6) 
Identifying and fulfilling individual 
MS submission criteria requires a 
substantial amount of work. 
(n=4)   
If not designed and implemented 
properly, any form of EU HTA will 
simply represent an additional 
hurdle on top of current national 
requirements. (n=3) 
Defining the appropriate 
comparator is a key challenge for 
establishing any kind of EU HTA. 
(n=8) 
While universal agreement and 
acceptability on a methodology 
may be the ultimate goal, this is 
likely unachievable in the short 
term. (n=1) 
Option 4.1 is the most appropriate 
solution put forth by the EC. 
Economic evaluation should remain 
a national process. (n=6) 
Establishing an EU HTA that 
evaluates clinical effectiveness may 
reduce some inefficiency and 
workload, although local teams will 
still be required for negotiations and 
market access. Local studies will 
still be required. (n=4) 
There must be some form of 
guaranteed acceptability and 
uptake of the EU HTA findings. The 
EU HTA should be demand- driven, 
from MS, rather than supply-driven 
from the EC. (n=3) 
The EU HTA will either have to wrap 
its hands around a large number of 
comparators or there will need to 
be some kind of compromise at MS 
level. (n=8) 
A short-term solution may be 
agreement on binding or semi-
binding statements that we can 
build upon as outcomes of the 
European assessment. Over time, 
we would seek to reduce the 
differences in opinion on what is 
acceptable evidence. (n=1) 
EU HTA is a substantial risk, as a 
negative n EU HTA outcome no 
prevents access from all EU 
countries. This ismight be 
exacerbated in the situation of 
false negative, where evidence is 
misinterpreted. (n=6) 
Harmonization must consider 
simple design, how many arms 
are required, appropriate 
comparators, length of trial, 
population size, indirect compari-
sons, and RWE vs clinical trial 
endpoints. Conversations about 
economic model, productivity, and 
indirect costs can remain at local 
level. (n=7) 
It is possible to do both clinical and 
economic assessment at EU level, 
however issues such as burden of 
disease and willingness to pay 
remain local issues. (n=1) 
An EU HTA report could improve 
upon the EMA EPA report by a) 
taking an iterative approach which 
does more over time and b) 
expands on the evidence types 
that inform the report by using 
indirect comparisons, sub-group 
analyses and meta-analyses. 
(n=1) 
Appropriate governance is 
required for any EU HTA. There 
must be some type of appeal 
process. (n=1) 
An EU HTA will not impact on 
market access. But it may help to 
improve consistency in evidence 
interpretation, reduce some 
duplication, and reduce delays 
from misinterpretation of evidence 
(n=1) 
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 MedTech Industry results 7.1.13.3
Medical device company experience with EUnetHTA  
Out of the six medical device companies/associations interviewed, only one company 
directly participated in EUnetHTA. Four companies had not directly participated in pilots, 
but provided some comments on EUnetHTA. MedTech also provided some insights. 
Insights were captured in terms of problems with EUnetHTA pilots, potential solutions, 
and additional feedback on the impact of EUnetHTA. The number of companies highlight-
ing a problem, solution or additional insight is provided in brackets. 
 
Table 45: Medical device company experience with EUnetHTA  
Problems Solutions Additional feedback 
EUnetHTA appears to be largely 
an academic exercise thus far; it is 
unclear that they have had any 
impact outside the level of 
academia. It has yet to have a 
commercial impact. (n=4) 
EUnetHTA may not have 
sufficiently understood the 
fundamental differences between 
Pharma and medical devices. 
Medical devices are much more 
integrated in the process of care. 
There is poor transferability of HTA 
across settings. The methodology 
did not sufficiently account for the 
fragmentation of decision-making. 
(n=3)  
There were problems with product 
selection and with company 
identification in the EUnetHTA 
pilots for medical device 
companies. (n=1) 
There were issues with timelines 
for submissions and a lack of 
understanding about how industry 
works in practice. The EUnetHTA  
requests did not acknowledge the 
smaller capacity of medical device 
teams relative to Pharma teams. 
It was very resource-intensive and 
the request was not made over a 
realistic timeline. (n=1) 
EUnetHTA did not recognize the 
difference between medical 
devices and in vitro diagnostics. 
(n=1) 
Increased acceptability at MS level 
is required for pilots to provide 
value. (n=4) 
Design of HTA methodology for 
medical devices must be bottom-up 
and demand-driven, taking into 
account local information and 
decision-making needs. (n=3) 
Products selected for trials should 
be relevant to all EU markets. It is 
important that the assessments 
deliver valuable information, 
particularly if companies are 
expected to devote already limited 
resources towards the pilot. (n=1) 
Greater consultation with industry 
and appreciation of capacity would 
improve cooperation and 
participation. (n=1) 
A separate HTA methodology and 
template should be developed for in 
vitro diagnostics. (n=1) 
Better resourcing and funding is 
required for EUnetHTA to have a 
more substantial impact. This 
would likely require moving past a 
model of voluntary cooperation. 
(n=1) 
The assessments performed by 
EUnetHTA have improved over 
time. The involvement of 
physicians in the process is 
encouraging. (n=1) 
EUnetHTA was beneficial when the 
focus was more on clinical 
uncertainty than on value or 
pricing. It provided clarity on the 
clinical pathway and on appropri-
ate use of the product. (n=1) 
EUnetHTA implies additional risk. 
A ‘no’ at EU level excludes you 
from all European markets. (n=1) 
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Impact of national procedures on medical device manufacturers 
Insights were captured in terms of problems associated with national procedures, 
potential solutions through EU collaboration or other means, and additional feedback on 
the impact of national procedures. The number of companies highlighting a problem, 
solution or additional insight is provided in brackets. 
 
Table 46: Impact of national procedures on medical device manufacturers 
Problems Solutions Additional feedback 
HTA currently plays a minor role 
for medical devices in most 
settings. It is viewed largely as a 
barrier to access by medical 
device companies. It really only 
fits into access models to some 
extent for UK, France, Sweden, 
and Norway. (n=5) 
Medical devices far outnumber 
Pharmaceuticals. Many countries 
are starting to look at HTA for 
medical devices but lack the 
expertise and resources to do so 
properly. HTA is rarely used, 
typically access is through direct 
negotiation with health funds or 
hospitals. (n=1) 
Countries' are increasingly 
requesting national evidence. This 
is sometimes viewed as an 
artificial barrier and makes access 
pathways lengthy, quite costly, 
and lowers transparency. (n=1) 
If framed as an opportunity to 
leverage the value of a product, 
through an EU HTA report, there 
may be more appetite for an EU 
HTA. (n=5) 
HTA is likely unsuitable for all 
medical devices, if HTA is to 
become more formalized, 
restrictions will be required on the 
types of devices that are assessed. 
(n=1). 
More agreement and flexibility on 
evidence requirements would be 
more appropriate in certain 
circumstances and would reduce 
unnecessary costs and barriers to 
market access. (n=1) 
France has a national HTA 
framework for innovative medical 
devices, but this is largely a barrier 
to access and competition. In 
general, products are launched in 
France after other markets, and 
often at higher prices. A 
disproportionate amount of 
resources is used in France for 
market access. (n=4) 
There is extremely high fragmen-
tation for market access in medical 
devices. This depends on local 
requirements that vary substan-
tially. There are differences in 
methodology, frequency and 
transparency. Even within a 
country, there is significant 
fragmentation. (n=5) 
NICE assessment procedures are 
considered to be very transparent. 
(n=2) 
Regional health care systems such 
as Portugal, Spain, and Italy are 
more challenging for medical 
devices. You have regional officers 
running HTA, it becomes more 
complex, and you see differences 
in terms of how outcomes are 
dealt with and elicited. There are a 
lot of national specifics that make 
it difficult for companies to use any 
scaling effects (n=1) 
The medical device market is 
fundamentally different from the 
Pharmaceutical market. It is very 
dynamic and more open to 
competition. The effective life cycle 
of a medical device is much 
shorter than a Pharmaceutical, 
and patents are much easier to 
get around. (n=1) 
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Medical device manufacturers’ experiences with Early Dialogue and rapid 
assessment 
Out of the six companies interviewed, only two companies had participated directly in 
early scientific advice and Early Dialogue. Three companies had not participated but 
provided some comments. One company did not comment on Early Dialogue or rapid 
assessment. Insights were captured in terms of problems associated with Early Dialogue 
and rapid assessment, potential solutions through EU collaboration or other means, and 
additional feedback on Early Dialogue/rapid assessment. The number of companies 
highlighting a problem, solution or additional insight is provided in brackets. Only limited 
insights were collected for Early Dialogue and rapid assessment with medical device 
companies. 
 
Table 47: Medical device manufacturers’ experiences with Early Dialogue and rapid 
assessment 
Problems Solutions Additional feedback 
Early Dialogue across several 
countries suggests hugely 
fragmented and diverging views 
on evidence requirements and 
expectation. (n=1) 
An EU collaboration could help 
harmonizing these diverging to 
some extent. This would simplify 
clinical development. (n=1) 
Early Dialogue is a very useful 
process. All possible opportunities 
for engagement are used. It is 
useful to have a clear mandate 
from local authorities about what to 
do in terms evidence generation. 
(n=2) 
The value of rapid assessments is 
unclear for medical devices. Work is 
needed to establish what questions 
are being answered at local level 
and over what time frame. If this is 
not actively informing decisions, it 
simply becomes a hurdle. (n=1) 
Rapid HTAs may be acceptable as 
long as they are true assessments. 
Authorities need to recognize that 
all data may not be available at the 
time of rapid assessment. (n=1) 
 
Medical device manufacturers’ experience with evidence generation, resubmis-
sions 
Insights were captured on current problems and potential problems through collabora-
tion, potential solutions, and on additional feedback on evidence generation, resubmis-
sion and RWE. Only five out of six companies provided insights on evidence generation, 
resubmissions and RWE.  
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Table 48: Medical device manufacturers’ experience with evidence generation, 
resubmissions, and real world evidence 
Problems Solutions Additional feedback 
EU HTA in the context of medical 
devices would present a challenge 
for small companies in terms of 
fulfilling the evidence require-
ments. This would have significant 
impacts on the medical device 
market, where the majority of 
companies are SMEs. Currently, 
HTA is rarely used in the context 
of medical devices. An EU HTA 
would represent a significant 
barrier to entry for medical device 
companies. (n=3) 
Medical devices have a shorter life 
cycle than Pharmaceuticals. The 
market is much more competitive 
as patents are easier to get 
around for medical devices. While 
long RCTs may be desirable from 
an evidence standpoint, they may 
not always be appropriate or 
feasible for medical devices. 
(n=3) 
The number of medical devices far 
exceeds Pharmaceuticals. 
Performing HTA on all medical 
devices would be extremely 
resource-intensive for all 
stakeholders involved. (n=1) 
Reassessments can be problemat-
ic in the medical device sector 
given the level of competition. 
Following initial recommendations, 
competitors will enter the market 
and have an impact on the price 
of a product. This distorts cost-
effectiveness models. (n=1) 
Brand-specific evidence genera-
tion is not always efficient, 
particularly in situations where the 
procedure is the same. (n=1) 
Given the large proportion of small 
and medium medical device 
companies, any EU-wide HTA for 
medical devices ought to be 
cognizant of the resource 
constraints and impact on 
innovation and competition. (n=3) 
Evidence generation for medical 
devices likely requires greater use 
of RWE. (n=3) 
If HTA is applied to medical devices, 
it is likely only realistic to do so for a 
subset of devices. (n=1). 
HTA for medical devices must be 
cognizant of the short life cycle of 
medical devices and implications of 
competition. (n=1) 
HTA systems should try to identify 
situations in which there is a 
duplication of effort in evidence 
generation (n=1) 
Countries vary substantially in how 
they define the appropriate 
comparator for a treatment. It is 
unclear how they will reach 
agreement at EU level. (n=1) 
An EU HTA would be a hurdle for 
medical device companies. 
Evidence requirements would still 
exist at the national and local 
levels. (n=1) 
HTA would be unlikely to solve any 
issues pertaining to recalls or the 
safety of medical devices. These 
problems typically emerge through 
long-term studies and would not 
be present at the time of HTA. 
(n=1) 
Increased awareness and 
acceptability of indirect compari-
sons are needed in the medical 
device sector. (n=1) 
A key challenge to more extensive 
use of RWE is the high cost of 
establishing registries. RWE can be 
leveraged by medical device 
companies to create barriers to 
entry for competitors. A smart 
company will offer evidence to 
decision-makers that competitors 
cannot match. (n=2) 
Value-based procurement will help 
to promote sustainable evidence 
generation. Managed entry 
agreements are an effective tool 
to promote increased RWE 
generation. (n=1) 
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Impact of HTA on innovation and predictability for medical device manufacturers 
Insights were captured in terms of problems with predictability and innovation, potential 
solutions through EU collaboration or other means, and additional feedback on innova-
tion and predictability. Only five out of six companies interviewed provided insights on 
innovation and predictability. 
Table 49: Impact of HTA on innovation and predictability for medical device 
manufacturers 
Problems Solutions Additional feedback 
Evidence requirements tend to be 
strictest for the first-mover in a 
therapeutic area. HTA systems 
tend to incentivize me-too 
products or 2nd, 3rd, 4th 
entrants, rather than the 
innovator. The first-mover tend to 
pave the road, and subsequent 
entrants have an easier time. 
(n=2) 
HTA does not play a major role in 
the medical device market. 
Implementing EU HTA would 
represent a massive barrier to 
entry for SMEs, which make up 
the majority of the market. This 
would have significantly negative 
impacts on innovation and on 
prices of medical devices. (n=3) 
HTA designed from the top-down 
is likely to have a negative impact 
on diffusion of innovation as 
uptake will be poor. (n=1) 
Poor predictability, high complexi-
ty, poor transparency and high 
fragmentation are barriers to 
health innovation and investments 
in development programmes. 
(n=1) 
Additional incentives are needed to 
sustain innovation. (n=2) 
HTA requirements for medical 
devices must be very low in order 
to avoid disrupting competition and 
create barriers to entry. (n=3) 
In order to provide value, HTA 
must be designed from the bottom-
up and take into account the needs 
of local decision-makers. (n=1) 
Harmonization of evidence 
requirements, if accompanied by 
MS acceptability, would facilitate 
easier investment decisions. (n=1) 
HTA is seen as a cost for medical 
device manufacturers, not a 
business opportunity. If it can be 
presented as an opportunity to 
move towards more of a value-
based model, it may be more 
appealing. (n=1) 
Engaging in Early Dialogue can 
help improve predictability of 
submission outcomes. (n=1) 
 
 
Medical device manufacturers’ thoughts on EC Policy Options  
Insights were captured in terms of problems in collaboration, potential solutions, and 
additional feedback on the process of collaboration and on the impact of collaboration. 
The number of companies highlighting a problem, solution or additional insight is 
provided in brackets. 
  
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
                                                                                                       172 
    
Table 50: Medical device manufacturers’ thoughts on EC Policy Options 
Problems Solutions Additional feedback 
Given the decentralized and 
fragmented nature of decision-
making for medical devices, HTA 
at the European Union level does 
not make sense. (n=4) 
Differences in comparators, 
standards of care and patient 
population are significant barriers 
to harmonization.  (n=2)  
An EU HTA would represent a 
barrier to access in the medical 
device field where the majority of 
companies are SMEs. These 
companies would be less able to 
finance evidence generation. This 
will reduce competition and raise 
prices. (n=3) 
Academic discussion and sharing of 
best practices is useful, but 
‘evidence’ on how HTA operates in 
European countries, specifically for 
medical devices, does not currently 
support implementation of HTA for 
medical devices at the European 
Union level. (n=4) 
Harmonization will require 
compromise at the MS level. Some 
standards would be required for 
evidence generation. (n=2) 
Any form of collaboration would 
need to be a bottom-up approach, 
starting at the hospital level and 
taking into account local decision-
making needs. (n=3) 
An EU HTA would not reduce 
much workload or eliminate much 
duplication. Work at local level 
would still be required, given the 
engrained nature of medical 
devices in the process of care. It 
would likely be a hurdle on top of 
national/local requirements. 
(n=3) 
An EU collaboration on HTA would 
be favourable under the following 
conditions: a) Conditional 
reimbursement; b) Outcomes to 
be licensed to rewards; c) 
Collaboration to address 
considerations of uncertainty; d) 
Agreement to evaluation to be 
done when evidence is available, 
especially for some particular 
technologies (e.g. ‘disruptive 
technologies’, big ticket items, 
etc.); and e) Agreement on the 
‘when’ and ‘what’ to evaluate. 6. 
Need for national registries (n=1) 
In Pharma, an EU collaboration 
would potentially be replacing 
some activity and leading to 
efficiency gains. In medical 
devices, an EU collaboration would 
not be replacing activity, but 
rather, would represent new 
activity. Something quick and easy 
would not work in this context. 
More work is needed to identify 
and understand local contextual 
issues. (n=2) 
HTA is only useful in medical 
devices for technologies that a) 
address an unmet need, and b) 
require some form of organiza-
tional or structural reform for 
adoption. If we did have 
cooperation, it would need to be 
voluntary. (n=1) 
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 Concluding remarks from interview results  7.1.13.5
Overall the interviews across both industries, Pharmaceuticals and medical devices, 
showed that the different national procedures have a different impact on HTA assess-
ment, with national ‘methodology’ leading to substantial variations in the final outcome. 
Specifically, some HTA settings are driven by cost-per QALY and HTAs driven by clinical 
benefit show substantial variations in the way they value the same product. However, it 
is important to highlight that these differences are also influenced by the therapeutic 
areas in which the product fall.  
Manufacturers highlighted that the current fragmented HTA system across EU MS 
requires companies to cater to a diversified range of demands and this might lead to 
difficulty in submitting reports or multiple re-submission to the same HTA bodies 
depending from the country setting. There is a consensus across the Pharmaceuticals 
industry respondents that EU collaboration on HTA may be possible for generating a 
relative effectiveness assessment, but decision-making and appraisals should remain a 
local process. Yet, Pharmaceutical Industry respondents envisaged that agreement on 
evidence requirements at EU level would offer substantial benefits, allowing a separation 
between clinical benefit and reimbursement. By contrast, manufacturers highlighted the 
heterogeneity and diversity of the Medical devices market in comparison with the 
Pharmaceutical product one. Manufacturer highlighted that HTA currently plays a minor 
role for medical devices in most settings due to the extremely fragmented market access 
of medical devices and therefore the current impact of HTA on their business is low.  
Looking at the predictability of the process, the interviews agreed that it is a key 
element for investment and resourcing decisions, particularly for small and medium sized 
companies. It was commonly stated that the harmonization of process and evidence 
requirements would allow them to ensure there are no misunderstandings, and enhance 
the level of the predictability in the system.  
Transparency of evidence requirements, consistency of methods, acceptability of indirect 
comparisons, and predictability of outcomes have been highlighted by several companies 
as desirable characteristics. Specifically, interviewees advocated for a better summary 
and inclusion of information on indirect comparison and secondary endpoints and a clear 
definition of the appropriate comparators, currently considered an issue in some country 
settings. By contrast, the Medical devices interviewees suggested that, while long RCTs 
may be desirable from an evidence standpoint, they may not always be appropriate, 
feasible or sufficient for medical devices 
Finally, Early Dialogue and scientific advice are viewed as an extremely useful exercise 
and helps to increase transparency, suggesting that a system aligned to what is current-
ly done with EMA would be beneficial. However, few respondents stated the importance 
of not introducing a double system where countries apply additional requirements. 
 Summary conclusion of the baseline scenario and related impacts  7.1.14
Currently, Health technology assessment (HTA) has been implemented in a growing 
number of European countries providing evidence-based information for both decision-
making and policymaking regarding services and products to be made available as part 
of national health-care systems and/or for price negotiation. While HTA provides input 
for appraisals and pricing and reimbursement decisions, the study focuses on the 
assessment aspect, as in all Policy Options any subsequent appraisal and pricing and 
reimbursement decision for medical technologies, devices or Pharmaceuticals remain 
purely at national level.  
The case studies conducted on 40 technologies for the baseline scenario aimed to give a 
clear picture on HTA in Europe through a comparative analysis of HTA recommendations 
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
                                                                                                       174 
    
issued across MS.  Results provide an understandable picture of these complex decision-
making processes, differentiating by category of technologies considered. 
For the Pharmaceutical sector, the current situation depicted by the study has 
different impacts: 
● The average number of assessments per technology carried out in parallel by different 
HTA bodies is high across the sample (13.5 out of 19 agencies), showing a significant 
level of duplication. This is also confirmed by the Kappa score calculated and adjusted 
for proportions of agreement on the availability of reports showing that countries with 
established HTA bodies tend to assess the same Pharmaceutical products and the 
same drug-indication pairs. Yet the duplication is not homogenous.  Results showed 
that agencies have a fair level of agreement in the assessment of Pharmaceutical 
products, but the number of assessments carried out is highly influenced by the type 
of HTA body and the level of HTA development in the country. This, in most cases, 
can be related to the selection criteria for Pharmaceutical products to be assessed. 
HTA bodies such as HAS, G-BA and AIFA due to their topic selection process 
(evaluating all the new Pharmaceuticals) showed a high level of agreement and so did 
HTA bodies such as TLV and NICE or INFARMED.  Evidence also showed that agencies 
have different capacities for assessing technologies; only some well-developed 
systems can cover all the new Pharmaceuticals; others have topic selection processes 
in place enabling them to assess a proportion of newly launched Pharmaceuticals and 
some systems only assess a smaller number of technologies. Some countries are 
implementing HTA referencing. 
●  Looking at the recommendation level, the level of agreement across HTA bodies for 
the Pharmaceutical sample is generally low. Nevertheless, this should take into 
account the fact that in some cases HTA bodies perform assessments (the results of 
which could be transferrable across settings), while in other cases, HTA bodies 
perform appraisals, (which are context-specific and take into account factors and 
dimensions of value that are important in the setting concerned).  
●  A high degree of variability in the time of assessment of a Pharmaceutical product 
after MA was recorded, suggesting a general delay in assessment in a number of 
countries. This might lead to delays access by patients in some EU MS. However, it 
should be acknowledged that this difference might be related to other factors as well 
such as willingness to submit a report or delay a submission by the company, the 
different selection criteria in the choice of technologies to assess and the different 
role of the HTA body. 
●  Considering the evidence included in the different reports, a tendency in 
‘homogenization’ across Europe is observed with a preference towards the same 
typologies of clinical and economic evidence. This suggests a growing trend towards 
the homogenization of clinical and economic evaluation. The primary trial types 
considered and the main economic evidence considered were generally of the same 
type, suggesting that there is a clear preference for phase III trials and cost-utility 
analysis.  
●  There is still not enough predictability in the system. Nonetheless, manufacturers 
highlighted that a key challenge is the agreement on evidence, highlighting that the 
preferences of national policy makers could have a high impact on the process and 
the fact that harmonization of evidence requirements is strongly favoured by the 
industry sector. SVJs are not routinely considered and where they are, significant 
variation was shown across MS, indicating how the HTA processes and the quality of 
the evidence considered vary quite significantly.  
●  Looking at the baseline costs for the Pharmaceutical industry the heterogeneity in the 
assessment of the evidence at national level can be associated with the non-
feasibility to draw a clear average of the HTA spending across companies. Our results 
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showed a high variability in HTA spending (between EUR 73 000 and EUR 1 700 000 
per HTA submission), as well as in the additional evidence generation (between EUR 
50 000- 20 000 000). Interviews highlighted the wide heterogeneity in the level of 
acceptability of different types of evidence across countries representing an 
important driver of costs, impacting in some cases on their business decisions.  
The landscape of medical devices/technologies clearly differs from that of Pharma-
ceutical products:  
●  Substantial inter-country variability in HTA recommendations across countries for 
medical devices sector was observed as well as a lower number of HTA per 
technology leading to a lower duplication of reports but to a difference in access 
across countries.  The level of agreement in the availability of assessments showed 
by the Kappa score was mainly poor, showing that HTA is still underdeveloped in this 
sector. In line with the literature (32, 34), these results were also confirmed during 
interviews where manufacturers highlighted the heterogeneity and diversity of the 
medical technologies market including the market access process in comparison with 
the Pharmaceutical sector. This is propagated by the short life cycle of medical 
technologies (including fast development phase) and the limited requirements for 
clinical evidence, according to the current regulatory framework. Manufacturers 
highlighted that HTA currently plays a minor role in the market access process for 
medical devices in most settings due to the extremely fragmented market access of 
medical devices. Indeed, medical devices have a faster and dynamic life cycle than 
Pharmaceuticals and the market is much more competitive as patents are easier to 
obtain and the property rights are mildly enforced (35, 36). 
●  Regarding the processes of HTA in the medical device sample, the timing in 
evaluating the same category of medical devices varied significantly, probably related 
to the fragmented system in place for obtaining CE mark.  
●  The fragmentation of the MedTech sector was also shown in the evidence considered 
by the HTA bodies; despite a preference for RCTs, the other clinical evidence 
considered varied substantially across the sample. This might be related to absence 
of RCT data and the need for multiple sources of less strong evidence to prove the 
clinical effectiveness therefore raising also questions regarding the central role of 
RCTs in the evaluation of medical devices as the main evidence of HTA assessment. 
The interviews and the literature suggested that, while long RCTs may be desirable 
from an evidence standpoint, they may not always be appropriate, feasible or 
sufficient for medical devices (69). Confirming the literature, therefore, agreement 
on the best evidence and methodology for assessing medical devices is still lacking. 
●  With regards to baseline costs, the underdevelopment of the current role of HTA for 
medical devices, can be associated with the non-feasibility to draw a clear average of 
HTA spending across participating companies, the high variability in the HTA 
submission spending (EUR 17 000 - EUR 12 800 000) and in the generation on 
additional evidence for the purpose of HTA submission.  
Finally, for other technologies the results generally showed:   
●  A low number of agencies actively engaging in HTA in this category of technology 
(n=14); in general, there is also a lack of publicly available reporting of country 
specifics in public health interventions for instance. There are large differences across 
MS in vaccinations programs due to different products considered and the different 
policies employed in implementing preventive programs, which do not allow clear 
conclusions to be drawn.  
●  Nonetheless, there seems to be some agreement in the use of a common 
methodology for retrieving and considering clinical and economic evidence and the 
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outcomes of HTA reports across countries. Further research in these types of 
intervention is needed. 
Overall, the literature confirmed that there is a heterogeneity in the way health technolo-
gies are considered across EU MS. An analysis at micro-level of assessments performed 
by different HTA bodies, highlighted a tendency towards common methods in assessing 
products. Differences in health systems, political traditions, national income, and local 
practice patterns will continue to translate into different ways of appraising health 
technologies. Yet, a tendency towards homogenization in assessments is growing, 
leading to a duplication of assessments, specifically for the assessment of clinical and 
economic evidence. This is confirmed in the case of Pharmaceuticals, whereas for 
MedTech and other technologies the picture is still quite fragmented. There remains 
considerable room for improvement in moving HTA towards greater predictability and 
rationality. This will, of course, require resources as well as leadership, not only among 
governments, but also across industry stakeholders. The main goal should be to improve 
the science and to reduce uncertainty. 
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7.2 Costs of Policy Options 
Information and calculations presented in this section should be considered with the 
underlying assumptions mentioned in the respective parts and associated limitations (see 
6.2.2.6). They refer to a specific anticipated scenario and should not be considered in 
isolation, but rather in combination with other aspects, especially the social/health 
impacts of section 6.3, as many effects are not quantifiable but should be considered 
nonetheless. Figures presented are rough and rather conservative estimates.  
 Cost of implementation mechanisms for governance structures 7.2.1
This section displays the results of cost estimations for the implementation mechanisms. 
Indicated numbers are rounded estimates in thousand Euros per year. 
The project-based cooperation includes estimates based on average salaries of EUnetHTA 
JA 3 and respective partners. The European staff regulations formed the basis for the 
cost calculations for the remaining four implementation mechanisms, i.e. the MS secre-
tariat, the EU secretariat, the integration in an existing agency and establishment of a 
new EU agency. 
The salary scheme for temporary agents working at EU institutions was used to calculate 
basic salaries. The salary scheme is comprised of 16 function groups and five steps 
within each function group. At first, qualification profiles were matched with applicable 
function groups and the average of the fiver steps of each function group were used for 
calculations. Moreover, basic allowances, like the dependent child allowance, assuming 
1.58 (47) children per employee, and the household allowance, were included in salaries. 
Education allowance, pre-school allowance, expatriation or foreign residence allowances, 
installation allowance, daily subsistence allowance and additional pays, e.g. business 
travel costs, were not considered in the calculations, as they are particularly case-
specific. Thus, calculated salaries are basic assumptions not accounting for specific 
characteristics of each case but include 13th and 14th salary. 
The qualification profiles listed in Table 20 were matched with 16 function groups: 
Table 51: Qualification profiles 
Function group Qualification profiles 
AD 12+ Unit head 
AD 9 (senior level) Head 
AD 7  Project manager, Scientific officer, Financial officer and IT officer 
AST 3 Administrative assistants, Communication assistants 
According to EU staff regulations, qualification profiles assigned to function group AD 12, 
AD 9 and AD 7 presume a university degree of four years of education or more, a 
university degree of three years and at least one year work experience in a relevant field, 
or equivalent training and professional experience. Classification in function group AST 3 
necessitates post-secondary education, secondary education and a minimum of three 
years of relevant work experience or equivalent professional training and a minimum 3 
years of relevant work experience. 
                                                                                                                                    
 
(47) Fertility rate in EU 28 according to Eurostat: 
http://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=en&pcode=tsdde220&plugin=1 
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Other relevant costs for calculations were travel costs for the coordination team, one-
time costs for sufficiently elaborated IT systems (data protection), expenditures for 
software licences and licences to access literature databases, premises costs and costs 
associated with the management board and the independent review process by the 
expert committee. Costs for the independent review process of the committee include 
fees payed to experts according to the expert fees of the EC and travel costs for respec-
tive meetings, i.e. either four times or eight times p.a. Due to the high number of 
anticipated assessments, online meetings seem more efficient. Finally, 15% overhead 
were included to account for other potential incidental costs. Cost calculations do not 
include costs resulting from adaptation of existing facilities or acquisition costs for 
new facilities. In the case of POs 1 to 4, i.e. project-based cooperation, a MS secretariat, 
an EU secretariat or integration in an existing agency, existing facilities might be used. 
Moreover, there are no special requirements like considering an extensive IT system as 
was the case for eu-LISA. Consequently, costs incurred by adapting existing facilities or 
acquiring new facilities were not considered as a major cost element for implementation 
cost calculations. Running costs of premises were considered for calculations. With 
respect to the different price levels of the MSs, staff costs and premise costs derived 
from the EU salary scheme required adjustment according to the salary indexation list 
(48). Three categories representing countries with a high price level (Category 1: Indices 
113.8-141.8), a medium price level (Category 2: Indices 85.7-108) and a low price level 
(Category 3: Indices 51.1-80.6) account for respective differences. Moreover, premise 
costs were adjusted according to the salary indices to ensure comparability within the 
calculation. 
Licences for IT software, including a strong firewall and literature databases, are neces-
sary to provide state-of-the-art conditions to optimally support HTA assessments 
contracted to HTA bodies and ensure efficient processes within the coordination unit and 
between the coordination unit and contracted partners. Estimates on IT software licenses 
include only HTA-specific requirements (e.g. for maintaining the POP-database). General 
software licenses were not estimated because the costs depend on the location and 
existing licenses. It was assumed that these costs are covered by the overall EC budg-
et/agency budget (as is the case for energy supply and basic internet connection). 
Licenses for literature databases are exclusive licenses, thus only available for the 
coordination team, for this a lump sum was estimated because costs depend on the 
number of databases and licenses. 
The management board is mainly responsible for running the agency, and the expert 
committee provides scientific expertise. 
Table 52 depicts an overview of estimations for the different implementation mechanisms 
in combination with the respective policy option presented in Table 7. Cost positions 
include running costs and implementation costs for respective outputs projected in Table 
16 and Table 17, hence including 65 REAs.
                                                                                                                                    
 
(48) Provided by EC services. 
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Table 52: Costs of running a central coordination body covering 40 EDs, 65 REAs and 11 Full HTA, costs are given in EUR 1 000 p.a. 
N/A= Not applicable; all amounts are indicated in Euros (EUR); Cat 1=MS with high price level, Cat 2=MS with medium price level, Cat 3=Ms with low price level 
                                                                                                                                                                                                          
 
(49) Implementation costs not estimable within this study. 
(50) Based on EUnetHTA JA 3. 
(51) Based on respective qualification profile displayed in Table 51: Qualification profiles and EU staff regulations; adjusted to price levels if applicable. 
(52) Based on information of EUnetHTA JA 3 budget. 
(53) Based on EUnetHTA JA 3 budget and expert opinion. 
(54) Based on EMA premise costs; adjusted for price levels if applicable. 
(55) Based on ‘Ramboll/Euréval/Matrix- Evaluation of the EU decentralised agencies in 2009’; PO 2 includes project-based participation rate. 
(56) Fees and travel costs. 
(57) Based on expert fees of EC, incl. travel costs. 
Type of costs Project-based 
cooperation (PO2) 
MS secretariat 
(PO3a) 
EU secretariat 
(PO3b) 
Existing EU agency 
(PO 4.1) 
Existing EU agency 
(PO 4.2) 
New EU agency (49) 
(PO 5) 
 Implementation Costs 
IT (implementation costs) 17 (50) 
 Cost depend to a large extent of the 17,4situation in the premise (e.g. is there already an IT network established or not, are premised equipped with 
computers, are specific communication tools necessary, ‘power’ of firewall) 
 Running Costs 
Staff costs (Total costs) (51) 785 
1 871 (Cat 1) 
1 463.8 2 954.9 3 264.3 4 170.2 1 417.7 (Cat 2) 
963.9 (Cat 3) 
Travel costs (52) 132.6 42.5 42.5 42.5 42.5 42.5 
IT software licenses (53) 10 10 10 10 10 10 
Licences for literature 
databases (36) 
20 20 20 20 20 20 
Premises (54) 
254 (Cat 1) 295.5 (Cat 1) 
231.3 512 573 753.6 192.5 (Cat 2) 224 (Cat 2) 
130.9 (Cat 3) 152.3 (Cat 3) 
Management Board (55) 1 118.6(56) 205.3 205.3 63.7 308 308 
ED Committee (57) N/R 723.6 723.6 241.2 723.6 723.6 
REA Committee N/R N/R N/R 732.6 2 197.8 2 197.8 
Full HTA Committee N/R N/R N/R N/R N/R 135.2 
 Overhead for running costs (+15%) 
Total costs 
2 685.2 (Cat 1) 3 642.8 (Cat 1) 
3 100.9 5 263.4 8 210.1 9 615 2 614.5 (Cat 2) 3 039.5 (Cat 2) 
2 543.6 (Cat 3) 2 435.2  (Cat 3) 
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) 
 
 
                                                                                                       180 
    
When introducing project-based cooperation, one coordination team would be responsible 
for overall coordination. This may cause a minimum of 120 travels p.a. just for the 
coordinating team. Based on cost information available from previous EUnetHTA JAs, an 
average of EUR 850 per travel (including round-trip flights and one overnight stay at a 
hotel) is necessary. Relating to the other implementation mechanisms, meetings will be 
organised at the secretariat’s or agency’s location, thus a significant reduction of travel 
costs for the coordination team would be achieved, assuming a maximum of one third of 
the travel costs compared to project-based cooperation.  
Moreover, the extensive management board foreseen for the project-based cooperation 
causes high costs compared to the Management Board of other implementation mecha-
nisms’ structures. Providing quarterly meetings for participating partners, the number of 
EUnetHTA partners of JA3 accounts for 79, represents a substantial cost burden. The 
introduction of a Management Board provides a leaner structure by organising quarterly 
meetings for representatives of each participating MS, even with the assumption of two 
additional meetings per year accounting for increased output production. 
Taking that into account, after establishment of processes and structures, ideally 115 
REAs in total should be performed (90 on Pharmaceuticals and 25 on medical devices). 
Cost estimates are presented in section 7.2.3.4.  
 Costs related to production of joint outputs 7.2.2
Table 53 to Table 55 depict relevant unit costs for outputs (Early Dialogues, REA and Full 
HTA) as far as available. Additionally, costs for the adaptation of joint products (in order 
to be applied at national level) have been estimated. It was also planned to take the 
costs of additional evidence generation requested by HTA bodies, which could be as-
sumed to be decreased with the conduct of joint Early Dialogues, into consideration. 
However, this could not be incorporated because of missing data/information on the one 
hand and because very few of the survey respondents reported a reduction in HTA costs 
due to Early Dialogues (see Table 36 and Table 37). It may nonetheless be assumed that 
with mandatory options for REAs and full HTA, such cost reductions will become more 
likely due to harmonisation of MS requirements. 
Costs are shown separately from the perspective of HTA bodies/MS and industry – 
specifically, the Pharmaceutical and medical devices industries.  
Costs for joint outputs are given separately for EU level and industry.  
Costs for REA, Full HTA and their adaptations have been estimated separately for 
reports done mainly by HTA bodies and reports/submissions done mainly by industry and 
reviewed by HTA bodies. It is assumed that costs to industry for HTA body-based reports 
are negligible. 
It has proven very difficult to gather data on the costs for an industry HTA submission 
(see also 7.1.12). Cost estimates available for Pharmaceutical and medical devices’ 
industry are highly variable and higher than that for HTA body-based reports. Moreover, 
costs for ‘REA submission’ and costs for ‘Full HTA submission’ cannot be distinguished 
between (although, according to estimates derived from Chamova 2017, economic 
considerations and calculations mostly have to be included within submissions at national 
level). 
Even if all inputs are combined, it remains rather unclear what part of industry submis-
sion costs can be assumed to be replaced by joint assessment at MS level.  
Therefore, it was assumed that the cost savings to industry may be estimated 
by the costs of one Joint Assessment (REA or Full HTA). 
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The following examples illustrate some further assumptions: 
• A reduction of 40 HTA body-based REAs at national level leads to cost savings 
equivalent to the costs of 40 HTA body-based national REAs and the additional 
costs of the adaptions of 40 joint REAs in the national context. These savings and 
costs occur on the side of HTA bodies for, respectively, MS and their authorities. 
• For Full HTA similar assumptions are made, despite that in systems with industry-
based submissions it is assumed that HTA bodies/MS bear the costs for adapting 
the four REA domains in the national context and industry adapts the ECO domain, 
and if necessary, other domains.
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N/R=Not relevant.  Sources are given in the Footnotes 
Table 53: Unit costs per outputs, costs on the level of HTA bodies/MS (national outputs) and costs at EU level (joint assessments), 
cost in EUR 1 000 p.a. 
 Current costs of HTA bodies/MS respectively EU (for Joint Assessments) 
 Performed at national level Performed as Joint Assessments 
 Average Min Max Average Min Max 
 
 
Early Dialogue (58) 
 
€41.7 €19.4 €64.0 €45.9 €22.0 €70.4 
Assumptions: The final report of the SEED consortium reports ‘fees for single HTA EDs’. Out of that information, UK 
costs were taken as an estimate for national costs, because ‘this activity receives no public funding’ and operates ‘on a 
cost neutral basis’. They are given as a range within the report; the average has been calculated by the authors. These 
values should indicate total ED costs on the side of the HTA body, which may be paid by HTA bodies OR industry. 
Assumptions: A markup for additional administrative costs could be assumed (based on UK fees) for the production of joint ED, 
assumed to be 10%. EMA-fees for scientific advice amount to EUR 42 300 to EUR 84 700 (as given on the website). On the 
other hand, the costs for 11 SEED Early Dialogues were EUR 250 000 (22,727 pro ED; information provided by DG SANTE). 
REA produced mainly by HTA 
body (with no or only some 
evidence/data submission provided 
by industry) (59,60)  
€35.0 €10.0 €100.0 
€117.0 for Pharma 
€85.7 for MedTech 
€58.5 for Pharma 
€42.9 for MedTech 
€234.0 for Pharma 
€171.4 for MedTech 
Assumptions: For national products information sources were studied, and rounded values taken based mainly on 
survey data for REA vs. HTA. 
Assumptions: For joint output, a wide range of one half to double of the amount was assumed (being one third to threefold at 
national level). 
REA produced by industry and 
reviewed by HTA body (61) 
€20.0 €5.0 €55.0 N/R 
Assumptions: Out of the survey results, rounded values were taken for those MS that reported costs and have reports 
based on industry submission (cave: small sample of available data). 
Assumptions: Joint assessments are always done mainly by the HTA institutions being authors/reviewers and may include 
industry submissions as data input (see EUnetHTA  JA2). 
Full HTA produced by HTA body 
(with no or some evidence/data 
submission provided by industry) 
(62) 
€95.0 €20.0 €300.0 €228.9 €114.5 €457.8 
Assumptions: For national products information sources were studied, and rounded values taken based mainly on 
survey data for REA vs. HTA. 
 
Assumptions: For joint output, a wide range of one half to double of the amount was assumed (being less than one third to 
threefold at national level). It is assumed that the ECO domain of a Full HTA at EU level mainly includes literature review and basic 
collection of cost parameters for ECO domain. 
Full HTA produced by industry 
and reviewed by HTA body (63) 
€40.0 €5.0 €100.0 N/R 
Assumptions: Out of the survey results, rounded values were taken for those MS that reported costs and have reports 
based on industry submission (cave: small sample of available data). 
Assumptions: Joint assessments are always done mainly be the HTA institutions being authors/reviewers, but may include 
industry submissions as data input (see EUnetHTA  JA2). 
  National adaptation of a joint REA (64) €17.5 €5.0 €50.0 
Assumptions: It is assumed that HTA bodies always perform the adaptation of the Joint REA.  
  National adaptation of a joint Full HTA (65), done by HTA body €47.5 €10.0 €150.0 
  Assumptions: See Footnote 
  National adaptation of a joint Full HTA (66), done by HTA body and 
industry 
€17.5 €5.0 €50.0 
  Assumptions: See Footnote – It is assumed that HTA bodies do the necessary adaptation of REA domains. 
                                                                                                                                                                                                    
 
(58) Based on final study of the SEED consortium (UK costs p. 29); see also https://www.nice.org.uk/about/what-we-do/scientific-advice/frequently-asked-questions; 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000327.jsp&mid=WC0b01ac0580024596 
(59) Based on ECORYS-study (p 30) and Survey results (national output).  
(60) Evaluation study JA2 (p 65) and estimations of the authors (joint output). 
(61) Based on Survey results and Chamova 2017.  
(62) Numbers are based on ECORYS-study (p 30) and Survey results (national output); Evaluation study JA2 (p 65) and estimations of the authors (joint output) 
(63) Numbers are based on Survey results and Chamova 2017 
(64) Estimations by authors: It is assumed that this mainly includes adaptation (if necessary) of CUR, TEC and epidemiological data plus translation of relevant parts into national language, 
maybe update of literature search. 
(65) Cost estimations by authors: It is assumed that this includes the adaptation of CUR, TEC and other domains, as described above for REA, plus part of the ECO domain (without literature 
review and basic collection of cost parameters), and, if relevant, parts of other domains. 
(66) Cost estimations by authors: It is assumed that this includes the adaptation of CUR, TEC and other domains, as described above for REA, plus part of the ECO domain (without literature 
review and basic collection of cost parameters), and, if relevant, parts of other domains. 
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Table 54: Unit costs for outputs, costs on the level of Pharmaceutical Industry, cost in EUR 1 000 p.a. 
 Costs for Pharmaceutical Industry  
 
Outputs performed at national level 
Total unit costs in EUR 
Outputs performed as Joint/Collaborative Assessment 
Total unit costs in EUR 
 Average Min Max Average Min Max 
Early Dialogue (67) 
€55.8; 
0.7 FTE 
not feasible not feasible not feasible 
€0.0; 
0.6 FTE 
€85.0; 
2.0 FTE 
Assumptions: For national output report survey, results are shown (for more information see 
section on baseline costs, 7.1.12). Alternatively UK fees can be assumed as a proxy for industry 
costs (see Table 53), which cover not all, but probably the main part of industry costs for Early 
Dialogues (see 7.1.12.1). 
Assumptions: At the moment, EUnetHTA  EDs are done without fees for industry (SEED-study, p 28). So out of the 
study survey results only reported staff and other costs (no fee costs, see section 7.1.12.1, figure 26) are shown 
here as an approximation. Alternatively, UK fees can be assumed (see above). 
REA produced mainly by HTA 
body (with no or only some 
evidence/data submission 
provided by industry) 
0 0 0 €139.1 € 14.7 €334.2 
Assumptions: For national output, it is assumed that costs for inputs from industry are 
negligible 
Assumptions: For the costs to industry for joint output, no data or information are available. For calculation as a 
proxy, they have been assumed to be one fifth of submission costs as reported in the survey with according ranges 
from the sensitivity analysis. 
REA produced by industry and 
reviewed by HTA body (68) 
€695.5 €73.4 €1,671.0 Assumptions: Joint assessments are by definition done mainly be the HTA institutions being authors/reviewers and 
may include industry submissions as data input (see above). No distinction possible between REA and Full HTA, high range/variability and uncertainties. 
Full HTA produced by HTA 
body (with no or only some 
evidence/data submission 
provided by industry) 
0 0 0 €173.9 €18.4 €417.7 
Assumptions: For national output, it is assumed that costs for inputs from industry are 
negligible. 
Assumptions: For the costs to industry for joint output, no data or information are available. For calculation as a 
proxy, they have been assumed to be one fourth of submission costs as reported in the survey with according 
ranges from the sensitivity analysis. 
Full HTA produced by 
industry and reviewed by HTA 
body (69) 
€695.5 €73.4 €1,671.0 N/R 
No distinction possible between REA and Full HTA, high range/variability and uncertainties 
Assumptions: Joint assessments are always done mainly by the HTA institutions being authors/reviewers, and may 
include industry submissions as data input (see EUnetHTA  JA2). 
   
National adaptation of a joint 
REA (70) 
Assumed to be done by HTA body/MS 
   
National adaptation of a joint 
Full HTA (71), done by HTA body 
  
   
National adaptation of a joint 
Full HTA (72), done by HTA body 
and industry 
€30.0 €5.0 €100.0 
   
Assumptions: It is assumed that this, on the side of industry, includes the supplementary production of part of the 
ECO domain (without literature review and basic collection of cost parameters), and, if relevant, parts of other 
domains. 
FTE=full time equivalent, N/R=Not relevant Sources are given in Footnotes   
                                                                                                                                                                                                    
 
(67) Based on Survey results. 
(68) Based on Survey results. 
(69) Based on Survey results. 
(70) Estimates by authors: It is assumed that this mainly includes adaptation (if necessary) of CUR, TEC and epidemiological data plus translation of relevant parts into national language, 
maybe update of literature search. 
(71) Cost estimates by authors: It is assumed that this includes the adaptation of CUR, TEC and other domains, as described above for REA, plus part of the ECO domain (without literature 
review and basic collection of cost parameters), and, if relevant, parts of other domains. 
(72) Cost estimates by authors: It is assumed that this includes the adaptation of CUR, TEC and other domains, as described above for REA, plus part of the ECO domain (without literature 
review and basic collection of cost parameters), and, if relevant, parts of other domains. 
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Table 55: Unit costs for outputs, costs on the level of MedTech Industry, cost in EUR 1 000 p.a. 
 Costs for MedTech Industry 
 
Performed at national level 
Total unit costs in EUR  
Performed as joint/collaborative assessment 
Total unit costs in EUR  
 Average Min Max Average Min Max 
Early Dialogue (73) 
€21.7; 
 0.7 FTE 
not feasible not feasible 
€21.7;  
0.7 FTE 
not feasible not feasible 
Assumptions: For national output report survey, results are shown (for more information see section on baseline 
costs, 7.1.12). Alternatively, UK fees can be assumed as a proxy for industry costs (see Table 53), which cover 
not all, but probably the main part of industry costs for Early Dialogues (see 7.1.12.2).  
Assumptions: Joint output: At the moment, EUnetHTA  EDs are done without fees for industry (SEED-report, p 28). As 
also no fees have been reported in the survey, these reported costs and resources are taken to be staff and other costs. 
Alternatively UK fees can be assumed (see above). 
REA produced mainly by HTA 
body (with no or only some 
evidence/data submission 
provided by industry) 
N/R €82.1 €0.2 €668.0 
Assumptions: For national output, it is assumed that costs for inputs from industry are negligible 
Assumptions: For the costs to industry for joint output, no data or information are available. For calculation as a proxy, 
they have been assumed to be one fifth of submission costs as reported in the survey with according ranges from the 
sensitivity analysis. 
REA produced by industry and 
reviewed by HTA body (74) 
€410.4 €1.0 €3,340.0 N/R 
No distinction possible between REA and Full HTA, high range / variability and uncertainties 
Assumptions: Joint assessments are always done mainly by the HTA institutions being authors/reviewers, and may 
include industry submissions as data input (see above) 
Full HTA produced by HTA 
body (with no or some 
evidence/data submission 
provided by industry) 
N/R €102.6 €0.3 €835.0 
For national output, it is assumed that costs for inputs from industry are negligible 
Assumptions: For the costs to industry for joint output, no data or information are available. For calculation as a proxy, 
they have been assumed to be one fourth of submission costs as reported in the survey with according ranges for the 
sensitivity analysis. 
Full HTA produced by 
industry and reviewed by HTA 
body (75) 
€410.4 €1.0 €3,340.0 N/R 
No distinction possible between REA and Full HTA, high range/variability and uncertainties 
Assumptions: For the costs to industry for joint output, no data or information are available. For calculation as a proxy, 
they have been assumed to be one fifth of submission costs as reported in the survey with according ranges from the 
sensitivity analysis. 
 
National adaptation of a joint REA (76) Assumed to be done by HTA body / MS 
National adaptation of a joint Full HTA 
(77), done by HTA body 
  
National adaptation of a joint Full HTA 
(78), done by HTA body and industry 
€30.0 €5.0 €100.0 
Assumptions: It is assumed that this, on the side of industry, includes the supplementary production of part of the ECO 
domain (without literature review and basic collection of cost parameters), and, if relevant, parts of other domains. 
   FTE=full time equivalent, N/A=Not applicable. Sources are given in Footnotes 
                                                                                                                                                                                                    
 
(73) Based on Survey results. 
(74) Based on Survey results. 
(75) Based on Survey results. 
(76) Estimates by authors: It is assumed that this mainly includes adaptation (if necessary) of CUR, TEC and epidemiological data plus translation of relevant parts into national language, 
maybe update of literature search. 
(77) Cost estimates by authors: It is assumed that this includes the adaptation of CUR, TEC and other domains, as described above for REA, plus part of the ECO domain (without literature 
review and basic collection of cost parameters), and, if relevant, parts of other domains. 
(78) Cost estimates by authors: I t is assumed that this includes the adaptation of CUR, TEC and other domains, as described above for REA, plus part of the ECO domain (without literature 
review and basic collection of cost parameters), and, if relevant, parts of other domains. 
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 Cost prognosis 2020+  7.2.3
The following sections describe the results on projected costs and/or savings for the 
different Policy Options arising at EU level and at national level (across coun-
tries). They are also grouped by stakeholders (EU, MS / HTA bodies and industry). This 
is based on the current allocation of costs across stakeholders (as described in the 
previous sections).  
Section 7.2.3.1 describes total costs arising at EU level, that is, coordination costs 
depending on implementation mechanisms as well as costs for the production of joint 
outputs.  
Section 7.2.3.2 shows total costs and/or savings that arise at MS and industry level, 
through a reduction in previous national outputs on the one hand and national adapta-
tions of joint outputs (as well as industry costs for joint outputs) on the other hand.  
Section 7.2.3.3 summarises all these costs within one table and adds additional items 
that may cause costs and/or savings, but cannot reliably be quantified. Differences in the 
results between stakeholder groups are discussed and analysed.  
Section 7.2.3.4 provides an alternative calculation with a higher amount of joint outputs.  
Section 0 gives an overview about the performed sensitivity analyses. 
 Total costs arising at EU level 7.2.3.1
Combining implementation mechanisms of respective Policy Options with costs 
of output production, Table 56 displays costs arising at EU level from the proposed 
business models. Not implementing a sustainable model at EU level for future coopera-
tion in the field of HTA would lead to sunk costs as outcomes of previous cooperation 
within EUnetHTA JA-JA3 and previous cooperation in HTA would be lost. 
The following table depicts total costs of implementation mechanisms when matching 
with direct costs of subcontracting (for the production of the joint outputs) for the 
respective Policy Options. Cost calculations do not examine potential fees for output 
production because implementation and the level of fees is out of the scope of this study.  
Maintenance of common tools, templates and methodologies will be performed in 
the central coordination unit and is included in the costs for implementation mechanisms.  
Joint Early Dialogue, joint REA (65 REAs in total for PO 4.2, PO 4.2 and PO 5, comprising 
40 REAs on Pharmaceuticals and 25 REAs on medical technologies) and joint Full HTA are 
subcontracted to HTA bodies and represent subcontracting expenses.  
According to Table 7, PO 3 includes two options for implementation mechanisms: 
• A permanent secretariat hosted by a MS. 
• A permanent secretariat hosted by the EC.  
Hence, PO 3a represents cost estimates for a permanent secretariat hosted by a MS and 
accounting for different price levels for the MS. PO 3b shows the permanent secretariat 
hosted by the EC. 
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Table 56: Costs of Business models assuming output production of 40 EDs, 65 REAs and 
11 joint Full HTA, cost in EUR 1 000 p.a.* 
 Project-
based co-
operation 
(PO 2) 
MS 
secretariat 
(PO 3a) 
EU 
secretariat 
(PO 3b) 
Existing EU 
agency 
(PO 4.1) 
Existing EU 
agency 
(PO 4.2) 
New EU 
agency (PO 5) 
(79) 
 
Costs for common tools, 
templates and methodolo-
gies (Maintenance) (80) 
210.0 
included in 
implementa-
tion 
mechanism 
included in 
implementation 
mechanism 
included in 
implementation 
mechanism 
included in 
implementation 
mechanism 
included in 
implementation 
mechanism 
Costs for common tools, 
templates and methodolo-
gies (Development) (81) 
300.0 300.0 300.0 300.0 300.0 300.0 
Costs for joint Early 
Dialogues (82) 
596.3 1 834.8 1 834.8 1 834.8 1 834.8 1 834.8 
Costs for joint REA (83,84) 
1 598.3 
(Pharma: 
1 170 
MedTech: 428) 
N/R N/R 
6 821.6 
(Pharma: 4 679 
MedTech: 2 142) 
6 821.6 
(Pharma: 4 679 
MedTech: 2 142) 
6 821.6 
(Pharma: 4 679 
MedTech: 2 142) 
Costs for joint Full HTA (85) N/R N/R N/R N/R N/R 
2 479.9 
(Pharma: 1 526 
MedTech: 954) 
Costs for implementation 
mechanism 
 
2 685.2 
(Cat 1) 
3 642.8 
(Cat 1) 
3 100.9 5 263.4 8 210.1 9 615 
2 614.5 
(Cat 2) 
3 039.5 
(Cat 2) 
2 543.6 
(Cat 3) 
2 435.2  
(Cat 3) 
Total costs (86) 
5 389 8  
(Cat 1) 
5 777.6 
 (Cat 1) 
5 235.7  14 219.8 17 166.5 21 051.3 
5 319.1 
 (Cat 2) 
5 174.3  
(Cat 2)  
5 248.2 
 (Cat 3)  
4 570 
 (Cat 3) 
Cat 1: MS with high price level; Cat 2: MS with medium price level; Cat 3: MS with low price level 
*PO2 includes 8-10 REAs Pharma and 3-5 REAs medtech 
What becomes apparent looking at Table 56 is that PO 3a and 3b do not include produc-
tion of joint REAs because the policy structure anticipates voluntary participation and 
voluntary uptake. Voluntary uptake means that if joint assessments would lead to 
unfavourable results, participants do not have to accept these, which would lead to 
inefficiency of processes. Hence, the combination of voluntary participation and voluntary 
uptake would not incentivise participation of stakeholder groups. This assumption aligns 
with the findings of the report survey and the additional follow-up. MedTech industry 
stakeholders pointed out that because PO 3 foresees a voluntary participation as well as 
voluntary uptake for joint REA, cooperation on joint REA production would not fulfil its 
purpose if participants are not tied to a mandatory uptake. Hence, industry stakeholders’ 
interest in participation would be much lower compared to other options.  
                                                                                                                                    
 
(79) Implementation costs not estimable within this study. 
(80) Based on information of EUnetHTA JA 3 for PO 2; costs for PO 3a- PO 5 are included in costs for implementation 
mechanisms. 
(81) Assumption by study authors, development of new guideline not included as not quantifiable. 
(82) PO 2: 9 EDs on Pharmaceuticals, 4 on medical technologies; PO 3a - PO 5: 30 EDs on Pharmaceuticals and 10 on medical 
technologies. 
(83) Does not include costs arising to industry within the production of joint assessments (e.g. submission templates). 
(84) PO 2: 8-10 REAs Pharma, 3-5 REAs medtech; PO 4.1, PO 4.2 and PO5: 40 REAs Pharma, 25 medtech. 
(85) Does not include costs arising to industry within the production of joint assessments (e.g. submission templates); 7 joint 
full HTAs on Pharmaceuticals and 4 on medical technologies. 
(86) Including implementation costs; Overhead costs are included in the respective cost elements; not adjusted for inflation. 
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 Total costs or savings arising at national level, across countries 7.2.3.2
Table 57 shows the results of average additional costs or savings at national level 
from the perspective of the different stakeholder groups. Figures in red (negative 
numbers) are savings and figures in black (positive numbers) additional costs.  
These figures have been calculated with a high number of assumptions (as justified in 
sections 5.2.2 and 6.3.2) and a high degree of underlying uncertainty. They can 
therefore only be seen as estimates showing the general trend.  
Table 57: Potential savings per policy option regarding the production of REAs and Full 
HTA for each stakeholder group related to different business models; cost in EUR 1 000 
p.a. 
Costs/savings from the perspective of MS (across countries) 
  
Project-based 
co-operation 
(PO 2) 
MS/EU 
secretariat 
(PO 3) 
Existing EU 
agency 
(PO4.1) 
Existing EU 
agency 
(PO 4.2) 
New EU agency 
(PO 5) 
Pharmaceutical products  -256 N/R -1 567 -2 673 -3 801 
Medical Technologies -127 N/R -1 186 -1 965 -2 594 
Sum of costs/savings from the perspective of 
MS  
-383 N/R -2 753 -4 638 -6 395 
Costs/savings from the perspective of industry (across countries) 
  
Project-based 
co-operation 
(PO 2) 
MS/EU 
secretariat 
(PO 3) 
Existing EU 
agency 
(PO 4.1) 
Existing EU 
agency 
(PO 4.2) 
New EU agency 
(PO 5) 
Pharmaceutical products -3 744 N/R -35 117 -63 833 -69 608 
Medical Technologies -92 N/R -3 288 -6 797 -7 758 
Sum of costs/savings from the perspective of 
industry  
-3 836 N/R -38 405 -70 629 -77 366 
N/R=Not relevant 
Comments: Results do not include costs (and savings) of ED due to a lack of reliable data.  
 
There are no savings or costs given for PO 3, since in this policy option both production 
and uptake are defined to be voluntary and thus not included in the estimates. For the 
other POs, it can be seen that with regard to the production of REA and Full HTA savings 
(through the reduction of national output production) exceed costs (for adaptation of 
joint output and industry submissions for joint assessments) for both sectors, from the 
perspective of MS as well as from the perspective of industry.  
Results clearly show that PO 4.1 and onward lead to a significant amount of savings, 
especially for the industry. 
However, there are differences between the Pharmaceutical and the MedTech industry. 
Savings for the Pharmaceutical Industry, as presented in Table 57, are much higher than 
savings for MedTech industry. This has several drivers:  
• Joint MedTech reports are assumed to be less costly than joint Pharma reports 
(based on JA 2). 
• The amount of joint REAs for Pharmaceuticals is assumed to be much higher than 
the amount of joint REAs for medical devices (40 vs 25). 
• The proportion of joint REAs that are assumed to be (topic) relevant for the na-
tional context are also assumed to be higher (an assumption that was made be-
cause of the higher heterogeneity of the medical device sector).  
• Many more countries have a reimbursement system based on industry submission 
for the Pharmaceutical sector than those who do for the medical devices sector.  
• Average annual numbers of reports within countries are in general higher for the 
Pharma sector than for the MedTech sector. The latter two have the biggest influ-
ence on the difference between Pharma and MedTech. 
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 Total costs and savings  7.2.3.3
Table 58 provides an overview about the results of the cost prognosis for the future 
cooperations on HTA after 2020, displaying costs that arise due the creation of joint 
output and the governance structure necessary for facilitating HTA cooperation and the 
potential savings due to a reduction of duplication of HTA assessments, including related 
adaptation costs (from MS and industry perspective separately).  
Table 58: Summary of potential costs and savings per policy option costs, EUR 1 000 p.a. 
 Project-based 
co-operation 
(PO2) 
MS/EU 
secretariat 
(PO3a) 
EU  
secretariat 
(PO3b) 
Existing EU 
agency 
(PO 4.1) 
Existing EU 
agency 
(PO 4.2) 
New EU 
agency 
(PO 5) 
Sum of costs at EU level: 
joint output 
2 705 2 29 2 542 9 465 9 465 12 046 
Sum of costs at EU level: 
Implementation Mechanism  
2 685.2 3 642.8 
3 100.9 5 263.4 8 210.1 9 615 2 614.5 3 039.5 
2 543.6 2 435.2 
Sum of costs/savings from 
the perspective of MS  
-383 N/R N/R 
 
-2 753 
 
-4 638 
 
-6 395 
Sum of costs/savings from 
the perspective of industry  
-3 836 N/R N/R -38 405 -70 629 -77 366 
N/R=Not relevant 
Results of the calculation show that, especially with PO 4.1, 4.2 and 5, overall savings 
can be expected and that these savings rise with each subsequent policy option.  
However, several additional impact factors have to be taken into consideration addition-
ally, which cannot reliably be quantified but may have an impact on overall costs/savings 
and may change, reverse or diminish some of the results into the opposite direction:  
Non-quantifiable potential savings 
• Avoided duplication of national assessments through an increased number of col-
laborative (intergovernmental) assessments (with tools being mandatory) 
• Reduced amount of national activities related to tools and methods 
• Reduced national Horizon Scanning costs plus potential collaborations can be iden-
tified quicker 
• Reduced number of Early Dialogues done at national level 
• Reduction in additional evidence generation requested by HTA bodies through the 
production of joint Early Dialogues 
Non-quantifiable potential costs 
• Implementation of the mandatory uptake of joint output within national proce-
dures, laws and regulations 
• Joint Early Dialogues may have to be adapted to the national context or may not 
be transferable (see SEED report) 
Savings for industry as a whole are higher than savings from the perspective of MS. The 
main driver is the fact that it is assumed that industry gains more from the replacement 
of national submissions through joint assessments – gains are assumed to be just 
equivalent to the costs of the joint assessment (of around EUR 100 000 for REAs). For 
MS, savings from the replacement of national assessments with joint assessments 
amount to the costs of a national report (around EUR 35 000 for REAs). Additionally, the 
analysis assumes that national adaptations are mostly financed by MS. 
Although costs of implementation mechanisms and business models increase by ascend-
ing policy option, potential savings for the respective stakeholders rise accordingly. In 
the long run, it seems vital that the number of joint assessments on Pharmaceuticals 
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N/R=Not relevant 
supplements the number of centrally authorized new Pharmaceutical substances and new 
indications, ensuring comprehensive processes. To optimise processes, specifically those 
concerning the MedTech Industry, initial temporary workgroups including all stakeholders 
offer the potential to design the most efficient respective processes. 
Finally, it must be considered that costs and savings from the perspective of the different 
stakeholders are based on current cost allocations and funding mechanisms.  
 Increasing joint output for Pharmaceutical products from 40 to 90 7.2.3.4
REA 
It may be argued that a higher amount of joint assessments, especially for Pharmaceuti-
cal products, may be useful or that the amount of these joint assessments may be 
increased step by step. With respect to the total number of EMA decisions, an amount of 
90 joint REAs for Pharmaceutical products might be a relevant alternative to the 40 
assumed above.  
Costs estimated for running a central coordination body with an output production of 40 
EDs and/or 115 REAs (90 on Pharmaceuticals and 25 on medical technologies) and/or 11 
Full HTAs are depicted in the table below. 
Table 59: Increased output - Costs of Running a Central Coordination Body coordinating 
40 EDs, 115 REAs and 11 Full HTA, cost in EUR 1 000 p.a. 
                                                                                                                                    
 
(87) Implementation costs not estimable within this study. 
(88) Based on EUnetHTA JA 3.  
(89) Based on respective qualification profile displayed in Table 51: Qualification profiles and EU staff regulations; adjusted to 
price levels if applicable. 
(90) Based on information of EUnetHTA JA 3 budget. 
(91) Based on EUnetHTA JA 3 budget and expert opinion. 
(92) Based on EMA premise costs; adjusted for price levels if applicable. 
(93) Based on ‘Ramboll/Euréval/Matrix- Evaluation of the EU decentralised agencies in 2009’; PO 2 includes project-based 
participation rate. 
(94) Fees and travel costs. 
(95) Based on expert fees of European Commission, incl. travel costs. 
Type of costs 
Project-based co-
operation (PO 2) 
MS  
secretariat 
(PO 3a) 
EU  
secretariat 
(PO 3b) 
Existing EU 
agency 
(PO 4.1) 
Existing EU 
agency 
(PO 4.2) 
New EU agency 
(PO 5) (87)  
 
 Implementation Costs 
IT  
 (implementation costs) 
17 (88) 
Costs depend to a large extent on the situation in premise (e.g. is there already an IT network established, are premises 
equipped with computers, are specific communication tools necessary, ‘power’ of firewall?) 
 Running Costs 
Staff costs  
(Total costs) (89) 
785 
1 871 (Cat 1) 
1 463.8 3 595.1 4 095.1 5 001.9 1 417.7  (Cat 2) 
963.9 (Cat 3) 
Travel costs (90) 132.6 42.5 42.5 42.5 42.5 42.5 
IT software licenses (91) 10 10 10 10 10 10 
Licences for literature 
databases (94) 
20 20 20 20 20 20 
Premises (92) 
254 (Cat 1) 295.5 (Cat 1) 
231.3 628 9 724 9 905 4 192.5 (Cat 2) 224 (Cat 2) 
130.9 (Cat 3) 152.3 (Cat 3) 
Management Board (93) 1 118.6 (94) 205.3 205.3 63.7 328.4 328.4 
ED Committee (95) N/R 723.6 723.6 241.2 723.6 723.6 
REA Committee N/R N/R N/R 1 238.6 3 715.8 3 715.8 
Full HTA Committee N/R N/R N/R N/R N/R 135.2 
 Overhead for running costs (+15%) 
Total costs 
2 685.2 (Cat 1) 3 642.8 (Cat 1) 
3 100.9 6 716 11 109.3 12 515 2 614.5 (Cat 2) 3 039.5 (Cat 2) 
2 543.6 (Cat 3) 2 435.2  (Cat 3) 
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Besides the cost estimates for a coordination unit, costs of the respective business 
models were adapted to the increase in REAs performed. 
Table 60 shows an alternative calculation for the business models, including production of 
115 REAs in total, including 90 REAs on centrally authorized new substances and new 
indications for Pharmaceuticals and 25 REAs on medical technologies 
 
Table 60: Increased output - Business models; costs in thousands of Euro p.a. (Pharma 
and MedTech) for 40 EDs, 115 REAs and 11 joint Full HTA* 
 Policy Option  
2 
Policy Option  
3a 
Policy 
Option 3b 
Policy Option  
4.1 
Policy Option  
4.2 
Policy Option  
5 
Costs for Common tools, 
templates and 
methodologies 
(Maintenance) (96) 
210.0 
included in 
implementation 
mechanism 
included in 
implementa-
tion 
mechanism 
included in 
implementation 
mechanism 
included in 
implementation 
mechanism 
included in 
implementation 
mechanism 
Costs for Common tools, 
templates and 
methodologies 
(Development) (97) 
300.0 300.0 300.0 300.0 300.0 300.0 
Costs for Joint Early 
Dialogues (98) 
596.3 1 834.8 1 834.8 1 834.8 1 834.8 1 834.8 
Costs for Joint REA (99,100) 
1 598.3 
(Pharma: 1 170 
MedTech: 428) 
N/R N/R 
12 669.8 
(Pharma: 10 527.8 
MedTech: 2 142) 
12 669.8 
(Pharma: 10 527.8 
MedTech: 2 142) 
12 669.8 
(Pharma: 10 527.8 
MedTech: 2 142) 
Costs for Joint Full HTA (101) N/R N/R N/R N/R N/R 
2 479.9 
(Pharma: 1 526 
MedTech: 954) 
Costs for Implementation 
Mechanism  
 
2 685.2 (Cat 1) 3 642.8 (Cat 1) 
3 100.9 6 716 11 109.3 12 515 2 614.5 (Cat 2) 3 039.5 (Cat 2) 
2 543.6 (Cat 3) 2 435.2 (Cat 3) 
Total costs (102) 
5 389 8  (Cat 1) 5 777.6 (Cat 1) 
5 235.7 21 520.6 25 913.9 29 799.5 5 319.1 (Cat 2) 5 174.3 (Cat 2) 
5 248.2 (Cat 3) 4 570  (Cat 3) 
*PO2 includes 8-10 REAs Pharma and 3-5 REAs medtech 
Table 60 includes costs for the increased number of REAs on Pharmaceuticals and 
respective output-related staff increases. Presented estimates do not account for 
potential mixed funding mechanisms. 
Table 61 depicts the quantitative results for that assumption. As this is only relevant for 
PO 4.1, 4.2 and 5, no changes apply for the other options. 
                                                                                                                                    
 
(96) Based on information of EUnetHTA JA 3for PO 2; costs for PO 3a- PO 5 are included in costs for implementation mecha-
nisms. 
(97) Assumption by study authors, development of new guideline not included as not quantifiable. 
(98) PO 2: 9 EDs on Pharmaceuticals, 4 on medical technologies; PO 3a & PO 5: 30 EDs on Pharmaceuticals and 10 on medical 
technologies. 
(99) Does not include costs arising to industry within the production of joint assessments (e.g. submission templates). 
(100) PO 2: 8-10 REAs Pharma, 3-5 REAs medtech; PO 4.1, PO 4.2 and PO5: 40 REAs Pharma, 25 medtech. 
(101) Does not include costs arising to industry within the production of joint assessments (e.g. submission templates); 7 joint 
full HTAs on Pharmaceuticals and 4 on medical technologies. 
(102) Including implementation costs; Overhead costs are included in the respective cost elements; not adjusted for inflation. 
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Table 61: Increased output – Summary of potential costs and savings per policy option – 
results for 40 EDs, 115 REAs and 11 Joint Full HTAs 
 
Project-
based co-
operation 
(PO2) 
MS/EU 
secretariat 
(PO3a) 
EU 
secretariat 
(PO3b) 
Existing EU 
agency 
(PO 4.1) 
Existing EU 
agency 
(PO 4.2) 
New EU 
agency 
(PO 5) 
Sum of costs at EU 
level: joint output 
2 411 2 051 2 051 14 721 14 721 17 201 
Sum of costs at EU 
level: Implementa-
tion Mechanism 
2 685 3 643 
3 101 6 716 11 109 12 515 2 544 3 040 
2 603 2 435 
Sum of 
costs/savings from 
the perspective of 
MS 
-383 N/R N/R -3 192 (*) -5 388 (*) -7 203 (*) 
Sum of 
costs/savings from 
the perspective of 
industry 
-3 836 N/R N/R -54 627 (*) -103 213 (*) -109 997 (*) 
N/A=Not applicable 
(*) For these calculations, the cut-off for the grouping of MS according to the volume of annual output had to be adapted. 
Again, a cut-off of 1.5 of the joint output volume was chosen. 
 
Results clearly show that PO 4.1 & onwards lead to a significant amount of savings, 
especially for the industry, however these are only valid taking the underlying assump-
tions into account. 
Sensitivity analysis 
Uni- and multivariate sensitivity analyses have been done for the output cost prognosis 
through setting cost parameters at minimum and maximum values. Table 62 displays the 
major results. 
Furthermore, assumptions on the amount of national output reduction (replacement of 
national through joint output) have been varied within plausible ranges (e.g. only half of 
joint Pharma assessments are relevant, even with mandatory uptake and group1 
countries; or for mandatory uptake and group1 countries all MedTech joint assessments 
are relevant instead of one half as assumed now).  
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Table 62: Sensitivity analysis for results on potential savings related to REAs and Full 
HTA 
Parameter(s) Product sector 
Direction and dimension of resulting changes in expected 
savings when setting the selected parameter at MIN/MAX 
values 
Blue: changes in MS expected savings 
Green: changes in industry expected savings 
Number of arrows shows the extent of change (*) 
Parameter(s) set to MIN value Parameter(s) set to MAX 
value 
MS costs of national adaptations 
Pharma products 
 
 
 
No savings in all PO 
MedTech products 
 
 
 
No savings in all PO 
MS costs of national REA, Full HTA 
and national adaptations 
Pharma products   
MedTech proucts   
MS costs of national REA, Full HTA 
and national adaptations 
Pharma products   
MedTech proucts   
Industry cost of joint REA and Full 
HTA 
Pharma products   
MedTech products  
 
No savings in all PO 
Industry savings due to reduction of 
national REA and Full HTA 
Pharma products   
MedTech proucts 
 
No savings in PO 2 
 
 
Industry savings due to reduction of 
national REA and Full HTA set to MIN 
+ MS Costs of national adaptations 
set to MIN 
Pharma products 
Industry savings in PO 4.1, 4.2 and 5 reduced to around 200% of the 
amount of MS savings 
MedTech proucts 
Industry savings in PO 4.1, 4.2 and 5 reduced to around 50% of the 
amount of MS savings 
Costs of joint assessments reduced by 
30% 
Pharma and MedTech products 
Reduces overall costs at EU level for joint output production (common 
tools, Early Dialogues, REA, Full HTA) by 20% in PO 2 up to 25% in PO 5. 
Number of arrows indicating (in both directions): =major changes; =medium changes; =small changes 
(*) Setting the cost parameters to their minimum and maximum values normally affected all PO in roughly the same way, otherwise it is 
indicated. Sometimes savings were reduced to a degree that there were no savings anymore (costs exceeded savings), e.g. when MS costs of 
national adaptations were set to maximum. 
Higher replacement rates directly lead to higher savings and vice versa. Specifically 
expected industry savings are sensitive – in absolute numbers – to changes. Increas-
ing/Decreasing opt-in rates for options with voluntary opt-in has a similar effect. Increas-
ing opt-in rates in PO 4.1 brings results in the vicinity of PO 4.2 results (100% opt in, 
leading to the same quantitative results as mandatory opt-in). Reducing opt-in and 
uptake for Full HTA in PO 5 in the same way brings PO 5 results in the vicinity of those of 
PO 4.2 (except the additional production costs of the joint Full HTA).  
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7.3 Overall assessment of Policy Options  
 Outline 7.3.1
In this section, the potential effects of the different Policy Options (POs) under considera-
tion are analysed for different impacts, thereby including multiple sources of information 
as depicted in Figure 33. Details on economic and social/health impacts can be found in 
6.2.1.  
Figure 33: Overview on gathered information for assessing impacts 
 
 
In order to draw a full picture of the expected effects of the POs, information utilized for 
the overall assessment included:  
• the survey results, which included quantitative elements (assessing stakeholders’ 
perception of how the different POs might affect impacts measured by one or more 
indicators per impact) and qualitative elements (comments to the survey) 
• relevant literature which was identified and selected by a literature review (chap-
ter 5.1) 
• information gathered via focus group meetings with Public Administration, Phar-
maceutical and Medtech companies (section 5.3.4) 
• information gathered via interviews with industry and patient groups (section 
7.1.13) 
Though the study team covered all impacts (except environment) defined in the EU 
‘Better Regulation Guideline’, only the most relevant for the different stakeholders 
are described and analysed in the following sections. While the economic impacts are 
primarily relevant for public authorities and/or industry, the social impacts are also 
relevant for citizens/patients and health professionals. Results of impacts not included in 
the main report can be found in Annex 24 for Public Administration, Annex 25 for 
Pharmaceutical Industry and Annex 26 for MedTech Industry.  
Survey results are presented per impact (combining all indicators) as well as per specific 
indicator as the mean value of responses per stakeholder group and Policy 
Option. Results are displayed as line charts, however it is highlighted that impacts do 
not represent a continuous trend. Still responses per Policy Option are shown in one 
graph in order to allow for better comparison. Results of the subgroup analysis for SME 
and large companies are mentioned when significant differences were identified.  
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Key stakeholders addressed were from Public Administrations (HTA Bodies), the Pharma-
ceutical and MedTech industries, patients and health professionals. For the two latter 
groups, however, not enough responses to the survey were obtained, so they could not 
be assessed in great detail. 
For all impacts described additional information is provided in footnotes on: 
• Average responses: average number of responses per sub-question (for all POs) 
• Response rate: average response rate as a percentage of number of responses 
persub-question of all answers taken into account for the analysis (e.g. for 
MedTech Industry 99 questionnaires were taken into account; if for one sub-
question on average 90 answers were filled, the response rate is depicted with 
90,9%) 
• Average standard deviation: average standard deviation per sub-question (for all 
POs)  
• No trend: percentage of answers showing no trend (value of Policy Option 5 less 
value of Policy Option 1 = zero) 
• Negative trend: percentage of answers showing a positive trend (value of Policy 
Option 5 less value of Policy Option 1 > zero)  
• Positive trend: percentage of answers showing a negative trend (value of Policy 
Option 5 less value of Policy Option 1 < zero)  
Final data set for analysis 
The number of responses to the survey used for analyses (among other input) differs 
from the total number of responses outlined in section 5.3.2 since not all respondents 
provided information on costs (Part 2 of the questionnaires) and impacts (Part 4 of the 
questionnaires) alike. Finally, 23 responses from Public Administration and 115 
responses by industry could be included. Figure 34 provides an overview of the 
respondents by product scope.  
Figure 34: Survey - Industry response by Product Scope 
 
Source: GÖ FP / LSE survey 2017  
Companies or trade associations from the medical technologies sector provided 99 
of 115 industry responses and Pharmaceutical manufacturers or trade associations 
16 responses. Regarding the company size, 7 out of 16 Pharmaceutical companies 
were indicated to be a SME while nine were stated to be large-sized companies. For the 
MedTech Industry, 54 respondents were stated to be SMEs, while 45 were indicat-
ed to be large-sized companies.  
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Figure 35: Survey - Industry responses by product scope and company size 
 
Source: GÖ FP / LSE survey 2017  
 Public Administration 7.3.2
 Costs 7.3.2.1
For this impact, potential cost evolution was investigated in relation to Horizon Scanning, 
Early Dialogues, REA submissions, Full HTA submissions, and additional data requests by 
respective HTA organisations, personnel requirements and HTA reassessments.  
National Public Administrations perform HTA-related processes, at least to some extent, 
in most European countries with varying related expenses. When assessing Pharmaceuti-
cals in the context of pricing and reimbursement, a study found that manufacturers are 
obliged to submit evidence-based applications to national Public Administrations in 36 
European countries (37). In some European countries, Public Administrations produce the 
respective evidence reports completely or partly themselves (37), resulting in different 
costs as compared to reviewing input from industry. In both cases, an evaluation 
committee comprised of scientific personnel is needed, whose cost are usually covered by 
Public Administrations. 
Currently, costs arising from HTA processes vary considerably across European countries 
as shown in the case study (7.1.12.1). This is driven by the overall economic situation of 
a country but also by the scope of HTA processes, the granularity of performed assess-
ments as well as the institutional setting for the implemented HTA processes. When it 
comes to the potential costs of future development of HTA at EU level, the current state-
of-play of HTA in a country is paramount.  
Countries that have no or only little HTA related activities will most likely benefit more 
from joint output and central governance, as they (a) have not made major investments 
in building up national HTA systems and (b) are more open to use resources to adapt 
joint results for national decision-making purposes. Still, the data that were available to 
the study team did not allow the team to quantify the effects for the different systems.  
In our survey, we asked respondents to provide estimates on cost development for 
several cost components from their perspective, trying to account for the potentially 
different perspectives based on the current system. Figure 36 displays the overall results 
of the eight surveyed cost indicators across all respondents from Public Administration.  
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Figure 36: Public Administration – survey results on perceived average effect of Policy 
Options on costs (aggregated) (103,104) 
 
Source: GÖ FP / LSE survey 2017  
On an aggregate level responses show that experts from a representative number of 
countries and different types of HTA systems (105) do not expect major changes in their 
HTA-related costs irrespective of the future model.  
Investigating cost indicators in detail (Figure 37), it becomes apparent that costs are 
expected to rise especially for REA and Early Dialogue for Policy Option 4.2 onwards. This 
might reflect the fact that both participation to and uptake of these joint outputs are 
mandatory for these POs, which is a very new situation for the countries and thus higher 
(initial) expenses are expected. The need for Human Resources also increases for all POs, 
especially from PO3 onwards.  
                                                                                                                                    
 
(103) Inverted data for submission fees 
(104) positive value indicates increase in costs, negative value indicates decrease in costs 
(105) For analysing the baseline costs for Public Administration a taxonomy was applied, differentiating HTA bodies based on 
their level of integration within governmental bodies and the function they are performing. Due to insufficient responses per 
type of system, no detailed analysis for the estimated costs per Policy Options was possible. However, at least one body per 
type of HTA system was included within the survey responses, thereby covering the scope of currently existing systems. 
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Figure 37: Public Administration – survey results on perceived average effect of Policy 
Options on cost indicators (unaggregated) (106,107)  
  
Source: GÖ FP / LSE survey 2017 
Discussions in the focus group with Public Administration revealed opposing views. 
Experts pointed out that stronger EU cooperation would lead to a cost decrease per 
product, rather than even a small increase. This mainly relates to reduced current 
duplication of efforts and increases in efficiency. Current experience suggests that work-
sharing lowers the costs for agencies significantly (in one case, where only two agencies 
agreed to cooperate on clinical guidelines, they were able to save 30% each). Whilst 
there are higher overheads, particularly at the start of a cooperation, this is expected to 
be more than compensated by work-sharing arrangements.  
For smaller agencies, which currently conduct only a limited number of HTA activities, 
cooperation could increase the scope of their activities with a relatively small investment. 
This could explain some of the answers, since this would increase costs. Looking at the 
direction of responses, it becomes apparent that expected cost increases and decreases 
are quite equally distributed across survey respondents, highlighting that some countries 
would rather profit in the sense of cost saving, while others expect higher costs.  
Points discussed and highlighted within the focus group meeting are in line with costs 
calculations done within this study (see 7.2.3 for details). Since HTA systems are quite 
different in Europe, the potential effects of changes in HTA cooperation at EU level will 
differ between MS. Still, at an aggregate level, the cost prognosis indicates that (taking 
into account the underlying assumptions) savings (through the reduction of national 
output production) are likely to exceed costs (for adaptation of joint output and industry 
submissions for joint assessments) for all POs and for both industry sectors.  
                                                                                                                                    
 
(106)  
Additional information as 
described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Horizon Scanning 18.0 78% 32.0 39% 39% 22% 
Early Dialogue 17.5 76% 36.0 18% 35% 47% 
REA 17.0 74% 40.6 6% 47% 47% 
Full HTA 19.0 83% 40.1 0% 47% 53% 
Submission Fees 14.2 62% 33.4 29% 36% 36% 
Additional Data 16.3 71% 34.6 25% 31% 44% 
Human Resources 19.0 83% 42.3 0% 47% 53% 
Re-Assessment 18.0 78% 36.3 17% 33% 50% 
 
(107) positive value indicates increase in costs, negative value indicates decrease in costs. 
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These estimated savings will amplify with the extent to which joint outputs are covered 
within the cooperation. Options comprising a permanent secretariat and higher 
joint output lead to substantially larger savings compared to the project-based 
cooperation (below EUR 500 000 across all countries in PO2 versus over EUR 3 million 
across all countries in PO 4.1). Additional savings might arise through an increased 
amount of intergovernmental assessments as well as a reduced number of Early Dia-
logues done at national level (these could not be quantified within the calculations).  
Summing up the findings derived from costs prognosis, focus group meetings and survey 
results, POs providing a legislative framework for HTA cooperation in Europe will poten-
tially have a positive effect on cost evolution for national Public Administration across MS. 
While this result on a macro level might not directly translate to all countries, since 
potential cost evolutions are also related to the current situation and spending’s for HTA 
processes in a specific country, an overall positive effect can still be expected.  
 Administrative burden 7.3.2.2
Administrative burden derived from HTA processes was understood in a broader sense in 
the study than in the Better Regulation Guidelines, where it refers to the costs as a result 
of administrative activities performed to comply with information obligations included in 
the European legislation. Thus, the following indicators were defined: overall administra-
tive burden; number of HTA submissions for the same product across European coun-
tries; time needed for an HTA process and complexity of HTA assessment processes. 
Literature indicates efficiency gains for HTA bodies when joint assessments are produced, 
since resources for national assessments can be replaced (38, 39), which is also related 
to a decrease in administrative burden for national assessments. While of course joint 
work also requires administrative processes, POs providing a sustainable central organi-
sation have the potential to limit the associated administrative burden by providing 
adequate administrative support. Representatives of Public Administration commented 
that reacting to legislative demands is easier as compared to voluntary demands, 
emphasizing the value of a potential legislative framework.  
Moreover, time and resources were assessed as critical factors in the framework of 
establishing more efficient cooperation and outputs (40, 41), thus requiring optimised 
processes between different stakeholder groups. With respect to the time needed for 
performing an HTA, differences have been reported across European countries, but also 
within countries, based on the scope and the regulatory framework of the specific 
country settings (2). When it comes to joint assessment, time has therefore been 
identified as an important factor for national uptake and adaption of joint work on EU-
level (38), which will be also true for future cooperation in the field of HTA.  
Our analysis of agencies comparable with the outlined governance model of a new EU 
agency showed that stronger governance, enabled through a legislative framework as 
well as the establishment of a permanent secretariat, might facilitate a faster as-
sessment of more health technologies as compared to current joint work. The 
same might be argued for the mandatory uptake: if joint outputs must be considered in 
a national setting, MS might put more focus on a swift proceeding and preparation as 
compared to entirely voluntary cooperation.  
Another point influencing the time of a joint HTA process is the time needed to adapt 
joint reports for national settings (especially for POs with mandatory uptake). This again 
highlights the importance of having clear processes and common methodologies to 
minimize national adaptions and ensure efficient processes. In general, national adaption 
of reports might be less problematic and time-consuming for joint REAs as compared to 
joint Full HTA. This is because of the inclusion of more domains (e.g. costs and economic 
evaluation and ethical aspects) within full HTA, which need to be more country-specific to 
fulfil their purpose.  
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Survey responses from Public Administration (Figure 38) indicate that a rather slight 
increase of overall administrative burden is expected for the respective POs compared to 
the status quo.  
Figure 38: Public Administration – survey results on perceived average effect of Policy 
Options on administrative burden (108) 
 
Source: GÖ FP / LSE survey 2017 
The number of HTA submissions for the same product across Europe is expected to 
decline by each Policy Option, reflecting the increase in joint output production at EU 
level that potentially replaces national assessments, which is backed by input from focus 
groups. In contrast, a slight increase in complexity of HTA processes is expected from 
PO2 onwards, which becomes more pronounced for PO5. Full HTA, which is covered in 
this option, seems to have an explicit impact on the complexity of HTA processes. This 
was confirmed by representatives of Public Administration in the focus group: complexity 
increases when trying to reach a common agreement on economic aspects of HTA 
reports, because these aspects are more context- and country-specific. 
Still, Public Administration representatives stressed that – despite administrative 
complexity potentially increases from Policy Option 1 to 5 – resources for research may 
be spent more efficiently, which ultimately would lead to a neutral effect. Experts 
highlighted that the administrative burden is likely to decrease for less-experienced 
countries, while it might grow initially for experienced countries (e.g. Germany, France) 
because major changes of established systems and resources for information sharing 
could be necessary. For example, most public bodies are legally bound to assess newly 
authorised Pharmaceuticals within 90 or respectively 180 days after public reimburse-
ment is requested (38). Related processes might need to be adapted when legislation 
covering joint work on REA is installed. 
                                                                                                                                    
 
(108)  
Additional information  
as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Overall administrative burden 21.0 91% 35.4 14% 29% 57% 
Number of HTA Submissions 22.0 96% 30.2 14% 64% 23% 
Time for one HTA Process 22.7 99% 34.1 14% 24% 62% 
Complexity of HTA process 21.5 93% 30.0 10% 10% 81% 
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 Innovation and Research 7.3.2.3
Here we assessed the effect of the various Policy Options on the research climate and 
innovation in the European Market. We linked our questions to the predictability of the 
market as well as the reduction of fragmentation as key factors for a favourable business 
climate that is meant to facilitate innovation to thrive.  
When examining publications of scientific evidence in the context of HTA, its relevance 
becomes apparent since it represents the basis for decision-making processes in several 
European countries. Moreover, the diversity of methodologies applied for producing HTAs 
across Europe accentuates this. Different types of HTA organisations defined different 
evidence requirements for assessing the value of health technologies and different 
methodological approaches are applied for Pharmaceuticals, medical devices and other 
technologies (41, 42), showing the diversity in research in this academic area.  
In general, the uncertainty surrounding the benefit and value of innovative products and 
innovative processes, and its wider impact on health systems and patients requires 
special attention (43). HTA is one approach for valuing innovation when informing the 
relative effectiveness of a treatment or health technology and a tool to increase efficiency 
in health-care (44, 45).  
Challenges for innovation and research resulting from cooperation in HTA are, among 
others, to maintain local context, to ensure compatibility of methodologies (specifically 
for countries with well-established assessment processes) and to introduce transparent 
topic selection and prioritization (41, 46-48). 
Figure 39: Public Administration – survey results on perceived average effect of Policy 
Options on innovation and research (109) 
 
Source: GÖ FP / LSE survey 2017  
While an HTA assessment per se is not decisive for reimbursement or the price that can 
be achieved for a specific product, several EU countries (e.g. France and Sweden) have 
linked the evidence provided by HTA assessments to pricing and reimbursement decision 
(45). Even if the proposed Policy Options will not affect the autonomy of MS in setting 
                                                                                                                                    
 
(109)  
Additional information as  
described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Research Climate 21.0 91% 22.0 5% 10% 86% 
Innovation 20.0 87% 18.9 10% 5% 85% 
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prices for Pharmaceuticals and medical devices, a joint REA might provide recognizable 
evidence at EU level. This can be utilized especially in countries where no structured HTA 
process is yet in place, thus supporting these countries to make more efficient decisions. 
Survey results show that no change for this impact is expected for PO1 and PO2 com-
pared to the status quo (Figure 39). Other contrary, positive effects on innovation and 
research are expected for both indicators with an implementation of PO3, PO4 and PO5.  
This is congruent with the expected increase of the predictability of the HTA systems and 
the expected decrease of fragmentation of the HTA system in Europe (see 7.3.2.8) (110). 
An estimated positive effect is therefore visible for all Policy Options that include a 
legislative framework and provide a more structured framework to European HTA 
cooperation.  
Overall, these options (PO3-PO5) are indicated to promote the research climate and to 
facilitate innovation to thrive in Europe. A legal framework at EU level will highlight the 
importance of HTA processes and has the potential to create a more favourable research 
climate in countries where HTA currently has a low priority. 
 Governance, participation and good administration 7.3.2.4
For assessing future effects on governance, participation and good administration the 
following indicators were surveyed:  
• The involvement of different stakeholders in HTA processes; 
• The responsibilities of Public Administrations and other organisations in the field of 
HTA at MS level; 
• The uptake of joint outputs (e.g. HTA reports, Early Dialogues, developed tools, 
etc.) 
• Resource efficiency of HTA processes in general; and  
• The sustainability of European cooperation in the field of HTA. 
The assessment of previous collaboration at EU level identified potential for optimisation 
in the fields of topic selection, priority setting within cooperation and expert involvement 
with respect to time and management (48), thus impacting the resource efficiency of a 
collaboration. When enforcing joint assessments, topic selection processes between 
stakeholders have been identified as key issues due to diverging national interests (38). 
Moreover, collaboration between different stakeholders requires sufficient political 
support in the first place to converge opposing interests (40). Strengthening the coop-
eration on HTA in Europe by introducing a legislative framework can provide positive 
impulses and support in this context.  
In order to assure consideration of all relevant stakeholder perspectives, studies suggest 
an inclusion of all relevant stakeholders in assessment processes, especially of those not 
regularly included in assessment processes so far. Positive developments were already 
achieved in increasing involvement of consumers (including patients and patient advoca-
cy groups) in different steps of assessment processes, as reported in a study assessing 
consumer involvement in HTA activities in INAHTA agencies (49). However, the degree 
and scope in patient involvement still varies widely across Europe (50) and several points 
for improvement remain (51). These could be addressed by the establishment of a 
                                                                                                                                    
 
(110) Full question, as stated in the questionnaire for indicator innovation: ‘To what extent do you expect each Policy Option to 
impact on the actual innovation for the European market? (i.e. focus on predictability and deduction of fragmentation as 
key factors for favourable business climate for industry facilitating innovation thrive)’. 
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permanent secretariat, which might facilitate such involvement processes (since they can 
be organised in a central way).  
Beneficial effects when implementing PO3, PO4 and PO5 are perceived by survey 
respondents, while PO1 and PO2 seem to have a slightly negative or no effect, respec-
tively (Figure 40).  
Figure 40: Public Administration – perceived average effect of Policy Options on 
governance, participation and good administration (aggregated) 
 
Source: GÖ FP / LSE survey 2017 
 
This overall expectation is mainly driven by the positive assessment of Policy Options on 
the sustainability of HTA cooperation and the uptake of joint work from PO3 onwards. 
Uptake of joint work is an important factor, because it is a prerequisite for a functional 
system in which joint outputs are valued and used. 
Survey responses indicate almost no effect from the different POs on the involvement of 
different stakeholders groups in HTA processes (Figure 41). Still, POs with a permanent 
secretariat can be assumed to have a positive effect on stakeholder involvement, since 
all organisational issues will be dealt from one instance.  
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Figure 41: Public Administration – survey results on perceived average effect of Policy 
Options on indicators for governance, participation and good administration 
(unaggregated survey results) (111) 
 
Source: GÖ FP / LSE survey 2017 
No Policy Option is expected to impact on the responsibility of the MS, showing that none 
of the POs is seen to interfere with the autonomy of Public Administrations in this area. 
Resource efficiency is expected to be lowest for PO1 and to increase slightly with each 
subsequent Policy Option (Figure 41). Cost estimates and statements by representatives 
of Public Administration confirm this finding.  
Hence, Policy Options covering a legislative framework will have a positive impact on the 
sustainability of HTA cooperation by providing a stable framework for joint work. Even if 
only common tools and templates are covered in a legislative framework (PO3) positive 
effects are perceived, which is in line with literature highlighting the importance of 
common tools and methodologies for joint work (52). 
Increases in the uptake of joint outputs and the sustainability of the HTA cooperation, 
especially, have to be highlighted. Moreover, the potential to structure stakeholder 
involvement processes at EU level in an efficient way must be stressed, as this might 
improve the inclusion of patient perspectives within HTA assessments.  
 Access to social protection and health systems 7.3.2.5
In order to investigate the impact on ‘access to social protection and health systems’, the 
potential effect of Policy Options on the access to treatments that could be considered as 
‘innovative’ was surveyed.  
The addressed POs foresee that appraisal of technologies as well as pricing and 
reimbursement decisions remain at national level. However, even if Policy Options might 
                                                                                                                                    
 
(111)  
Additional information  
as described in 7.3.1 
av. responses response rate av. std. dev no trend negative trend positive trend 
Stakeholder Involvement 22.0 96% 23.4 23% 18% 59% 
Responsibilities Member States 20.0 87% 29.9 15% 45% 40% 
Uptake Joint Outputs 21.0 91% 32.5 0% 10% 90% 
Resource Efficiency 21.7 94% 36.5 0% 24% 76% 
Sustainability HTA Cooperation 21.2 92% 28.9 5% 10% 86% 
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not directly affect access to innovative treatments, HTA assessments inform these 
decisions and thus have an influence. Especially joint REA can provide significant 
input for decision-making, in particular when limited resources within a country 
do not allow the assessment of all new technologies.  
Literature indicates that close collaboration between different stakeholders involved in 
this processes could improve access to and availability of health technologies on the 
market (47, 48). Ensuring access to innovative products is highly relevant for patients 
(7.3.5). Moreover, HTA is a valuable tool to support the use of products with higher 
additional value as compared to already marketed products. Survey results indicate that 
a positive effect on the access to innovative treatments is expected for PO3 which even 
increases for PO4 and PO5 (Figure 42), and no opposing statements were made in the 
focus group meetings with HTA-experts from academia and Public Administration.  
Figure 42: Public Administration – survey results on perceived average effect of Policy 
Options on access to social protection and health systems112 
 
Source: GÖ FP / LSE survey 2017 
Reasons for this judgement are that closer collaborating HTA systems lead to a better 
selection of innovative products with high added value and increase the availability of 
relevant evidence for health technologies, as industry might adapt and refocus studies to 
assess outcomes that are more relevant for patients (e.g. quality of life) and payer’s 
needs. Results for this impact match with a perceived increase in innovation as described 
in section 7.3.2.3. 
As Public Administration are often responsible for assessing and/or appraising health 
technologies, mandatory joint REA especially can provide significant input for 
decision-making across Europe. This would also contribute to reduce a divergent 
evidence basis across Europe for medical technologies.  
                                                                                                                                    
 
(112)  
Additional information  
as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Access to Innovative Treatments 19.0 83% 16.9 26% 5% 68% 
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 Sustainability of health systems 7.3.2.6
The sustainability of health systems was surveyed by the effect of the various Policy 
Options on the financing of expensive treatments with little or no added value and the 
negotiation power of MS in setting prices. These were chosen due to the tendency of 
rising public expenditures and increases in treatment costs in the Pharmaceutical and 
MedTech sectors linked to limited public funds. Especially investing in expensive 
treatments with little or no added value is questionable, since these resources might 
provide a higher benefit for the patients when used elsewhere.  
Success factors like institutional capacity, timing, expertise and efficient processes have 
been identified to be decisive for improving cooperation in the field of HTA (40), thus 
affecting national health systems and its sustainability. Moreover, political support is 
important to improve the acceptance of cooperations and the benefits associated with 
them, especially in the light of conflicting interests and knowledge gains resulting from 
information exchange (40, 53, 54). Introducing a legislative framework for joint work on 
HTA could be seen as a sign for political support as it aims to enhance a more 
coordinated cooperation regarding HTA at EU level.  
Studies indicate that a thorough examination of scientific evidence is needed for 
supporting health policy decision makers, as this can reduce the uncertainty in decision-
making. Thereby it should be accounted for conflicting interests among different 
stakeholders and potentially biased publications should be identified (53, 55). This will be 
addressed by the introduction of MS expert committees when establishing permanent 
secretariats to organise the cooperation and the active involvement of national HTA 
bodies in output production. For goverance structures forseeing the establishment of a 
permanent secretariat (Po4 – PO5) this will be addressed by the introduction of MS 
expert committees, which will organise the cooperation and the active involvement of 
national HTA bodies in output production. 
Figure 43: Public Administration – survey results on perceived average effect of Policy 
Options on sustainability of health systems113 
 
Source: GÖ FP / LSE survey 2017  
                                                                                                                                    
 
(113)  
Additional information  
as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Financing of expensive treatments with little or no 
added value 
20.0 87% 29.9 25% 55% 20% 
Negotiation power of Member States in setting 
prices 
19.0 83% 35.0 16% 21% 63% 
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Survey results for the effects of Policy Options on the sustainability of health systems 
indicate no changes for PO1, PO2 and PO3. For PO4.1, a small increase in the negotiating 
power of MS is expected, while the financing of expensive treatments with little or no 
added value is expected to slightly decrease (see Figure 43). For PO4.2 and PO5, 
estimated effects are more pronounced when it comes to the negotiating power of MS in 
setting prices, anticipating stronger standing based on joint output.  
Asymmetric information between industry and authorities can cause difficulties for 
authorities in decision-making processes. The availability of reliable and sufficient 
information on health technologies is vital and requires corresponding assessments of 
health technologies to provide support (39). As joint REAs are planned to be covered 
within the legislative framework from PO4.1 onwards, positive effects on the availability 
of assessments are reasonable to expect.  
Public Administration representatives stressed that a joint perspective on the added value 
of a new technology, whether Pharmaceuticals, medical device or other technology, has 
the potential to improve sustainability in their health systems. Stronger cooperation 
would improve the negotiating power of MS and thus help to achieve lower prices for 
technologies with limited added value. Nonetheless, it would still be difficult to discontin-
ue the financing of already marketed technologies since investment decisions are taken 
at national level and will remain so. 
Overall, Policy Options with a legislative framework (PO3 to PO5) are more 
likely to positively influence the sustainability of health systems than further 
non-binding cooperation. Joint output will reduce the financing of expensive treat-
ments with little or no added value. Also, all types of legal frameworks are enablers of 
sustainability. On the one hand, a legislative mandatory process helps Public Administra-
tions to make more well-informed choices and, on the other hand, pricing and reim-
bursement processes might be accelerated due to the improved level of information.  
 Public Health 7.3.2.7
For assessing the effect of the Policy Options on Public Health the indicators ‘overall 
public health’ and ‘availability of health technologies on the market’ were surveyed and 
complemented by literature findings and expert input.  
Public health puts a focus on health promotion, prevention of disease, epidemiology, 
innovative cures, patient access to Pharmaceuticals, safe Pharmaceuticals and efficacious 
treatments and thus aims to improve the health and well-being of patients. The national 
structures of health systems in the European Union reflect the needs of their population 
and aim to guarantee supply of required treatments. A study investigating the use of 
scientific evidence for pricing and reimbursement decisions in Germany showed a few 
years ago (56) that evidence supporting decisions on the availability of health technolo-
gies mainly originated from a few actors in the field and was often based on few studies. 
Moreover, the potential of evidence affecting national guidelines and decisions is high in 
some countries (57). Thus, evidence should be generated in a transparent manner by 
various stakeholders to avoid misinformation and information withheld (55) and to 
provide a solid evidence base for decision-makers (41) in order to ensure availability of 
health technologies and maintain public health. In the case of European collaboration, 
involvement of different stakeholders appears vital to account for different needs, 
interests and national structures (42, 46, 54).  
Survey responses indicate no expected change for PO1 and PO2, while all subsequent 
Policy Options are expected to increase public health (Figure 44). Looking at the individ-
ual indicators on public health, the availability of health technologies is expected to be 
highest in PO 4.1, while this slightly decreases for the two subsequent Policy Options.  
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One important topic mentioned was that HTA has been slowly also used as tool to assess 
other health care issues, e.g. vaccination or screening programmes. This is considered to 
be of even more relevance in the future. Still, in the evidence generation done for the 
baseline scenario (see 7.1.3), only a little information could be found for assessment of 
such topics. One expert commented that the current HTA models are just in the process 
of adaptations to properly answer questions related to health promotion, rather than for 
a single medicinal product.  
Figure 44: Public Administration – survey results on perceived average effect of Policy 
Options on public health (114)  
 
Source: GÖ FP / LSE survey 2017  
The availability of technologies also depends on other factors, in particular the marketing 
authorisation or certification process as well as the national pricing and reimbursement 
systems. Therefore, the impact of HTA cooperation on this factor is difficult to quantify 
with precision. During the focus group meeting with Public Administration, it was 
considered that increased convergence of HTA methods would increase the availability of 
health technologies with added benefits, and as such benefit public health. 
Overall, public health across MS might be positively affected. Specific stakeholder groups 
such as health professionals and patients could further benefit through transparent 
assessment processes and improved health technology monitoring. 
 Further impact  7.3.2.8
The study team also surveyed a few other parameters how Public Administrations could 
be affected by various Policy Options. The ones briefly outlined here showed only little 
relevance in our analysis. Detailed survey responses can be obtained from Annex 24.  
Regarding ‘employment’ we considered the number of personnel, including consultants, 
who are involved in HTA activities. The scope of HTA activities, both in terms of the 
specific expertise needed as well as the depth and scope of assessment, define the 
personal capacities needed to perform an HTA assessment. Across Europe, assessment 
groups within public bodies that include up to 30 members, depending on the scope of 
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Additional information 
 as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Availability of Health Technologies 20.0 87% 29.9 25% 55% 20% 
Overall public health 19.0 83% 35.0 16% 21% 63% 
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assessments, are usually in charge of determining the value of Pharmaceuticals (37). 
Therefore, assessment groups require expertise from different disciplines, e.g. the 
Pharmaceutical, epidemiological, mathematics, economics and medical fields (37). 
Moreover, specific requirements might relate to the assessment of a drug versus a 
medical device. A study found that there is considerable variance in the number of staff 
(full-time equivalents, or FTEs) dedicated to HTA activities in HTA organisations across 
EU countries and Norway: between none to 604 FTEs who are permanently em-
ployed were reported. Moreover, commissioning external experts to perform or contrib-
ute to HTA is done frequently independent of the size or scope of the mandate owned by 
the respective organisation (2).  
HTA experts and Public Administration representatives see no changes in future 
overall employment levels for PO1, PO2 and PO3. From PO4.1 onwards, a slight 
increase in employed staff for HTA activities is expected by Public Administration. This 
corresponds with the foreseen increase in output production and its mandatory uptake 
for REA and Full HTA (only PO5), as these assessments have to be conducted by skilled 
staff. Comparing the results on employment level to the expected costs for human 
resources (see 7.3.2.17.3.3.1), the perceived developments are congruent across the 
different Policy Options.  
For the impact ‘Consumer and households’, we surveyed the number of health 
technologies assessed and the number of health technologies available on the European 
market, focusing on the availability of medical technologies for patients. HTA processes 
and systems differ between European countries regarding the capacity to conduct 
assessments (46) and not all HTA bodies can assess all new health technologies. A lack 
of comprehensive evidence-based information might hamper the process of decision-
making, thus leading to delays in availability in health systems where a positive assess-
ment required for reimbursment. Hence, joint work has the potential to increase the 
availability of new technologies in countries with less developed HTA systems (41).  
Survey results for Public Administration indicate an expected increase in the number of 
health technologies assessed especially for PO4.2 and PO5. This corresponds with the 
foreseen mandatory nature of joint REAs for these Policy Options, which could increase 
the number of health technology assessments across Europe. No effect is expected for 
the number of available health technologies, which can be linked to the fact that pricing 
and reimbursement decisions will remain on national level.  
For the impact on ‘competitiveness of EU health technology sector’, two investigat-
ed indicators (competitiveness of SMEs and revenues) apply primarily to the industry 
sector since Public Bodies are usually financed mostly or exclusively via a dedicated 
budget (2). Still, the survey also aimed at gathering the expectations of HTA bodies as 
key players in the HTA sector for these indicators. The third indicator surveyed (predicta-
bility of HTA system in Europe) is also relevant for Public Administration.  
We found an expected positive effect for the competitiveness of SME from PO3 onwards, 
while no effect is anticipated for PO1 and PO2. Revenues are not expected to be affected 
by any of the Policy Options under consideration, which most likely is a reflection of the 
above mentioned caveat regarding applicability of the indicator. The predictability of 
the HTA system in Europe is expected to considerably increase for PO3 and the 
positive effect is amplified by each of the subsequent Policy Options. This 
judgement is based on the legislative nature of PO3 to PO5. Public Administration 
representatives emphasized that predictability is also an important component for 
academic research institutions, and that stronger cooperation across Europe should lead 
to a significantly reduced fragmentation of HTA systems.  
For the impact ‘Functioning of the internal market and competition’, the fragmen-
tation of the HTA system in Europe, the convergence of HTA methodologies in Europe 
and the attractiveness of the European market for industry stakeholders, particularly 
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resulting from a lower fragmentation of HTA systems, were defined as indicators. While 
differences in HTA methods and processes across countries are not a disadvantage per se 
for the respective countries and their patients, the potential value and related efficiency 
gains of joint work has been recognised and lead to a number of international coopera-
tion’s, most notably EUnetHTA . Still, literature (2, 32, 58) and the case study (section 
5.2) confirmed current differences in HTA processes and methods.  
Survey responses and statements by Public Administration show an expected decrease 
in the fragmentation of HTA systems across Europe from PO3 onwards, corre-
sponding to the increasing number of outputs by each Policy Option. For PO1, an 
increase in fragmentation is expected, reflecting its entirely voluntary nature 
and the lack of a potential funding mechanism. The convergence of HTA methodolo-
gies is expected to increase from PO3 onwards with each enhancement of covered 
outputs and has been highlighted as the most pronounced and influential effect of the 
Policy Options. Public Administration expects an increase regarding the attractiveness of 
the European market for industry stakeholder from Policy Options 3 onwards, in line with 
the decrease in fragmentation which was defined as key component for attractiveness 
within the survey. HTA outputs currently produced at EU level often require additional 
national adaption because national procedures differ from European standards, provided 
that endpoints included in the Joint Assessment are considered relevant at national level 
(41, 59, 60). Further convergence of HTA methodologies might reduce the need for 
national adaptation for some countries.  
The impact ‘International trade’ is not directly linked to Public Administration and 
altogether, the expected effect of the Policy Options on international trade across all 
respondents in this stakeholder group is relatively low, even though there is a slight 
increase in PO5. This might be related to the fact that Public Administrations are not 
directly affected and are thus hesitant to give estimates.  
Results for the impact ‘Macroeconomic environment’ show no major changes for PO1 
to PO4.1 from the perspective of Public Administrations. For PO4.2 and PO5, overall a 
slightly positive effect is foreseen, which might be related to expected efficiency gains for 
policy options where both the participation and the uptake of joint REA is mandatory, 
thus impeding duplicated REAs across European countries.  
 Concluding remarks for Public Administration 7.3.2.9
Literature (41) and direct statements by various stakeholders indicate that HTA bodies 
have mixed opinions regarding the extent of collaboration: some representatives of HTA 
bodies prefer loose collaboration, merely exchanging information and developing com-
mon methodologies, while others prefer clear-cut cross-border assessments. Obviously 
the current situation of the country might influence the perception of current cooperation 
on HTA. As frequently highlighted, HTA systems in Europe differ from an organizational 
point of view and in other ways, and related agencies also differ in many dimensions. 
Still, different preferences and views regarding joint work are likely to also depend on the 
final arrangement and organisational details of a future cooperation on HTA. 
Summarising, no major effects with regard to HTA-related processes for PO1 and 
PO2 are expected (as indicated in Table 63). With Policy Options comprising a legisla-
tive framework (PO3-PO5), slightly more positive effects are perceived by Public 
Administration, amplified by each joint output that is covered by the coopera-
tion. 
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Table 63: Overview of relevant impacts for Public Administration 
(*) Inverted: - means that cost would go up, + means that cost would go down. 
Legend: + positive effect, - negative effect, 0 neutral (+) or (–) representing the direction of results, as indication even if the expected effect is low) 
This increase in positive effects with stronger central governance relates to the expecta-
tion that the uptake of joint outputs will increase with each subsequent Policy Option. 
Stricter regulation regarding uptake of joint outputs seems to be seen as a key element 
for sustainable and successful collaboration, since otherwise the impact of cooperation is 
limited. Moreover, agencies have different capacities for assessing technologies, there-
fore the number of evidence-based assessments can be increased with joint outputs and 
potentially more health technologies can be covered.  
Positive effects are perceived for innovation and the research. This might relate to the 
expectation that HTA – as an approach for the identification of the added-value of one 
health technology compared to another – will be strengthened when a legislative 
framework is provided. Countries without structured HTA processes could especially profit 
from joint output, in particular from joint REAs.  
Convergence of methodologies was emphasized to be a highly influential indicator by 
Public Administrations, as joint methodologies are a prerequisite for a successful and 
timely production of joint outputs. This important basic condition will be already fulfilled 
for PO3, since common tools, templates and methodologies are covered with mandatory 
participation and uptake. Moreover, increased cooperation is expected to improve the 
predictability of the HTA system in Europe, also due to an expected lower fragmentation 
of HTA systems.  
No or slightly negative effects were expected by survey respondents across all Policy 
Options when it comes to the costs for HTA-related outputs as well as the administrative 
burden imposed on Public Administration. However, these results were mitigated by the 
focus group and the cost calculations performed within this study. Representatives of 
Public Administration expressed the expectation that, in fact, a closer collaboration would 
lead to a decrease in costs. Moreover, the cost calculations also indicate potential savings 
across MS especially from PO4.1 onwards. Administrative burden will most likely differ 
between MS, which was also highlighted in the focus group. While a decrease for less 
experienced countries is possible, administrative burden might increase for countries with 
an established HTA systems, since then more changes are necessary for adapting to a 
new situation.  
Overall, all policy options covering a legislative framework entail positive effects on an 
aggregate level, although these might differ for the respective MS due to the current, 
varied landscape for HTA processes in Europe. A general secretariat is considered a 
potentially useful instrument to ensure stronger governance, which is needed to improve 
the number of outputs and the functioning of cooperation on HTA.  
Impacts 
Policy  
Option 1 
Policy  
Option 2 
Policy 
 Option 3 
Policy  
Option 4.1 
Policy 
Option 4.2 
Policy 
Option 5 
Costs (EC1)* 0(-) 0(-) 0(-) + + + 
Administrative Burden (EC2) 0(-) 0(-) 0(-) 0(-) 0(-) 0(-) 
Innovation and research (EC4) 0(-) 0(+) + + + + 
Governance, Participation, good 
administration (SH2) 
0(-) 0(+) + + + + 
Access to social protection and 
health systems (SH3) 
0(-) 0(+) 0(+) + + + 
Sustainability of Health systems 
(SH4) 
0 0(+) + + + + 
Public Health (SH5) 0(-) 0(+) 0(+) 0(+) 0(+) 0 
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 Pharmaceutical Industry  7.3.3
 Costs 7.3.3.1
For this impact, potential cost evolution was investigated in relation to Horizon Scanning, 
Early Dialogues, REA submissions, Full HTA submissions, and additional data requests by 
respective HTA organisations, personnel requirements and HTA reassessments.  
Costs for industry arise from providing specific data or reports for health technologies 
that are subject to an HTA process, especially when this has an obligatory nature within 
the specific country. The assessment of Pharmaceuticals in the field of HTA is quite 
common in a number of European countries, with structured processes in a number of 
settings. In several European countries, HTA is a part of the decision-making process 
regarding pricing and reimbursement for Pharmaceuticals (58, 61, 62). A recent study 
found that, for Pharmaceuticals, 23 EU countries and Norway use HTA for informing 
reimbursement decisions and 20 for pricing decisions (2). The high frequency of HTA 
processes indicates a higher level of experience as compared to the MedTech sector. 
In general, the framework and extent of assessments performed, as well as the organisa-
tional structure at national and EU levels, are decisive for the costs connected to HTA 
processes. Specific country settings influence the related costs per industry, i.e. whether 
the manufacturer has to submit an evidence-based application or not, and the extent of 
such evidence requirements. This is also reflected in the costs per general HTA submis-
sion, which were found to vary quite widely in the case study. Pharmaceutical companies 
are directly affected by HTA processes in a number of European countries and particularly 
by costs for (additional) data generation, and human resources needed to deal with HTA 
submission were reported to be especially important in the case study. Therefore, 
expected changes for these cost components might be especially relevant.  
When surveying the potential effects of the different Policy Options on costs, the re-
spondents from Pharmaceutical Industry indicated overall a substantial increase in costs 
for Policy option 5. For all other Policy Options, almost no change in costs was estimated 
on an aggregate level (see Figure 45). Expected slight increases in costs for PO1 are 
mainly driven by SMEs, while large companies in fact don´t expect an increase in costs 
for PO1. The opposite trend was visible for PO5 when conducting this subgroup analysis: 
SMEs expect less increases in costs for PO5 than large companies. No differences 
between expected costs for SMEs and large companies were visible in subgroup analysis 
for PO2 through PO4.  
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Figure 45: Pharma Industry - survey results on perceived average effect of Policy 
Options on costs (aggregated)(115) 
 
Source: GÖ FP / LSE survey 2017  
Looking at the responses indicated for the respective sub questions, Figure 46 displays 
that the Pharmaceutical Industry expects an increase in costs, especially for Early 
Dialogues, Full HTAs and additional data requirements when implementing Policy Option 
5. With regard to relative effectiveness assessments (REAs), a decrease in costs is 
expected for Policy Option 4.1 and 4.2, which probably reflect the fact that joint REAs are 
covered within the legislative framework for these options, potentially leading to a lower 
number of dossiers that need to be prepared across Europe. 
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Figure 46: Pharma Industry - survey results on perceived average effect of Policy 
Options on cost indicators (unaggregated) (116,117) 
 
Source: GÖ FP / LSE survey 2017  
When discussing the results with representatives of the Pharmaceutical Industry, it was 
highlighted that overall no significant changes in their current costs are expected for PO2 
to PO4. Possible increases and decreases of cost components are expected to level each 
other out. Giving some background information on the work processes in Pharmaceutical 
companies, it was explained that usually a central value dossier per product is prepared, 
which is used as a main source of input for the HTA submissions in different countries. 
One member mentioned that joint HTA reports at EU level could replace 20-25% of the 
HTA costs in local settings, since there are still e.g. epidemiological differences between 
countries that need to be addressed and companies still have to go through national 
reimbursement procedures. However, looking at the broader picture, it was also men-
tioned that overall consistency would increase with stronger cooperation on HTA in 
Europe, resulting in better business predictability and thus a positive effect on invest-
ment as well as research and innovation.  
Costs prognosis (section 7.2.3) indicates that (taking into account the underlying 
assumptions) all Policy Options potentially lead to cost savings on the side of Pharmaceu-
tical Industry. However, potential savings are considerably higher in POs that comprise 
both mandatory production and mandatory uptake of joint REAs (PO4.2 and PO5). 
Options comprising a permanent secretariat and higher joint output lead to substantially 
larger savings compared to project-based cooperation (in total nearly EUR 4 million 
across all countries in PO2, versus almost EUR 64 million in PO 4.2).  
                                                                                                                                    
 
(116)  
Additional information  
as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Horizon Scanning 6.3 40% 12.6 100% 0% 0% 
Early Dialogue 14.0 88% 10.2 0% 0% 100% 
REA 14.0 88% 12.7 0% 92% 8% 
Full HTA 14.0 88% 16.3 7% 14% 79% 
Submission Fees 12.0 75% 4.6 100% 0% 0% 
Additional Data 14.0 88% 5.9 0% 7% 93% 
Human Resources 14.0 88% 7.0 7% 7% 86% 
Re-Assessment 13.0 81% 8.5 85% 8% 8% 
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Moreover, additional evidence generation requested by national HTA bodies might be 
reduced when (mandatory) joint EDs and joint REAs are in place. This is a relevant factor 
for potential savings, but couldn´t be integrated into the cost calculations. 
Overall, Policy Options providing a legislative framework for HTA cooperation in Europe 
will potentially have a positive effect on cost evolution for the Pharmaceutical Industry 
across MS. While survey results indicate no changes for the Pharmaceutical Industry, 
additional information from focus group and costs prognosis indicate potential savings 
from PO4 onwards.  
 Administrative burden 7.3.3.2
For assessing this impact, the following indicators were defined: overall administrative 
burden; number of HTA submissions for the same product across European countries; 
time needed for an HTA process and complexity of HTA assessment processes. 
Literature and the case study investigating the baseline scenario indicate that currently 
the same products are assessed by a number of countries, irrespective of the type of HTA 
system (63). From an industry perspective, the number of HTA submissions required 
across Europe for the same product and indication is related to the administrative 
burden, especially for the Pharmaceutical Industry, since structured HTA processes are 
common across European countries in this sector.  
Reducing duplication in submissions might lead to a decrease in administrative burden 
for industry, although the extent and effect is difficult to predict. It was reported that 
approximately 12 to 15 percent of European HTA products address the same technolo-
gies, which mainly include Pharmaceuticals or single technologies. A publication including 
four case studies from EUnetHTA  Joint Action 1 showed that an overlap of 30 percent 
can be avoided if interventions for specific indications are bundled, illustrating the 
potential to reduce duplication (64).  
 
Reviewing the survey responses from the Pharmaceutical Industry, Figure 47 depicts the 
results of the online survey, showing almost no expected change in the administrative 
burden (aggregated) for Policy Options 1 to 4 and a steep increase of expected 
administrative burden for Policy Option 5. 
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Figure 47: Pharma Industry - survey results on perceived average effect of Policy 
Options on administrative burden (118) 
 
Source: GÖ FP / LSE survey 2017  
Examining the responses of the Pharmaceutical sector in detail, the complexity of the 
HTA process is expected to decrease especially for Policy Options 4.1 and 4.2 while an 
increase in complexity is estimated for Policy Option 5. With regard to the number of HTA 
submissions, no change is expected for Policy Options 3 and 4 as compared to the status 
quo, while for Policy Option 1 and 2, a slight increase in the number of HTA submissions 
for the same product and indication across European countries is expected. For PO5, a 
higher increase is expected with regard to the number of HTA submissions, and also the 
time for one HTA process is expected to increase. When looking at survey responses 
separately for SMEs and large companies, no differences between these two groups were 
visible for the Policy Options, expect for PO1. SMEs expect a higher administrative 
burden (+20) while no change is foreseen by large companies. 
During the focus group meeting with respondents from the Pharmaceutical sector, it 
was highlighted that this expected increase in administrative burden for PO5 is largely 
triggered by the fact that this Policy Option also covers Full HTA, which includes an 
economic assessment. Joint economic assessments are considered especially complex, 
since these have to account for the specific country setting. Therefore, additional national 
submissions for the economic assessment were expected even if Full HTA is mandatory, 
which ultimately means more administrative burden for industry representatives.  
Overall, policy options 4.1 and 4.2 are favoured by the Pharma sector, since they 
are expected to reduce the overall administrative burden, since joint REA with a manda-
tory uptake will lead to a reduction of the number of national HTA submissions. Moreo-
ver, the complexity of HTA processes is expected to decrease. This also becomes visible 
when summarizing the additional comments that were received within the survey. 
Respondents clearly stated that more divergent requirements across Europe are expected 
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Additional information  
as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Overall administrative burden 14.0 88% 5.8 0% 7% 93% 
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for PO1 and PO2, which increases complexity from the perspective of the Pharmaceutical 
Industry.  
 Competitiveness of EU health technology sector 7.3.3.3
For assessing the competitiveness of EU health technology sector, the potential effect of 
Policy options on the predictability of HTA system in Europe, the competitiveness of 
small- and medium-sized companies and the revenues of health technology developers 
were surveyed. 
Representatives of Pharmaceutical Industry frequently highlighted the predictability of 
HTA system in Europe as very important impact. This was also reflected when rating the 
relevance of the different impacts in the online survey: on average, the respondents from 
Pharmaceutical Industry rated the importance of this impact to be 8 on a range from 0 
(least important) to 10 (most important).   
Currently, the predictability of the HTA landscape in Europe is low due to different 
national requirements regarding e.g. comparators or endpoints in HTA processes. 
Moreover, divergent outcomes derived from HTA assessments for the same Pharmaceuti-
cal and indication were frequently reported in country comparisons (23, 63) and these 
findings are confirmed by our case study (see section 7.1).  
When it comes to the competitiveness of SMEs in relation to HTA processes, this is linked 
to the predictability of the HTA system as well as to the evidence requirements for HTA 
submissions, especially regarding additional data requirements on top of clinical data 
relevant for marketing authorisation. These additional data requirements in the course of 
an HTA submission might be harder to fulfil by SMEs because costs and organisational 
effort have a greater impact on them compared to larger companies that can easier 
attribute resources to this tasks (65). The current HTA landscape in Europe has direct or 
at least indirect influence on revenues for the industry in several EU countries as pricing 
and reimbursement decisions are informed by these assessments in a number of them.  
Survey responses from the Pharmaceutical Industry show that no effect on any of the 
surveyed indicators for this impact is expected for PO2 (see Figure 48). For PO1, a 
positive effect on the competitiveness of SMEs is stated, while no effects from the other 
indicators are expected. For PO2, PO3 and both variants of PO4 a positive effect on the 
predictability of HTA system is expected. On the contrary, no changes for the other 
indicators are foreseen. For PO5, a negative effect regarding the predictability of HTA 
systems and the competitiveness of SME is expected. The perceived challenges regarding 
joint economic assessments, which lead to an increase in complexity, can serve as 
explanation (see 7.3.3.2 for detailed description). In general, no major effect on the 
revenues is expected across all Policy Options. 
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Figure 48: Pharma Industry - survey results on perceived average effect of Policy 
Options on competitiveness of EU health technology sector (119) 
 
Source: GÖ FP / LSE survey 2017 
When discussing the expected neutral effect of all Policy Options on the revenues with 
the representatives of the Pharmaceutical Industry, it became apparent that the underly-
ing reasons for these responses are twofold: on the one hand, they derive from the 
uncertainty of whether any of the POs will have a positive or negative effect on the 
revenues. Industry respondents stated that both directions can be plausible, depending 
on the specifications of the Policy Options. On the other hand, it was stated that no effect 
on pricing and reimbursement across Europe is expected, since the Policy Options are not 
linked to this. However, a more harmonized system could lead to faster market access if 
heterogeneity in assessment is reduced. This was also indicated during the interviews, 
stating that greater consistency in HTA assessments would be beneficial because it would 
de-risk the submission process (see 5.2.5), which can be attributed especially to PO 4.1 
and 4.2, as these will cover REAs including an mandatory uptake, which was highlighted 
to be important by the Pharmaceutical Industry as well.   
For Pharmaceutical Industry a positive effect on the competitiveness of EU health 
technology sector can be expected especially for PO 4.1 and 4.2. This is driven by the 
expected increase of predictability in HTA processes with regard to REA across Europe.  
 Innovation and research 7.3.3.4
The assessment of innovation and research, focused on the effect of the various Policy 
Options on: the research climate and innovation for the European Market.  
HTA has been identified as a tool to increase efficiency in health-care and to steer 
innovation in the development of health technologies (44, 45). While an HTA assessment 
per se is not decisive for reimbursement or the price that can be achieved for the specific 
product, several countries across Europe (e.g. France and Sweden) have linked the 
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Additional information 
as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Predictability of HTA System 14.0 88% 10.3 0% 93% 7% 
Competitiveness of SME 2.0 13% - 80% 10% 10% 
Revenues 13.0 81% 4.5 100% 0% 0% 
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evidence provided by this HTA assessments to pricing and reimbursement decision (45). 
A stable and predictable HTA system that values and rewards the innovative features of a 
health technology could incentivize the development of innovative products.  
However, this system also needs to work for Industry, since currently industry stake-
holders have reported perceiving requirements of HTA processes as a hurdle for patient 
access and innovation (54). Challenges for innovation and research resulting from 
cooperation in HTA are among other to maintain local context, to ensure compatibility of 
methodologies, specifically for countries with well-established assessment processes and 
to introduce transparent topic selection and prioritization (41, 46-48).  
For the Pharmaceutical Industry, Figure 49 depicts the anticipated overall effect of the 
respective Policy Options on innovation and research. It shows an expected positive 
effect for Policy Options 3 to 4 but a negative effect for Policy Option 5. There is no 
expected effect of PO1 and PO2.  
Figure 49: Pharma Industry - survey results on perceived average effect of Policy 
Options on innovation and research (120) 
 
Source: GÖ FP / LSE survey 2017  
Results are in line with conclusions drawn from interviews with the Pharmaceutical 
sector. Interviewees highlighted that harmonization of evidence requirements are 
accompanied by MS acceptability and would facilitate easier investment decisions (see 
7.1.12.1). Moreover, the predictability of the market was highlighted as a main driver for 
innovation by representatives of the Pharmaceutical sector. This is due to its contribution 
to a less risky environment which positively influences investment decisions. Hence, 
predictability of HTA systems and harmonization of evidence requirements are underlying 
drivers for innovation in the Pharmaceutical sector when it comes to the HTA landscape 
in Europe.  
Underlying reasons for the expected decrease of PO5 are most likely due to the coverage 
of Full HTA within the legislative framework of this Policy Option. Comments to the 
survey and discussions during the focus group with respondents from the Pharmaceutical 
Industry revealed scepticism about the applicability of joint Full HTA across European 
countries.  
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Research Climate 14,0 88% 9,0 0% 100% 0% 
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 Functioning of the internal market and competition 7.3.3.5
Potential effects of the Policy Options on the functioning of the internal market and 
competition were assessed by investigating the fragmentation of the HTA system in 
Europe, convergence of HTA methodologies in Europe and the attractiveness of the 
European market for industry stakeholders, particularly resulting from a lower fragmen-
tation of HTA systems. 
Literature provides several examples illustrating the fragmentation of the HTA system 
and the level of convergence of HTA methodologies in Europe. Different methodological 
approaches can lead to varying pathways for pricing and reimbursement decisions, 
specifically for innovative products, thus imposing challenges on manufacturers (47) as 
also outlined in interviews with industry representatives. In general, the different steps of 
assessment, appraisal and pricing and reimbursement decisions are clearly separated in 
most EU countries and pricing and reimbursement decision are national or sometimes 
also local competences (66,37).  
Analysing survey responses from Pharmaceutical stakeholders, Figure 50 displays the 
overall effect on the internal market and competition and the specific indicators.  
Figure 50: Pharma Industry – survey results on perceived average effect of Policy 
Options on internal market and competition (121) 
 
Source: GÖ FP / LSE survey 2017 
Overall, almost no change is expected for PO1 and PO2. On the contrary, positive effects 
are expected for PO 3, PO 4.1. and PO4.2: the fragmentation of HTA systems is expected 
to decline while the attractiveness of the EU market and the convergence of HTA meth-
odologies increase, thus improving the conditions for the internal market and competition 
in Europe.  
Differences between the specific indicators and the overall impact are visible for PO5. 
Pharmaceutical sector stakeholders expect the highest level of convergence of methodol-
ogies and simultaneously an increased fragmentation of methodologies, which might 
                                                                                                                                    
 
(121) Aggregation: inverted for fragmentation of HTA system 
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av. responses response rate av. std. dev no effect negative effect positive effect 
Fragmentation of HTA System 14.0 88% 9.4 0% 0% 100% 
Convergence of HTA Methodologies 14.0 88% 7.4 0% 0% 100% 
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seem counterintuitive. An explanation for this is the expectation of industry representa-
tives that converged methodologies in economic assessment will not be able to fully 
replace national submission in this field. Thus, it was presumed that national submissions 
will still be necessary for PO5, which was pointed out in interviews as well as in com-
ments to the online survey. The drop in the perceived attractiveness of the EU market for 
PO5 might relate to this issue as well. 
 Further impacts 7.3.3.6
Several impacts were surveyed but do not directly affect Pharmaceutical Industry, thus a 
quick summary for these impacts is displayed in this section while graphs for the 
respective survey results can be found in Annex 25.  
For the impact ‘consumer and households’, the number of health technologies 
assessed and the number of health technologies available on the European market, 
focusing on the availability of medical technologies for patients, were surveyed 
Equal access to affordable Pharmaceuticals is an important aim across many OECD 
countries, including those in the European Union (23). An important factor regarding the 
availability of health technologies is the time to market. For this, differences are seen 
across EU countries when it comes to Pharmaceuticals (67). Increased collaboration at 
EU level could have a positive effect on this, but might also slow down availability due to 
national adaptation in countries with highly developed HTA system.  
Overall, Pharmaceutical Industry respondents estimated that especially PO3, PO4.1 and 
PO4.2 have a slight positive effect on the availability of health technologies, whereas PO 
5 is perceived to have a more pronounced and negative effect. This might be due to the 
expected longer timeframe for Full HTAs, which could prolong time to access for Pharma-
ceuticals or the fact that Full HTAs, which constitute more comprehensive assessments 
including, e.g., economic or social effects, are perceived to reduce the chances of a 
positive HTA outcome. Adddtionally, negative full HTAs at EU level might have further 
reaching consequences in terms of national HTA recommendations across Europe than 
joint REAs, as for these country-specific economic evaluations can still facilitate a positive 
outcome. In contrast, no change is expected in the number of health technologies 
assessed with the exception of PO5 for which a decrease is estimated.  
For the impact ‘International Trade’, the survey aimed to assess the effect of the 
different Policy Options on international trade related to Pharmaceuticals and medical 
technologies, specifically the effect on related product import and export possibilities.  
As five of the Top 10 Pharmaceutical markets worldwide (regarding sales in 2015) sre 
European countries (68), it is fair to say that for the Pharmaceutical Industry , Europe is 
an important market. Hence, possible effects of the current HTA system in Europe on the 
import and export of products were investigated.  
Changes in HTA cooperation in Europe are not expected to impact on related product 
import and export possibilities from the Pharmaceutical Industry perspective, as indicated 
in the survey. An exception is Policy Option 5, where Pharmaceutical Industry expects a 
negative effect, which might relate to the overall perception that PO5 is too extensive.  
 
For the impact ‘macroeconomic environment’, the survey aimed to assess the effect 
of the different Policy Options on the overall economic growth and labour market, the 
health care sector (including health care providers) and the health technology sector.  
There are quite a number of factors influencing the macroeconomic environment of 
organisations, including changes in the legal framework organisations operate in. The 
need for national adaptation of collaborative European assessments, the differential 
methodologies applied at European, national or local level and associated legal re-
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strictions (41) might limit the applicability of joint assessments in a national context. 
However, they still carry the potential to increase resource efficiency in the health 
technology sector and the health care sector. Early engagement between the different 
stakeholders (69) might lead to efficiency gains on both sides, the industry and Public 
Administrations and other organisations.  
Overall, no major changes in the macroeconomic environment for the different Policy 
Options was expected with the exception of the MedTech industry which assumes a 
negative effect for all Policy Options with a legislative framework.  
The impact ‘Access to social protection and health systems’, focused on access to 
innovative treatments. Especially for innovative treatments, hurdles to market access 
and reimbursement have been reported to be higher due to the uncertainty surrounding 
its value and potential barriers resulting from HTA requirements (43, 47). In general, the 
determination of a health technologies’ value und communicating its value to other 
stakeholders has been described as vital for industry stakeholders to ensure timely 
patient access (70).  
For the Pharmaceutical sector, the results of the online survey indicate that PO3 to PO4 
are expected to increase the availability of innovative products, while PO5 is expected to 
have a negative impact. This is in line with the results of the indicator ‘innovation and 
research’ and related explanations apply (section 7.3.3.4).  
For the impact ‘employment’, the survey aimed to assess the effect of the different 
Policy Options on number of personnel employed, including consultants, who are involved 
in HTA activities. Employees dealing with THA processes from the industry side need an 
understanding about the methods and requirements defined by the assessing body in 
order to successfully prepare these assessments. Additional to the scope of activities, the 
organizational capacity is decisive for performing HTA activities in-house or contracting 
consultants, both for HTA bodies as well as manufacturers.  
In the Pharmaceutical sector, submissions related to HTA are quite common across 
Europe and organizational entities handling submissions are set up at least within larger 
companies. This both addresses people employed to deal with HTA-related issues at the 
specific company sites in European countries but also at EU-Level.  
The expected effect of the different Policy Options on the number of staff employed for 
HTA-related activities indicates that no substantial change regarding the number of 
personnel employed is foreseen by the respondents of the Pharmaceutical sector. Given 
that quite a number of responses were given from a European perspective (e.g. market 
access manager at EU level), this might indicate that, across European countries, the 
staff level remains stable, even if more HTA activities are organized at EU level, which 
was confirmed by representatives of the Pharmaceutical Industry. It was moreover 
highlighted that the basis for HTA-related activities (e.g. evidence generation/value 
dossiers) is often performed at EU level and adapted afterwards in specific countries in 
Europe. Thus, the number of staff might not change, but the allocation of employed 
personnel across countries might change. 
The ‘sustainability of health systems’, was surveyed by assessing the effect of the 
various Policy Options on the financing of expensive treatments with little or no added 
value and the negotiating power of MS in setting prices. All Policy Options are expected 
to have almost no effect on these indicators from the perspective of Pharmaceutical 
Industry except for PO1. Reasons underlying these results may be the fact that the POs 
do not address pricing and reimbursement decisions because these remain the compe-
tency of national authorities. This is in line with the results regarding the revenues with 
no anticipated effect of the Pharmaceutical Industry (see 7.3.3.3).  
For the impact ‘Public Health’, the estimated effect of the Policy Options on two 
indicators (overall public health and the availability of health technologies on the market) 
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was investigated. Pharmaceutical Industry expects a negative effect of Policy Option 5 
regarding Public Health, while there is no effect expected for Policy Option 2 and an 
increase for all other Policy Options. The availability of health technologies is expected to 
be highest for Policy Options 3 and 4.  
For the impact ‘Governance, participation and good administration’, how the Policy 
Options affect the involvement of different stakeholders in HTA processes, the responsi-
bilities of Public Administrations in the field of HTA at MS level, the uptake of joint 
outputs, the resource efficiency of HTA processes in general and the sustainability of 
European cooperation in the field of HTA was surveyed. 
Over all indicators, a slightly positive effect of PO3, PO4.1 and PO4.2 is expected by 
Pharmaceutical Industry, while the Policy Options (PO1 and PO2) and PO 5 are expected 
to have a negative effect. This is mainly driven the expectation of a strong negative 
effect regarding the sustainability of the HTA cooperation PO1, PO2 and PO5, which can 
be related to the entirely voluntary nature of cooperation for PO1 and PO2 and the 
absence of a legislative framework. For PO5 the expected negative effect might relate to 
the high level of agreement that would be necessary for joint economic evaluations, 
which could be assumed to hamper sustainability of cooperation. On the contrary, 
respondents from the Pharmaceutical Industry do not expect any effect on the 
responsibilities of MS when assessing the different Policy Options. A slight increase is 
expected in the number of uptakes for joint outputs for PO4 and PO5. No change is 
foreseen for resource efficiency with the exception of PO5, for which a decrease is 
indicated. The expectation of additional national submission can serve as an explanation 
for this.  
 Concluding remarks for Pharmaceutical Industry  7.3.3.7
For Pharmaceutical Industry, overall results indicate positive effects for Policy Options 
including a joint work on REA at EU level. This especially relates to positive effects for 
innovation and research, functioning of the internal market and access to innovative 
treatments as displayed in Table 64. However, industry expects negative effects for PO 5, 
which includes a strictly mandatory and binding HTA process also covering Full HTA in 
Europe. The highest number of positive effects across all impacts is seen with PO 
4.1 and 4.2. 
Table 64: Overview of relevant impacts for Pharmaceutical Industry  
Impacts 
Policy 
 Option 1 
Policy  
Option 2 
Policy  
Option 3 
Policy 
 Option 4.1 
Policy 
 Option 4.2 
Policy  
Option 5 
Costs (EC 1) 
 
0(-) 0(-) 0(-) + + - 
Administrative Burden (EC2) 0(-) 0(-) 0(+) + + -- 
Competitiveness of EU health 
technology sector (EC 3) 
0(-) 0(-) 0(+) + + -- 
Innovation and research  
(EC 4) 
0(+) 0(-) ++ ++ ++ -- 
Functioning of the internal market 
and competition (EC6) 
0(-) 0(-) + + + 0 (-) 
(*) Inverted: - means that cost would go up, + means that cost would go down. 
Legend: + positive effect, - negative effect, 0 neutral (+) or (–) representing the direction of results, as indication even if the expected effect is 
low) 
Underlying reasons for a negative expectation for PO5 were indicated during the inter-
views as well as in comments to the survey and in the focus group with Pharmaceutical 
companies. It was emphasized that mandatory joint economic evaluations as foreseen in 
Policy Option 5 are perceived as an unrealistic scenario due to country specificities with 
regard to economic requirements and the fact that pricing and reimbursement decisions 
remain at national level. However, joint work on REA has been indicated to potentially 
reduce inefficiencies and workload for the Pharmaceutical sector.  
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One important positive impact for the Pharmaceutical Industry relates to the expected 
increase in the predictability of HTA related processes in Europe, which is especially the 
case for joint REAs. The positive impact can be linked to less administrative burden due 
to the reduction of multiple submission for the same Pharmaceutical across Europe. 
Predictability of processes and evidence requirements has been mentioned to be a very 
important factor in the interviews with industry representatives as well as in comments 
provided to the survey, also facilitating innovation drive due to easier investment 
decisions.  
Subgroup analysis showed that perceptions of the Policy Options are quite similar for 
SMEs and large companies, except for PO1, where SMEs indicated a more positive 
assessment across most impacts compared to large companies. No additional analysis 
could be done for HTA-experienced companies as all responding Pharmaceutical manu-
facturers had at least some experience with HTA.  
With regard to costs for HTA processes, no major changes are expected by the respond-
ents of the Pharmaceutical sector. According to discussions within the focus group 
meeting this is because possible increases and decreases of cost components are 
expected to level each other out. Results of cost calculations within this study, however, 
indicate that potentially savings due to a reduction in duplicated assessments can be 
achieved for the Pharmaceutical Industry across Europe for all Policy Options. However, 
potential savings calculated in the cost prognosis are considerably higher in POs that 
comprise both a mandatory production and mandatory uptake of joint REAs (PO4.2 and 
PO5). Options comprising a permanent secretariat and higher joint output lead to 
substantially larger savings as compared to the project-based cooperation (EUR 3.7 
million in PO2 versus more than EUR 60 million in PO 4.2). Moreover, it has to be taken 
into account that additional evidence generation due to requests by national HTA bodies 
will be limited when joint REAs are in place, which is a relevant factor for potential 
savings but couldn’t be integrated into the cost calculations. 
 MedTech Industry 7.3.4
 Costs 7.3.4.1
For this impact, potential cost evolution was investigated in relation to: Horizon Scan-
ning, Early Dialogues, REA submissions, Full HTA submissions, additional data requests 
by respective HTA organisations, personnel requirements and HTA reassessments.  
Currently, few countries in Europe have formal HTA processes for assessing Medical 
technologies, which is unlikely to change completely until 2020, when the current Joint 
action on HTA ends. Moreover, the pricing and reimbursement system for medical 
technologies is substantially different from that for Pharmaceutical products because 
decisions are more often based on regional level and the scope of products is very broad.  
In the survey, MedTech Industry expected a substantial cost increase (see Figure 51) for 
all POs with a legislative framework (PO3 to PO5), which is in contradiction to our cost-
prognosis. The latter indicates that the MedTech industry might benefit in terms of 
savings from options with stronger governance and regulations in the long run as the 
current duplication of dossiers will be strongly reduced and economy of scale would 
apply. These potential savings would increase for POs with a legislative framework and 
mandatory participation and uptake (PO4.1, 4.2 and 5). 
But, initial investments to build up capacity for HTA in the MedTech sector are needed 
and have not yet occurred right now, giving a proper explanation for results of the survey 
shown below. MedTech representatives also explained that any legal requirements in 
addition to the two new regulations in the field are considered as drivers of cost. This 
explains why PO3 is expected to increase cost much stronger as PO 2 with mandatory 
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uptake of REA (where there is no real experience so far in many MedTech companies). 
Also, MedTech expect a legal system to significantly increase HTA activities in and across 
MS in the field of medical devices and IVDs at the time of the market launch of the 
product, where currently there are limited activities (if at all).  
Figure 51: MedTech Industry - survey results on perceived average effect of Policy 
Options on cost indicators from survey (unaggregated) (122,123) 
 
Source: GÖ FP / LSE survey 2017  
Another simple reason for the expected high increase in costs is that many medical 
device companies have only very limited experiences with HTA and thus might have a 
less realistic perception of the related cost. This assessment is true for both SMEs and 
other companies. Generation of evidence is considered a key cost-driver. Companies 
noted that efficacy data is not currently required (in the revised regulation it will only be 
required for a limited number of technologies). Costs for regulatory and HTA data 
generation differ; HTA evidence generation is estimated to be four times more expensive. 
Also discussed was that, for products requiring additional clinical data, it may be benefi-
cial to align requirements if possible to maximise use of data and reduce duplication.  
 Administrative burden 7.3.4.2
For assessing this impact, the following indicators were defined: overall administrative 
burden; number of HTA submissions for the same product across European countries; 
time needed for an HTA process and complexity of HTA assessment processes. 
Since development pathways for medical technologies and market-access requirements 
differ from those of Pharmaceuticals, some issues have to be accounted for when it 
comes to the potential administrative burden of HTA processes, including timing issues.  
                                                                                                                                    
 
(122)  
Additional information  
as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Horizon Scanning 92.7 94% 25.0 0% 2% 98% 
Early Dialogue 91.8 93% 27.4 2% 1% 97% 
REA 91.7 93% 20.9 1% 0% 99% 
Full HTA 90.7 92% 19.4 0% 0% 100% 
Submission Fees 89.3 90% 21.9 7% 0% 93% 
Additional Data 90.2 91% 18.1 1% 0% 99% 
Human Resources 91.2 92% 20.4 0% 1% 99% 
Re-Assessment 90.2 91% 24.4 5% 1% 94% 
 
(123) positive value indicates increase in costs, negative value indicates decrease in costs 
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Figure 52: MedTech Industry - survey results on perceived average effect of Policy 
Options on administrative burden (124) 
 
Source: GÖ FP / LSE survey 2017 
Survey results indicate that respondents from the medical technologies industry expect a 
decrease in administrative burden for Policy Option 2, turning to an expected increase 
with Policy Option 3 and onwards (see Figure 52). 
Separating the responses for each indicator, the expected effects align. This is also the 
case when looking at the subgroups of SMEs and large companies, which stated almost 
the same effect.  
While discussing the results with MedTech representatives, it became apparent what 
reasons caused the sharp expected increase in administrative burden for PO3. Industry 
representatives explained, that a legally mandated REA at the time of launch (PO3) 
substantially increases HTA activities in MS, and might fundamentally change the 
business model even without mandatory uptake. At the same time, once evidence needs 
to be generated for HTA, there is little difference in terms of administrative burden, if 
additional data should focus on effectiveness or on economic aspects. This accounts for 
the relative stability of the curve from Policy Option 3 to 5.  
When asked about the level of the figures given within the survey (which are quite high 
for PO4 and PO3), it was highlighted that this impact is quite important to the MedTech 
sector. This is in line with the ranking respondents provided in the survey (9 out of 10, 
while 10 represents high priority, see section 7.3.6). With regard to PO2, it was men-
tioned that common templates will reduce the administrative burden as it simplifies 
collaboration.  
For the medical technologies industry, Policy Option 2 is most favourable, becuase it does 
not entail a legislative framework. Setting up new processes for HTA in the medical 
technologies sector would increase the administrative burden from the stakeholders’ 
                                                                                                                                    
 
(124)  
Additional information as 
described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Overall administrative burden 91.0 92% 33.7 0% 2% 98% 
Number of HTA Submissions 90.8 92% 41.0 2% 7% 91% 
Time for one HTA Process 90.5 91% 35.2 0% 3% 97% 
Complexity of HTA process 90.5 91% 38.0 2% 6% 92% 
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perspective. However, this only holds true for the establishment phase. Once established, 
processes will be standardised and not impose a considerable burden any more. Accord-
ing to our judgement findings indicate that Policy Options with stronger governance 
and at least the use of common tools, standards and methodologies in evidence 
generation and outputs would be beneficial for the sector, since redundancies as 
observed in the Pharmaceutical sectors could be avoided to some extent.  
 Competitiveness of EU health technology sector 7.3.4.3
For assessing the competitiveness of the EU health technology sector, the potential effect 
of Policy Options on the predictability of the HTA system in Europe, the competitiveness 
of small- and medium-sized companies and the revenues of health technology developers 
were surveyed. 
When it comes to the competitiveness of SMEs in relation to HTA processes, this is linked 
to the predictability of the HTA system as well as to the evidence requirements for HTA 
submissions, especially regarding additional data requirements on top of clinical data 
relevant for marketing authorisation. These additional data requirements in the course of 
an HTA submission might be tougher to fulfil by SMEs, since costs and organisational 
effort have a greater impact on them compared to larger companies that can more easily 
attribute resources to these tasks. This is especially relevant for the Medical technologies 
sector, since many companies in the sector are SMEs (39, 71).  
For the Medical technologies sector, survey results regarding the predictability of HTA 
systems and the competitiveness of SMEs show no effect for PO1, a perceived positive 
effect for PO2 and a perceived negative effect for PO3 onwards. This negative effect 
remains stable for PO4 and PO5. Given that HTA processes are currently not as common 
for medical technologies as they are for Pharmaceuticals, the survey results might reflect 
the uncertainty linked to new structures that will arise when a legislative process is 
established (39, 65).  
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Figure 53: MedTech Industry - survey results on perceived average effect of Policy 
Options on competitiveness of EU health technology sector (125) 
 
Source: GÖ FP / LSE survey 2017 
A relevant aspect arising during discussions with the MedTech focus group relates to the 
time of assessment. When HTA is conducted at the time of market launch, the first 
company needs to generate comprehensive evidence. This might be used by an early 
follower, creating a considerable disadvantage for the first mover. In the view of partici-
pants, this could explain the sharp expected decline for these impacts from a completely 
voluntary cooperation (PO2) to an at least partly mandatory one (PO3-PO5).  
Another point stressed by MedTech representatives is that increased harmonisation might 
delay first revenues. This can be challenging, since a quick access to market is highly 
important especially, but not only, for SMEs. Even if harmonization means access to 
more countries, losing the quick access to the first market (which is currently easy to 
access) might override the advantage of accessing more countries. Moreover, concerns 
were expressed with regard to a possible increase in evidence requirements when a new 
EU system is in place. This could be challenging especially for SMEs.  
When it comes to medical technologies, policy option 2 appears to be the most favoura-
ble from the perspective of this sector because it offers the opportunity of joint output 
production without the undesired legal binding. However, voluntary cooperation has the 
disadvantages of less efficient processes and low target orientation. Thus, scarce 
resources in the health care sector should be used with caution and ensure efficient and 
sustainable cooperation. 
 Innovation and research 7.3.4.4
Here we investigated the current climate for research and innovation in Europe. In 
general HTA has been identified as a tool to increase efficiency in health-care and to 
steer innovation in the development of health technologies (44, 45). However, for 
                                                                                                                                    
 
(125)  
Additional information  
as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Predictability of HTA System 90.8 92% 41.0 2% 84% 14% 
Competitiveness of SME 91.8 93% 32.8 1% 93% 6% 
Revenues 90.5 91% 34.3 3% 90% 7% 
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Medical Technologies HTA-related processes are not as common and methodologies are 
still less developed compared to Pharmaceuticals. Moreover, the research cycles for 
Medical Devices are a bit different as compared to Pharmaceutical Industry as the scope 
of products is even more technology driven, resulting in shorter life-cycles, e.g. for 
medical software.  
Survey responses show that a slight positive effect for innovation and research is 
anticipated for Policy Option 2 while negative effects are estimated for Policy Options 3 to 
5. The most pronounced effect is expected when implementing Policy Option 5. 
Figure 54: MedTech Industry - survey results on perceived average effect of Policy 
Options on innovation and research (126) 
 
Source: GÖ FP / LSE survey 2017  
Reviewing the effect on innovation and research for the two specific indicators investigat-
ed, a more pronounced negative effect is expected for innovation as compared to the 
indicator research climate (see Figure 54). 
An explanation for this expected deterioration of the innovation and research climate can 
be related to the shorter life cycle of medical devices. This among others impact the 
conduct of long RCTs while evidence-based on such studies is currently viewed as high-
level evidence 45. As explained in the previous section (7.3.3.3), MedTech representa-
tives argued that evidence requirements for new innovative products will increase with 
strengthened HTA cooperation in Europe. Representatives of the medical device industry 
explained, that when HTA is conducted at the time of market launch the first company 
needs to generate comprehensive evidence which then might be used by an early 
follower, creating a considerable disadvantage for the first mover. This point was also 
highlighted in Interviews with representatives of Medical device companies in the course 
of the case study (7.1.13.2). Expected increases in study requirements can therefore 
serve as underlying explanation of the expected sharp decline in innovation from a 
voluntary cooperation in PO1 and PO2 to a mandatory one in PO3 and onwards.  
                                                                                                                                    
 
(126)  
Additional information  
as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Research Climate 91,0 92% 26,0 2% 91% 7% 
Innovation 90,3 91% 29,7 2% 93% 5% 
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 Functioning of the internal market and competition 7.3.4.5
Potential effects of the Policy Options on the functioning of the internal market and 
competition were assessed by investigating the fragmentation of the HTA system in 
Europe, convergence of HTA methodologies in Europe and the attractiveness of the 
European market for industry stakeholders, particularly resulting from a lower fragmen-
tation of HTA systems. 
Literature provides several examples illustrating the fragmentation of the HTA system 
and the level of convergence of HTA methodologies in Europe which were confirmed by 
results of the case study. For example, the definition of medical devices and, therefore, 
the associated structures, procedures and applied methodologies for HTA processes differ 
between governmental institutions among Europe (58). Different types of public organi-
sations engage in assessing medical devices. Depending on the organisation, the scope 
differs: either new medical devices or other technologies, only those used in the outpa-
tient sector, or other technologies for specific purposes are assessed (32, 58).  
Different methodological approaches can lead to varying pathways to pricing and 
reimbursement decisions for medical technologies, specifically for innovative products, 
thus imposing challenges on manufacturers (47). In general, the different steps of 
assessment, appraisal and pricing and reimbursement decisions are clearly separated in 
most EU countries and pricing and reimbursement decision are national or sometimes 
also local competences (66, 37). This is especially true for Medical Technologies, on 
which different pricing and reimbursement processes apply as compared to Pharmaceuti-
cals. 
When assessing input from the medical technologies industry a slightly negative effect is 
perceived from PO3 onwards, which is mainly due to a considerable decrease in their 
estimated attractiveness of the EU market (see Figure 55).  
Figure 55: MedTech Industry – survey results on perceived average effect of Policy 
Options on internal market and competition (127) 
 
Source: GÖ FP / LSE survey 2017 
                                                                                                                                    
 
(127) Aggregation: inverted values for fragmentation of HTA system 
Additional information  
as described in 7.3.1 
av. responses response rate av. std. dev no effect negative effect positive effect 
Fragmentation of HTA System 88.0 89% 21.3 84% 9% 7% 
Convergence of HTA Methodologies 88.0 89% 21.2 86% 2% 11% 
Attractiveness of EU Market 89.2 90% 28.1 6% 87% 7% 
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MedTech stakeholders do not expect changes for PO1 compared to the status quo. 
Looking at PO2, respondents indicated a slight increase of fragmentation of HTA systems, 
convergence of methodologies and attractiveness of EU market. The attractiveness of the 
EU market is expected to go down, reaching its bottom for PO5. MedTech experts 
emphasised in the focus group that the reason for the expected unattractiveness is the 
fear of slower market access in particular for first movers/innovators and due to the fact 
that the legislation is not linked to pricing and reimbursement. Hence, it might impose 
additional work without resulting in a monetary benefit.  
 
 Further impacts 7.3.4.6
The study team also surveyed a few other parameters on how MedTech Industry could be 
affected by the various Policy Options. Those judged as less relevant are summarised in 
this section; detailed survey results can be found in Annex 26.  
For the impact ‘consumer and households’, the number of health technologies 
assessed and the number of health technologies available on the European market, 
focusing on the availability of medical technologies for patients, were surveyed. Overall, 
MedTech indicated that PO1 and PO2 will not affect the number of health technologies 
assessed and available compared to the status quo to a great extent. For PO3 to 5 
stakeholders expected a slight increase in the number of health technologies assessed, 
but with little variance compared to the status quo. Turning to the number of health 
technologies available, representatives of the medical technologies’ sector expect 
availability to decrease for all options including a legislative framework (PO3-PO5). This 
might relate to an expectation of joint processes increasing the time s to market access.  
For the impact ‘International Trade’, the survey aimed to assess the effect of the 
different Policy Options on international trade related to Pharmaceuticals and medical 
technologies, specifically the effect on the related import and export possibilities for 
products. With regard to medical technologies, Europe is one of the biggest markets, 
comprising of over 500,000 different registered products and showing an increased 
number of MD patent applications since 2004 (58). Responses by the medical device 
sector indicate that all options from PO3 onwards are expected to have a negative effect 
on international trade, while for PO1 and PO2 no effect is anticipated. This corresponds to 
the stated assumption that all options from PO3 onwards are considered to raise the level 
of utilization regarding HTA in Europe when it comes to Medical Technologies, which is 
seen as an additional burden by the MedTech sector. According to our analysis, a 
potential legislation in the field will, however, be of less relevance for investors than the 
two new EU regulations that are basically preparing the ground for more HTA processes 
in Europe since they also call for more evidence generation. 
Regarding ‘employment’, the effect of the different Policy Options on the number of 
personnel employed, including consultants who are involved in HTA activities was 
assessed. Skilled staff are needed for all industry sectors, thus also MedTech to prepare 
value / submission dossiers. Industry experts in charge of HTA need an understanding 
about the methods and requirements defined by the assessing bodies in order to 
successfully prepare the evidence and dossiers needed. Additional to the scope of 
activities, the organisational capacity is decisive for performing HTA activities in-house or 
contracting consultants, both for HTA bodies as well as manufacturers.  
Survey results indicate a slight increase in employed personnel for PO2, while the level of 
employment is expected to decrease from PO3 onwards. This was explained by the 
expectation of MedTech representatives that more tasks will be done at a central level 
which is in line with other fields where a centrally organised process reduced the capaci-
ties needed at regional or local levels. Still, it is possible that the type of expertise 
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needed will change (e.g. more communication expertise or behavioural science for Early 
Dialogues) to account for new developments in HTA for Medical Technologies. 
However, we do not agree with this expectation as HTA activities are not very common in 
the MedTech sector yet. Therefore, the number of people dealing with HTA-related 
activities should rather increase across Policy Options especially since more joint activi-
ties in the field of medical devices and IVD are foreseen from PO4 onwards.  
For the impact ‘macroeconomic environment’, we aimed to assess the effect of the 
different Policy Options on economic growth and labour market, the health care sector 
including health care providers and the health technology sector.  
No changes for the macroeconomic environment are expected for PO 1 compared to the 
status quo while for PO2 a positive effect is stated. On the contrary, negative effects are 
expected from PO 3 onwards with PO 5 seemingly to have the most negative effect. This 
might relate to the establishment of a legislative framework from PO3 onwards and the 
increase of mandatory elements for joint cooperation, which are generally speaking not 
preferred by MedTech. Despite thorough literature search and expert interviews, we 
could not find enough evidence to verify or falsify the assessment of MedTech sector 
representatives.  
The ‘sustainability of health systems’ was surveyed by assessing the effect of the 
various Policy Options on the financing of expensive treatments with little or no added 
value and the negotiating power of MS in setting prices. With respect to the sustainability 
of health systems, respondents from the MedTech industry expect the negotiating power 
of MS in setting prices to remain unchanged. On the contrary, they responded that less 
expensive treatments with little or no added value are funded from PO3 onwards; a 
statement that we challenged. Following that, industry representatives responded that, 
due to the weak link between health technology assessments and pricing and 
reimbursement decisions for medical technologies, the changes in the HTA processes 
would not affect the negotiating power or the funding of technologies. We argued against 
that, e.g. strengthening HTA research and developing common tools in this field are likely 
to have an impact on national reimbursement procedures, as the example of the 
Pharmaceutical market shows. 
For the impact on ‘Public Health’, the estimated effect of the Policy Options on two 
indicators (overall public health and the availability of health technologies on the market) 
was investigated. Relating to the effects of the POs on public health from the perspective 
of the medical device industry, a negative effect is estimated for all Policy Options 
featuring a legislative framework, while for Policy Option 2 assessments of MedTech go in 
the opposite direction. These effects are mainly driven by the estimated negative effect 
for the availability of health technologies while no impact on overall public health is 
foreseen. The latter finding is challenged by us because more stringent assessment 
procedures will definitely have a positive impact on the quality and safety of medical 
devices and IVD, which furthermore is also one of the objectives of new regulations in 
this field.  
On the subject of ‘Governance, participation and good administration’, we looked 
how the POs might affect the involvement of different stakeholders in HTA processes, the 
responsibilities of Public Administrations in the field of HTA at MS level, the uptake of 
joint outputs, the resource efficiency of HTA processes in general and the sustainability of 
European cooperation in the field of HTA. 
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Survey results from the Medical Device industry indicate a positive effect for PO2 and 
negative effects for the subsequent Policy Options, as is the case for most options. 
Almost no change is foreseen with regard to the responsibilities of MS when it comes to 
PO3 to PO5, while an increase is expected for PO2. The other indicators were rated 
similarly, with a perceived increase for PO2 per indicator and an expected decrease from 
PO3 on. From the perspective of the MedTech industry, only the introduction of PO2 
would result in positive effects, while negative effects are expected from PO3 onwards, 
thus including all Options that cover a legislative framework. No explanation was 
given, but it seems that all ‘legislative’ options were downgraded by MedTech 
industry. 
The impact ‘Access to social protection and health systems’, focused on access to 
innovative treatments. Responses given by the MedTech industry indicate that PO3, PO4 
and PO5 are perceived to have a negative effect on access to innovative treatments, 
which increases in magnitude from PO3 to PO5. On the contrary, almost no effect is 
expected for PO1 and PO2. The anticipated hurdles for the medical device industry and 
uncertainty about future evidence requirements might play a role in this context.  
 Concluding remarks for MedTech Industry 7.3.4.7
Results for MedTech Industry are very different compared to the Pharmaceutical Indus-
try. All data collected point towards a negative effect of all Policy Options with the 
exception of Policy Option 2 (Table 65) for this sector.  
In many discussions, by interview and in the focus group meeting, MedTech representa-
tives explained some of the facts they gave. Policy Options covering a legislative frame-
work are expected to function as a driver for further increase of HTA activities in MS, 
which industry perceived as a very important element of unpredictable change and a 
major driver of cost. 
Table 65: Overview of relevant impacts for MedTech Industry 
Impacts Policy 
 Option 1 
Policy  
Option 2 
Policy  
Option 3 
Policy 
 Option 4.1 
Policy 
 Option 4.2 
Policy  
Option 5 
Costs (EC 1)* 0(+) 0(-) -- - - - 
Administrative Burden 
(EC2) 
0(+) + - -- -- -- 
Competitiveness of EU 
health technology sector 
(EC 3) 
0 + -- -- -- -- 
Innovation and research 
(EC 4) 
0(-) + -- - -- -- 
Functioning of the internal 
market and competition 
(EC 6) 
0 0(+) 0(-) 0 - - 
(*) Inverted: - means that cost would go up, + means that cost would go down. 
Legend: + positive effect, - negative effect, 0 neutral (+) or (–) representing the direction of results, as indication even if the expected effect is low) 
Since HTA activities currently do not play a major role in the medical technolo-
gies’ market access path, any change is expected to increase burden on 
MedTech companies. This subsequently could also reduce the attractiveness of the 
European market and potential delays in first revenues are feared because currently 
there are only very few pre-market obligations in place. One key impact is the expected 
decrease in competitiveness and innovation. According to the focus group and the 
interviews, this is due to the perceived unpredictable change in the market access path 
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(also attributed to the two new EU Regulations on Medical Devices) (128), resulting in yet 
an additional new administrative hurdle, which are typically the strictest for the first 
movers (innovators).  
Summarising, Med Tech respondents expect any – from their perspective additional 
- regulatory approach and mandatory uptake at EU level to increase the costs 
and reduce the predictability of the market for medical device and IVD compa-
nies. This relates to the fact that standardised HTA processes are far less common for 
Medical devices (or currently only being developed) and is also linked to some uncertain-
ties companies expect with the implementation of the new Medical Devices Regulations.  
A particularly important aspect is the expected increase in costs for PO3 to PO5 driven by 
additional evidence generation, which however needs to be challenged. In our opinion, 
this could be largely overestimated by the respondents, due the low level of HTA experi-
ence in the MedTech Industry. Moreover, our cost calculations did not show a major cost 
increase for MedTech Industry on a unit base in the long run, provided that the number 
of joint outputs will increase. It, on the contrary, indicated that the MedTech industry 
might also benefit from the POs under consideration when it comes to costs (aggregated 
across Europe). Potential savings are especially noticeable for the POs with a legislative 
framework (PO 4.1, 4.2 and 5).  
We concluded that the underlying negative association of yet another new 
legislative framework was subsequently leading to negative expectations for a 
number of indicators. This is why some of the results, e.g. the negative impact 
on costs, could be overestimated. Subgroup analysis was performed comparing SMEs 
to large companies, but no noticeable differences were identified in results across all 
impacts and POs. It has to be mentioned that the actual level of experience with HTA for 
the respondents from the MedTech sector is considerably lower than for the respondents 
from Pharmaceutical Industry. Whereas Pharmaceutical products have a well-established 
pathway from marketing authorisation to HTA evaluation, followed by appraisal and an 
established HTA process in a large number of European countries, medical devices and 
other technologies follow heterogeneous rules or processes regarding their evaluation. 
Follow-up questions were distributed to respondents from the MedTech survey, trying to 
capture the level of experience of survey respondents. However, only 31 out of 99 survey 
respondents replied to these follow-up questions, with 22 of these stated to have 
experience with HTA submissions and 9 declared to have no experience in this field. For 
those few companies, we saw no significant differences in their position.  
Summarising, it seems obvious that Med Tech needs another approach than Phar-
maceuticals because of the peculiarities of the sector. Option 4.1 and up appear 
currently not applicable, but the further development and use of methods and 
common tools that would enable the same or similar level of assessment for 
MDs around Europe would surely be beneficial from a Public Health perspective. 
Still, the time horizon for introducing the same standards for medical devices and other 
technologies should be longer than for Pharmaceuticals. A phased approach on the 
development and implementation of legislation seems more promising.  
 Patients and patient organisations 7.3.5
The stakeholder groups of patients and patient organisations are heterogeneous and their 
involvement in HTA processes remains limited so far, taking place mainly in the appraisal 
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phase (51). Information presented here is derived from literature and expert talks as the 
participation in the survey was far too low to be analysed by MCA. 
Literature shows that the availability and accessibility of health technologies is considered 
highly important for patients, thus affecting public health. In many European countries, 
funding of public health research, which includes research in HTA, is limited (72). 
Although HTA is a transparent method to support decision-making processes in public 
health, HTA research on, for example, prevention programmes or vaccinations tend not 
to reach decision-makers (73). The lack of information exchange and focus on HTA 
imposes additional barriers for patients. To be better acknowledged by decision-makers, 
HTA methods should include other outcomes such as differences in access to health care 
or effects on patients’ social environment, which are important factors from a patient 
perspective (74). Moreover, accelerated HTA processes would lead to faster patient 
access (34) in case of favourable assessments.  
HTA results hold the potential to improve, restrict or deny patient access to health 
technologies depending on the assessment results and the role HTA plays in the decision 
processes regarding reimbursement. On the other hand, HTA is a tool to limit continued 
use of health technologies with little or no added value (43). Thereby it also restricts 
access to health technologies but improves quality of care and the efficient use of health 
care resources (43). Furthermore, involvement of patients in health policy processes is 
important and potential related benefits resulting from increased involvement could top 
related risks caused by an insufficient level stakeholder involvement (75).  
The importance of HTA from a patient perspective and its impact on patient access is 
illustrated by the observation that patients tend to experience greater disadvantages 
from losing access to health technologies (e.g., caused by delisting) compared to denying 
access to health technologies (43). Concluding, HTA has an indirect effect on patients 
which should be considered in future cooperation models in the field of HTA. 
In order to assure consideration of all relevant stakeholder perspectives, studies suggest 
an inclusion of all relevant stakeholders in assessment processes, especially of those not 
regularly included in assessment processes so far. Positive developments were already 
achieved in increasing involvement of consumers (including patients and patient advoca-
cy groups) in different steps of assessment processes as reported in a study assessing 
consumer involvement in HTA activities in INAHTA agencies (49). However, patient 
involvement in general and the scope of patient involvement still varies widely across 
Europe (50) and several points for improvement remain (51). Especially, a clear defini-
tion of the role of patient involvement in HTA (51) is necessary to increase the efficiency 
of such processes. 
Relating to the survey first, respondents indicated following aspects for consideration:  
• ‘Co-operation would increase the reliability of HTA assessments and safety of new 
technologies’. (general stakeholder comment) 
• ‘EU cooperation on HTA is needed also for hospital-based HTA, rehabilitation and 
prevention programmes, disease management programmes, organisational and 
supportive procedures (including surgeries) as well as ethical use of health tech-
nologies (e.g. with respect to end of life, assisted reproduction, prenatal diagnosis, 
health data) and, comparisons between Pharmaceutical and non- Pharmaceutical 
interventions’. (general stakeholder comment) 
• Predictability of HTA systems is a key issue; full integration will strongly influence 
predictability. 
• Policy option 1 to 5 might limit innovation initiatives on the one hand, but reduce 
risks and uncertainty of use resulting from innovative products on the other. 
• Anticipated structures, i.e. PO 1 to 5, could limit the number of technologies avail-
able but the health care sector would be more harmonized and uniform, thus sup-
porting availability of safer and more efficient technologies 
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Second, stakeholders contacted in the follow-up provided additional information on the 
current situation of patient involvement in HTA processes and key points for future 
involvement. Interview partners indicated that patient involvement in HTA varies 
considerably between countries (see also Scott and Wale, 2017) (51). Countries with 
more advanced HTA systems are more engaged to increase patient involvement and 
include their perspective adequately. Besides specific countries, patient involvement in 
the EUnetHTA JA 3 aims to improve patient involvement, but faces restrictions due to 
limited financial resources. Overall, there are clear signals to improve patient involve-
ment in HTA processes throughout Europe (see also Scott and Wale, 2017) (51).  
Stakeholders mentioned the following key points for future cooperation in HTA: 
• Conflict of interest: The independence of HTA processes must be ensured and the 
influence of stakeholder groups should be limited; thus, future cooperation in the 
field of HTA should be mainly funded through public sources; 
• Improving the transparency of HTA processes; 
• Ensure patient involvement, including development of best practice design; 
• Matching patients with respective topics most expedient; 
• Patient involvement in Early Dialogues (enhances predictability); 
• Inclusion of patient relevant outcomes including well-being. 
From the consumer perspective, any stronger, more binding collaboration between MS 
will reduce duplication of work, increase the number of outputs and transparency of 
results and thus is likely to be beneficial for European patients.  
Patient representatives indicated that EMA and future HTA cooperative models 
should closely work together, but in an independent and thus separate way. The 
development of common methodology, which needs to meet ethical requirements, is vital 
to include all relevant aspects. Implementation of a life-cycle approach would support 
evidence generation throughout the whole life cycle of a health technology, specifically 
whenever additional evidence is required. Regardless of the specific characteristics of the 
implementation structure, sufficient funding and investments were highlighted as 
necessary to adapt sustainable and transparent HTA processes. 
We see a number of indications that patients would benefit from regulated assess-
ments of health technologies since these would serve as a sound evidence base 
for decision-makers and improve the availability of new and safe technologies. 
Increased regulation and guarantee of assessment processes support quality and safety 
aspects, specifically for innovative treatments. Uncertainty surrounding the prescription 
of (innovative) products would be lower and support health professionals to ensure 
appropriate and secure use of health technologies. Moreover, health risks for patients 
would be lower through improving access to assessed (innovative) health technologies.  
Overall, increased patient empowerment might affect public health in a positive manner. 
Specific stakeholder groups such as health professionals and patients could further 
benefit through transparent assessment processes and improved monitoring of health 
technologies. Therefore, all relevant stakeholder perspectives should be considered for 
final assessments of Policy Options. Irrespective of assessment results, a mandatory 
legislative framework offers the opportunity to reduce selective assessment of 
health technologies and guarantee transparent processes as well as easier 
transferability to national systems. Due to the currently low involvement of patients 
and scarce publicly available information regarding HTA results, this framework has the 
potential to permit patients to follow current developments. Continuous consultation of 
patients in health policy processes might not only optimise respective processes, but also 
result in greater understanding of different stakeholder groups positions (75), i.e. 
patients get better insights in decision-making processes and vice versa. 
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 Rating on the relevance of impacts 7.3.6
Within the online survey, respondents were asked to rank the relevance they attribute to 
the impacts on HTA cooperation after 2020 on a scale from 0 to 10 (Q1 in Part 4 within 
the questionnaire, see Annex 3 and 4).  
Figure 56 displays the result of this exercise for each impact, split into Public Administra-
tion, Pharma and MedTech Industry, which illustrates that the relevance of the respec-
tive impacts is divergent between the stakeholder groups. This is especially 
apparent for Costs, which is considered to be very relevant by MedTech companies, while 
Pharma companies only attribute a low relevance to the effect of this impact.  
Figure 56: Relevance of impacts by respondent group 
  
Source: GÖ FP / LSE survey 2017  
 
 Data plausibility check  7.3.7
An additional plausibility check for the data gathered through the survey and used for 
analysing the different impacts of the Policy Options was performed. This check was done 
especially to account for possible differences regarding response behaviour in the three 
different stakeholder groups (Public Administrations, Pharma Industry, and MedTech 
Industry). 
Four different additional checks were performed: 
a. A test for elimination of duplicated responses to account for prearranged answers. 
b. A comparison of usage of mode (most frequently appearing value in a data set). 
c. A comparison of standard deviation between stakeholder groups, impacts and 
Policy Options. 
d. A calculation of intracorrelation coefficients, describing how strongly answers in 
the same stakeholder group resemble each other. 
The results from these data checks are described in the following subsections.  
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 Test for elimination of duplicated responses 7.3.7.1
A plausibility test was performed to check for the similarity between responses 
to the survey by stakeholder group (Table 66) because the similarity of assessment 
by MedTech raised the suspect of strongly coordinated responses.  
Table 66: Percentage of duplications in data sets (exactly matching responses) 
Pharma Industry MedTech Industry Public Administration All 
2 out of 16 12 out of 99 0 out of 23 14 out of 138 
12.5% 12.1% 0.0% 10.1% 
Source: GÖ FP / LSE survey 2017  
For Public Administration, no duplications of answers were found, though for several sub 
questions, answers coincided.  
For both, Pharma and MedTech, around 12% of answers were found to be complete 
matches, meaning that all answers for all sub questions included the same values.  
For the whole survey, answers taken into account for analysis of the percentage of 
similarity amounted to around 10 percent of all responses (138 responses taken into 
account in total). 
Table 67: Mean of all answers before and after elimination of duplicates 
Means Pharma Industry MedTech Industry Public Administration All 
Before elimination 3.46 3.63 NA NA 
After elimination 3.56 3.67 NA NA 
Source: GÖ FP / LSE survey 2017 
Even though this might appear to be a non-negligible fact, the question is whether this 
was due to pre-agreed answers or simply because of similar assessments by stakehold-
ers. To find out if duplicate answers had an impact on the result, those exactly matching 
responses were eliminated for testing. A comparison between the means of all 
questions before and after elimination of duplicates showed that there is only a 
very low difference in the responses from the Pharma and MedTech industries, 
irrespective if duplicate answers were eliminated or not (Table 67). For Public 
Administration, no duplicates were found at all. Subsequently also similar assessments 
were considered for our analysis. 
 Comparison of usage of mode 7.3.7.2
The mode is the most frequently appearing value in a data set (which could be every 
value on the scale of -100 to +100). The percentage of usage of mode can also be used 
to analyse how ‘aligned’ answers of the respondents to the questionnaire were. The 
overall percentage of usage of modes is 69% for Pharma Industry, 52% for the MedTech 
Industry and 32% for Public Administration (see Annex 22 for further details).  
Answers from the Pharma Industry show comparatively high percentages of usage of 
mode (69%, expressing how often the mode was stated per impact). This shows that 
respondents of the Pharma Industry often assessed Policy Options in a similar way. 
Answers from the MedTech Industry show slightly lower percentages of usage of mode 
(52%). Respondents from Public Administration seemed to assess Policy Options the 
least alike. This is most probably also due to the fact that respondents from Public 
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Administration represented different countries and therefore different HTA process 
characteristics.  
 Comparison of standard deviation 7.3.7.3
Another supplementary data analysis is based on the comparison of standard deviation. 
These were sorted and compared by: 
• Stakeholder group (Public Administration, Pharma Industry and MedTech Industry) 
• Policy Options (PO1, PO2, PO3, PO4.1, PO4.2, PO5) 
• Impacts (EC1-EC8, SH1-SH5) 
As display format box-plots were chosen for the different elements, see Figure 57. 
Figure 57: Box-plot elements 
 
           Source: Flowing Data 
For the interpretation of the results following statements are relevant: 
• The lower the LEVEL of the median, the lower the mean variance of answers from 
the different respondents in the stakeholder group. 
• The lower the SPREAD of standard deviation, the lower the differences in variance 
between answers from different respondents in the stakeholder group. 
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Figure 58: Standard deviation by stakeholder group 
 
 
Source: GÖ FP / LSE survey 2017 
There is comparatively low standard deviation in the Pharma Industry stakeholder group, 
suggesting a low variance in answers from different respondents. The medians for the 
standard deviation for MedTech Industry and for Public Administration are higher and 
close to each other. There is respectively more variance in answers from the different 
respondents in each stakeholder group. For Public Administration, variation in standard 
deviation is higher, meaning that standard deviation between single answers varies to a 
higher extent. Even if mean standard deviations from around 25 seem to be non-
negligible, it is to be reminded that the scales provided within the questionnaire range 
from -100 to +100 and respondents within the Public Administration stakeholder group 
again represent different countries and therefore different HTA process characteristics.  
Standard deviations were further compared not only by stakeholder group but also by 
Policy Option (see Figure 59). Lowest standard deviation was found again for the Pharma 
Industry for all Policy Options except Policy Option 1. Standard deviation for the MedTech 
Industry increases with ascending Policy Options. The same observation can be made for 
the Public Administration stakeholder group of (except Policy Option 1). This seems to 
represent the fact that assessments for Policy Options closer to the status quo are 
probably easier to picture (with the exception of Policy Option 1 for Public Administration, 
which could be argued with the different systems of HTA represented in the survey). 
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Figure 59: Standard deviation by stakeholder group and Policy Option 
 
Source: GÖ FP / LSE survey 2017 
Finally, standard deviation was compared by impact and stakeholder group (see Figure 
60). Besides the comparatively lowest standard deviations for Pharma Industry for all 
impacts, no further pattern could be recognised through this additional itemization. 
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Figure 60: Standard deviation by stakeholder group and impact 
 
Source: GÖ FP / LSE survey 2017 
 Calculation of intracorrelation coefficients 7.3.7.4
As a fourth and final test for plausibility of data, a calculation of intracorrelation 
coefficients (ICC) for each stakeholder group was performed. This coefficient describes 
how strongly units in the same group resemble each other. It is zero if no system-
atic resemblance between respondents and answers can be found and one if there is 
complete resemblance between respondents and answers. Figure 61 shows the calculat-
ed ICCs for the three stakeholder groups.  
Figure 61: Intracorrelation coefficients (ICC) per stakeholder group 
 Pharma Medtech Public Administration 
ICC 0.18 0.02 0.04 
Lower Confidence Interval 0.10 0.01 0.02 
Upper Confidence Interval 0.35 0.03 0.08 
Source: GÖ FP / LSE survey 2017 
The ‘highest’ ICC was found for answers given by respondents of the Pharma Industry. 
This also corresponds well to the findings in the previous sections. Nonetheless, there are 
very low ICCs for all stakeholder groups, leading to the conclusion that no systematic 
resemblance between respondents and answers could be found. This means that 
similar answers are rather built on common assessment than concordance of 
answers. 
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 Conclusions 7.3.7.5
The data checks for robustness and validity of results show that there is a common view 
on the different Policy Options, but no intra-sectorial coordinated assessments could be 
verified. Therefore, survey results are considered robust and reliable.  
7.4 Summary conclusions for effects of Policy Options 
HTA is considered a valuable tool that can contribute to the sustainability of national 
health systems. Still, the generation of HTA outputs (namely Early Dialogues, REA and 
finally Full HTA reports with economic evaluation) is quite diverse in Europe, because HTA 
systems are fragmented.  
To support MS activities in the field, the EC has set a number of steps, including the co-
funding of in the meantime three Joint Actions in the field and the establishment of the 
HTA-Network of MS’ competent authorities.  
In 2016, the EC developed a number of so-called ‘Policy Options’ with the objectives to: 
1) Ensure a better functioning of the internal market of health technologies and to 2) 
Contribute to a high level of human health protection, as stated in Article 168 TFEU and 
Article 35 of the Charter of Fundamental Rights.  
The potential Policy Options (PO) reach from PO1 (No EU action after 2020) to PO5 
(Legislation covering Joint work on full HTA (including REA) plus common tools and Early 
Dialogues), see section 4.2 for a detailed explanation.  
For each of these POs, different combinations of voluntary or mandatory participation 
and uptake per joint output are possible (leading e.g. to a further differentiation of PO 
4.1. and PO 4.2 in the analysis, depending if the national uptake of joint REA is voluntary 
or mandatory, see Table 7). 
For organizing the creation of these joint HTA outputs, a number of different organisa-
tional mechanisms (so-called Business models) are conceivable, ranging from MS-only 
project-based cooperation to a permanent secretariat in a new EU agency 
(6.2.2.5). 
This study investigated, based on the Better Regulation Guidelines (5), a number of 
economic and social health impacts (e.g., costs, administrative burden, innovation, 
employment, public health, see 6.2.1) in order to establish a comprehensive picture of 
how the different POs and Business Models under consideration would affect different 
stakeholder groups.  
The analysis of impacts focused on three main stakeholder groups, i.e. Public Admin-
istration, Pharmaceutical Industry and MedTech Industry (see section 5 for data 
collection and section 6 for methodology) due to data availability. Whenever information 
was available the potential impact on patient groups were analysed as well (129). Health 
professionals were covered mainly in their roles in the abovementioned sectors, but could 
not be captured as separate group. Moreover, a cost prognosis on the different Policy 
Options was performed (section 7.2).  
Information collected indicates that, for Public Administration, there will be no major 
effects with regard to HTA-related processes for PO1 and PO2. However, with 
Policy Options covering a legislative framework (PO3-PO5), positive effects on 
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national Public Administrations are likely, which are amplified with each output that 
is covered by the legislative framework. This increase in positive effects with stronger 
and central governance can be related to the expectation that the uptake of joint outputs 
will increase with each subsequent Policy Option.  
Apparently, the number of evidence-based assessments available for decision-
making can be increased with joint outputs since potentially more health technologies 
could be covered due to the fact that single HTA bodies might not have the capacities to 
assess the same numbers per year. Countries with less established HTA processes 
might especially profit from joint output, in particular from joint REAs.  
None of the Policy Options is estimated to have a substantial effect on the administrative 
burden of Public Administrations across Europe and no or only little effect on costs for 
HTA-related outputs were indicated in the online survey. This might relate to the fact that 
national processes will still remain in some way. However, some HTA bodies voiced the 
expectation that indeed a closer collaboration would lead to potential cost decreases, 
which was confirmed by our cost calculations. These indicate potential savings across 
MS especially from PO4.1 onwards.  
For Pharmaceutical Industry, gathered information indicates no changes for PO1 and 
PO2, while positive effects of Policy Options including joint work on REA at 
European Union level, namely PO3 and PO4, are stated. These POs seem likely to 
lessen inefficiencies, increase the functioning of the internal market and reduce workload 
for the Pharmaceutical sector. Furthermore, an increase in predictability of HTA processes 
and requirements is expected, which is a very important factor for companies and their 
research and investment decisions. 
The Pharmaceutical Industry expects negative effects for PO5, which includes a 
strictly mandatory and binding HTA process also covering Full HTA in Europe. Underlying 
reasons are mandatory joint economic evaluations, as foreseen in Policy Option 5, were 
perceived as an unrealistic scenario due to country specificities with regard to economic 
requirements and the fact that pricing and reimbursement decisions remain at national 
level. Especially joint work on REA was repeatedly indicated to have the potential 
to reduce inefficiencies and diminish workload for the Pharmaceutical sector. 
With regard to costs for HTA processes, the respondents of the Pharmaceutical sector 
expect no major changes with the exception of PO5, where a substantial cost increase is 
anticipated. This relates to the fact that possible increases and decreases of cost compo-
nents would level each other out according to discussions in a focus group.  
Still, the results of our cost prognosis for 2021+ indicate that actual savings due to a 
reduction in duplicated assessments can be achieved for the Pharmaceutical Industry 
across Europe for all Policy Options. Potential savings are considerable higher in Policy 
Options that comprise both a mandatory production and mandatory uptake of joint REAs 
(PO4.2 and PO5). Options comprising a permanent secretariat and higher joint output 
lead to substantially larger savings as compared to the project-based cooperation (EUR 
3.7 million in PO2 versus more than EUR 60 million in PO 4.2). 
For the MedTech sector, information gathered reveal a different picture: MedTech 
industry perceived negative effects of all Policy Options except for Policy Option 2. This 
assessment is in our opinion related to the peculiarity of the Medical devices market. 
Whereas Pharmaceutical products have a well-established pathway from Marketing 
Authorisation to HTA evaluation and an established HTA process in a large number of 
European countries, medical devices, IVD and other technologies follow heterogeneous 
rules or processes regarding their evaluation. This is also reflected in the sample selected 
for the case study. Indeed, Pharmaceuticals were selected only if they had undergone an 
evaluation for the exact same indication across settings. In the medical device sample, 
there would be the same generic type, but with a different branded name or/and a 
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different manufacturer. Additionally, medical devices should have undergone an evalua-
tion for the same disease area and not the exact same indication. This is because the 
market for medical devices is intrinsically different from that of Pharmaceuticals with a 
higher level of competition from market entry onwards. While HTA has been largely 
developed for Pharmaceuticals, there appears to be a need for adaptation and develop-
ment of established HTA processes to the medical devices sector as well. 
The negative assessment of Policy Options covering a legislative framework can 
be related to the expectation that this will function as a driver for an upsurge of HTA 
activities in MS. This was perceived as a very important element of unpredictable change 
and additional burden for the MedTech industry. This uncertainty was seen to subse-
quently lessen the attractiveness of the European market and potential delays in first 
revenues are anticipated due to the expected longer processes. Another key impact is the 
expected decline in competitiveness and innovation. According to MedTech Industry, this 
is caused by unpredictable changes in the market access path (also attributed to the two 
new EU Regulations on Medical Devices (132) and potential new hurdles, which are 
typically the most burdensome for the first movers (innovators).  
A further important aspect is the expected increase in costs, driven by additional 
evidence generation. However, the cost calculations within our study did not 
confirm the expectation of cost increase for the MedTech Industry. On the contrary, 
findings indicate that the MedTech industry might also benefit from the ‘tighter’ Policy 
Options under consideration when it comes to costs (aggregated across Europe). 
Potential savings are especially noticeable for POs with a legislative framework (PO 4.1, 
4.2 and 5). It thus seems that this impact is overestimated by the Med Tech industry, 
one identified reason being that the actual level of experience with HTA for the respond-
ents from this sector is considerably lower than for the respondents from the Pharmaceu-
tical Industry. 
Table 68 allows a concise overview of the potential effects of the Policy Options – 
aggregated across all investigated impacts – for each stakeholder group. Green colours 
indicate positive and red colours negative perceptions based on the judgment of the 
study team, considering all collected evidence and information.  
Table 68: Conclusion – Effect of Policy Options 
Stakeholder 
group 
Baseline 
scenario 
(PO1) 
Project-based 
co-operation 
(PO 2) 
MS/EU 
secretariat 
(PO 3) 
Existing EU 
agency 
(PO4.1) 
Existing EU 
agency 
(PO 4.2) 
New EU agency 
(PO 5) 
Public Administration       
Pharma       
MedTech       
  Source: The authors 
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Overall, the estimated effects of the Policy Options as well as the perceptions and 
expectations regarding the future cooperation on HTA in Europe differ between the 
stakeholder groups:  
• For Public Administration, POs providing a legislative framework for HTA coop-
eration in Europe (PO3 onwards) will potentially have a positive effect. 
• For Pharmaceutical Industry POs with mandatory uptake of joint REAs will have 
a positive effect, while PO5 is considered unrealistic by industry representatives. In 
the view of the authors, working with common tools and technologies is important 
in the future, and there is sound evidence that more joint REA will be benefi-
cial.  
• MedTech Industry is in favour of voluntary Project-based cooperation (PO2), as 
any legislative framework is perceived as additional burden with negative 
effects. This relates to the fact that HTA is not as common and related methods 
are not as developed for the medical devices sector as compared to the Pharma-
ceutical sector. Moreover, market access pathways for medical technologies are 
different, with less connection to HTA assessment. While these are issues that 
have to be taken into account when establishing a system for joint output produc-
tion, ultimately positive effects regarding the safety of medical devices and in-
creased transparency of processes are expected by authors. However, because of 
the peculiarities of the market and the yet unknown effects of the two new regula-
tions in the field a different timeline for implementing mandatory joint 
work, as compared to the Pharmaceutical sectors, is advisable. 
Future effects on the stakeholder groups depend on the final structure and specifici-
ties of the joint cooperation. Success factors identified for sustainable joint coopera-
tion include: 
• Use of common tools and templates 
• Business models with stronger governance 
• Cross-country expertise and inputs 
• Mandatory uptake of joint outputs 
Those success factors are closely interrelated. Sufficient institutional capacity and strong 
governance is helpful to provide timely assessment processes and to allow for faster 
market availability of health technologies, correspondingly, adequate expert input is 
needed to ensure the quality of assessments performed, thus increasing the efficiency of 
processes for all stakeholder groups involved (40). 
These factors will be relevant for setting up future cooperation on HTA. A legislative 
cooperation can especially create institutional capacity for this cooperation and expertise 
can be bundled. Our analysis indicates that processes can be set up more efficiently 
when they are coordinated and facilitated by one institution, since all relevant infor-
mation are in one hand, thus leading to savings for current stakeholders.  
Potential savings are considerably higher in policy options that comprise both a mandato-
ry production and mandatory uptake of joint REAs and Joint HTA (PO4.2 and PO5). 
Options comprising a permanent secretariat or a new Agency (which is linked to higher 
joint output) lead to substantially larger savings as compared to project-based coopera-
tion for European industry (in total nearly EUR 4 million across all countries in PO2 versus 
around EUR 70 million with PO 4.2 and EUR 77 million in the case of PO 5). The results of 
the cost prognosis being impressive, we need to point out that there is still need for 
additional data and discussions to verify the informed assumptions that were made for 
the cost prognosis. 
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8 Key findings 
 Overall, the vast majority of clinical evidence considered by HTA bodies in the case of 
Pharmaceuticals comes from phase III clinical trials and less so from phase II trials. 
The latter are increasingly used in those cases where the production of evidence from 
phase III trials is challenging, or in those circumstances where the likely clinical bene-
fit is considered significant and the treatment would merit conditional marketing au-
thorisation (CMA). Only a fraction of the clinical evidence is considered related to other 
types of clinical evidence (extension trials or observational studies). It is thus reason-
able to suggest that there is a fair amount of duplication taking place as the 
evidence considered across settings is by and large the same. 
 There is a clear difference in the preferences of HTA bodies for the type of evidence 
required for Pharmaceuticals compared with medical devices/technologies and ‘other 
technologies’; this is partly driven by what is feasible in the context of either medical 
devices or ‘other technologies’ and is highlighted by the high proportion of retrospec-
tive studies and safety studies (in the medical devices sample) and literature reviews 
(in the ‘other technologies’ sample).  
 In terms of economic evidence, although there are both similarities and differences 
across MS in terms of preferences in approach, modelling or models, one issue worth 
noting was that across MS, and for those MS pursuing economic evaluation, in 68% 
of all cases, the comparator was the same across HTA bodies. 
 From an industry perspective, harmonisation of evidence requirements, if accompa-
nied by MS acceptability, would facilitate easier investment decisions. Additionally, an 
EU HTA with a solid methodology would de-risk the submission process and help elim-
inate arguments resulting from low-quality assessments and data misinterpretation. 
Greater consistency in HTA assessments would be beneficial, and could be facilitated 
by early advice and greater clarity on payer expectations. Finally, harmonisation of 
evidence requirements would give the EU a stronger influence on clinical trial devel-
opment. 
 The Pharmaceutical Industry is in favour of options covering mandatory 
uptake of joint REAs. Due to the currently fragmented HTA systems, they will bene-
fit from a reduction in submissions and better predictability across the EU. It might be 
necessary to relocate staff to a central level, but the number of staff is expected to 
remain stable.  
 Both the MedTech and the Pharmaceutical Industry perceive Full HTA at EU 
level as not meaningful, despite cost estimates showing that industry in gen-
eral could benefit from additional savings compared to REA only. That, howev-
er, very much depends on the nature of topics that are chosen for coverage under Full 
HTA. Experience with Full HTA at EU level so far is limited. The additional domains of 
Full HTA (economic, organizational, legal, ethical and social aspects) tend to contain 
many ‘non-transferable’ issues; to that end, they need to be substantially adapted at 
national level. These points may explain in part the perceived scepticism on the indus-
try side.  
 The MedTech industry sees the most challenges when introducing a legisla-
tive framework for future cooperation in HTA at EU level. Currently, the 
MedTech industry faces lower regulations regarding market access for their products 
due to the significant heterogeneity of products, pointing out the great fragmentation 
within the sector. Two recently established regulations on medical devices at EU level 
aim to better govern the heterogeneous market. Because the MedTech industry has 
little experience with HTA processes, they expect a massive burden on procedures and 
processes and slower market access for their products.  
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 Synergies for Public Administration can be expected since potentially more 
assessments will be available for decision-making. One HTA body might not 
have the capacity to conduct all assessments decision-makers would need in their 
country. Additionally, with potential future growth in patient mobility in Europe, as 
addressed by the Cross-Border Healthcare Directive, it can be seen as advisable to 
base decision-making on the same evidence.  
 General success factors identified for sustainable joint cooperation include 
(1) the use of common tools and templates, (2) business models with 
stronger governance structures (3) timely assessment processes (4) cross-
country expertise and inputs and (5) mandatory national uptake of joint out-
puts (130), all of which are inter-related. The latter applies in the Pharmaceutical 
sector only. Using common tools and templates facilitates joint work while sufficient 
institutional capacity and strong governance form the basis to provide timely assess-
ment processes. Timely assessment is important to ensure that uptake can occur at a 
time when the results are relevant in national settings. Adequate expert input is need-
ed to ensure the quality of assessments performed, thus increasing efficiency of pro-
cess for all stakeholder groups. Finally, mandatory uptake of results is important and 
ensures that the purpose of joint work is met. These factors will be relevant for setting 
up future cooperation on HTA, although the peculiarities of the MedTech sector may 
need to be taken into account and success factors may be more relevant for HTA in 
Pharmaceuticals. 
 Legislative cooperation can create institutional capacity for HTA cooperation 
and expertise can be better streamlined. Our study findings suggest that process-
es can be set up more efficiently when they are coordinated and facilitated by one 
permanent institution, since all relevant information is centralised, expertise can be 
streamlined and overall savings can materialise.  
 Potential savings are considerably higher in POs that comprise both a manda-
tory production and mandatory uptake of joint REAs and Joint HTA (PO4.2 
and PO5). Options comprising a permanent secretariat or a new Agency, which is 
linked to higher joint output, lead to substantially higher savings in the long run as 
compared to project-based cooperation (in total nearly EUR 4 million across all coun-
tries in PO2 versus around EUR 70 million with PO 4.2 and EUR 77 million with PO 5). 
Regarding the results of the cost prognosis, there are uncertainties in data collection, 
as is clearly outlined in the corresponding sectors of our study.  
 Improved sustainability and a mandatory nature to HTA cooperation in 
Europe potentially leads to benefits for patients. An increase in the number of 
health technologies assessed will increase the evidence-base for decision-making 
across the EU, especially in MS where HTA is not well-developed, thus also contrib-
uting to a decrease in cross-country inequalities.  
 From a patient perspective, future EU cooperation in HTA POs with mandatory 
participation and uptake will increase availability of safe and effective Pharma-
ceuticals and medical technologies and ensure standardised monitoring of 
health technologies prior to market access. Transparent and independent HTA 
processes require consideration of all relevant stakeholder perspectives to increase 
efficiency and prevent conflict of interest. Sufficient financial resources are vital to 
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establish a respective mechanism. Besides required investments, stakeholders should 
draw their attention to the potential return on investment different mechanisms offer. 
 Previous patient involvement in HTA processes is characterised by good intentions on 
the part of involved stakeholder groups, but successful implementation was limited so 
far by either the extent or the role of involvement. There are clear signals both from 
Public Administration and the Pharmaceutical Industry to improve and standardise 
patient involvement in HTA processes. Stronger governance regarding HTA 
assessment might positively influence patient involvement. Overall, sustainable 
and transparent long-term cooperation in the field of HTA offers the potential to pre-
vent selective assessment of Pharmaceuticals, reduce availability of health technolo-
gies with little or no added value and improve the accessibility of publicly available 
information. 
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